<SEC-DOCUMENT>0001047469-15-001057.txt : 20150223
<SEC-HEADER>0001047469-15-001057.hdr.sgml : 20150223
<ACCEPTANCE-DATETIME>20150223160200
ACCESSION NUMBER:		0001047469-15-001057
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20150223
DATE AS OF CHANGE:		20150223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Xencor Inc
		CENTRAL INDEX KEY:			0001326732
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				201622502
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-201384
		FILM NUMBER:		15639684

	BUSINESS ADDRESS:	
		STREET 1:		111 WEST LEMON AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		626-305-5900

	MAIL ADDRESS:	
		STREET 1:		111 WEST LEMON AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>a2223193z424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg49601_table_of_contents">  TABLE OF CONTENTS</A> <BR>
<A HREF="#bg49602_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="bc49601_filed_pursuant_to_rule_424(b)(__fil01394"> </A>
<A NAME="toc_bc49601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  FILED PURSUANT TO RULE 424(b)(5)<BR>  REG. STATEMENT NO.&nbsp;333-201384    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_TXTHEX,"" -->


</FONT> <FONT COLOR="#FF4040" SIZE=2><B>The information in this preliminary prospectus supplement is not complete and may be changed. A registration
statement relating to these securities has become effective by rule of the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer
to sell these securities, and we are not soliciting offers to buy these securities, in any state or other jurisdiction where the offer or sale is not permitted.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_TXTHEX,"" -->


 </B></FONT><FONT COLOR="#FF4040" SIZE=2><B>SUBJECT TO COMPLETION, DATED FEBRUARY 23, 2015</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> PRELIMINARY PROSPECTUS SUPPLEMENT<BR>  </B></FONT><FONT SIZE=2>(To Prospectus dated January&nbsp;23, 2015) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>5,500,000 Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>
<IMG SRC="g1039421.jpg" ALT="LOGO" WIDTH="280" HEIGHT="75">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Common Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=4><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are offering up to 5,500,000 shares of our common stock. Our common stock is listed on The NASDAQ Global Market under the symbol "XNCR". On
February&nbsp;20, 2015, the last reported sale price for our common stock on The NASDAQ Global Market was $15.06 per share. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>We are an "emerging growth company" under applicable Securities and Exchange Commission rules and are subject to reduced public company reporting requirements.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=3><B>Investing in our common stock involves a high degree of risk. Please read "Risk Factors" on page S-9 of this prospectus
supplement and the documents incorporated by reference into this prospectus supplement.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved these
securities or determined if this prospectus supplement or the accompanying prospectus is accurate or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="63%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Per Share</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Total</B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1><B> </B></FONT><FONT SIZE=2>Public offering price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting discounts and commissions(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds, before expenses, to us</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>We
have agreed to reimburse the underwriters for certain expenses. See "Underwriting."  </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have granted the underwriters an option for 30&nbsp;days from the date of this prospectus supplement to purchase up to 825,000 additional shares of our common stock. See
"Underwriting" for more information. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters expect to deliver the shares to the investors on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>Sole Book-Running Manager  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>Leerink Partners  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>Co-Managers  </I></FONT></P>
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<P style="font-family:times;"><FONT SIZE=4><B>


<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->


  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="291pt" style="font-family:times;"></TD>
<TD WIDTH="19%" style="font-family:times;"></TD>
<TD WIDTH="183pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=4><B>Wedbush PacGrow Life Sciences</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=4><B>Oppenheimer &amp; Co.</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>

<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"> <FONT SIZE=2>
February&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=78675,FOLIO='blank',FILE='DISK135:[15ZAN1.15ZAN49601]BC49601A.;18',USER='GKIBBE',CD='23-FEB-2015;13:08' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bg49601_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG49601A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg49601_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG49601_TOC2"></A> </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Prospectus Supplement</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#bi49601_about_this_prospectus_supplement"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>About this Prospectus Supplement</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#bi49601_about_this_prospectus_supplement"><FONT SIZE=2><BR>
S-1</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ca49601_prospectus_supplement_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prospectus Supplement Summary</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ca49601_prospectus_supplement_summary"><FONT SIZE=2>S-2</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc49601_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc49601_risk_factors"><FONT SIZE=2>S-9</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc49601_note_regarding_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Note Regarding Forward-Looking Statements</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc49601_note_regarding_forward-looking_statements"><FONT SIZE=2>S-11</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc49601_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of Proceeds</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc49601_use_of_proceeds"><FONT SIZE=2>S-12</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de49601_price_range_of_our_common_stock"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Price Range of our Common Stock</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de49601_price_range_of_our_common_stock"><FONT SIZE=2>S-13</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de49601_dividend_policy"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dividend Policy</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de49601_dividend_policy"><FONT SIZE=2>S-14</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de49601_dilution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de49601_dilution"><FONT SIZE=2>S-15</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg49601_material_u.s._federal_income_a__mat02797"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Material U.S. Federal Income and Estate Tax Consequences to Non-U.S. Holders</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg49601_material_u.s._federal_income_a__mat02797"><FONT SIZE=2>S-17</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#di49601_underwriting"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#di49601_underwriting"><FONT SIZE=2>S-21</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#DI_LM"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Matters</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#DI_LM"><FONT SIZE=2>S-25</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#DI_EX"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Experts</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#DI_EX"><FONT SIZE=2>S-25</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#DI_WH"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Where You Can Find More Information</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#DI_WH"><FONT SIZE=2>S-25</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#DI_IN"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Incorporation of Certain Information by Reference</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#DI_IN"><FONT SIZE=2>S-25</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG49601_TOC"></A> </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Prospectus</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#bi49602_about_this_prospectus"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>About this Prospectus</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#bi49602_about_this_prospectus"><FONT SIZE=2><BR>
i</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ca49602_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Summary</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ca49602_summary"><FONT SIZE=2>1</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da49602_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da49602_risk_factors"><FONT SIZE=2>4</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da49602_special_note_regarding_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Special Note Regarding Forward-Looking Statements</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da49602_special_note_regarding_forward-looking_statements"><FONT SIZE=2>4</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da49602_ratio_of_earnings_to_fixed_charges"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ratio of Earnings to Fixed Charges</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da49602_ratio_of_earnings_to_fixed_charges"><FONT SIZE=2>4</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da49602_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of Proceeds</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da49602_use_of_proceeds"><FONT SIZE=2>5</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da49602_description_of_capital_stock"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Capital Stock</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da49602_description_of_capital_stock"><FONT SIZE=2>5</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc49602_description_of_debt_securities"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Debt Securities</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc49602_description_of_debt_securities"><FONT SIZE=2>10</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de49602_description_of_warrants"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Warrants</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de49602_description_of_warrants"><FONT SIZE=2>17</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de49602_legal_ownership_of_securities"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Ownership of Securities</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de49602_legal_ownership_of_securities"><FONT SIZE=2>20</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg49602_plan_of_distribution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Plan of Distribution</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg49602_plan_of_distribution"><FONT SIZE=2>23</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg49602_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Matters</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg49602_legal_matters"><FONT SIZE=2>25</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg49602_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Experts</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg49602_experts"><FONT SIZE=2>25</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg49602_where_you_can_find_more_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Where You Can Find More Information</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg49602_where_you_can_find_more_information"><FONT SIZE=2>25</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg49602_incorporation_of_certain_information_by_reference"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Incorporation of Certain Information by Reference</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg49602_incorporation_of_certain_information_by_reference"><FONT SIZE=2>26</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#DG_DIS"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Disclosure of Commission Position on Indemnification for Securities Act Liability</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#DG_DIS"><FONT SIZE=2>27</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>We have not, and the underwriters have not, authorized anyone to provide you with information different than that which is contained in or incorporated by
reference in this prospectus supplement, the accompanying prospectus and in any free writing prospectus that we have authorized for use in connection with this offering. We are not, and the
underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus
supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and in any free writing prospectus that we have
authorized for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have
changed since those dates. You should read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying
prospectus, and any free writing prospectus that we have
authorized for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have
referred you in the sections of this prospectus supplement entitled "Where You Can Find More Information" and "Incorporation of Certain Information by Reference."</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=361771,FOLIO='i',FILE='DISK135:[15ZAN1.15ZAN49601]BG49601A.;12',USER='JFUSS',CD='23-FEB-2015;08:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bi49601_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bi49601_about_this_prospectus_supplement"> </A>
<A NAME="toc_bi49601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THIS PROSPECTUS SUPPLEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering of common stock
and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The
second part, the accompanying prospectus dated January&nbsp;23, 2015, including the documents incorporated by reference therein, provides more general information. Generally, when we refer to this
prospectus, we are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the
information contained in the accompanying prospectus or in any document incorporated by reference that was filed with the Securities and Exchange Commission, or SEC, before the date of this prospectus
supplement, on the other hand, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having
a later date&#151;for example, a document incorporated by reference in the accompanying prospectus&#151;the statement in the document having the later date modifies or supersedes the
earlier statement. You should assume that the information contained in this prospectus supplement is accurate as of the date on the front cover of this prospectus supplement only and that any
information we have incorporated by reference or included in the accompanying prospectus is accurate only as of the date given in the document incorporated by reference or as of the date of the
prospectus, as applicable, regardless of the time of delivery of this prospectus supplement or the accompanying prospectus or any sale of our
common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
the context indicates otherwise, as used in this prospectus supplement, the terms "Xencor," "we," "us" and "our" refer to Xencor,&nbsp;Inc. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus supplement, the accompanying prospectus and the information incorporated herein and therein by reference may include trademarks, service marks and trade names owned by us
or other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus supplement or the accompanying prospectus are the property of their
respective owners. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=110487,FOLIO='S-1',FILE='DISK135:[15ZAN1.15ZAN49601]BI49601A.;3',USER='JFUSS',CD='23-FEB-2015;08:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ca49601_1_2"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ca49601_prospectus_supplement_summary"> </A>
<A NAME="toc_ca49601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUPPLEMENT SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>This summary highlights selected information contained elsewhere or incorporated by reference in this
prospectus supplement and the accompanying prospectus. This summary does not contain all the information you should consider before investing in our common stock. You should read and consider
carefully the more detailed information in this prospectus supplement and the
accompanying prospectus, including the factors described under the heading "Risk Factors" in this prospectus supplement and the financial statements, notes to financial statements, financial and other
information incorporated by reference in this prospectus supplement and the accompanying prospectus, as well as the information included in any free writing prospectus that we have authorized for use
in connection with this offering, before making an investment decision.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Company  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibodies to treat
severe and life- threatening diseases with unmet medical needs. We use our proprietary XmAb technology platform to create next-generation antibody product candidates designed to treat autoimmune and
allergic diseases, cancer and other conditions. In contrast to conventional approaches to antibody design, which focus on the portion of antibodies that interact with target antigens, we focus on the
portion of the antibody that interacts with multiple segments of the immune system and that anchors antibody structural organization. This portion, referred to as the Fc domain, is constant and
interchangeable among antibodies. Our engineered Fc domains, the XmAb technology, can be readily substituted for natural Fc domains. We believe our Fc domains enhance antibody performance by, for
example, increasing immune inhibitory activity, improving cytotoxicity, extending circulating half- life or stabilizing novel antibody structures, while maintaining 99.5% identity in structure and
sequence to natural antibodies. By improving over natural antibody function, we believe that our XmAb-engineered antibodies offer innovative approaches to treating disease and potential clinical
advantages over other treatments. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
business strategy is based on the plug-and-play nature of the XmAb technology platform to modify features of natural antibodies and create numerous differentiated antibody product
candidates. We have internally generated a pipeline that has allowed us to selectively partner certain development programs while maintaining full ownership of other programs. We also have a number of
technology licenses under which we have licensed the XmAb technology platform to pharmaceutical and biotechnology companies for use in a limited number of programs, providing multiple revenue streams
that require no further resources from Xencor. There are currently eight antibody product candidates in clinical trials that have been engineered with XmAb technology, including six candidates being
advanced by licensees and development partners. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
internally-generated pipeline includes the following three lead XmAb- engineered antibodies that are currently in development:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>XmAb5871,</I></B></FONT><FONT SIZE=2> our most advanced wholly-owned program recently completed a
Phase&nbsp;1b/2a clinical trial in rheumatoid arthritis (RA) and we are planning to initiate an open-label pilot clinical trial in IgG4-related disease (IgG4-RD) to assess disease control activity
measured by the IgG4-RD Responder Index (Carruthers, et al., 2012, Int J Rheum) in 2015. XmAb5871 uses our XmAb Immune Inhibitor Fc Domain and targets B cells, an important component of the immune
system. In January 2015, we announced that in the Phase&nbsp;2a part of the trial 15 XmAb5871-treated patients and eight placebo-treated patients were evaluable for RA disease activity at the
protocol specified disease activity assessment time point of two weeks following the sixth biweekly infusion. 33% of patients (5 of 15)&nbsp;that received all six biweekly doses of XmAb5871 achieved
DAS28-CRP remission or low disease activity compared to zero patients that were treated with the placebo achieving DAS28-CRP remission or low disease activity. </FONT></DD></DL>
</UL>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=848200,FOLIO='S-2',FILE='DISK135:[15ZAN1.15ZAN49601]CA49601A.;15',USER='JFUSS',CD='23-FEB-2015;12:55' -->
<A NAME="page_ca49601_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>Three
ACR70 responses (20%) and six ACR50 responses (40%) occurred in the XmAb5871 group compared to zero and one (13%) respectively in the placebo group. ACR70 and ACR50 responses refer, respectively
to 70% and 50% reductions in the American College of Rheumatology rheumatoid arthritis symptom scale, a common measure of RA disease activity. Across the entire Phase&nbsp;1b/2a clinical trial,
biweekly administration of XmAb5871 for 12&nbsp;weeks was generally well tolerated. The most common XmAb5871 treatment related adverse related events (AEs) observed were predominantly mild to
moderate gastrointestinal toxicities (nausea, vomiting, diarrhea) occurring during the first infusion of XmAb5871. These gastrointestinal AEs did not typically recur on subsequent infusions and no
infusions were discontinued due to these AEs. Other treatment related AEs experienced in more than two XmAb5871 treated patients were pyrexia (fever) and headache. Treatment related serious adverse
events (SAEs) occurred in two patients that received XmAb5871: infusion related reaction and venous thrombosis (blood clot). Two patients in the placebo treated group also reported SAEs. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>We
believe XmAb5871 has the potential to address a key unmet need in autoimmune therapies due to its combination of potent B-cell inhibition without B-cell depletion and will be exploring other
indications in 2015. In October 2014, we announced that we sought and regained all rights to XmAb5871from our partner, Amgen&nbsp;Inc. (Amgen), who had an option to acquire an exclusive worldwide
license. In return, we granted Amgen a first right to negotiate a proposed license for XmAb5871 prior to seeking future partners. This right expires upon the earlier of the initiation of
Phase&nbsp;3 clinical testing of XmAb5871, a change of control of Xencor, or October 2019. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>XmAb7195</I></B></FONT><FONT SIZE=2> is our wholly-owned program being developed for the treatment of severe
asthma and allergic diseases. It uses our XmAb Immune Inhibitor Fc Domain and is designed to reduce blood serum levels of IgE, which mediates allergic responses and allergic disease. Its three
specific mechanisms of action give it potential advantages over current therapies: (i)&nbsp;increased IgE binding, (ii)&nbsp;inhibition of IgE production and (iii)&nbsp;rapid clearance of IgE
from circulation. In 2014 we filed an IND for XmAb7195 for allergic asthma with the FDA and in May initiated a Phase&nbsp;1a single ascending dose clinical trial in healthy volunteers and in
allergen-sensitive subjects with high IgE levels. In January 2015 we reported that interim data from the trial show rapid reduction of circulating free IgE levels to below the limit of detection at
the end of the XmAb7195 infusion in 90% of XmAb7195 treated subjects that had detectable free IgE pre-dose, including those at the lowest dose evaluated of 0.3 mg/kg. Total IgE levels were also
reduced in a parallel fashion. Two subjects with high pre-dose IgE levels (above 400 IU/mL) were treated with XmAb7195, one each at 0.75 mg/kg and 3.0 mg/kg doses, and both had reduction of free IgE
levels to below the limit of detection lasting for at least one week. A dose limiting toxicity of transient, asymptomatic thrombocytopenia (low blood platelet count) was observed at the 3.0 mg/kg
dose. The decrease in platelet count was transient with a minimum by 24&nbsp;hours post-dose, recovery starting by 48&nbsp;hours post-dose and near full platelet count recovery by study Day 8 in
all cases, at which time serum drug concentrations still exceeded levels that eliminate detectable IgE. No evidence of thrombocytopenia has been observed in any of the clinical trials of XmAb5871, an
anti-CD19 antibody with the identical XmAb Immune Inhibitor Fc domain as that of XmAb7195. Moderate urticaria (hives) was reported in a total of seven XmAb7195 treated subjects with an apparent
correlation of dose with frequency of occurrence. In all cases regardless of dose, the signs/symptoms of urticaria were mild, non-diffuse and easily treated with oral antihistamine, and the study drug
infusions were continued to completion without worsening of symptoms. Otherwise, there were no other adverse events that occurred in more than two XmAb7195 treated subjects. There were no serious
adverse events reported and no subject discontinued Part&nbsp;1 of trial early. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>XmAb5574/MOR208</I></B></FONT><FONT SIZE=2> is being developed by our partner MorphoSys AG (MorphoSys) for the
treatment of blood- based cancers and uses our XmAb Cytotoxic Fc Domain. In a Phase&nbsp;1 </FONT></DD></DL>
</UL>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=416780,FOLIO='S-3',FILE='DISK135:[15ZAN1.15ZAN49601]CA49601A.;15',USER='JFUSS',CD='23-FEB-2015;12:55' -->
<A NAME="page_ca49601_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>clinical
trial of XmAb5574/MOR208 completed by Xencor in patients with high-risk, heavily-pretreated chronic lymphocytic leukemia (CLL), in which the antibody showed encouraging signs of preliminary
anti-tumor activity and an acceptable safety profile and was well tolerated. The trial protocol was amended to include a period of extended dosing for a total of eight patients at the 12 mg/kg dose to
study the effect of longer duration of exposure on safety and response rate. Overall response rate by IWCLL 2008 criteria was 29.6% (eight partial responses in 27&nbsp;evaluable patients). Using
NCI-WG CLL 1996, response criteria resulted in a response rate of 66.7% (18 partial responses). At the highest dose studied, 12 mg/kg, 12 of 16 patients (75%) had a partial response by NCI-WG CLL 1996
and six patients (37.5%) had a partial response using additional CT criteria (IWCLL 2008). Median progression free survival for all patients was 199&nbsp;days and for the extended treatment arm (at
12 mg/kg) was 420&nbsp;days. Blood disease cleared in most patients, with median reduction in absolute lymphocyte count from baseline of 90.8%. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>XmAb5574/MOR208
was generally well tolerated with no maximum-tolerated dose identified. Clinically-significant, treatment-related adverse events (AEs) classified as Grade 3 or higher occurred in 5 out
of twenty-seven patients. The most frequent treatment-related AEs were infusion-related reactions, which were reported for 66.7% of patients, all of which were grade 1 or 2, and no reactions were seen
following the first infusion. Treatment-related AEs each reported for 18.5% of patients were ALT increased, AST increased, neutropenia and thrombocytopenia; all other treatment-related AEs were
reported for <FONT FACE="SYMBOL">&#163;</FONT> 15% of patients. These events resolved, generally without requiring treatment, and did not lead to discontinuation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>MorphoSys
is currently conducting two Phase&nbsp;2 clinical trials of MOR208 in patients with B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphomas (NHL). </FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2014 our development efforts for XmAb bispecific antibodies expanded. Bispecific antibodies are designed with two different variable domains to elicit biological effects that require
simultaneous binding to two targets. Previously, industry efforts at bispecific antibody design have generally been frustrated by poor molecular stability, difficulties in production and short in vivo
half-life. Xencor's XmAb&reg; bispecific Fc domain technology is designed to maintain full-length antibody properties in a bispecific antibody, potentially enabling stable molecules with
favorable in vivo half-life and allowing for the use of standard antibody production methods. These bispecific Fc domains are used to generate a broad array of novel drug candidates. In November 2014,
we announced preclinical data from three programs using the our XmAb bispecific Fc technology showing that bispecific antibodies targeting CD123, CD20 and CD38 antigens each activated T-cells to
rapidly kill target cells from a single dose IV bolus in cynomolgus monkeys and demonstrated prolonged half-life of approximately one week in mice. We also announced that we had selected, our lead
anti-CD123xCD3 bispecific antibody, XmAb14045, for IND-enabling studies and cGMP process development and manufacturing. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we have licensed our XmAb technology to pharmaceutical and biotechnology companies for use in a limited number of their programs. These licensees include Boehringer
Ingelheim International&nbsp;GmbH (Boehringer Ingelheim), CSL Limited (CSL), Janssen R&amp;D,&nbsp;LLC (Janssen), Merck, Sharp and Dohme, a subsidiary of Merck&nbsp;&amp;&nbsp;Co.,&nbsp;Inc.
(Merck), Alexion Pharmaceuticals,&nbsp;Inc. (Alexion), and collectively these licensees have five Phase&nbsp;1 clinical development-stage programs and two pre-clinical development-stage programs.
In December 2014, we announced a discovery-collaboration with Novo Nordisk A/S (Novo Nordisk) to jointly discover novel biologic drug candidates for an undisclosed target by combining multiple Xencor
XmAb technologies, including our bispecific and immune inhibitor technologies. </FONT></P>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=6,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=471130,FOLIO='S-4',FILE='DISK135:[15ZAN1.15ZAN49601]CA49601A.;15',USER='JFUSS',CD='23-FEB-2015;12:55' -->
<A NAME="page_ca49601_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our XmAb Technology Platform  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our XmAb Fc domain technology is a platform of antibody components that enable the creation of therapeutic antibody candidates that
have novel interactions with the human immune and antibody regulation systems. We developed the XmAb technology platform from a systematic effort to engineer the Fc domain of antibodies to manipulate
its interactions with a variety of its natural receptors. We used our patented screening technology, consisting of algorithms and computer models of the three-dimensional structure of the Fc domain,
to focus on, from the vast number of possibilities, manageable sets of possible amino acid changes that result in small modifications to the Fc domain structure which effect significant changes in
antibody function and performance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have identified a set of Fc domains, each of which is engineered to have a specific function based on its Fc receptor binding profile,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Immune Inhibitor Fc Domain</I></B></FONT><FONT SIZE=2>&#151;selective immune inhibition and rapid target
clearance, targeting the receptor Fc<FONT FACE="SYMBOL">g</FONT>RIIb </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Cytotoxic Fc Domain</I></B></FONT><FONT SIZE=2>&#151;increased cytotoxicity, targeting the receptors
Fc<FONT FACE="SYMBOL">g</FONT>RIIIa on natural killer (NK) cells and Fc<FONT FACE="SYMBOL">g</FONT>RIIa on other immune system cells </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Xtend Fc Domain</I></B></FONT><FONT SIZE=2>&#151;extended antibody half-life, targeting the receptor FcRn
on endothelial cells </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Bispecific Domain</I></B></FONT><FONT SIZE=2>&#151;heterodimeric Fc domains enabling molecules with dual
target binding </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we have engineered XmAb Fc domains with other properties, including rapid antigen clearance, antibody stability and multiple-antigen specificity (heterodimer). Each XmAb Fc
domain consists of a naturally occurring Fc domain with a small number of amino acid changes, usually two that we found to be critical for modulating interactions with the desired Fc receptors or
manipulating Fc structural organization. With such limited modifications of the natural Fc domain, XmAb-engineered antibodies are typically over 99.5% identical in structure and sequence to natural
antibodies, simplifying product development yet enhancing function. In contrast to other engineering approaches for next-generation antibodies, we believe this conservative design allows our
engineered antibodies to retain the beneficial stability, pharmacokinetics, and ease of discovery of natural </FONT></P>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=7,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=700640,FOLIO='S-5',FILE='DISK135:[15ZAN1.15ZAN49601]CA49601A.;15',USER='JFUSS',CD='23-FEB-2015;12:55' -->
<A NAME="page_ca49601_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <P style="font-family:times;"><FONT SIZE=2>antibodies,
as well as to allow well-validated methods for antibody manufacturing. We believe we can thereby avoid the problems many new antibody platforms have had in production and drug stability. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g74988.jpg" ALT="GRAPHIC" WIDTH="679" HEIGHT="438">
  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Strategy  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our goal is to become a leading biopharmaceutical company focused on developing and commercializing engineered monoclonal antibodies to
treat severe and life-threatening diseases with unmet medical needs. Key elements of our strategy are to: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I> Advance the clinical development of our lead Immune Inhibitor Fc
Domain product candidates.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We are developing XmAb5871 for the treatment of autoimmune diseases, including IgG4-related disease, and are
developing XmAb7195 for the treatment of asthma and allergic diseases.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I> Build a large and diversified portfolio of product
candidates.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We aim to create new XmAb-engineered antibody product candidates that exploit the novel properties of our XmAb technology
platform for preclinical and clinical development by us.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I> Continue to monetize and expand the use of our XmAb technology
platform.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We are seeking additional licensing and partnering opportunities, similar to our collaborations with MorphoSys and Novo
Nordisk with other leading pharmaceutical and biotechnology companies.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I> Broaden the functionality of our XmAb technology
platform.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We are conducting further research into the function and application of antibody Fc domains in order to expand the scope of
our XmAb technology platform. Our bispecific technology, which uses our hetrodimeric Fc domain enabling molecules with dual target binding, is an example of the expanding functionality of our XmAb
technology platform. </FONT></DD></DL>
</UL>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=8,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=679722,FOLIO='S-6',FILE='DISK135:[15ZAN1.15ZAN49601]CA49601A.;15',USER='JFUSS',CD='23-FEB-2015;12:55' -->
<A NAME="page_ca49601_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
 <UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I> Continue to expand our patent portfolio protecting our XmAb technology
platform.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We seek to expand and protect our development programs and product candidates by filing and prosecuting patents in the United
States and other countries. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We were incorporated in California in August 1997 under the name Xencor. In September 2004, we reincorporated in the state of Delaware
under the name Xencor,&nbsp;Inc.
Our principal offices are located at 111 West Lemon Avenue, Monrovia, CA 91016, and our telephone number (626)&nbsp;305-5900. Our website address is www.xencor.com. We do not incorporate by
reference into this prospectus the information on, or accessible through, our website, and you should not consider it as part of this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012, and therefore we may take advantage of certain exemptions from various public company
reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section&nbsp;404
of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the
requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments. We will remain an emerging growth company until the earliest of
(1)&nbsp;December&nbsp;31, 2018, (2)&nbsp;the last day of the fiscal year (a)&nbsp;in which we have total annual gross revenue of at least $1.0&nbsp;billion, or (b)&nbsp;in which we are
deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700.0&nbsp;million as of the prior June&nbsp;30th, and
(3)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in non-convertible debt during the prior three-year period. We have chosen to irrevocably opt out of the extended transition
periods available under the JOBS Act for complying with new or revised accounting standards. </FONT></P>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=9,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=898114,FOLIO='S-7',FILE='DISK135:[15ZAN1.15ZAN49601]CA49601A.;15',USER='JFUSS',CD='23-FEB-2015;12:55' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_cc49601_1_8"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cc49601_the_offering"> </A>
<A NAME="toc_cc49601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  The Offering    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock offered by us</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,500,000 shares</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock to be outstanding immediately after this offering</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>36,934,272 shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Option to purchase additional shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We have granted the underwriters an option to purchase up to 825,000 additional shares of our common stock. This option is
exercisable, in whole or in part, for a period of 30&nbsp;days from the date of this prospectus supplement.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of proceeds</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We intend to use the net proceeds from this offering for general corporate purposes, which may include clinical development
of our lead drug candidates, product candidate discovery, technology development, patent prosecution activities, working capital and other general corporate purposes. See "Use of Proceeds."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk factors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investing in our common stock involves a high degree of risk. See "Risk Factors."</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>NASDAQ Global Market Symbol</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Our common stock is listed on The NASDAQ Global Market under the symbol "XNCR".</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of shares of our common stock to be outstanding immediately after this offering is based on 31,434,272 shares outstanding as of December&nbsp;31, 2014, and excludes as of
that date:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 2,826,794 shares of common stock issuable upon the exercise of outstanding stock options under our equity incentive plans, with a
weighted-average exercise price of $5.12 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 2,583,186 shares of common stock available for future grants under our 2013 equity incentive plan; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 517,422 shares of common stock available for issuance under our 2013 employee stock purchase plan. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise indicated, all information in this prospectus supplement assumes no exercise by the underwriters of their option to purchase additional shares and assumes no exercise
of the outstanding stock options described above. </FONT></P>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=10,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=592505,FOLIO='S-8',FILE='DISK135:[15ZAN1.15ZAN49601]CC49601A.;7',USER='ABEAULI',CD='23-FEB-2015;14:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc49601_1_9"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc49601_risk_factors"> </A>
<A NAME="toc_dc49601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Investing in our common stock involves a high degree of risk. Our business, prospects, financial condition or
operating results could be materially adversely affected by the risks identified below, as well as other risks not currently known to us or that we currently consider immaterial. The trading price of
our common stock could decline due to any of these risks, and you may lose all or part of your investment. In assessing the risks described below, you should also refer to the information contained in
our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2014, including the section titled "Risk Factors," and in the other documents which are incorporated by reference in this
prospectus supplement and the accompanying prospectus in their entirety.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to this Offering  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Management will have broad discretion as to the use of the net proceeds from this offering, and we
may not use the proceeds effectively.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in
ways that do not improve our results of operations or enhance the value of our common stock. Our failure to apply these funds effectively could have a material adverse effect on our business, delay
the development of our product candidates, and cause the price of our common stock to decline. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If you purchase the common stock sold in this offering, you will experience immediate and
substantial dilution in your investment. You will experience further dilution if we issue additional equity securities in the future.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since the price per share of our common stock being offered is substantially higher than the net tangible book value per share of our
common stock, you will suffer substantial dilution with respect to the net tangible book value of the common stock you purchase in this offering. Based on the public offering price of $15.06 per
share, which is the last reported sale price for our common stock on The NASDAQ Global Market on February&nbsp;20, 2015, and our net tangible book value as of December&nbsp;31, 2014, if you
purchase shares of common stock in this offering, you will suffer immediate and substantial dilution of $11.61 per share with respect to the net tangible book value of the common stock. See "Dilution"
for a more detailed discussion of the dilution you will incur if you purchase common stock in this offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we have a significant number of stock options and warrants outstanding. To the extent that outstanding stock options or warrants have been or may be exercised or other
shares issued, investors purchasing our common stock in this offering may experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic
considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt
securities, the issuance of these securities could result in further dilution to our stockholders or result in downward pressure on the price of our common stock. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Sales of a substantial number of shares of our common stock by our existing stockholders in the
public market could cause our stock price to fall.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the
trading price of our common stock could decline. In addition a substantial number of shares of common stock are subject to outstanding options are or will become eligible for sale in the public market
to the extent permitted by the provisions of various vesting schedules. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the
trading price of our common stock could decline. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=11,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=1019490,FOLIO='S-9',FILE='DISK135:[15ZAN1.15ZAN49601]DC49601A.;10',USER='GKIBBE',CD='23-FEB-2015;12:35' -->
<A NAME="page_dc49601_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
holders of 10,149,071 shares of our common stock, or approximately 32.3% of our total outstanding common stock as of December&nbsp;31, 2014, will be entitled to rights with respect
to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the
Securities Act, except for shares held by affiliates, as defined in Rule&nbsp;144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the
trading price of our common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
executive officers and directors have agreed that, subject to certain exceptions, during the period ending 90&nbsp;days after the date of this prospectus supplement, they will not
offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any shares of our common stock or securities convertible into or exchangeable or exercisable for any shares of
our common stock, enter into a transaction that would have the same effect, or enter into any swap, hedge or other arrangement that transfers, in whole or in part, any of the economic consequences of
ownership of our common stock, whether any of these transactions are to be settled by delivery of our common stock or other securities, in cash or otherwise, or publicly disclose the intention to make
any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement, without, in each case, the prior written consent of Leerink Partners&nbsp;LLC, who may
release any of the securities subject to these lock-up agreements at any time without notice. Exceptions to the lock-up restrictions are described in more detail in this prospectus supplement under
the caption "Underwriting." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=12,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=863749,FOLIO='S-10',FILE='DISK135:[15ZAN1.15ZAN49601]DC49601A.;10',USER='GKIBBE',CD='23-FEB-2015;12:35' -->
<A NAME="page_dc49601_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc49601_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_dc49601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus supplement, the accompanying prospectus, and the documents incorporated by reference herein and therein contain
forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as
amended, or the Exchange Act, that involve a number of risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be
based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ
materially from results and outcomes discussed in the forward-looking statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forward-looking
statements can be identified by the use of forward-looking words such as "believes," "expects," "hopes," "may," "will," "plan," "intends," "estimates," "could," "should,"
"would," "continue," "seeks," "pro forma," or "anticipates," or other similar words (including their use in the negative), or by discussions of future matters such as the development of new products,
technology enhancements, possible collaborations, possible changes in legislation and other statements that are not historical. These statements include but are not limited to statements under the
captions "Business," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and in other sections incorporated by reference from our Annual Report
on Form&nbsp;10-K and Quarterly Reports on Form&nbsp;10-Q, as applicable, as well as our other filings with the SEC. You should be aware that the occurrence of any of the events discussed under
the heading "Risk Factors" in any applicable prospectus supplement and any documents incorporated by reference herein or therein could substantially harm our business, operating results and financial
condition and that if any of these events occurs, it could adversely affect the value of an investment in our securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
qualify all of the forward-looking statements in the foregoing documents by these cautionary statements. Unless required by law, we undertake no obligation to update or revise any
forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or
implied in such forward-looking statements. Before deciding to purchase our common stock, you should carefully consider the risk factors incorporated by reference herein, in addition to the other
information set forth in this prospectus supplement, the accompanying prospectus and in the documents incorporated by reference herein. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=13,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=451434,FOLIO='S-11',FILE='DISK135:[15ZAN1.15ZAN49601]DC49601A.;10',USER='GKIBBE',CD='23-FEB-2015;12:35' -->
<A NAME="page_dc49601_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc49601_use_of_proceeds"> </A>
<A NAME="toc_dc49601_3"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We estimate that we will receive net proceeds of approximately $77.4&nbsp;million, based on an assumed public offering price of
$15.06 per share (the last reported sale price of our common stock on The NASDAQ Global Market on February&nbsp;20, 2015) (or approximately $89.0&nbsp;million if the underwriters' option to
purchase additional shares is exercised in full), from the sale of the shares of common stock offered by us in this offering, after deducting the underwriting discounts and commissions and estimated
offering expenses payable by us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
intend to use the net proceeds from this offering for general corporate purposes, which may include </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Continued clinical development of XmAb5871, including clinical trials for IgG4-related disease and potential development of XmAb5871
in additional indications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Continued development of our initial bispecific candidate, XmAb14045 through IND enabling activities and into clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Research and development of additional XmAb bispecific product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Additional clinical development of XmAb7195; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Working capital and general corporate purposes, which may include other research and development programs, in-licensing or acquiring
other products or technologies. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
amounts and timing of these expenditures will depend on a number of factors, such as the timing and progress of our research and development efforts, the timing and progress of any
partnering efforts, and the competitive environment for our product candidates. As of the date of this prospectus supplement, we cannot specify with certainty all of the particular uses for the net
proceeds to us from this offering. Accordingly, our management will have broad discretion in the application of these proceeds. Pending application of the net proceeds as described above, we intend to
temporarily invest the proceeds in short term, interest-bearing instruments. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=14,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=427778,FOLIO='S-12',FILE='DISK135:[15ZAN1.15ZAN49601]DC49601A.;10',USER='GKIBBE',CD='23-FEB-2015;12:35' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de49601_1_13"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de49601_price_range_of_our_common_stock"> </A>
<A NAME="toc_de49601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PRICE RANGE OF OUR COMMON STOCK    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock has been listed on The NASDAQ Global Market since December&nbsp;3, 2013 under the symbol "XNCR". Prior to that date,
there was no public market for our common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
February&nbsp;20, 2015, the closing price for our common stock as reported on The NASDAQ Global Market was $15.06 per share. The following table sets forth the ranges of high and
low sales prices per share of our common stock as reported on The NASDAQ Global Market for the periods indicated. Such quotations represent inter-dealer prices without retail markup, markdown or
commission and may not necessarily represent actual transactions. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>High </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Low </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Year Ended December&nbsp;31, 2014</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>First Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.41</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.77</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Second Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12.01</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.92</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.06</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fourth Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17.65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Year Ending December&nbsp;31, 2015</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>First Quarter (through February&nbsp;20, 2015)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19.50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13.67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2014, there were 314 stockholders of record of our common stock, which excludes stockholders whose shares were held in nominee or street name by brokers. The
actual number of common stockholders is greater than the number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other
nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=15,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=716466,FOLIO='S-13',FILE='DISK135:[15ZAN1.15ZAN49601]DE49601A.;12',USER='ABEAULI',CD='23-FEB-2015;14:34' -->
<A NAME="page_de49601_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de49601_dividend_policy"> </A>
<A NAME="toc_de49601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  DIVIDEND POLICY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any
future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future. Any future
determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital
requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=16,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=385311,FOLIO='S-14',FILE='DISK135:[15ZAN1.15ZAN49601]DE49601A.;12',USER='ABEAULI',CD='23-FEB-2015;14:34' -->
<A NAME="page_de49601_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de49601_dilution"> </A>
<A NAME="toc_de49601_3"> </A>
<BR></FONT><FONT SIZE=2><B>  DILUTION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investors purchasing shares of our common stock in this offering will experience immediate and substantial dilution in the pro forma
net tangible book value of their shares of common stock. Dilution in pro forma net tangible book value represents the difference between the public offering price per share and the pro forma net
tangible book value per share of our common stock immediately after the offering. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
historical net tangible book value of our common stock as of December&nbsp;31, 2014 was $50.2&nbsp;million, or $1.60 per share. Historical net tangible book value per share of
our common stock represents our total tangible assets (total assets less intangible assets) less total liabilities divided by the number of shares of common stock outstanding as of that date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
giving effect to (1)&nbsp;the issuance of 5,500,000 shares of common stock in this offering and (2)&nbsp;the receipt of the net proceeds from the sale of 5,500,000 shares of
common stock in this offering at an assumed public offering price of $15.06 per share, which is the last reported sale price for our common stock on The NASDAQ Global Market on February&nbsp;20,
2015, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our net tangible book value as of December&nbsp;31, 2014 would have been approximately
$127.5&nbsp;million, or $3.45 per share of common stock. This represents an immediate increase in net tangible book value of $1.85 per share to existing stockholders and an immediate dilution of
$11.61 per share to new investors purchasing our common stock in this offering. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table illustrates this dilution on a per share basis to new investors: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Assumed public offering price per share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15.06</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Historical net tangible book value per share as of December&nbsp;31, 2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.60</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase in net tangible book value per share attributable to new investors purchasing shares in this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.85</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>As adjusted net tangible book value per share after giving effect to this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.45 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution per share to new investors participating in this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11.61</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the underwriters exercise their option in full to purchase an additional 825,000 shares of common stock in this offering, the as adjusted net tangible book value per share after the
offering would be $3.69 per share, the increase in the net tangible book value per share to existing stockholders would be $2.09 per share and the dilution to new investors purchasing our common stock
in this offering would be $11.37 per share. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
above discussion and table are based on 31,434,272 shares of common stock outstanding as of December&nbsp;31, 2014, which does not
include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 2,826,794 shares of common stock issuable upon the exercise of outstanding stock options as of December&nbsp;31, 2014, at a
weighted-average exercise price of $5.12 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 2,583,186 shares of common stock reserved for future issuance under the 2013 Equity Incentive Plan as of December&nbsp;31, 2014; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 517,422 shares of common stock reserved for future issuance under the 2013 Employee Stock Purchase Plan as of December&nbsp;31,
2014. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent that outstanding exercisable options or warrants are exercised, you may experience further dilution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future
operating plans. To </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=17,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=106338,FOLIO='S-15',FILE='DISK135:[15ZAN1.15ZAN49601]DE49601A.;12',USER='ABEAULI',CD='23-FEB-2015;14:34' -->
<A NAME="page_de49601_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
extent that we raise additional capital by issuing equity securities or convertible debt, your ownership will be further diluted. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent that new options are issued under our share-based compensation plans or we issue additional shares of common stock under the ESPP in the future, there will be further
dilution to investors participating in this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=18,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=789167,FOLIO='S-16',FILE='DISK135:[15ZAN1.15ZAN49601]DE49601A.;12',USER='ABEAULI',CD='23-FEB-2015;14:34' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg49601_1_17"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg49601_material_u.s._federal_income_a__mat02797"> </A>
<A NAME="toc_dg49601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MATERIAL U.S. FEDERAL INCOME AND ESTATE TAX CONSEQUENCES<BR>  TO NON-U.S. HOLDERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following discussion describes the material U.S. federal income and estate tax consequences of the acquisition, ownership and
disposition of our common stock acquired in this offering by Non-U.S. Holders (as defined below). This discussion does not address all aspects of U.S. federal income and estate taxes, does not discuss
the potential application of the alternative minimum or Medicare Contribution tax, and does not deal with state, local or non-U.S. tax consequences that may be relevant to Non-U.S. Holders in light of
their particular circumstances, nor does it address U.S. federal tax consequences other than income and estate taxes. Rules different from those described below may apply to certain Non-U.S. Holders
that are subject to special treatment under the Internal Revenue Code of 1986, as amended (the "Code") such as financial institutions, insurance companies, tax-exempt organizations, "foreign
governments," international organizations, broker-dealers and traders in securities, U.S. expatriates, "controlled foreign corporations," "passive foreign investment companies," corporations that
accumulate earnings to avoid U.S. federal income tax, persons that hold our common stock as part of a "straddle," "conversion transaction," or other risk reduction strategy, partnerships and other
pass-through entities, and investors in such pass-through entities or entities that are treated as disregarded entities for U.S. federal income tax purposes (regardless of their places of organization
or formation). Such Non-U.S. Holders are urged to consult their own tax advisors to determine the U.S. federal, state, local and other tax consequences that may
be relevant to them. Furthermore, the discussion below is based upon the provisions of the Code, and Treasury regulations, rulings and judicial decisions thereunder as of the date hereof, and such
authorities may be repealed, revoked or modified, perhaps retroactively, so as to result in U.S. federal income or estate tax consequences different from those discussed below. We have not requested a
ruling from the Internal Revenue Service (the "IRS") with respect to the statements made and the conclusions reached in the following summary. This discussion assumes that the Non-U.S. Holder holds
our common stock as a "capital asset" within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Persons considering the purchase of our common stock pursuant to this offering should consult their own tax advisors concerning the U.S. federal income and estate
tax consequences of acquiring, owning and disposing of our common stock in light of their particular situations as well as any consequences arising under the laws of any other taxing jurisdiction,
including any state, local and non-U.S. tax consequences, and any U.S. federal non-income tax consequences, and the possible application of tax treaties that might change the general provisions
discussed below.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purposes of this discussion, a "Non-U.S. Holder" is, for U.S. federal income tax purposes, a beneficial owner of common stock that is not a U.S. Holder. A "U.S. Holder" means a
beneficial owner of our common stock that is for U.S. federal income tax purposes (a)&nbsp;an individual who is a citizen or resident of the United States, (b)&nbsp;a corporation or other entity
treated as a corporation created or organized in or under the laws of the United States, any state thereof or the District of Columbia, (c)&nbsp;an estate the income of which is subject to U.S.
federal income taxation regardless of its source or (d)&nbsp;a trust if it (1)&nbsp;is subject to the primary supervision of a court within the United States and one or more U.S. persons have the
authority to control all substantial decisions of the trust or (2)&nbsp;has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person. Also, partnerships,
or other entities that are treated as partnerships for U.S. federal income tax purposes (regardless of their place of organization or formation) and entities that are treated as disregarded entities
for U.S. federal income tax purposes (regardless of their place of organization or formation) are not addressed by this discussion and are, therefore, not considered to be Non-U.S. Holders for the
purposes of this discussion. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=19,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=218965,FOLIO='S-17',FILE='DISK135:[15ZAN1.15ZAN49601]DG49601A.;4',USER='JFUSS',CD='23-FEB-2015;08:50' -->
<A NAME="page_dg49601_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Distributions  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the discussion below regarding backup withholding and foreign accounts, distributions, if any, made on our common stock to a
Non-U.S. Holder of our common stock generally will constitute dividends for U.S. tax purposes to the extent made out of our current or accumulated earnings and profits (as determined under U.S.
federal income tax principles) and will be
subject to withholding tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. To obtain a reduced rate of withholding under a treaty, a Non-U.S. Holder generally
will be required to provide us or our paying agent with a properly executed IRS Form&nbsp;W-8BEN, W-BEN-E or other appropriate form, certifying the Non-U.S. Holder's entitlement to benefits under
that treaty. Such form must be provided prior to the payment of dividends and must be updated periodically. In the case of a Non-U.S. Holder that is an entity, Treasury regulations and the relevant
tax treaty provide rules to determine whether, for purposes of determining the applicability of a tax treaty, dividends will be treated as paid to the entity or to those holding an interest in that
entity. If a Non-U.S. Holder holds stock through a financial institution or other agent acting on the holder's behalf, the holder will be required to provide appropriate documentation to such agent.
The holder's agent may then be required to provide certification to us or our paying agent, either directly or through other intermediaries. If you are eligible for a reduced rate of U.S. federal
withholding tax under an income tax treaty, you should consult with your own tax advisor to determine if you are able to obtain a refund or credit of any excess amounts withheld by timely filing an
appropriate claim for a refund with the IRS. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Withholding
tax is generally not imposed on dividends paid to a Non-U.S. Holder that are effectively connected with the Non-U.S. Holder's conduct of a trade or business within the United
States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment that such holder maintains in the United States) if a properly executed IRS
Form&nbsp;W-8ECI, stating that the dividends are so connected, is furnished to us or our paying agent (or, if stock is held through a financial institution or other agent, to such agent). In
general, such effectively connected dividends will be subject to U.S. federal income tax, on a net income basis at the regular graduated rates, unless a specific treaty exemption applies. A Non-U.S.
Holder that is a corporation for U.S. federal income tax purposes that receives effectively connected dividends may also be subject to an additional "branch profits tax," which is imposed, under
certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable treaty) on the corporate Non-U.S. Holder's effectively connected earnings and profits, subject to
certain adjustments. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent distributions on our common stock, if any, exceed our current and accumulated earnings and profits, they will first reduce your adjusted basis in our common stock as a
non-taxable return of capital, but not below zero, and then any excess will be treated as gain and taxed in the same manner as gain realized from a sale or other disposition of common stock as
described in the next section. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Gain on Disposition of Our Common Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the discussion below regarding backup withholding and foreign accounts, a Non-U.S. Holder generally will not be subject to
U.S. federal income tax with respect to gain realized on a sale or other disposition of our common stock unless (a)&nbsp;the gain is effectively connected with a trade or business of such holder in
the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment that such holder maintains in the United States), (b)&nbsp;the Non-U.S. Holder is
a nonresident alien individual and is present in the United States for 183 or more days in the taxable year of the disposition and certain other conditions
are met, or (c)&nbsp;we are or have been a "United States real property holding corporation" within the meaning of Code Section&nbsp;897(c)(2) at any time within the shorter of the five-year
period preceding such disposition or such holder's holding period. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=20,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=425602,FOLIO='S-18',FILE='DISK135:[15ZAN1.15ZAN49601]DG49601A.;4',USER='JFUSS',CD='23-FEB-2015;08:50' -->
<A NAME="page_dg49601_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you are a Non-U.S. Holder described in (a)&nbsp;above, you will be required to pay tax on the net gain derived from the sale at regular graduated U.S. federal income tax rates, and
corporate Non-U.S. Holders described in (a)&nbsp;above may be subject to the additional branch profits tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. If
you are an individual Non-U.S. Holder described in (b)&nbsp;above, you will be required to pay a flat 30% tax on the gain derived from the sale, which gain may be offset by U.S. source capital
losses (even though you are not considered a resident of the United States). With respect to (c)&nbsp;above, in general, we would be a United States real property holding corporation if interests in
U.S. real estate constituted (by fair market value) at least half of our total worldwide real property interests plus business assets. We believe that we are not, and do not anticipate becoming, a
United States real property holding corporation; however, there can be no assurance that we will not become a U.S. real property holding corporation in the future. Even if we are treated as a U.S.
real property holding corporation, such treatment will not cause gain realized by a Non-U.S. Holder on a disposition of our common stock to be subject to U.S. federal income tax so long as
(1)&nbsp;the Non-U.S. Holder owned, directly, indirectly and constructively, no more than five percent of our common stock at all times within the shorter of (i)&nbsp;the five-year period
preceding the disposition or (ii)&nbsp;the holder's holding period and (2)&nbsp;our common stock is regularly traded on an established securities market. There can be no assurance that our common
stock will continue to qualify as regularly traded on an established securities market. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Information Reporting Requirements and Backup Withholding  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally, we or certain financial middlemen must report information to the IRS with respect to any dividends we pay on our common
stock including the amount of any such dividends, the name and address of the recipient, and the amount, if any, of tax withheld. A similar report is sent to the holder to whom any such dividends are
paid. Pursuant to tax treaties or certain other agreements, the IRS may make its reports available to tax authorities in the recipient's country of residence. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends
paid by us (or certain financial middlemen) to a Non-U.S. Holder may also be subject to U.S. backup withholding. U.S. backup withholding generally will not apply to a Non-U.S.
Holder who provides a properly executed IRS Form&nbsp;W-8BEN or Form&nbsp;W-8BEN-E, as applicable, or otherwise establishes an exemption. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
current U.S. federal income tax law, U.S. information reporting and backup withholding requirements generally will apply to the proceeds of a disposition of our common stock
effected by or through a U.S. office of any broker, U.S. or non-U.S., unless the holder provides a properly executed IRS Form&nbsp;W-8BEN or IRS Form&nbsp;W-8BEN-E, as applicable, or otherwise
establishes an exemption. Generally, U.S. information reporting and backup withholding requirements will not apply to a payment of disposition proceeds to a Non-U.S. Holder where the transaction is
considered effected outside the United States through a non-U.S. office of a non-U.S. broker. Information reporting and backup withholding requirements may, however, apply to a payment of disposition
proceeds if the broker has actual knowledge, or reason to know, that the holder is, in fact, a U.S. person. For information reporting purposes, certain brokers with substantial U.S. ownership or
operations will generally be treated in a manner similar to U.S. brokers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
backup withholding is applied to you, you should consult with your own tax advisor to determine if you are able to obtain a tax refund or credit with respect to the amount withheld. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign Accounts  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A U.S. federal withholding tax of 30% may apply to dividends and the gross proceeds of a disposition of our common stock paid to a
foreign financial institution (as specifically defined by applicable rules), including when the foreign financial institution holds our common stock on behalf of a Non-U.S. Holder, unless such
institution enters into an agreement with the U.S. government to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=21,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=731767,FOLIO='S-19',FILE='DISK135:[15ZAN1.15ZAN49601]DG49601A.;4',USER='JFUSS',CD='23-FEB-2015;08:50' -->
<A NAME="page_dg49601_1_20"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>withhold
on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding U.S. account holders of such institution (which includes certain equity holders of
such institution, as well as certain account holders that are foreign entities with U.S. owners). This U.S. federal withholding tax of 30% will also apply to dividends and the gross proceeds of a
disposition of our common stock paid to a non-financial foreign entity unless such entity provides the withholding agent with either a certification that it does not have any substantial direct or
indirect U.S. owners or provides information regarding direct and indirect U.S. owners of the entity. The withholding tax described above will not apply if the foreign financial institution or
non-financial foreign entity otherwise qualifies for an exemption from the rules. An intergovernmental agreement between the United States and an applicable foreign country may modify these
requirements. Under certain circumstances, a Non-U.S. Holder might be eligible for refunds or credits of such taxes. Holders are
encouraged to consult with their own tax advisors regarding the possible implications of this withholding tax on their investment in our common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
general, the withholding provisions described above currently apply to payments of dividends and will apply to payments of gross proceeds from a sale or other disposition of common
stock on or after January&nbsp;1, 2017. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Federal Estate Tax  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An individual who at the time of death is not a citizen or resident of the United States and who is treated as the owner of, or has
made certain lifetime transfers of, an interest in our common stock will be required to include the value thereof in his or her taxable estate for U.S. federal estate tax purposes, and may be subject
to U.S. federal estate tax unless an applicable estate tax treaty provides otherwise. The test for whether an individual is a resident of the United States for federal estate tax purposes differs from
the test used for U.S. federal income tax purposes. Some individuals, therefore, may be "Non-U.S. Holders" for U.S. federal income tax purposes, but not for U.S. federal estate tax purposes, and vice
versa. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EACH
PROSPECTIVE INVESTOR SHOULD CONSULT HIS, HER OR ITS OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE
CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAW, AS WELL AS TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL, NON-U.S. OR U.S. FEDERAL NON-INCOME TAX LAWS. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=22,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=728747,FOLIO='S-20',FILE='DISK135:[15ZAN1.15ZAN49601]DG49601A.;4',USER='JFUSS',CD='23-FEB-2015;08:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di49601_1_21"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di49601_underwriting"> </A>
<A NAME="toc_di49601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  UNDERWRITING    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Leerink Partners&nbsp;LLC is acting as representative of each of the underwriters named below and as sole bookrunning manager for
this offering. Subject to the terms and conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has
agreed, severally and not jointly, to purchase from us, the number of shares of common stock set forth opposite its name below. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:43pt;"><FONT SIZE=1><B>Underwriter

<!-- COMMAND=ADD_SCROPPEDRULE,43pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leerink Partners&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Wedbush Securities Inc.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Oppenheimer &amp; Co. Inc.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed, severally and not jointly, to purchase all of the shares sold under the
underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the non-defaulting underwriters may be
increased or the underwriting agreement may be terminated. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to
make in respect of those liabilities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel, including the
validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officers' certificates and legal opinions. The underwriters reserve the
right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Commissions and Discounts  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The representative has advised us that the underwriters propose initially to offer the shares to the public at the public offering
price set forth on the cover of this prospectus and to dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. After the initial offering, the public offering price,
concession or any other term of the offering may be changed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table shows the public offering price, underwriting discount and proceeds before expenses to us. The information assumes either no exercise or full exercise by the
underwriters of their over-allotment option to purchase additional shares of our common stock. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Per<BR>
Share </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Without<BR>
Option </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>With<BR>
Option </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Public offering price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting discount</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds, before expenses, to us</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately $500,000. We also have
agreed to reimburse the underwriters for up to $35,000 for their FINRA counsel fee. In accordance with FINRA Rule&nbsp;5110, this reimbursed fee is deemed underwriting compensation for this
offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=23,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=426194,FOLIO='S-21',FILE='DISK135:[15ZAN1.15ZAN49601]DI49601A.;11',USER='JFUSS',CD='23-FEB-2015;13:29' -->
<A NAME="page_di49601_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Option to Purchase Additional Shares  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have granted an option to the underwriters, exercisable for 30&nbsp;days after the date of this prospectus, to purchase up to
825,000 additional shares at the public offering price, less the underwriting discount. If the underwriters exercise this option, each will be obligated, subject to conditions contained in the
underwriting agreement, to purchase a number of additional
shares proportionate to that underwriter's initial amount reflected in the above table. The option may be exercised only to cover any over-allotments of common stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


No Sales of Similar Securities  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have agreed that we will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, or file with the
Securities and Exchange Commission a registration statement under the Securities Act of 1933, as amended (the Securities Act) relating to, any shares of our common stock or securities convertible into
or exchangeable or exercisable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, disposition or filing, without the prior written consent of the
representative for a period of 90&nbsp;days after the date of this prospectus supplement except (a)&nbsp;issuances pursuant to the conversion or exchange of convertible or exchangeable securities
outstanding on the date hereof or the exercise of warrants or options outstanding on the date hereof, (b)&nbsp;grants of employee stock options pursuant to our existing plans or (c)&nbsp;issuances
pursuant to the exercise of such employee options or issuances in connection with any acquisition, collaboration, merger, licensing or other joint venture or strategic transaction involving us,
provided that, in the case of clause&nbsp;(c), such issuances shall not be greater than 5% of our total outstanding shares immediately following the closing of this offering. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
executive officers and directors have agreed that they will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any shares of our common stock
or securities convertible into or exchangeable or exercisable for any shares of our common stock, enter into a transaction that would have the same effect, or enter into any swap, hedge or other
arrangement that transfers, in whole or in part, any of the economic consequences of ownership of our common stock, whether any of these transactions are to be settled by delivery of our common stock
or other securities, in cash or otherwise, or publicly disclose the intention to make any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement,
without, in each case, the prior written consent of the representative, for a period of 90&nbsp;days after the date of this prospectus, subject to limited exceptions. In addition, certain of our
executive officers have been granted exceptions to sell shares of our common stock acquired upon the exercise of options to purchase our common stock, solely to cover the exercise price and tax
obligations in connection with such options, or pursuant to our Employee Stock Purchase Plan, in an aggregate amount of up to 116,704 shares of our common stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


NASDAQ Global Market Listing  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is listed on The NASDAQ Global Market under the symbol "XNCR." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Price Stabilization, Short Positions and Penalty Bids  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group members from bidding for and
purchasing our common stock. However, the representative may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the offering, the underwriters may purchase and sell our common stock in the open market. These transactions may include short sales, purchases on the open market to
cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=24,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=101709,FOLIO='S-22',FILE='DISK135:[15ZAN1.15ZAN49601]DI49601A.;11',USER='JFUSS',CD='23-FEB-2015;13:29' -->
<A NAME="page_di49601_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>underwriters
of a greater number of shares than they are required to purchase in the offering. "Covered" short sales are sales made in an amount not greater than the underwriters' option described
above. The underwriters may close out any covered short position by either exercising their option or purchasing shares in the open market. In determining the source of shares to close out the covered
short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the
option granted to them. "Naked" short sales are sales in excess of such option. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position
is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely affect
investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriters in the open market prior to the closing of
the offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the
representative has repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Similar
to other purchase transactions, the underwriters' purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock
or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The
underwriters
may conduct these transactions on The NASDAQ Global Market, in the over-the-counter market or otherwise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of
our common stock. In addition, neither we nor any of the underwriters make any representation that the representative will engage in these transactions or that these transactions, once commenced, will
not be discontinued without notice. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Electronic Distribution  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means,
such as e-mail. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Relationships  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some of the underwriters and their affiliates may in the future engage in investment banking and other commercial dealings in the
ordinary course of business with us or our affiliates. They may in the future receive customary fees and commissions for these transactions. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of investments and actively trade debt and equity
securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment
recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short
positions in such securities and instruments. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=25,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=163812,FOLIO='S-23',FILE='DISK135:[15ZAN1.15ZAN49601]DI49601A.;11',USER='JFUSS',CD='23-FEB-2015;13:29' -->
<A NAME="page_di49601_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One
of our directors, Mr.&nbsp;Jonathan Fleming, is also a member of the Board of Managers of Leerink Holdings&nbsp;LLC and a trustee of Leerink Swann Massachusetts Business Trust,
which are affiliates of Leerink Partners&nbsp;LLC, the representative of the underwriters in this offering. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Selling Restrictions  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in the European Economic Area  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In relation to each Member State of the European Economic Area (each, a "Relevant Member State"), no offer of shares may be made to the
public in that Relevant Member State other than: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;&nbsp;&nbsp;&nbsp;to
any legal entity which is a qualified investor as defined in the Prospectus Directive; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;&nbsp;&nbsp;&nbsp;to
fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than
qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representative; or </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.&nbsp;&nbsp;&nbsp;&nbsp;in
any other circumstances falling within Article&nbsp;3(2) of the Prospectus Directive, provided that no such offer of shares shall require the Company or the
representative to publish a prospectus pursuant to Article&nbsp;3 of the Prospectus Directive or supplement a prospectus pursuant to Article&nbsp;16 of the Prospectus Directive. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
person in a Relevant Member State who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed that it is a "qualified
investor" within the meaning of the law in that Relevant Member State implementing Article&nbsp;2(1)(e) of the Prospectus Directive. In the case of any shares being offered to a financial
intermediary as that term is used in Article&nbsp;3(2) of the Prospectus Directive, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares
acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may
give rise to an offer of any shares to the public other than their offer or resale in a Relevant Member State to qualified investors as so defined or in circumstances in which the prior consent of the
representative has been obtained to each such proposed offer or resale. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We,
the representative and each of our and the representative's affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus has been prepared on the basis that any offer of shares in any Relevant Member State will be made pursuant to an exemption under the Prospectus Directive from the
requirement to publish a prospectus for offers of shares. Accordingly any person making or intending to make an offer in that Relevant Member State of shares which are the subject of the offering
contemplated in this prospectus may only do so in circumstances in which no obligation arises for the company or any of the underwriters to publish a prospectus pursuant to Article&nbsp;3 of the
Prospectus Directive in relation to such offer. Neither the company nor the underwriters have authorized, nor do they authorize, the making of any offer of shares in circumstances in which an
obligation arises for the company or the underwriters to publish a prospectus for such offer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purpose of the above provisions, the expression "an offer to the public" in relation to any shares in any Relevant Member State means the communication in any form and by any
means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase or subscribe the shares, as the same may be varied in the
Relevant Member State by any measure implementing the Prospectus Directive in the Relevant Member State and the expression "Prospectus Directive" means Directive 2003/71/EC (including the 2010 PD
Amending Directive, to the extent implemented in the Relevant Member States) and includes any relevant implementing measure in the Relevant Member State and the expression "2010 PD Amending Directive"
means Directive 2010/73/EU. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=26,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=349584,FOLIO='S-24',FILE='DISK135:[15ZAN1.15ZAN49601]DI49601A.;11',USER='JFUSS',CD='23-FEB-2015;13:29' -->
<A NAME="page_di49601_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="DI_LM"></A>LEGAL MATTERS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The validity of the shares of common stock being offered by this prospectus will be passed upon for us by Cooley&nbsp;LLP, San Diego,
California. The underwriters are being represented by Davis Polk&nbsp;&amp; Wardwell&nbsp;LLP, Menlo Park, California. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="DI_EX"></A>EXPERTS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financial statements and schedule as of December&nbsp;31, 2014 and 2013 and for each of the years in the three-year period ended
December&nbsp;31, 2014 incorporated by reference in this prospectus supplement and the accompanying prospectus have been so incorporated in reliance on the reports of BDO USA,&nbsp;LLP, an
independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="DI_WH"></A>WHERE YOU CAN FIND MORE INFORMATION  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus supplement and the accompanying prospectus are part of the registration statement on Form&nbsp;S-3 we filed with the
SEC under the Securities Act and do not contain all the information set forth in the registration statement. Whenever a reference is made in this prospectus supplement or the accompanying prospectus
to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the
reports or other documents incorporated by reference in this prospectus supplement and the accompanying prospectus for a copy of such contract, agreement or other document. Because we are subject to
the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC's website at http://www.sec.gov. You may also read and copy any document we file at the SEC's Public Reference Room at 100&nbsp;F Street, N.E., Washington, D.C.
20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the Public Reference Room. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="DI_IN"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to "incorporate by reference" the information we file with it, which means that we can disclose important information
to you by referring you to those
documents. Information incorporated by reference is part of this prospectus supplement and the accompanying prospectus. Later information filed with the SEC will update and supersede this information. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
incorporate by reference the documents listed below and any future filings made with the SEC under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this
prospectus supplement until the termination of the offering of the shares covered by this prospectus supplement (other than current reports furnished under Item&nbsp;2.02 or Item&nbsp;7.01 of
Form&nbsp;8-K and exhibits filed on such form that are related to such items):</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2014 filed with the SEC on February&nbsp;20,
2015 and amendments thereto; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our Current Reports on Form&nbsp;8-K (other than information furnished rather than filed) filed with the SEC on January&nbsp;5,
2015 and January&nbsp;26, 2015; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the description of our common stock which is registered under Section&nbsp;12 of the Exchange Act, in our registration statement on
Form&nbsp;8-A, filed with the SEC on November&nbsp;7, 2013, including any amendments or reports filed for the purpose of updating such description. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=27,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=5809,FOLIO='S-25',FILE='DISK135:[15ZAN1.15ZAN49601]DI49601A.;11',USER='JFUSS',CD='23-FEB-2015;13:29' -->
<A NAME="page_di49601_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may request a copy of these filings at no cost, by contacting us at the following address or telephone number: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Investor
Relations<BR>
Xencor,&nbsp;Inc.<BR>
111 West Lemon Avenue<BR>
Monrovia, CA 91016<BR>
(626)&nbsp;305-5900 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
accordance with Rule&nbsp;412 of the Securities Act, any statement contained in a document incorporated by reference herein shall be deemed modified or superseded to the extent that
a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=28,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=272751,FOLIO='S-26',FILE='DISK135:[15ZAN1.15ZAN49601]DI49601A.;11',USER='JFUSS',CD='23-FEB-2015;13:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g585699.jpg" ALT="LOGO" WIDTH="280" HEIGHT="75">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>$150,000,000  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Common Stock<BR>
Preferred Stock<BR>
Debt Securities<BR>
Warrants  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time, we may offer up to $</FONT><FONT SIZE=2><B>150,000,000</B></FONT><FONT SIZE=2> of any combination of the securities described
in this prospectus in one or more offerings. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder,
including any applicable antidilution provisions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus provides a general description of the securities we may offer. Each time we offer securities, we will provide specific terms of the securities offered in a supplement to
this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus
may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as
well as any documents incorporated by reference, before you invest in any of the securities being offered. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>This prospectus may not be used to consummate a sale of any securities unless accompanied by a prospectus supplement.</B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
common stock is traded on the Nasdaq Global Market under the symbol "XNCR." On January&nbsp;22, 2015, the last reported sales price of our common stock was $17.00 per share. The
applicable prospectus supplement will contain information, where applicable, as to any other listing on the Nasdaq Global Market or any securities market or other exchange of the securities, if any,
covered by the prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will sell these securities directly to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For
additional information on the methods of sale, you should refer to the section entitled "Plan of Distribution" in this prospectus. If any agents or underwriters are involved in the sale of any
securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts or over-allotment options will be set
forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=3><B><I>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties
described under the heading "Risk Factors" contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are
incorporated by reference into this prospectus.</I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=3>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE
SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>The
date of this prospectus is January&nbsp;23, 2015. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=29,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=580912,FOLIO='blank',FILE='DISK104:[15ZAN2.15ZAN49602]BC49602A.;8',USER='CHE108067',CD='22-FEB-2015;04:13' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG49602A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg49602_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG49602_TOC"></A> </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#bi49602_about_this_prospectus"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#bi49602_about_this_prospectus"><FONT SIZE=2>i</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ca49602_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SUMMARY</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ca49602_summary"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da49602_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da49602_risk_factors"><FONT SIZE=2>4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da49602_special_note_regarding_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da49602_special_note_regarding_forward-looking_statements"><FONT SIZE=2>4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da49602_ratio_of_earnings_to_fixed_charges"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RATIO OF EARNINGS TO FIXED CHARGES</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da49602_ratio_of_earnings_to_fixed_charges"><FONT SIZE=2>4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da49602_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da49602_use_of_proceeds"><FONT SIZE=2>5</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da49602_description_of_capital_stock"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da49602_description_of_capital_stock"><FONT SIZE=2>5</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc49602_description_of_debt_securities"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF DEBT SECURITIES</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc49602_description_of_debt_securities"><FONT SIZE=2>10</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de49602_description_of_warrants"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF WARRANTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de49602_description_of_warrants"><FONT SIZE=2>17</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de49602_legal_ownership_of_securities"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL OWNERSHIP OF SECURITIES</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de49602_legal_ownership_of_securities"><FONT SIZE=2>20</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg49602_plan_of_distribution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg49602_plan_of_distribution"><FONT SIZE=2>23</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg49602_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg49602_legal_matters"><FONT SIZE=2>25</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg49602_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg49602_experts"><FONT SIZE=2>25</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg49602_where_you_can_find_more_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg49602_where_you_can_find_more_information"><FONT SIZE=2>25</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg49602_incorporation_of_certain_information_by_reference"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg49602_incorporation_of_certain_information_by_reference"><FONT SIZE=2>26</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#DG_DIS"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DISCLOSURE OF COMMISSION'S POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITY</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#DG_DIS"><FONT SIZE=2>27</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=30,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=107801,FOLIO='blank',FILE='DISK104:[15ZAN2.15ZAN49602]BG49602A.;4',USER='CHE108062',CD='22-FEB-2015;09:04' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bi49602_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bi49602_about_this_prospectus"> </A>
<A NAME="toc_bi49602_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THIS PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is a part of a registration statement on Form&nbsp;S-3 that we filed with the Securities and Exchange Commission, or
SEC, utilizing a "shelf" registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one or more offerings up to a total
aggregate offering price of $150,000,000. This prospectus provides you with a general description of the securities we may offer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
time we sell securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering. We may also authorize
one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we
may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should
read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the heading
"Incorporation of Certain Information by Reference," before investing in any of the securities offered. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
we, nor any agent, underwriter or dealer has authorized any person to give any information or to make any representation other than those contained or incorporated by reference
in this prospectus, any applicable prospectus supplement or any related free writing prospectus prepared by or on behalf of us or to which we have referred you. This prospectus, any applicable
supplement to this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to
which they relate, nor do this prospectus, any applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy
securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to
the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even
though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All
of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as
exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading "Where You Can Find More Information." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=31,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=562751,FOLIO='i',FILE='DISK104:[15ZAN2.15ZAN49602]BI49602A.;2',USER='CHE108054',CD='22-FEB-2015;03:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ca49602_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ca49602_summary"> </A>
<A NAME="toc_ca49602_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This summary highlights selected information from this prospectus and does not contain all of the information that you need to consider
in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in
our securities discussed under the heading
"Risk Factors" contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this
prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which
this prospectus is a part. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
the context requires otherwise, references in this prospectus to "Xencor," "we," "us" and "our" refer to Xencor,&nbsp;Inc. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ca49602_company_overview"> </A>
<A NAME="toc_ca49602_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Company Overview    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases,
asthma and allergic diseases, and cancer. Currently, eight candidates are in clinical development internally and with partners that have been engineered with our XmAb&reg; technology. Our
internally-discovered programs include XmAb5871, in a Phase&nbsp;1b/2a clinical trial for the treatment of rheumatoid arthritis and is in preparation for a clinical trial in IgG4-related disease,
XmAb7195 in Phase&nbsp;1a development for the treatment of asthma, and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase&nbsp;2 clinical trials for the treatment of acute
lymphoblastic leukemia and non-Hodgkin lymphoma. Our XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic
action. Our partners include Merck, Janssen R&amp;D&nbsp;LLC, Alexion and Boehringer Ingelheim. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ca49602_corporate_information"> </A>
<A NAME="toc_ca49602_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Corporate Information    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We were incorporated in California in August 1997 under the name Xencor,&nbsp;Inc. In September 2004, we reincorporated in the state
of Delaware under the name Xencor,&nbsp;Inc. Our principal executive offices are located at 111 West Lemon Avenue, Monrovia, California, 91016, and our telephone number is (626)&nbsp;305-5900. Our
corporate website address is www.xencor.com. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is
an inactive textual reference only. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus,
including logos, artwork and other visual displays, may appear without the &reg; or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will
not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other
companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ca49602_the_securities_we_may_offer"> </A>
<A NAME="toc_ca49602_4"> </A>
<BR></FONT><FONT SIZE=2><B>  The Securities We May Offer    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may offer shares of our common stock and preferred stock, various series of debt securities and warrants to purchase any of such
securities, up to a total aggregate offering price of $150,000,000 from time to time in one or more offerings under this prospectus, together with any applicable prospectus supplement and any related
free writing prospectus, at prices and on terms to be determined by market conditions at the time of the relevant offering. This prospectus provides you with a general description of the securities we
may offer. Each time we offer a type or series of securities </FONT></P>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=32,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=491348,FOLIO='1',FILE='DISK104:[15ZAN2.15ZAN49602]CA49602A.;3',USER='CHE108069',CD='22-FEB-2015;03:15' -->
<A NAME="page_ca49602_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">


<P style="font-family:times;"><FONT SIZE=2>under
this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent
applicable:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> designation or classification; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> aggregate principal amount or aggregate offering price; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> maturity, if applicable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> original issue discount, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> rates and times of payment of interest or dividends, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> redemption, conversion, exchange or sinking fund terms, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or
exchange prices or rates and in the securities or other property receivable upon conversion or exchange; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ranking, if applicable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictive covenants, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> voting or other rights, if any; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> important U.S. federal income tax considerations. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or
in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time
of the effectiveness of the registration statement of which this prospectus is a part. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.</B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may sell the securities directly to investors or through underwriters, dealers or agents. We, and our underwriters or agents, reserve the right to accept or reject all or part of any
proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in the applicable prospectus supplement:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the names of those underwriters or agents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> applicable fees, discounts and commissions to be paid to them; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> details regarding over-allotment options, if any; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the estimated net proceeds to us. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common Stock.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We may issue shares of our common stock from time to time. Holders of our common stock are entitled to one vote
per share for the
election of directors and on all other matters that require stockholder approval. Subject to any preferential rights of any then outstanding preferred stock, in the event of our liquidation,
dissolution or winding up, holders of our common stock are entitled to share ratably in the assets remaining after payment of liabilities and the liquidation preferences of any then outstanding
preferred stock. Our common stock does not carry any preemptive rights enabling a holder to subscribe for, or receive shares of, any class of our common stock or any other securities convertible into
shares of any class of our common stock, or any redemption rights. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred Stock.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We may issue shares of our preferred stock from time to time, in one or more series. Under our certificate of
incorporation, our
board of directors has the authority, without further action by stockholders, to designate up to 10,000,000 shares of preferred stock in one or more series </FONT></P>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=33,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=11953,FOLIO='2',FILE='DISK104:[15ZAN2.15ZAN49602]CA49602A.;3',USER='CHE108069',CD='22-FEB-2015;03:15' -->
<A NAME="page_ca49602_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;border:#000000 solid 1pt;padding-top:12pt;padding-right:12pt;padding-bottom:1pt;padding-left:12pt;">


<P style="font-family:times;"><FONT SIZE=2>and
to fix the rights, preferences, privileges, qualifications and restrictions granted to or imposed upon the preferred stock, including dividend rights, conversion rights, voting rights, rights and
terms of redemption, liquidation preference and sinking fund terms, any or all of which may be greater than the rights of the common stock. To date, none of the 10,000,000 authorized shares of
preferred stock have been designated by our board of directors. Convertible preferred stock will be convertible into our common stock or exchangeable for our other securities. Conversion may be
mandatory or at the option of the holders of our preferred stock and would be at prescribed conversion rates. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will fix the rights, preferences, privileges, qualifications and restrictions of the preferred stock of each series that we sell under this prospectus and applicable prospectus
supplements in the certificate
of designation relating to that series. We will incorporate by reference into the registration statement of which this prospectus is a part the form of any certificate of designation that describes
the terms of the series of preferred stock we are offering before the issuance of the related series of preferred stock. We urge you to read the prospectus supplements (and any related free writing
prospectus that we may authorize to be provided to you) related to the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the
applicable series of preferred stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Debt Securities.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or
as senior or
subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be subordinate and junior in right
of payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible debt securities will be convertible into our common stock or
preferred stock. Conversion may be mandatory or at the holder's option and would be at prescribed conversion rates. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
debt securities will be issued under one or more documents called indentures, which are contracts between us and a national banking association or other eligible party, as trustee.
In this prospectus, we have summarized certain general features of the debt securities. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may
authorize to be provided to you) related to the series of debt securities being offered, as well as the complete indentures that contain the terms of the debt securities. A form of indenture has been
filed as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered
will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrants.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series.
We may issue warrants
independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. In this prospectus, we have summarized
certain general features of the warrants. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to
the particular series of warrants being offered, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants. Forms of the warrant agreements and forms
of warrant certificates containing the terms of the warrants being offered have been filed as exhibits to the registration statement of which this prospectus is a part, and supplemental warrant
agreements and forms of warrant certificates will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file
with the SEC. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will evidence each series of warrants by warrant certificates that we will issue. Warrants may be issued under an applicable warrant agreement that we enter into with a warrant agent.
We will indicate
the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of warrants being offered. </FONT></P>
 <p style="font-family:times;"><font style="font-size:1pt;line-height:1pt;">&nbsp;</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=34,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=623028,FOLIO='3',FILE='DISK104:[15ZAN2.15ZAN49602]CA49602A.;3',USER='CHE108069',CD='22-FEB-2015;03:15' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da49602_1_4"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da49602_risk_factors"> </A>
<A NAME="toc_da49602_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described under the
heading "Risk Factors" contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in our Annual Report on Form&nbsp;10-K for the year ended
December&nbsp;31, 2013, as updated by our annual, quarterly and other reports and documents that are incorporated by reference into this prospectus, before deciding whether to purchase any of the
securities being registered pursuant to the registration statement of which this prospectus is a part. Each of the risk factors could adversely affect our business, operating results and financial
condition, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks
not presently known to us or that we currently believe are immaterial may also significantly impair our business operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da49602_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_da49602_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus, each prospectus supplement and the information incorporated by reference in this prospectus and each prospectus
supplement contain forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act of 1934, as amended, or the Exchange Act, that
involve a number of risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors
currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes
discussed in the forward-looking statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forward-looking
statements can be identified by the use of forward-looking words such as "believes," "expects," "hopes," "may," "will," "plan," "intends," "estimates," "could," "should,"
"would," "continue," "seeks," "pro forma," or "anticipates," or other similar words (including their use in the negative), or by discussions of future matters such as the development of new products,
technology enhancements, possible collaborations and other statements that are not historical. These statements include but are not limited to statements under the captions "Business," "Risk Factors"
and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and in other sections incorporated by reference from our Annual Report on Form&nbsp;10-K and Quarterly
Reports on Form&nbsp;10-Q, as applicable, as well as our other filings with the SEC. You should be aware that the occurrence of any of the events discussed under the heading "Risk Factors" in any
applicable prospectus supplement and any documents incorporated by reference herein or therein could substantially harm our business, operating results and financial condition and that if any of these
events occurs, it could adversely affect the value of an investment in our securities. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
cautionary statements made in this prospectus are intended to be applicable to all related forward-looking statements wherever they may appear in this prospectus or in any prospectus
supplement or any documents incorporated by reference herein or therein. We urge you not to place undue reliance on these forward-looking statements, which speak only as of the date they are made.
Except as required by law, we assume no obligation to update our forward-looking statements, even if new information becomes available in the future. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da49602_ratio_of_earnings_to_fixed_charges"> </A>
<A NAME="toc_da49602_3"> </A>
<BR></FONT><FONT SIZE=2><B>  RATIO OF EARNINGS TO FIXED CHARGES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth our ratio of earnings to fixed charges and the ratio of our combined fixed charges and preference
dividends to earnings for each of the periods indicated. The following table is qualified by the more detailed information appearing in the computation table set forth in Exhibit&nbsp;12.1 to the
registration statement of which this prospectus is part
and the historical financial statements, including the notes to those financial statements, incorporated by reference in this </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=35,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=890365,FOLIO='4',FILE='DISK104:[15ZAN2.15ZAN49602]DA49602A.;4',USER='CHE106812',CD='22-FEB-2015;05:04' -->
<A NAME="page_da49602_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>prospectus.
We have paid no dividends on preferred shares during the periods indicated. Therefore, the ratios of earnings to combined fixed charges and preferred dividends are the same as the ratios
of earnings to fixed charges. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Nine<BR>
Months<BR>
Ended<BR>
September&nbsp;30,<BR>
2014 </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2011 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2012 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ratio of earnings to fixed charges</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ratio of combined fixed charges and preference dividends to earnings</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of computing the ratio of earnings to fixed charges and the ratio of our combined fixed charges and preference dividends to earnings, earnings consist of income (loss) from
continuing operations before income taxes plus fixed charges. Fixed charges consist of interest expense on indebtedness and an estimate of the interest within rental expense. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
did not record earnings for any of the years ended December&nbsp;31, 2013, 2012 and 2011 or the nine months ended September&nbsp;30, 2014. Accordingly, our earnings were
insufficient to cover fixed charges for such periods and we are unable to disclose a ratio of earnings to fixed charges for such periods. The dollar amount of the deficiency in earnings available for
fixed charges for the years ended December&nbsp;31, 2013, 2012 and 2011 and the nine months ended September&nbsp;30, 2014 was approximately $60.3&nbsp;million, $8.6&nbsp;million,
$11.2&nbsp;million and $15.1&nbsp;million, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da49602_use_of_proceeds"> </A>
<A NAME="toc_da49602_4"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Except as described in
any prospectus supplement or any related
free writing prospectus that we may authorize to be provided to you, we currently intend to use the net proceeds from the sale of the securities offered hereby for general corporate purposes, which
may include research and development, capital expenditures, working capital and general and administrative expenses. We may also use a portion of the net proceeds to acquire or invest in businesses,
products and technologies that are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus. We will
set forth in the applicable prospectus supplement or free writing prospectus our intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus supplement
or free writing prospectus. Pending these uses, we intend to invest the net proceeds primarily in a money market mutual fund with a large financial institution. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da49602_description_of_capital_stock"> </A>
<A NAME="toc_da49602_5"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF CAPITAL STOCK    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of the date of this prospectus, our amended and restated certificate of incorporation authorizes us to issue 200,000,000 shares of
common stock, par value $0.01 per share and 10,000,000 shares of preferred stock, par value $0.01 per share. As of January&nbsp;22, 2015, 31,443,556 shares of common stock were outstanding and no
shares of preferred stock were outstanding. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following summary describes the material terms of our capital stock and the registration rights under our Investor Rights Agreement. The descriptions of capital stock and the
registration rights under our Investor Rights Agreement are qualified by reference to our amended and restated certificate of incorporation, our amended and restated bylaws and our Investor Rights
Agreement, which are incorporated by reference as exhibits into the registration statement of which this prospectus is a part. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=36,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=614511,FOLIO='5',FILE='DISK104:[15ZAN2.15ZAN49602]DA49602A.;4',USER='CHE106812',CD='22-FEB-2015;05:04' -->
<A NAME="page_da49602_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Common Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Voting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders,
including the
election of directors, and does not have cumulative voting rights. Accordingly, the holders of a majority of the shares of our common stock entitled to vote in any election of directors can elect all
of the directors standing for election. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to preferences that may be applicable to any then-outstanding preferred stock, the holders of common stock are
entitled to receive
dividends, if any, as may be declared from time to time by our Board of Directors out of legally available funds. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liquidation.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event of our liquidation, dissolution or winding-up, holders of our common stock will be entitled to share ratably
in the net
assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders
of any outstanding shares of preferred stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rights and Preferences.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Holders of our common stock have no preemptive, conversion or subscription rights, and there are no redemption
or sinking
fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of
shares of any series of our preferred stock that we may designate and issue in the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fully Paid and nonassessable.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;All of our outstanding shares of common stock are fully paid and nonassessable. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preferred Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under our amended and restated certificate of incorporation, our board of directors has the authority, without further action by
stockholders, to designate up to 10,000,000 shares of preferred stock in one or more series and to fix or alter, from time to time, the designations, powers and rights of each series of preferred
stock and the qualifications, limitations or restrictions of any series of preferred stock, including dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption
(including sinking fund provisions), redemption price or prices, and the
liquidation preference of any wholly unissued series of preferred stock, any or all of which may be greater than the rights of the common stock, and to establish the number of shares constituting any
such series. To date, none of the 10,000,000 authorized shares of preferred stock have been designated by our board of directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors will fix the rights, preferences, privileges, qualifications and restrictions of the preferred stock of each series that we sell under this prospectus and any
applicable prospectus supplements in the certificate of designation relating to each such series. We will incorporate by reference as an exhibit to the registration statement of which this prospectus
is a part or as an exhibit to one or more Current Reports on Form&nbsp;8-K, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering
before the issuance of the related series of preferred stock. This description will include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the title and stated value; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of shares we are offering; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the liquidation preference per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the purchase price per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the dividend rate per share, dividend period, payment date or dates and method of calculation for dividends; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=37,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=201628,FOLIO='6',FILE='DISK104:[15ZAN2.15ZAN49602]DA49602A.;4',USER='CHE106812',CD='22-FEB-2015;05:04' -->
<A NAME="page_da49602_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our right, if any, to defer payment of dividends and the maximum length of any such deferral period; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the procedures for any auction and remarketing, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the provisions for a sinking fund, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and
repurchase rights; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any listing of the preferred stock on any securities exchange or market; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the preferred stock will be convertible into our common stock or other securities of ours, including warrants, and, if
applicable, the conversion price, or how it will be calculated, and under what circumstances and the mechanism by which it may be adjusted, and the conversion period; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the preferred stock will be exchangeable into debt securities or other securities of ours, and, if applicable, the exchange
price, or how it will be calculated, and under what circumstances it may be adjusted, and the exchange period; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> voting rights, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> preemptive rights, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions on transfer, sale or other assignment, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether interests in the preferred stock will be represented by depositary shares; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a discussion of any material or special U.S. federal income tax considerations applicable to the preferred stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our
affairs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any limitations on issuances of any class or series of preferred stock ranking senior to or on parity with the series of preferred
stock being issued as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other specific terms, rights, preferences, privileges, qualifications or limitations of, or restrictions on the preferred stock. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we issue and sell shares of preferred stock pursuant to this prospectus, together with any applicable prospectus supplement or free writing prospectus, the shares will be fully paid
and nonassessable and will not have, or be subject to, any preemptive or similar rights. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
laws of the state of Delaware, the state of our incorporation, provide that the holders of preferred stock will have the right to vote separately as a class on any proposal involving
fundamental changes in the rights of holders of such preferred stock. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
issuance of preferred stock could adversely affect the voting power, conversion or other rights of holders of common stock and reduce the likelihood that common stockholders will
receive dividend payments and payments upon liquidation. Preferred stock could be issued quickly with terms designed to delay, deter or prevent a change in control of our company or make removal of
management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=38,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=480936,FOLIO='7',FILE='DISK104:[15ZAN2.15ZAN49602]DA49602A.;4',USER='CHE106812',CD='22-FEB-2015;05:04' -->
<A NAME="page_da49602_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Registration Rights  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;According to the terms of the Third Amended and Restated Investor Rights Agreement dated June&nbsp;26, 2013 among us and certain of
our stockholders, as amended, or the Investor Rights Agreement, certain of our stockholders are entitled to demand, Form&nbsp;S-3 and "piggyback" registration rights. These stockholders hold an
aggregate of 10,149,071 shares eligible for registration under the Investor Rights Agreement, or approximately 32.3% of our total outstanding common stock, as of January&nbsp;22, 2015. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Demand registration rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;At any time beginning 180&nbsp;days after the effective date of this registration statement, the holders of
at least a
25% of the Underlying Securities having registration rights have the right to demand that we file&nbsp;a registration statement under the Securities Act to register the Underlying Securities
requested to be registered by the holders of Underlying Securities. These registration rights are subject to specified conditions and limitations, including a limitation on the number of such
registration statements that can be demanded by the holders of Underlying Securities, restrictions on the exercise of such demand registration rights during periods of time that may be detrimental to
the Company and its stockholders, and the right of the underwriters to limit the number of shares of Underlying Securities included in any such registration under certain circumstances. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;S-3 registration rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If we are eligible to file&nbsp;a registration statement on Form&nbsp;S-3, each holder of shares of
Underlying Securities having registration rights has the right to demand that we file no more than one registration statement for the holders on Form&nbsp;S-3 in any 12-month period so long as the
aggregate offering price of securities to be sold under the registration statement on Form&nbsp;S-3 is at least $1,000,000, subject to specified exceptions, conditions and limitations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Piggyback" registration rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If we register any securities for public sale, stockholders with registration rights will have the
right to include
their shares in the registration statement. The underwriters of any underwritten offering will have the right to limit the number of shares having registration rights to be included in the
registration statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expenses of registration.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We will pay all expenses, including up to $50,000 for the reasonable fees and costs of one counsel to the
holders of
Underlying Securities, relating to all demand registrations, Form&nbsp;S-3 registrations and piggyback registrations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expiration of registration rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The registration rights described above will terminate, as to a given holder of Underlying
Securities, at any time
following the Company's initial public offering when such holder can sell all of such holder's Underlying Securities pursuant to Rule&nbsp;144 promulgated under the Securities Act during any 90-day
period. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Delaware Anti-Takeover Law and Provisions of Our Amended and Restated Certificate of
Incorporation and Amended and Restated Bylaws  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our amended and restated certificate of incorporation and our amended and restated bylaws contain certain provisions that could have
the effect of delaying, deterring or preventing another party from acquiring control of us, and therefore could adversely affect the market price of our common stock. These provisions and certain
provisions of Delaware General Corporation Law, or DGCL, which are summarized below, may also discourage coercive takeover practices and inadequate takeover bids, and are designed, in part, to
encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate more
favorable terms with an unfriendly or unsolicited acquirer outweigh the disadvantages of potentially discouraging a proposal to acquire us. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=39,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=319204,FOLIO='8',FILE='DISK104:[15ZAN2.15ZAN49602]DA49602A.;4',USER='CHE106812',CD='22-FEB-2015;05:04' -->
<A NAME="page_da49602_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Delaware Anti-Takeover Law  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to Section&nbsp;203 of the Delaware General Corporation Law (Section&nbsp;203). Section&nbsp;203 generally
prohibits a public Delaware corporation from engaging in a "business combination" with an "interested stockholder" for a period of three years following the time that such stockholder became an
interested stockholder, unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> prior to such time the board of directors of the corporation approved either the business combination or the transaction which
resulted in the stockholder becoming an interested stockholder; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder
owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding
voting stock owned by the interested stockholder) those shares owned (i)&nbsp;by persons who are directors and also officers and (ii)&nbsp;employee stock plans in which employee participants do
not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at or subsequent to such time the business combination is approved by the board of directors and authorized at an annual or special
meeting of stockholders, and not by written consent, by the affirmative vote of at least 66<SUP>2</SUP>/<SMALL>3</SMALL>% of the outstanding voting stock which is not owned by the interested stockholder. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;203
defines a business combination to include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any merger or consolidation involving the corporation and the interested stockholder; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to
the interested stockholder; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the
stock of any class or series of the corporation beneficially owned by the interested stockholder; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits
provided by or through the corporation. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
general, Section&nbsp;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity
or person affiliated with or controlling or controlled by the entity or person. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Among other things, our amended and restated certificate of incorporation and amended and restated
bylaws:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> permit our Board of Directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they
may designate (including the right to approve an acquisition or other change in our control); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide that the authorized number of directors may be changed only by resolution of the board of directors; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=40,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=479888,FOLIO='9',FILE='DISK104:[15ZAN2.15ZAN49602]DA49602A.;4',USER='CHE106812',CD='22-FEB-2015;05:04' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc49602_1_10"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A> </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the
affirmative vote of a majority of directors then in office, even if less than a quorum; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders
and not be taken by written consent; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as
directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder's notice; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to
vote in any election of directors to elect all of the directors standing for election, if they should so choose); and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive Officer or by
our Board of Directors pursuant to a resolution adopted by a majority of the total number of authorized directors. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
amendment of any of these provisions, with the exception of the ability of our Board of Directors to issue shares of preferred stock and designate any rights, preferences and
privileges thereto, would require approval by the holders of at least 66<SUP>2</SUP>/<SMALL>3</SMALL>% of our then-outstanding common stock. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
provisions of the DGCL and the provisions of our amended and restated certificate of incorporation and amended and restated bylaws could have the effect of discouraging others from
attempting hostile takeovers and, as a consequence, they might also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover
attempts. These provisions might also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that
stockholders might otherwise deem to be in their best interests. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transfer Agent and Registrar  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar's address
is 250 Royall Street, Canton, MA, 02021. The transfer agent for any series of preferred stock that we may offer under this prospectus will be named and described in the prospectus supplement for that
series. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Listing on the Nasdaq Global Market  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is listed on the Nasdaq Global Market under the symbol "XNCR". </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc49602_description_of_debt_securities"> </A>
<A NAME="toc_dc49602_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF DEBT SECURITIES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or
subordinated convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of
any debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described
below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will issue the debt securities under the indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of
1939, as amended, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=41,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=182531,FOLIO='10',FILE='DISK104:[15ZAN2.15ZAN49602]DC49602A.;4',USER='CHE106812',CD='22-FEB-2015;05:06' -->
<A NAME="page_dc49602_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>or
the Trust Indenture Act. We have filed the form of indenture as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities
containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports
that we file with the SEC. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following summary of material provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture
applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing prospectuses related to the debt securities that we may
offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indenture does not limit the amount of debt securities that we may issue. It provides that we may issue debt securities up to the
principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and sale of all or substantially all of
our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against changes in our
operations, financial condition or transactions involving us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may issue the debt securities issued under the indenture as "discount securities," which means they may be sold at a discount below their stated principal amount. These debt
securities, as well as other debt securities that are not issued at a discount, may be issued with "original issue discount," or OID, for U.S. federal income tax purposes because of interest payment
and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more detail in any
applicable prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the title of the series of debt securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any limit upon the aggregate principal amount that may be issued; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the maturity date or dates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the form of the debt securities of the series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the applicability of any guarantees; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether or not the debt securities will be secured or unsecured, and the terms of any secured debt; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms
of any subordination; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a
price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the
principal amount of such debt securities that is convertible into another security or the method by which any such portion shall be determined; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to
accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=42,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=851776,FOLIO='11',FILE='DISK104:[15ZAN2.15ZAN49602]DC49602A.;4',USER='CHE106812',CD='22-FEB-2015;05:06' -->
<A NAME="page_dc49602_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our right, if any, to defer payment of interest and the maximum length of any such deferral period; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our
option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or
analogous fund provisions or otherwise, to redeem, or at the holder's option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral
multiple thereof; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for
our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the debt securities of the series shall be issued in whole or in part in the form of a global security or securities; the
terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or
securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions
upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or
optional (at our option or the holders' option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall be
payable upon declaration of acceleration of the maturity thereof; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> additions to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the
consolidation, merger or sale covenant; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> additions to or changes in the Events of Default with respect to the securities and any change in the right of the trustee or the
holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> additions to or changes in the provisions relating to satisfaction and discharge of the indenture; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders
of debt securities issued under the indenture; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S.
dollars; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether interest will be payable in cash or additional debt securities at our or the holders' option and the terms and conditions upon
which the election may be made; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=43,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=236151,FOLIO='12',FILE='DISK104:[15ZAN2.15ZAN49602]DC49602A.;4',USER='CHE106812',CD='22-FEB-2015;05:06' -->
<A NAME="page_dc49602_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any, and principal
amounts of the debt securities of the series to any holder that is not a "United States person" for federal tax purposes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any restrictions on transfer, sale or assignment of the debt securities of the series; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or
changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations. </FONT></DD></DL>
</UL>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Conversion or Exchange Rights  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or
exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option of the
holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive would be
subject to adjustment. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Consolidation, Merger or Sale  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not
contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety. However, any
successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Events of Default under the Indenture  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events
of default under the indenture with respect to any series of debt securities that we may issue:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become due and payable, and
such default continues for a period of 90&nbsp;days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto
shall not constitute a default in the payment of interest for this purpose; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and
payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that
a valid extension of the maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if
any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a
covenant specifically relating to another series of debt securities, and our failure continues for 90&nbsp;days after we receive written notice of such failure, requiring the same to be remedied and
stating that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if specified events of bankruptcy, insolvency or reorganization occur. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=44,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=298008,FOLIO='13',FILE='DISK104:[15ZAN2.15ZAN49602]DC49602A.;4',USER='CHE106812',CD='22-FEB-2015;05:06' -->
<A NAME="page_dc49602_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the
holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare
the unpaid principal of, premium, if any, and accrued interest, if any, of such series of debt securities due and payable immediately. If an event of default specified in the last bullet point above
occurs with respect to us, the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the
part of the trustee or any holder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its
consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture.
Any waiver shall cure the default or event of default. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the terms of the indenture, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or
powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity. The
holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy
available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided
that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the direction so given by the holder is not in conflict with any law or the applicable indenture; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability
or might be unduly prejudicial to the holders not involved in the proceeding. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
holder of the debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only
if:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the holder has given written notice to the trustee of a continuing event of default with respect to that series; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request, </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred by
the trustee in compliance with the request; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of
the outstanding debt securities of that series other conflicting directions within 90&nbsp;days after the notice, request and offer. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will periodically file statements with the trustee regarding our compliance with specified covenants in the indenture. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=45,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=825516,FOLIO='14',FILE='DISK104:[15ZAN2.15ZAN49602]DC49602A.;4',USER='CHE106812',CD='22-FEB-2015;05:06' -->
<A NAME="page_dc49602_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Modification of Indenture; Waiver  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may
change an indenture without the consent of any holders with respect to specific matters:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to comply with the provisions described above under "Description of Debt Securities&#151;Consolidation, Merger or Sale;" </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to provide for uncertificated debt securities in addition to or in place of certificated debt securities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for the
benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions
or provisions an event of default or to surrender any right or power conferred upon us in the indenture; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue,
authentication and delivery of debt securities, as set forth in the indenture; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to make any change that does not adversely affect the interests of any holder of debt securities of any series in any material
respect; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above
under "Description of Debt Securities&#151;General" to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities,
or to add to the rights of the holders of any series of debt securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority
in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement applicable to a particular series of
debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> extending the fixed maturity of any debt securities of any series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon
the redemption of any series of any debt securities; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or
waiver. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=46,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=7671,FOLIO='15',FILE='DISK104:[15ZAN2.15ZAN49602]DC49602A.;4',USER='CHE106812',CD='22-FEB-2015;05:06' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de49602_1_16"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Discharge  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities,
except for specified obligations, including obligations to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide for payment; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> register the transfer or exchange of debt securities of the series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> replace stolen, lost or mutilated debt securities of the series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> pay principal of and premium and interest on any debt securities of the series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> maintain paying agencies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> hold monies for payment in trust; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> recover excess money held by the trustee; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> compensate and indemnify the trustee; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> appoint any successor trustee. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium, if any, and
interest on, the debt securities of the series on the dates payments are due. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Form, Exchange and Transfer  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the
applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent global
form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in the applicable prospectus
supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book-entry securities will be
set forth in the applicable prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of
the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present
the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the
office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or
exchange, we will impose no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt
securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except
that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=47,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=4728,FOLIO='16',FILE='DISK104:[15ZAN2.15ZAN49602]DE49602A.;5',USER='CHE106812',CD='22-FEB-2015;05:12' -->
<A NAME="page_de49602_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we elect to redeem the debt securities of any series, we will not be required to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business
15&nbsp;days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> register the transfer of or exchange of any debt securities so selected for redemption, in whole or in part, except the unredeemed
portion of any debt securities we are redeeming in part. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Information Concerning the Trustee  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only
those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or
use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt
securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Payment and Paying Agents  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on
any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise
indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the
applicable prospectus
supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus
supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a
particular series. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years
after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Governing Law  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indenture and the debt securities, and any claim, controversy or dispute arising under or related to the indenture or the debt
securities, will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act of 1939 is applicable. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de49602_description_of_warrants"> </A>
<A NAME="toc_de49602_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF WARRANTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following description, together with the additional information we may include in any applicable prospectus supplements and free
writing prospectuses, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or
debt securities and may be issued in one or more series. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=48,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=912120,FOLIO='17',FILE='DISK104:[15ZAN2.15ZAN49602]DE49602A.;5',USER='CHE106812',CD='22-FEB-2015;05:12' -->
<A NAME="page_de49602_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Warrants
may be issued independently or together with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to or separate from those securities.
While the terms we have summarized below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants that we may offer
in more detail in the applicable prospectus supplement and any applicable free writing prospectus.
The terms of any warrants offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in
this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have filed forms of the warrant agreements as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of
which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant agreement, if any, including a form of warrant certificate, that describes
the terms of the particular series of warrants we are offering. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their
entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to the particular series of warrants that we may offer under this prospectus. We urge you to
read the applicable prospectus supplements related to the particular series of warrants that we may offer under this prospectus, as well as any related free writing prospectuses, and the complete
warrant agreements and warrant certificates that contain the terms of the warrants. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will describe in the applicable prospectus supplement the terms relating to a series of warrants being offered,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the title of such securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the offering price or prices and aggregate number of warrants offered; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the currency or currencies for which the warrants may be purchased; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with
each such security or each principal amount of such security; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if applicable, the date on and after which the warrants and the related securities will be separately transferable; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if applicable, the minimum or maximum amount of such warrants which my be exercised at any one time; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant
and the price at which, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the
case may be, purchasable upon the exercise of one warrant and the price at which, and the currency in which, these shares may be purchased upon such exercise; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the terms of any rights to redeem or call the warrants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the terms of any rights to force the exercise of the warrants; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=49,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=201904,FOLIO='18',FILE='DISK104:[15ZAN2.15ZAN49602]DE49602A.;5',USER='CHE106812',CD='22-FEB-2015;05:12' -->
<A NAME="page_de49602_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the dates on which the right to exercise the warrants will commence and expire; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the manner in which the warrant agreements and warrants may be modified; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a discussion of any material or special U.S. federal income tax consequences of holding or exercising the warrants; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the terms of the securities issuable upon exercise of the warrants; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other specific terms, preferences, rights or limitations of or restrictions on the warrants. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before
exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest
on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our
liquidation, dissolution or winding up or to exercise voting rights, if any. </FONT></DD></DL>
</UL>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Exercise of Warrants  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise
price that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to
the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to
be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set
forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent in
connection with the exercise of the warrant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in
the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such
exercise. If fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate
in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Governing Law  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless we provide otherwise in the applicable prospectus supplement, the warrants and warrant agreements, and any claim, controversy or
dispute arising under or related to the warrants or warrant agreements, will be governed by and construed in accordance with the laws of the State of New York. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=50,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=856506,FOLIO='19',FILE='DISK104:[15ZAN2.15ZAN49602]DE49602A.;5',USER='CHE106812',CD='22-FEB-2015;05:12' -->
<A NAME="page_de49602_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Enforceability of Rights by Holders of Warrants  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or
relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or
responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any
demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive
the securities purchasable upon exercise of, its warrants. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de49602_legal_ownership_of_securities"> </A>
<A NAME="toc_de49602_2"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL OWNERSHIP OF SECURITIES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater
detail below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee or depositary maintain for this purpose as the "holders" of
those securities. These persons are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in
their own names, as "indirect holders" of those securities. As we discuss below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be
indirect holders. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Book-Entry Holders  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may
be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the
depositary's book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their
customers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only
the person in whose name a security is registered is recognized as the holder of that security. Global securities will be registered in the name of the depositary or its
participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The
depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so
under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a result, investors in a global security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial
institution that participates in the depositary's book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders,
and not legal holders, of the securities. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Street Name Holders  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A global security may be terminated in certain situations as described under "&#151;Special Situations When a Global Security
Will Be Terminated," or issue securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in "street name." Securities held by an
investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those
securities through an account he or she maintains at that institution. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=51,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=333664,FOLIO='20',FILE='DISK104:[15ZAN2.15ZAN49602]DE49602A.;5',USER='CHE106812',CD='22-FEB-2015;05:12' -->
<A NAME="page_de49602_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in whose names the
securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments
they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold
securities in street name will be indirect holders, not holders, of those securities. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Legal Holders  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal
holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an
investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
example, once we make a payment or give a notice to the legal holder, we have no further responsibility for the payment or notice even if that legal holder is required, under
agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of the holders to amend an
indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of an
indenture, or for other purposes. In such an event, we would seek approval only from the legal holders, and not the indirect holders, of the securities. Whether and how the legal holders contact the
indirect holders is up to the legal holders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Special Considerations for Indirect Holders  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you hold securities through a bank, broker or other financial institution, either in book-entry form because the securities are
represented by one or more global securities or in street name, you should check with your own institution to find out:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> how it handles securities payments and notices; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether it imposes fees or charges; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> how it would handle a request for the holders' consent, if ever required; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in
the future; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to
protect their interests; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if the securities are in book-entry form, how the depositary's rules and procedures will affect these matters. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Global Securities  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all
securities represented by the same global securities will have the same terms. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
security issued in book-entry form will be represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we
select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, The Depository Trust Company, New York,
New York, known as DTC, will be the depositary for all securities issued in book-entry form. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=52,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=121461,FOLIO='21',FILE='DISK104:[15ZAN2.15ZAN49602]DE49602A.;5',USER='CHE106812',CD='22-FEB-2015;05:12' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg49602_1_22"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special
termination situations arise. We describe those situations below under "&#151;Special Situations When a Global Security Will Be Terminated." As a result of these arrangements, the depositary,
or its nominee, will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global
security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that
does. Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the prospectus supplement for a particular security indicates that the security will be issued as a global security, then the security will be represented by a global security at all
times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be
held through any book-entry clearing system. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Special Considerations for Global Securities  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As an indirect holder, an investor's rights relating to a global security will be governed by the account rules of the investor's
financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the
depositary that holds the global security. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
securities are issued only as global securities, an investor should be aware of the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her
interest in the securities, except in the special situations we describe below; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of
his or her legal rights relating to the securities, as we describe above; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are
required by law to own their securities in non-book-entry form; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an investor may not be able to pledge his or her interest in the global security in circumstances where certificates representing the
securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the depositary's policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating
to an investor's interest in the global security; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we and any applicable trustee have no responsibility for any aspect of the depositary's actions or for its records of ownership
interests in the global security, nor will we or any applicable trustee supervise the depositary in any way; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the global security within
its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> financial institutions that participate in the depositary's book-entry system, and through which an investor holds its interest in the
global security, may also have their own policies affecting payments, notices and other matters relating to the securities. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=53,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=492773,FOLIO='22',FILE='DISK104:[15ZAN2.15ZAN49602]DG49602A.;6',USER='CHE108066',CD='22-FEB-2015;08:59' -->
<A NAME="page_dg49602_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Special Situations When a Global Security Will Be Terminated  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In a few special situations described below, a global security will terminate and interests in it will be exchanged for physical
certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks
or brokers to find out how to have their interests in securities
transferred to their own names, so that they will be direct holders. We have described the rights of holders and street name investors above. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
global security will terminate when the following special situations occur:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security
and we do not appoint another institution to act as depositary within 90&nbsp;days; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if we notify any applicable trustee that we wish to terminate that global security; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities covered by the
prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee, is responsible for deciding the names of the institutions that will be the initial
direct holders. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg49602_plan_of_distribution"> </A>
<A NAME="toc_dg49602_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PLAN OF DISTRIBUTION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a
combination of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in
one or more transactions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at a fixed price or prices, which may be changed; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at market prices prevailing at the time of sale; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at prices related to such prevailing market prices; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at negotiated prices. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may also sell equity securities covered by this registration statement in an "at the market offering" as defined in Rule&nbsp;415 under the Securities Act. Such offering may be made
into an existing trading market for such securities in transactions at other than a fixed price, either:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> on or through the facilities of the Nasdaq Global Market or any other securities exchange or quotation or trading service on which
such securities may be listed, quoted or traded at the time of sale; and/or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to or through a market maker other than on the Nasdaq Global Market or such other securities exchanges or quotation or trading
services. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
at-the-market offerings, if any, may be conducted by underwriters acting as principal or agent. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=54,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=466014,FOLIO='23',FILE='DISK104:[15ZAN2.15ZAN49602]DG49602A.;6',USER='CHE108066',CD='22-FEB-2015;08:59' -->
<A NAME="page_dg49602_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities,
including, to the extent applicable:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the name or names of any underwriters, dealers or agents, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the purchase price of the securities and the proceeds we will receive from the sale; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any over-allotment options under which underwriters may purchase additional securities from us; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any agency fees or underwriting discounts and other items constituting agents' or underwriters' compensation; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any public offering price; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any discounts or concessions allowed or reallowed or paid to dealers; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any securities exchange or market on which the securities may be listed. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only
underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public
offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable
underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain
conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement. Any public offering price and any discounts or concessions allowed or reallowed
or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of
any such relationship. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities, and we will describe any
commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the
prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the
commissions we must pay for solicitation of these contracts in the prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may provide agents and underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with
respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary
course of business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
securities we offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will
not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids. Overallotment involves sales in excess of the offering size, which
create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve
purchases of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=55,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=36652,FOLIO='24',FILE='DISK104:[15ZAN2.15ZAN49602]DG49602A.;6',USER='CHE108066',CD='22-FEB-2015;08:59' -->
<A NAME="page_dg49602_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities
originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would
otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. These transactions may be effected on any exchange or over-the-counter market or otherwise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
underwriters who are qualified market makers on the Nasdaq Global Market may engage in passive market making transactions in the securities on the Nasdaq Global Market in accordance
with Rule&nbsp;103 of Regulation&nbsp;M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must
comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest
independent bid for such security; if all independent bids are lowered below the passive market maker's bid, however, the passive market maker's bid must then be lowered when certain purchase limits
are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at
any time. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg49602_legal_matters"> </A>
<A NAME="toc_dg49602_2"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise indicated in the applicable prospectus supplement, certain legal matters in connection with the offering and the
validity of the securities offered by this prospectus, and any supplement thereto, will be passed upon by Cooley&nbsp;LLP. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg49602_experts"> </A>
<A NAME="toc_dg49602_3"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financial statements as of December&nbsp;31, 2013 and 2012 and for each of the three years in the period ended
December&nbsp;31, 2013 incorporated by reference in this Prospectus have been so incorporated in reliance on the report of BDO USA,&nbsp;LLP, an independent registered public accounting firm,
incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg49602_where_you_can_find_more_information"> </A>
<A NAME="toc_dg49602_4"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set
forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to
the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with
different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any
date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement, as well as any other document filed
by us with the SEC, at the SEC's Public Reference Room at 100&nbsp;F Street NE, Washington, D.C. 20549. You can also request copies of these documents by writing to the SEC and paying a fee for the
copying cost. You may obtain information on the operation of the Public Reference Room by calling the SEC at&nbsp;(800)&nbsp;SEC-0330. The SEC maintains a website that contains reports, proxy
statements and other information regarding issuers that file electronically with the SEC, including Xencor. The address of the SEC website is www.sec.gov. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=56,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=740081,FOLIO='25',FILE='DISK104:[15ZAN2.15ZAN49602]DG49602A.;6',USER='CHE108066',CD='22-FEB-2015;08:59' -->
<A NAME="page_dg49602_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
maintain a website at www.xencor.com. Information contained in or accessible through our website does not constitute a part of this prospectus. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg49602_incorporation_of_certain_information_by_reference"> </A>
<A NAME="toc_dg49602_5"> </A>
<BR></FONT><FONT SIZE=2><B>  INCORPORATION OF CERTAIN INFORMATION BY REFERENCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to "incorporate by reference" information into this prospectus, which means that we can disclose important
information to you by referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is 001-36182. The documents
incorporated by reference into this prospectus contain important information that you should read about us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following documents are incorporated by reference into this document:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2013 and filed with the SEC on March&nbsp;31,
2014; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our Quarterly Reports on Form&nbsp;10-Q for the quarterly periods ended March&nbsp;31, 2014, June&nbsp;30, 2014 and
September&nbsp;30, 2014 which were filed with the SEC on May&nbsp;5, 2014, August&nbsp;1, 2014 and November&nbsp;10, 2014, respectively; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the information specifically incorporated by reference into our Annual Report on Form&nbsp;10-K for the fiscal year ended
December&nbsp;31, 2013 from our definitive proxy statement on Schedule&nbsp;14A (other than information furnished rather than filed) filed with the SEC on April&nbsp;29, 2014; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our Current Reports on Form&nbsp;8-K (other than information furnished rather than filed) filed with the SEC on January&nbsp;24,
2014, February&nbsp;27, 2014, March&nbsp;19, 2014, March&nbsp;26, 2014, May&nbsp;16, 2014, June&nbsp;18, 2014, July&nbsp;15, 2014, July&nbsp;31, 2014, October&nbsp;29, 2014,
November&nbsp;10, 2014 and January&nbsp;5, 2014; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the description of our common stock, which is registered under Section&nbsp;12 of the Exchange Act, in our registration statement on
Form&nbsp;8-A, filed with the SEC on November&nbsp;7, 2013, including any amendments or reports filed for the purpose of updating such description. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also incorporate by reference into this prospectus all documents (other than current reports furnished under Item&nbsp;2.02 or Item&nbsp;7.01 of Form&nbsp;8-K and exhibits filed
on such form that are related to such items) that are filed by us with the SEC pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act (i)&nbsp;after the date of the initial filing
of the registration statement of which this prospectus forms&nbsp;a part and prior to effectiveness of the registration statement, or (ii)&nbsp;after the date of this prospectus but prior to the
termination of the offering. These documents include periodic reports, such as Annual Reports on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q and Current Reports on Form&nbsp;8-K, as well
as proxy statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that
are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits which are specifically incorporated by reference into such documents. You should direct any
requests for documents by writing us at 111 West Lemon Avenue, Monrovia, California 91016 Attn: Corporate Secretary or telephoning us at (626)&nbsp;305-5900. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
statement contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or superseded for purposes of the
document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the
statement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=57,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=183379,FOLIO='26',FILE='DISK104:[15ZAN2.15ZAN49602]DG49602A.;6',USER='CHE108066',CD='22-FEB-2015;08:59' -->
<A NAME="page_dg49602_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg49602a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="DG_DIS"></A>DISCLOSURE OF COMMISSION'S POSITION ON INDEMNIFICATION FOR<BR>
SECURITIES ACT LIABILITY  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons
controlling the Company pursuant to the DGCL, we
have been informed that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=58,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=439821,FOLIO='27',FILE='DISK104:[15ZAN2.15ZAN49602]DG49602A.;6',USER='CHE108066',CD='22-FEB-2015;08:59' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg49601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>5,500,000 Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>
<IMG SRC="g1039421.jpg" ALT="LOGO" WIDTH="280" HEIGHT="75">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>Xencor,&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Common Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=4><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>PROSPECTUS SUPPLEMENT  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>February&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2015  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=2><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>Leerink Partners  </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<p style="font-family:times;"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="291pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=4><B>Wedbush PacGrow Life Sciences</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=4><B>Oppenheimer &amp; Co.</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=59,EFW="2223193",CP="XENCOR INC.",DN="1",CHK=784895,FOLIO='blank',FILE='DISK135:[15ZAN1.15ZAN49601]HO49601A.;26',USER='JFUSS',CD='23-FEB-2015;13:07' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g1039421.jpg
<DESCRIPTION>G1039421.JPG
<TEXT>
begin 644 g1039421.jpg
M_]C_X``02D9)1@`!`0$`V`#8``#__@`N35),3%]'4D%02$E#4SI;6$5.0T]2
M7TE.0UU814Y#3U)?-$-?3$]'3RY%4%/_VP!#``$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0'_VP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!+`1@#`2(``A$!`Q$!
M_\0`'P```@("`P$!`0````````````H("0<+`0,&!00"_\0`01```00"`0,#
M`@('`PD)````!`(#!08!!P@`"1$2$R$4,0H5%A<B05%QL1DR81@C)#0V.8&1
MH24F*#-6=G>'\/_$`!P!``(#`0$!`0`````````````'!08(!`,!`O_$`#`1
M``("`@$$`@$#`P('``````(#`00%!A$`!Q(3%"$(%2(C,3-!%D(7&"0E)C)1
M_]H`#`,!``(1`Q$`/P!_CHZ.C.?'SGHZ.CHZX\X_QQ^_YQG']<8_Y??I;_NC
M]VWDGIKD8OB!P?UO!VO9%/KD%9]KW*PUDZ[+B2;)'M3<14ZU60I.,!:<$KY<
M5,6"P3)!R,*FA(B/BQWA"SUS6!P-_8K_`,#'P@6"EEE[[3PK5:M9,C#+%A[)
M\5K$V+#F((I-@#`S,]5W9]HQ6HXR<KESL>DK":=>O3K,N7;EQ_E*JM2JJ)-S
MS`&,@(XX!9E,Q`],@]>/V!?J?JRD6S8^P+!'56DT>ORMIM5CEG?9CX6!A`W3
MY*0*5C"EJ0.,RM2&64.$$.Y;&';<?=;;4FPUW/.^T[XRG7%/\9^V5<?F<?UL
M?S_T^?C^'4=>6?);O$\N=*S.GMT4_(>LS)2)LEI!HFL\TPN=8K;CAX$58#1Y
M206?7!Y/`DT_%*9:;(DXN+)?<6T)["[Q3[76SN5EW]CU5%0WJ&TU&;0YZT28
MPTDJE8BQL!Y0H2(1(_&"F!F9A9W^]V+70N-QNJ[Q9O+K-.HE^K9%-=EB%S*1
M<Z(F5ID^/:8Q)"OF1B2XCK!7,[N]\M.3F]+;>M<[KVGI/48<D9&ZIUS0;2?3
M4151&=2U'RUI5`NB%3=SL*&43,Z5)EFHB""_R*'^FC8]&'FD^Q#S?VUS)XP7
M(3>,N3;]BZ0V$U0B-A%CACR%UK<M7(^R5LV>^@'$$)L\2T^=#2TDT,TY+C"Q
M<L=[LF8>0\B)0=(;=V7M:EZ0HU2D9K96P;-'U&M5[+:QG'I:1=RC#I[RTX0%
M$QX[1,I-2K^<#1<.$?)$J2P*YGK97<!>&-$X(\:Z5HFFY8DY4)M=@V1=$,98
M*O\`LB88&S9K20A7[;0:ECCQ%<`7E68FKQ<-&Y6XX.\\\Q>[]?4<'JV*PE"C
M2#(L8AF,.LI,6$4J\>-BS8L!$-:%KGU3[2*;3Y)\R1URD5)^/UK?=FW3/[3E
M,Q>L8:`L)RB;36_%=D+!"5:G7JE/K0RB,2SA8!\5$`B8$;$"4T.CHZ\G>[O6
MM:TVS[`N1Q$74J;!R-DLLH-%3$VY&0<0.LR3D51D"!*2Y3``C3I96`@"76AF
M7GU-^TTXI.:A$C(0`2,S*!`!B2(B*8@1$8B9(BF8B(B)F9F(B.>MC,8M*S:T
MP4I0$QC&$(+6L!DC,S*8$``8DB(I@1&)F9B(Z]9T=5D8[R?;/SC&<<KZ8K&<
M><936=E*PK&<><93E-)SA6,X^<93YQG&<9QYQG'F?6L-H:_W/0JSL_5MKB+O
M0;C')E:W9X(A1$=*!9=<8<4WEQ#1`Y`Q++X9P)C`Q\><.0"<,.6P\RCON8C+
M8X`;D,7D:"F%X+9<I6:H&?$EX`;U`)%XQ)>(S,\1,\<1/4/C-EUS-M97PVP8
M3+O2OVM3C,K0OM4KR$/8Q=5[3!?D0CYD,#Y$(\\S$=>]Z.CK'NU=K:[TAK^S
M[3VO;(JCZ_IH&).R6>96\D",$60R(SE:!F2"R2"C"1P@00AB3CS2&!`AGR7F
MVE<*UL:P%*`VM:8K6M8D;&,,H$``!B2,S*8$1&)(BF(B)F>I9SDUDML6&J17
M0LW/>Y@J2E*ADV-:TY$%K6`R9F90(#$D4Q$3/60NCJL=7>4[9R,*4KE?3<80
ME2E?]V-E9SC",9RK/C%(SGXQC.?&,><_NQG/5D<#-QUEA(>Q1#KST5/14?-1
MCQ(1L:0['RH;)P3A$=)CAR0#S@I#2W0I`04X5:LL%C,/H<:3V7<5E,;"YR.-
MOT(;)0J;M.Q5ALA`R<+EZUP<A!#)0/,C!#,\<QS&8O8<!G"<.%SF'S!5H`K`
MXO)TL@2!9)0LG14>Z50R0.`DX&"D"@>9&>/J]'1T=<'4QT='1T='1T='1T='
M1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T=5
M)=SKF5.ZC@(OC[I68=%WAM`+W9*;B'4KE-;4-YY0KTL/G"7/H[/:W&R8FL.>
M$DQXC,O81U,DA1;CL\.37(*I<8].6O;5NPHMN'80#78!AUMJ0MUOD_6Q7*M&
M^YG_`%B4-QY*?2AS$;$CR4L\C(P#V<+N:=CS3C-C<VN2A:)68EY,FP>R2G+3
M,S//-);AZ[##NYSD>#APV0XR-%1Y0##!,MY_SKJUKF\34#[OV%^Q*3A==$QS
M\NX7'K5`S$P0!,P;>?J?VC,2)%PE>[NZ/Q=56IX2W%3-YJLVQ?R,'XQKVO*\
MHNY-AC,$ISA%B*?CP?,.8L@<"//"U-V'R*X!['UU;1[U.S+%W(B92X:PF;)+
M3H5P@Y"1:$)'EXZ4)-^DL1K1+SL!/BX;EAY#V%NO$AN$B%3<[F/:*W]O;D8W
MR^X9[1K5&V3;:[`U[:U,O$S-58*<>K((\-"V6"L<##3V&C7H`>/A[#`2L:T,
M_F&#DP)9)#Y@3GY>WSQVL?,#><GS2W<$HO7=.L[R=65\]I7T%JN4,_Z1Y=H9
M7I2NJZ^(;:0"C"?II*UL(:S[@\`:T2QOU/NV.Y@<I7M4)J3D@INJ96#K*=3M
M+LRLYHO2<2+@1ZPY*>#%@AP<$O@:KVNT0L_IN23L#LL6MY/*ULEJ*'W7HR^.
M"F#E_K5:RN1.DS)RV6+4O^,5P;!$PLPUB@".V!WIFV4LIV=HSPC&,8S^N6W>
M?C_ZZ_C\_;K%6V>+'=^X942=Y'7N3HFQJ/KK(\O=8:@[!G;A,@5;+OM2\Z97
M)*JPB3ZU$L*P[9'172R8V,<>E7051@4B6$ZIU^8P,60$)!.&8,",8>%+$*9;
M(&*&(;4R^.2.\E;3X[[*UM/L.H6T\TM;3B%-K4G/NKN'<]@1:P.LV*I&/R4!
MB5US<GR'VK!ZV>:3,((18,3X$7GXEQQ-V=V?QL*,J6U;O5N@L_AV6;%8M+KV
M('^%QU7!Z;`+/@C2W]K0B0DAY\H08VI$A;\I57YD\298RC;/U[,Q=FE0JP2D
M.QZ^NT6\@X>0`6UCU+CWRV_?!<=0\$\VIR/-;>$?>:=:O[6G<4K?/G2/U4Y^
M75KD/K)`%>WCKYG/T^1I9:%LQ]ZKH;JLOYIEUR*24`C.75P,PQ*U@QYUV.&+
M.7([@7%FZ=HCE&)OS2$&1(\--Z3A,>54<X>+@://26'C9O4DPG.7$LPQ@R39
MC5YY/AQ$:.;65/.&5QA^0QZ3-V3C%L'77<IX3FIDJL2M;=YI2WW&HNPUL]3+
MEPUC=F!\+PVP6VRE0$@L=QV+E0XFR1Z<GQ3.%L#+8C';'A,?6KV(;3MPQFFY
MFQ,>ZG:+@K.IYIG,^!2R)"NTRD1:(O`B63O8JL#G\OI>RY6W=JRF]3E*^X>O
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M#:<R#JK8)>'Y&2H+JT>6Q:]-)09-T!2_;0R(U+59*/\`L&/=/_!V?NYR?PPV
M0UJ?;,T0[Q@V7-H7-N$*=(1J.WR/M"HV+&,I2X]BN'9;&&V%%CXS_H;;-K":
M<DHHT68=BWQH_77(_4EXTKM:$3/T:_0KT/,!I7A@T5?K03&S,.9E"\QT]`R;
M`<S!R*$J6#*!"OX2M*5MKUT/-'B3L7A1ORV:1V`VLU,<XF:I%O;$4-&[`H4B
M^^F`MD<CRMII]Y+#T=/1J''/R6Q@R4;E;C#0KY&EM$S^/[@Z[9T[9>'9&O6@
M5.,HBQ:K*\1KW4,+G_N%$I&&E,$3`\''#1.R,8/[NZ;F>S&[4.YVBP5;"W;T
MG8K+$OB8^^^?*WBK20@0G#Y=<,.NOD10WVH3Z#31(ME@%(`R0(LG'&"R$<<*
MP<$>$0R4$8&4R@@4L0IA:QR!26'&WQR6G%LO,N(>;6IM:591T[UG<@7RMVLY
MH34L\X]QYT[/$-%R,<5YC]J[,C5$`R%J]UK/M&52I*47#4K'ET8\M4O;&UO-
MF02Q(W4+NN<CZ!P<MW"B+/<=CY9QBO5':&94MNW4/4DD.8W;]9Q.,-9RZ-(*
M6P!6)KZQ@NH5T^?A`F7TKKI,%'+A+Q$OW-?D!4-(45L@`(Q:9F_6YL7#X6OM
M=QA([<]:"$94EA9+;;[$56XU:V\2]B/C`<92-@MYCYIG;E&F7LKLFS6*Y(P\
MNG%MF1E45P"#+*M#DY6Z5E"*]>?)@.ELA!G\9G7Z[H][[7=#$ZYHVAT[X7-F
M&I&P5A$HL3=8Z%AKZ7>*Q;5!P3:N71\$.K?'%DJ7%U,6C]CGMU9Y(;13R9VW
M!9*T9IN?:_1*(E&,N1VR]L1;@YP@S@[V?2?5=?+4+,S>'4*"E+,N&@\_4L`V
M$1MVW&/'_P"_YY_XY^<]8TTYJ*A:%U?2-/:Q@V:[1-?0`==KD4UG"UMB"XRI
MXLXC"4J.EY4QPF5FI-[&2)26,-D"5+?)6K/D^27(_5'%'4%IW7N2P8@:=666
MT);';27-V*;,RIN&JM6BO=9<F+).$IRQ'`-N--H0@B0D"0HH$\\5+[;LF0WC
M8IL+4XP-@TL/CUC+&`DC\4K%8<^=JR<PQ\CY233\!F5K7`ZE[;Z/ANTVE#2=
M8JK<I!939<TXA2EMH4P5EIN9X^NA16,HJP?@(5U^XQASG$6=\YQCYSGQC^.>
MN,*3G[9QG^6<9_ITCMR/_$!<R]I3TL-HS]&>.]$RMX>)&C8.%O.Q'@<K7ELJ
M<MMJ`D8,60=:]"UCUJM!#QZ\J8;DI+"4F.X`U_WM^Y!1Y9$J3OD;88/N,*)K
M^P]?T.8A2L,JRK#&7Z]!U>=!][&5)=7'30CV<83G"O*4YQ;*_9/<'58L&S$5
MG$,%\)]QTV!\HB8$S15=6@_OCB'D,3'$G'2ZN?E7VSK9$J24;)?K`R5SE*N-
MJC3*(GB6J7;R%6\:H_K/-,&3$\BLOJ)V!/1U3_VTN[AK'G>AS7-IAQ-4\BHF
M,)E2J+^8NGUN[Q$>EK,E8-<S!B&2ROH,.8(FJE)HS/P@F<G,/SL0R3+,93[K
M',C9?!KC)&[GU3!4FQ6<S:]-HK@%]!FI"#3%6&.LQ9A"&(&<KQN#VG(85(SJ
MCU#H0X_[HSRE-Y10&:OFTYY.M6:95LM8L*KJ0\P!;"=/"F`^))1H9_M<LB7/
M$\%S$Q#C3O\`JMK4+&\TLD-[7*M-UVQ:J*8QR@KC!/2RI(C85:5Y1#*S0!PS
M,3(^)#,V6]<9SC'SG.,8_CG/CI1CC9^(EVY.[:B!.350TQ5=+BU^[S%IE-=U
M:]+O)!D+49B1JT%5F9:^2T<1+V2TCQ$$.R:'@523G'23(X9IX\>&G(3OS\Y]
ML624?U18X7CQ0UE9Q"UVH5ZN6>SH!9<5D9=@O-PAIA9\DZG.,FY@HF`BTYQ[
M`XKS:<E/7&MV@W-]XZ3*]*J*TJ<=U]KFG'M)H@D6(6YC'QZB(UK47J`EDT@]
MJ_)8WOR7[7U,0O*HN93(&ZV^HK&5,?`9.9KK0QEAB;CZJD5/^H`%N<\)>P7`
M@&RAW@]GC.,_.,^<?QQT=)4\3/Q!G)?7=KB(GE./$[TUF2\*',S\-7(2I;4K
MHF%>TY+Q2H!F+J]N4*VK+Y$%*1$6=)X;](=@$)4EI]R>@7VH;1I%4V-09X"S
MTJ[P$7:*O8(QWW0I:#F1&CH\UG*L)<;]UAU/NL/H;(%?2Z,2TT0RZVFL[3IF
M<U!ZE99*I38\HK7*K"=4>0<28"9`I@,")B96Y2CF)\@@AB2ZOG;[NEJ7<JK9
M?KMIXV:7KF[B\@D:V1J@W^VTU`UZ6H.8D8=6>]8E'@P@.8&?7]<94G'WSC'\
M\XQ_7JE/N:=XJA\()%>H=:5^,VSR(>`'/DX0^1?$I6L09`=),47?"HW/YF?-
MR@SK1\52HET$]Z*6B5F)>"#+B<RBSUV[V?<DN,KB2:Y!,T@5#ZG1H2AZ[UW#
M0[.%J]?L9S-5VQ2YS*,8PA.)"9,<PC^\XO*LJS.:YVLVK9*:\BA=2A2?'E7=
MDG-3-D)XX8E*$6'2HN8D&,!8,']ZY,?OJI[O^0?;[1\H["VW9',92J<KNUL'
M7KV!HMCQ\D6;-JW3K0\(G^1*6N:DXE;A4<2,;`[HZ2>XV_B%N5^OK)'B\C(2
MJ[YHCSX[,P3%0,/KO9,<+Z\(=-A9""0%3I@EEK*GL1$U`1S<BXA+.+!%86HC
M#@.AM[ZPY*ZKJ6YM/V5BTT2Y`J+C)!MIT4P4D=Y8DG#3,:1A)<1/0L@R_'3$
M48A!`1K#B,^XTIEYV&VC1]@U$E3EJRYK/+P1>J,E]1C('R]7G(+8IDC$D(/4
MHF")DN#@#D;/H'=C3>Y(6!UVZ\+]1<.M8G(I&IDDH(H"'PH6N181!D(&VK8>
M"B-8NE9-7!Y@Z,YQCYSGQC^.>H><U.;VE."VK/UD[=D2R3I<@J*H5!@$CD7#
M8%@&&P2Y&P8A+S`XP`#2V2)^Q23P\-`"/L+,?669'`'*1;R_$`<YMDS$DO5I
MM&X_U%SW&X^+K=9B;O9V`E95Z7)6Y7N/D!B3\)4G"B(BKP`S6<>&A_.,.9Z-
M7[?[)MBRLXZNI-$3E<W[S"16,QF(($^"VN?(S]'*4F`%$@9B7UUQ[]WFT;MR
M\*.<NV+65-8N_2,2@+=]:3CE;;$,=7JU19$Q*QLV5-8$PQ2S7R4//XSC/VSC
M/\LXS_3KGK7^Z][X/<>I!C93^]8G9(#9"'R(?86O:'-`$X3Z<9'</K,159X9
MES"<8RD28'<0K*EMJ2K*O++/;8[R6L^;DH+J/8L`%I_D,H(@J-KS,F[(4C9+
M`#"B9%Z@RQZ6I$2:"&;=/-I,WA^3:C6W3X:6L0H<HY'2&Q=K=JURHS(/35OT
MDC)V'XUS'?'7$1,L<ER*[X4//)L6MBUQ$DP@&.>H;2?R![?;ODD8:M8R&&RM
MHH54J9VLFK%UQ3P**UJM:N5"><\0I#GI<XI$$@PY\>KJ>CJ`O<OY37[AMQ(N
M^^M9P]2GK=6[#KZ)!C;L)+'5YT>V7.(KL@X4/"2\'(+>9"/>=$4U(M(02EM;
MK;[>%-*H6XY_B*=IR=YFG^35&U'#ZSA->76?8&UC7KH->+/=HT8#%,I\"1/7
M6=AV';#(E.CDDR(*`P@V2)`DT4<-WW(C#:-L6P8JQF,5479J5GMK&,/7%DW)
M6EI+57F?-DR-A?CQ]3,S',0,S%EVCNUI.F[%2UC8<BZAD;U1%Y;#JM*BJK8=
M90#K%R/XDB)U72?E]B(Q,1,D,2W%YQCQC.<8SG[8\_?^7\>CI#;8'?1[@VQ-
MH@62I;$@]15%%G&5$ZYJ-+J4Y!CQ9,@.,B-L<W;H&7G;6_\`1KPV8<LB&'>(
MRX5'QD0E33+1U:&]G-K2"":_#@;EP9)FW8(TS/'\;""D:B..8YE3&!S]"91]
MROJWY.]N[;+0HJ;,U5=WJ"P.-I0JR/'TY(MR:WBLIY@8>E+>.))8S,C%C7<!
MY2Q&^.8'ZO+)-Y@-*Z"L1=3$2MM]34I:V_8:O-R+#1[BWGVWT.5>`1Z%J8BH
M\DECT*G2\===9!DNXEO2F\>M7%DU70=`CL3ENEAUM#'!4J.+&$D9-IE2\9>M
M-L/>8AH9.&7TQKIGYB6CZ6.=0O,?=AX1)H=S,Y8:[AW'*1<I(=&Z(H1KUM56
MVFK9#"OK32,9]B!M;V6`;'GTX9CK,L624KVK`6L6J:CVJ[:'O=6W7J*45"W"
MHG)/'6CW%Q\F$ZGVI6#F0VUIP?"38&7`)8%7C+H[GO#J:-'$)8Y**:MK'57X
M\X!Z*A(JPWQ)=>[(1[F,".)]Y',S#)DH@2$X7(SXDB=SMY#`]R\I6WQ+[>-R
MF=J9#)?%*5GE=>2^2QU2J\_N<<I(+$Z82LC=5*NVPMRA<IX*DTNKZZJ-<HE*
MA0J[4ZG#@0-?A(YKVA(V+C6$#BC-8^5N*PA'K>(>4L@HA;I)#CC[SCBO4=1K
MXH\FZ+RQT]`;4I;F`R'\8B[A57WT/2E+MXC+*Y:O2.4X3[J&\O-&1,AA"&I>
M&*!DFD(]];34E.EPY;5.:MXF+@,A;!\R<'$SY>4SSS,SS/ES/ESS$S$\];SQ
MEO'W\=2N8IJ'8VQ50VBRM$0@JI+&4PH1B(`1#Q&%^(ROCPD1D9&#HZ.C.?&,
MYS]L?.>O+KNZP+R@U?I+<>@=K:_Y&"0Y&EIFFS!&P"YPMJ,#K\##"KF7[:W-
M.^/R"0J*P$6.+L#:D/PDA&CR+*\+8]*M:J'R;MVHXO;6EM'WD^T:-L%CL45`
M3MNK+,?,VFH#RQ2*Y8BJZ\26+6IF3BVQ3B&&EN/BN$NM82/Y4,TPG^(/[EJK
M1+R7`#2,[C,#"E!O\FK-%%I6W*S0KH\E#Z9%)'7G'TD(^T+.;&0A6<O2N(:I
M/*2F/LP+RP]`UU<-JWNF:IUK7B;1L#85CBZC48`+&,OR<[,$)'%96]GP@81G
MRLN2D7U('C8T8V2*<;&%>7C5G:34CQ^M6LEL4C-#*,1DZN+N0N:M5-,98O+M
M%L<*>X.""8((BHM3&R4DN$X8[^[^G)[ECL!J2C/-8H+&)MYC'&P+MEV1(%.P
MBC04$ZLF9(&`<'S;8X%P$"1.99_"]SNWG-N\HX`9,D1HS]`*E.6-Q:B,0<9M
MURQ)!JOT#64K#;FIREM6I,SECVB7HN!@5&*<:%CTX<PZ@_V]>%-+X&<9:9HZ
MM."2]D1A=GVG=AQ\L.WO9<TP-^D4[G"TI=1$B)'%@*L&]CW(^KQ$2,]EPO!;
M[\X.D'ON>J;+M>6RU%(JJ.:M*"@?`K"ZJ5UAM,&>)@[,*]L#,00`0`?)B13J
MGMAK%W3]'P6!R+Y=>K5S;9'R@EU6VFG9*DF8F8E=66>KD9D#8+#"?`AB#JDG
MOPZ@X^7/A;.[*VU,"U#8FKSVG-&V=@3ZV:FKM/K;:7JYH%IQHB4A;T("MR5:
M2YANNYAF;NYX8KA39%U$G)1\-''R\L<'%Q46$5(R4E(E,A1\?'@L.%&G'&$K
M;'$##&:=(**?6AD=AMQYU:6T*5C7[]V+N#R/.C?CS=4D36>/FJR9&"U'$+4X
MRS87EK2+.[1DA%);<_,;<MA#<$P2CW8:HLQXR4,&R<UA^9[6Z_DLUM%.U2<Z
ME6P[57;MY7T0!$S`5`F8D"9>X-$K.""4>\C`Q"5G2_R!W/!:OH&3Q^4K5<G>
MV9#L5B\59_<#6R(DW(M$9%@)Q4DJT+5R+(N?$!9J(X<NJ[XQG./GQCQCS\?&
M/GU>,^,>?'SY_N^<8QGQCSG'3MGX>JN\=!.)4_8]9/XD-X2EO(`Y#DRK([-A
MB9,!TURAP`+3;SSB:"BM/9E*P8A6$2\N;9RC<,RXY@$>K[KSMW\C]G<0=C<S
MZO6<DZTU],_3MQ66",V6V5>'P6F_7VKA(QGZZM:^,;%&F7$H4X<AJQD1N5IJ
MI[9/R^`G-&Z<&>0U;V]7,&S%2+PS6]JT@5_T,W?7YA;3L@&PG+B1?TAA'<8G
MJ;(.9](LP/@-Q>(R7DT/:%WC'#NNN9?$X/)"R]B[@?(JH;'@ZY4"&SC;G](B
M3]D$OF?`+BE^PHE+(#%7:7-L[5[OK>P[9@6*Q.?QA13R%NN<MJXS(M^..=QL
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M"$CGGB1ZU/\`E-G+%?MIC4XVS$TMASM!-EZ#@UVL>%.WD4K`PF1-+WHJO@HD
MA,%1Q!"75Q79'[6ND]V:G,Y5\E*6'LD"?LLU7M24"PI)=IC,353%Q$]=)^(0
MMEBT&R5A9/AX./E,D0L8'#F'N!&GR`ST;=+R2[2'"#D!KJ;J<=HS7>H+<Y%D
MM5#8^IZ?#T>?J\WAIW,:>4Q71HR/L\0T4M'YK`3XY@<B"I]IE81OTIXJ56I>
M%G//;.OJ]?M,Z7W9;];3R#U5N?ILO[==-0!*FQDDD%E%K`PQD66#.%*:4&.M
M);#V5H5E7N+R-GMR]T3[8XY<D\?PS^<+\_?[_P"VOC&?MYS_``QXZO6>UZS?
MV&WE?^*M'&.5;/XU`+"PC'`AG@NIZOUE022H&`L0:`]S/:3E\F0]*33]SHX?
M2L=KW_+UE<]6L8U/SLL=1K2S;;21-^1&S.MV&P#R9+:4KM,^,CT!6;PL"ZB0
M,;M;B=R`<*BS'JIN7CYM*0$;)$<<RB.NFO[`7%F,*]649+AY%\$D$H9[U,2<
M#(D"D)<8*<2MKKO1[>B=^]I70^ZH-ML>-VEL?05Y8#:<4[B-=L5)N4@9%*<<
M0A2W(D]TJ,=RI.,J6*O.<?.<=+OO]KKN-%DN%E\2-UDE/NJ?(*)$A2B2'E9P
MI3I!)%F<?>=5G^\Z\M3BLX_:5G/CJV_F3KG9^I.P5QBUQN*HS%%V#4-]PT7+
M56?9''EXL)5NW<;!(,:%*,']1$(8`6RI#^?6.^TI:6U>4)E=I;ALCGNWU^ME
M,7?RE78:5)Y4+59K&(L*)S#E26M8*%6*T2N#(A5-B1@N3GSKO;^OM&$U'O+B
M+^!S^'P&0TW(Y2F.6HW4)5<J6:]92Q?8K5TG:=2NS#I6`%8&F)R'BH8"A_A_
MQTF.6G)34G'J%E$P+NQK*L.4GU-MOJ@JO"Q9]CMLR.,]X:,/CZY$2;D6$ZI+
M)DHH$=]26%NJ2[]&=E;MPQVNT4!SCS&RR_RM0+U\EK+:WMFDF+0GU3BKD-,B
M/ARRGT))2W&"A0HZ_4*-$-QREAJ52['O^\TX\XQY\?E^W_O_`/$%U^V?W_./
MO\>?'G]V.M@&G[8_EC^G5*[S;'FZ&P8['X_)7<?55BT7O"E8;5EEIUNVLFL)
M!@3/`*ZH4)S(KGS((B6%RU/Q=TC5,QIF;S>8P6,S&0L9ZSB9;E*5>^*J%?'8
MUXH0NTMHIAC;CB>0")NCUBR2A0<:TCG!QE*X?<IMN<?7I-Z<C:3.!$U6<*^G
M0;,4JT1`5FJ)T@D7"1T2R(B38`F$LM,M*E0#7F66AW6D):%[2O)@G2_9QV?M
M^TJ7+1W'*>WYFL1A+[CB"QXQJ-M\!7$JRII0XYUMMRXQEIMS*663/+64_#2*
M2>^SC']I=N?.?_1^E\YQ^_.?U:0F,?N_E]_MXSGQ\=2UT0DY?X='EOB/^H4M
M.^REE?395A7Y8C8.AU2.7\(SA60\"X6HM.?*?8]7KQE/GJW;/$[)HNBSDR%C
M<MEM2&VZ8@)D[ZI59;''$"3!<V2\8B(\N(X_I"VT,HT;NWW;'`@2*VN:YW&+
M&UH,F0*\.\;-)$^7),%1U4",'YS/KCRDIF>:&GGMF<BMQX<-)+NFWMV['80Z
M22ZXHJR;`V%8FQT*<<PE2F6")F3;:2E"?;`CVT---I8$0G#Y/%+M"\->/&JX
M6IVW3>N-W;"(C1%7W9&T*A$70Z>L&64YD<U\&R"'AU*M,%*=8AH:&&$7@%##
M\L1)2SA1SR:G;%S'8[A7#_\`-<,8&_7K5L-Y(\X;_,/II/$/Z?'S[WYTH#Z;
M]V"O9PK/SG/6QY1Y]"//W]*?/\_&//5:[U9S)8^QA<%C[#:%'X,W&!385>'%
M#BKH44ID9]58$>0*B8#R;!$,R"I"]?BMJ>#S5+:-NS5*MF,N65'');DDKNS6
M":R[ENP`V!8/R;S;4"VP0R[UID!.!<^#4:[L'9;?KL_3-H\#--V:8!MTI)P^
MQ=-TA"#HJJ&M`YD8FX54>6D65PL#)J9,BIB!;-7'`22XE^"%"'+.'1)3L,ZC
MYG\;+#N_46^](['USJ:V0\5L2I2MP%!9AH_8L6>)7)R-C_HI@[VB[97#HPPA
M/TZ4OYJ&'<NH=SG#S**L)SC]I.%8_P`4^K_IXSU_/I0GYPE*?E./.$^G[J3X
MQY\8_?X_X]+>SW%S-_5BU;))JY%$B(CD;?R&9(/4\'H+WR^`,T^'J$S61DF9
M`R+F9Z>=#LCJV'[@!W`P=B_A;D&PF8;'?$1A&Q8J%4M+FK%:3!5GR*P:E-!8
M6>&J`)@>-=SW6.4,YRGYK[?L#DF\92-<V66U%JZ-2^_F-`J=&E"H<V1"8=5E
M+9-OLPDM99)_"$N/_5@#+4H>-#0U>'V4>U9IN>TM6N7'(VC0FS+'L91DEJFC
M7.,'F*=4Z6$<1&@VN0K4@V[&3UFMCXA4E'/S0IP$+7LQ#T6*W)'&&]*E[`8+
M&OE\%+;?:/8NUT&):?PKZALQNRR[3[3WJ5E6'VWT*0YZLY5AW"O*_.//6QY[
M?!,67P7X@O0[@S@&>-VFVD+$;2TQE\>B0PYN$H2A&$K0<T2A[]G&<OI=SG.<
MYRK+?[G7;&L:1@,/A&LI5K,IHN=7*5-*M6IP9J]@3!1-MLPUYQ(FWQ8)20-9
M!9H["8NCOW=?<=DVJNK*7:(VLK7K70%]<+UW)PI;Y0Z"$XQZ!)%19`2J_FDU
MB#$)D<:\J^V)Q%Y4:^FZO-ZDH]#N;L8\S4MK:^J4#5KK4I=MC+<4;DN$$C46
M&&%=PTB0K$_@V(D`/=80T&7@4\77]V:$V/QLW?/UO\S+J.U]%[-DHAJ:AW7Q
M2H*[:^L;PXLU$/J\/):1(QS,F`M>%?4`/-(>PXT^XE>T.7_<7Y^WI5_3/6ND
M[K[T2_W&N72X7&,!XVFAE[.,KSC\V'IU3'G\^5+<SYS.-R.,XQG"$JPI*$-I
M3[:8/LAF<A;NY?!7'-N8Z<=-Q:K)$]:&#837:L(9,P*K`6.6*C]A2N)@>2.2
MMOY6ZOAL;B]:V[%U*^,S49J,:ZS06%1UI1U'W4/=*87)NI.IQ"7S_($6)&3D
M87X,6]Q7D"WRF[&D1OS`[89NQ6]"R5@#8]/L`VZ.VO!P-R`&QCXP.':8F7:%
MPK&%8%PQZDXSGI3_`(PZ&LG)_D!JC0-5+3'2^S[:%7ES*AEG,5^&0P1*66R/
MAM.-*+9K]<CI26R-[S*2W1&QE/-8>]S%Z7M%M_AL%9*QE++V\$N@>6W6\Y!S
MR>0C"O4Y^R]A12"E)=9QAK*<X1CRM#F<P)[)V<_VFW&GQG'_`)FU\9]/QYQ^
MIF__`!X^_P`^/G'V\XS]^K=JG_C>H]POT[B/T7/;=-"2&#%?P*-<JL%!<P?K
M]0043]3Q/U,3/*S[A\;SW'[+QG/,XVO4.W`Y;UE*R;&8R]H+Q`8^,KEGR&D$
MCQ(>43$Q,=-GZ@[-_;UU-6X>)5Q]K.R)N/9'4===JK.NUEFI%EMK"Y,E,@4F
M"C%NNM8?1'P$-%Q8;F<_2"-Y\K4=6B)^V/Y8_IT=9F?L.>M--UC-95K3F2(S
MR%J9F9^YXCV\#'_P1B!B.(B(B(CK>E/2M/H5U5:>K:]70H!`%JP^/&(@8B(F
M9^/,D4\<D9R1E/,D4S,S/Q;+6X*X5^;JEHB@IVN6.*/A)V&D64D`2D3*#.!G
M@&,J^'!RAGG&74_&?2KRG*5X2K"@?,/C3,\.-NFT8]!\CJFWY/F=0VHWR1DV
M!;=3]75)8S&,(7:*<LA@$]3F$+E(MV+G4-_Z<2T,XOU`7N75?2]EXD;&SN?+
MHPT2.R?K^2C&QW+.#M#.'1J:W6$$*2A\R3.>5&2PBUH%)K1,S]>XP$TZ4/Z8
M'(LI7`5XFQ%HUJ:H.9*"DH@&KCG^X$S]Q_O"2'ZGQ(:/WFT/&;CJENV]E>CD
M\!7LY&ADGD*E`I*_;;J6FS]#5L+5$P93$(L`EW/@+08M#Q`Y=3G#'>+-MB,F
MR^L+AD2+VG2Q',+_`#6$0^O(\Y$L.9]I%HJRR'SH5W.6L'C.R,"0^V/)I>%9
MZ'[D/!XAADA')#7:$/M-O)2^1+C/)2XA*TI?'?B4/#O)PK"7F'D)=8=PIEU*
M7$*3A<?C=Q0J\Q5Y39>Y91VMZ^@ADK/D\)0HJ1.6WY:`C<$J1AY:U_W,><82
MSC+CGCSC&<F(*[?;2\C-3=W(4VI2,X^G!1C/I_9QE*LO_*?CX^/M\^/G'5DR
M]?&9&U)"G(-<@858=12)@4Q$>`MDA*)8`_7,<3XS`ESP,#G+M[O^YZ5@5TE.
MUS]*N&5O&5]HOMK6%+F2%SJ24M%X4[3N2B&#ZC>#6HB"8XCOQ_M'>#WJ2G/)
M76:<K4E.,KDCVTXRI6$XRI:XQ*$)\YQZEK4E"<>5*5A.,YQCCN.\M9G1O;PW
M9R:X^2L-;Y=BI08NOKE!$"6.O1C]\ML'16;VR2$\^"<Q4<SS\T.EQ3X:I:.&
M%D6<CX*:Q1C;Y'@>W$F8!SL(DOZ=S`Z!G(E"E/90KV\9RZXI.$^KQYQG&?C&
M?CS\9L'[/E`3LKCMR6I6PJTJU<<;_=G:_6:M;AVI&MSP<C7R@-E",!NX]A^/
M+6Y!#2;H>$"YGF#W!W$2@QCJ(]6/QV..IEG5KKJM'(46VZ%\%KB_6BRLG5E$
M/C^YBX(2B8F/"2F>..FSJW=39=SRMO3S#`U[>6P>8_3\YK=FW;##7%4CE%NZ
M+Y8,KAI!"Y60%%B5#^[SB(2<V#IC8-(IU:VM="VY$?9F2YUJ6)F$2LQ(F2!1
M)1TC-$./.$N2)YF2S#R#%_4/DN/$O^?=PM397X?#MNNZRI[?.G<T`Z-L79L&
M^#H>!EA4H)IFK9=OTFWU;!"5/B6'9PWH;AW/2P0!K["%)5XN)[#.;P/PZG%8
M?<\!;Y7:>X[1HNLS*)Z+XW6:1C96M9?9(24S73KNMM%I/HR7$I')A'VL3\E'
M(_+I&W$L/%+(8*%%&"&8##'9$$%9:&&%&:;8'''8;2TPPPRTE#3+++2$----
MI2VTVA+:$I0G&,,7?>Z89G!+P>&LFR+Q,/*6HIG0]=*#YK8H%$UDR?A`C=:L
MY2P5PI9L6YT1Q=JNQC-;VFUM6QU@!](4KPU0KZ\K)W_2(W<TQXUZ\")M\RH(
M-</3+"8V%L2KKOZ/M]^CK&>Y$[87JZ\-:+Q34[>(KYHNOB-@F2(-+C[(6E(P
M,M8G8F(G)%Z/A_=7*JCQ8PA4J\&S&..",F.F#HU0>UBU^8+]A@'FTO!8>90/
MFPYY\0'GDRX_:,3/^.M-O;Z$.?ZVN]*F-]2`EKV^L)/UI7$Q+&GQXK")Y,Y@
M8^YZ6X[^/<8S"1QG!C34_C$O-ABE\C)^+>_SD5`&LM'0^I&2FE>MD^R#N#3E
MX0TIIT>MJB(!QQQNR2PS%"7;UX2W'G9R'@=50[AL/18A#%HV_=QFLY34J&.4
MADEL)UQ"V,6JSOIS`5$96',_7OE3+S#L9!2>46;67\/1S\N-AG[=:MS<=+):
M;/+R5AL,]+W;9I,I.3TN6[(2<K)%KU:I3ID@<^\00YA/I2MSPTA+2$-)90[<
MW!:I\"^/T7K4`F/L.QK(^S:=OWL,53*;1<GAL,X#C5D-H.14ZJ(K,)5`RL-N
M8$27+$CL2<U))SHINVZQHFE#B=3R=7*9RSR+;5<3GBXY8_)R3O8L8@$#'JI)
M*9XD408F(/(L2U^W&^]W>ZA;#W%P.0P&J49AB*%PUCY8RJWFE@JWI<12VV<R
M_*6@\(_?;)1K,ZHC,2BZZI6M:#6=84FN1E?HE/K<?4J]6@AD?EL?`182(\6/
MPRYA?U",C(S@IPGW73G72""U//$/+6CMWD>VZ_PUVYG:^K81QKC7N";,=@!P
MVU*$U=>RDO2,GKDE2,>D:!D&T%R^OG5^C&(MF0K.?4]`#O'/?]8CWOH_7/(_
M4UVTOM:#1/T>^0I$/+"X4AHT-Q?AV/FX8Q3;N8V?@9!L:7@Y1I&70),08A.%
M)2MM:GTK<KFIYP<A)ML4[90O+UR*3*RDCDB?'G/!6T$1-2PIY(I8LC@',F=%
M]U.V&,[BZD6%%=>GD\8N7:W=A8K"A96H5C5+UCR&/MK`*UE2QD0$4O!9-K)B
M%`>QMW'O\GO88_%/<$VVQI;;=B1F@SLJ7[0.L=HS+J!TB.OOJP@*G[%+4,&?
MEQ:!(2WY!F%)9'GIXK'=^(5XK3>NN2T'R@AHIU>O]]P</!V&5&9\CQ6V:3%8
MB'H\_P!&5H%<L](CH:2B5.8;5(%0%EPE*G1%Y7W6#\-]S`8G9L>L;<X\RE9:
ME9!FOR4].;`AIR1@D%O)BS)J*CM?2@49+$@>P[(@@2AP@AJGFQ#GV6VG<L9Z
M5XI;-V+PM3Q4[B36M=S'!`8J.;73YRQ2Q%DJ\4P/FF6J0EIVMUF8@]GUA>/I
M462+0^221%`6)9^9&1E!.FIFMEU;![71W?7,G3O#>B:6QXFM)KL/KV!`IO(6
MT%C[H-2CL**0D["5F7]VPP<\ZKHG<#;.WF5[4[Q@LEBCQ)#D](V.\"W4JMNF
M1KC$VG(-Q_$-3K"J;Q`_73LO6',5Z:#H$[)G=+U%QQI$YQ>Y*V%JD4M=HE+C
MJ[9,@(<7788NR*:=LU,M3T>P8[!A$R['Z00,ZZ'F*25)S84P:!A,<Z_>CNOO
M"=O[3]$F+;'[\H>V9P00A<#0-32XUSM-FE&T8R+&-?E:7HR"8(=4A+\U8CHV
M+"8PZ^IY]QM(SM!?)'\.IR-IL](27&2^4_<-*=>RN*K]WE6=>[)CFG7<^D$P
MMT-VC6#Z-G*$KF692KNFYPXYF`&<\(<B77>QAW*YZ6;C3],5JHAK(2T[.V?;
MNNL0XR%N*;R2M-;F[+-/-(PG#BDB0Q!"FUHRAE2\J0GVR.#[5;1D6;&6V+HC
M<,;-^A-RK3)KI@);/HN+&VHW%$R^%"R"9)$HAF8F.?";;^0V@82OI`]O'Y8\
M:HZ&)S,8R_E017&9&M$VL8X\=955&1&K+V)D%`M=@60N8G)?]N[W'KQ=/RNA
M.:P;*M]IQ'4NBQ6I8ZPR"";!+?2UJHQYQ1Z9&:,2X6%#CG$,H*D7\?5NM-9<
M6VW;QWQ`]CQ_:QT\)N"5BYK:K.U]&)V/)PD<+%0A5W74;HY9\Q$>"MP8:*9F
M%ECQZ6G',*$99=RM2UJ5G+7;5[+%$X;V.-W9N.RQFWM^QXSF*WF+`)%UYK`@
MP=T4\RJLR242EDLSPK[P;=OFQ(WZ`1]YN#@(LEUZ0>E!W6N&^S><?&*,TQJ>
M;I,!9P]KTR\N'7V0FHR#S$UZ-LP9K#9$#!6$W,@XY,BJ&94`D=:&W_<)94E&
M%UO(;'I8[KJ\:[1H8W#XC)H=>RP5?C_**#`9GR((L%5K`$_R-B#>TS.1D06Q
MEXPND=TC[6[\S=<KF,[LVR8.S6Q&MNO1<C'A(&<1X"R:@W[K2'E*2)=5"EJ\
MX-KE*4J['WG^TVX\?XQ^W\_Q\XSIZZ_?_C\_/^'[^M@(G[8_EC^G2O7;E[*_
M*3B-S"U5O_8]YT9,4ZCBWQB6C:98KN?8B,V>AV*L1_T`LS0H6/=2S(2PSQ67
MY,?T"-O+:P\[A#2FAL8\8QC^&/'4-W;S.+SFRU+>)NIOU@PU9!N1,R`N"W>8
M2YY$?W"#`*>(_H4?YZM/XW:QL&IZ)D,;L>*M8>^W9[UQ=6V(BPJS,;ATK<,`
M1QX$Q#@B>?\`V64?XYE!7OM?[R[<W_L_2_[\>?/ZM(7XQCSCXS_C]L^?'SGJ
MY?LWZ6C.1?:'W]HV7(2$)M+8^^:8B1<PM2(H^8J-):B)C*$84IS$1+I`DO1C
M'E?TF4X_O=><[E79AY0<Q.7VP-^ZSO&CH2GVJ!U]%Q\?=;#=@+$T15*A'P$B
MHL2%HDY'MLNF"..B*:DGUN#J0IU##GEO%H_:EX<;-X.<8Y+3&V)NDS]H,VO<
M[RT=09":DX-,388ZLB!,+)GH*O'8D&W88I9+6`%,(0XQ[9+V<KPBS[)M>(9V
MUUC'8[*USS6-G`-*LN2FQ6=2J%YE,$$#$I=`Q/!3'E_B>E_I';S9D]]=]S6:
MUZZK5LY.X(7?L"$4[M;*7URL`(62?C:K2?CR,3(1/WS]0@W*1>TN->YWHR9"
M.HNXM);#$=>'):RDJO7JCS@LD$2G&,I24']>$+(@/LN?32T.2,6*\X(:TZMX
MOBEWKN&&]=:0DSM/:=.X_;3'CVD7:A;$E'8".'F&6VTFFTZSR+>(:R5L\C+C
M\3AN0Q/"#9P),1@I3*EO>H[BG:9TMSS0U=V9->IM^1,8W&1NSX:)8E`K)&AI
MS^70>QJY@B/S90`$Y<'B)@20CK)!,N^P,>;%M)AU+)[#["W<7I4J0#6J'0-K
M1C;J4#SM$VA6HT8E"LN>EQ<7L%VE2XBT)2E3S:AB$-J=0ELA_P`K4B9M9G0N
MYV,Q_P"OY,=<SE$9$B8Y541ED!#P4ZT,U;-1QA#5`1C904<3XP1RZLT-8[P=
M@\[F?]'8)F[:GES`P!%5]\RA,E\5EBK09%^ED:RV$ES12=*T!<Q+"!45ID]W
M?O'!;/>IVF^$&W+Q"P57G7;/?]TZ\FK'1<VJ2;CB(V'I=3DQ51$Y)5B/4>?)
MV.1=:9BIB6'A&(GZX4!\US('8#O'+/?.]=N;'VMO'>.Q-3:YUNFK-Q]\V1;;
M35R=D76;AY"+;;C9^4,!*E(2K0,N<X^PTHF,8F@,N+;;E6TOQCXY_AXN5]^G
MP2N1%BIFB*0T^TN5%B9N/V3L@X?PAU8\.!"*>IL:Z]C*QOS.8LIWY>[Y>S`2
MK:,,/-V<<N..I.*>IJYI?2U9;K-+KN'W\(<?</F)V:/4AR7LUFF'\8*FK%-$
M(2_(2#_I3A*&`01PHL($`:#VS-:1K^J%J>K35R]VP/K?E(6FR20-HML.._"1
M!UA\#Z5+JSZT+F9D@]8`VV=N-4[K;EW##N-W`_4-;Q=,X=4U^76J(6FJ1**=
M5>(-Y,KTJI3%FP[(#[K;AB!%ON:U"-?>4XF3?&#FGL*:&B7F-9;ZF9?<&N9=
MIA#4=DN?+2;L"K-994IE@VK7`XQW`6<H=Q`3-?-PUZ"593:SV2.ZCJ&AZDC.
M(G).[Q&MR*5(G_J:OUK*;BZ?,5B>DWI5ZC3MB)5@*`G:_-2$BY`F33X,-+0!
M8\6T8Q)Q"!SV$>6G$72_-#4TCJ/=,"Y(13A&)6N6*+=:!ME'LK+#PX=GJ4NM
M@C`$FPR^Z.0P^P5%R\>\1%S(!T>0XQE2;?7X>;F10)L[.DIG7V^Z>MYY44[^
M?AZSO"1,)6M+<U7;4YBLY)\)PSER(N!;!+BTNX#";6MIGOQ.TZIN^I5M7V^_
M&)R./%`U\@TA4#"JA*:]Q=EL$@6^B91;KV)"&^9L24$42F'V+M_W#[3]QKV_
M=M</.Q83,G;.[AD+)[DKR#0LW,:ZE7(+;*\6PBSCK5(6E6]:E/"160VF/N7G
M=>XC<7]:S=BC-M:^VYLAV)+70]8:XM\/;Y6QSN4.-QJ9LRL$RP=3K2#$I<F)
MZ:?%2T"T0W&,2,FL4%Y"/"-G\D=T$9`CS;UN'>.R#C&HZ/86LNR7V_SY$BZV
M.UG*\L#/2<BZZXXZYAF,B6'2"WFA0GG46CZX["7<2N<N/'6.@:\U#$N/?Z3.
MW;9=8D!F$)]OUN-0^N7;E*G.^AQ7L-Y'$;<4TXVX4/Y0O+-7;O[2>C^!^57E
MZ1<V[ON0CW`"]H3T0/&!U@(Q'ID8G6];P1(XJXIZ,Y&E)HF1DK-,"X6*_)!Q
M1#L1UTT<OHW:_&Y"<+EE[-G;X"(D@UM5/K\O2#&UI96K55F4L<,/;9<7U`S`
MAZN#+:WW;[_Y[##M&NMT33\.PC,+:GUK$>^53::JO>A=Z]D7J7"*QE412J!$
MR<B3&R^(/<HT&'Q=[($;H(0IL]>LVM`0<M(L>K#$I9G]I0$M;I89*TH6@>5M
M$C+G#I4G"TL/M)5Y5CJ@OLG?[S;C5CSGX<VM]_X?J9V!C]WGS]\?],YSG/3C
M/<QXL[`YD\1[OH;6,O4H.WV6Q:]E@9&[&RL?7VAJI=(BQ2*"BH6'G9!#SP0#
MS8:6HYU#A*FT.N,-Y4ZFFKMW]D_E/Q-YAZAY`[%O>BIFG4%=V5+QU.L5X.L9
M/Z2:_M%5"_+Q9B@PT>[[<C-"O%8(DQO0(V^MKWGDH:7$ZIMF)5V]W&EE<JA>
M9RS=B>NNTB%UIU_%UU@8B(2/+[/L&)F1Y*)B8B/N;%W#[=[(_O1VSR>OZ]=?
MJ^N(TJFZ]7$)JX^MA\_9:Q9D;(/QITH29?M*?7,?<ESTT@G[8_EC^G1T8^,8
MQ_#&.CI#];`ZYZ7H[AUOF=H\TZ?HJY2[58U9KZKP%ICL%N9'CY*0M(9Q4[:B
MLK<]!I`PP6:Q$HRC&0L"2[;*<*E"5N,+]5/]U_4&N+5I^+V9-UIDB^5*19@H
M&T"R$O%28L+**=+,B2'(F0!;E(Y1;6"QPY5HY@(I;Y`38[Q)"W9;"M6J^$'!
M1+EL0I@0)&AK1\0<(E(Q,CS(S^Z)@2F8YF.)6'>#$7LQHV032L*5%.S3R=VL
M\W*KY2A0=[K&->U`,:`.F%MB1"8)B``I`3(QJXMK<WS6W30>(FB'"(/5\"O)
MUMGPV<K'A*C%.L(L-PE,M^&7Y`C#C8$&,^M*3IP^.!3E(R7W6KW(7M[<+(:(
MBX=/&W4TFF*C@XU,C-U")E9H](0[8V#9>4*843)296&_?//(4IXLMQU]S/J<
MSU@_M6:@UQ1./+-XJU7&CKAL*4,7<;(Z9*2DO-(A"'!XD1TR7./=$C@$$$+'
MBX]0D<@DD@SZ7);[SZ[.^O?)WS4V*5)CZ]>G)AS!RMMA\S'N>Z5E^XB*.`B9
MF!&.8@9(HB)[9:%1KX;]>V&MC,QF]B"O<89U%OIX['BJ(QV,QZ[2?X$UT3$L
M\%AYL*%S+`0LRB/_`)!'"[Y_\,&D_G&<?[`0?VS^[_5OMU)^O5R`J4)&5JK0
MD37*]"B-@1$'!QXL5$1@3/GVA`(X%I@00=OSG*6F&D(QE2E>,J4K.?L]'4.R
MP]T1#7-;`SS$,89Q$\<<Q!%,1/'US'^/KIJT\3B\<1GC\;0HFP8!ATZ=>L1A
M$\P)DE820Q,<P,S,<_?'/1T='1UY=2'1T='1T='1T='1T='1T='1T='1T='1
MT='1T>,8^V,8Z.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CH\8S]\>>CHZ.CHZ.C
CHZ.CHZ.CHZ.CH\8Q]L>.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g74988.jpg
<DESCRIPTION>G74988.JPG
<TEXT>
begin 644 g74988.jpg
M_]C_X``02D9)1@`!`0$!JP&K``#__@`_1$E32S$S-3I;,35:04XQ+C$U6D%.
M-#DV,#$N3U544%54734P.39?,5]834%"7U1%0TA?-$-?3U)'+D504__;`$,`
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_`
M`!$(`;0"IP,!(@`"$0$#$0'_Q``?``$``@("`P$!````````````"0H("P8'
M`0(%!`/_Q`!N$```!@(!`@($!0T,`P<0!0T"`P0%!@<!"``)$1(A$Q0QEQ49
M05'5"A88&B)255976&'4UA=3<8&1DI.5F-'2TR,R\"0S0G>QMK<F)R@T-C<X
M.4-(8G1VH;+!.F=R>(.TX25$151S@K7Q1D>'_\0`'@$!``$%`0$!`0``````
M``````8"`P0%!P$("0K_Q`!@$0`"`0(#`P0+"0P$"P8&`P`!`@,`!`41$@83
M(10Q87$'%A<B05%5DY2A\"-24U21T=+3U!48,D)68V2!DI6QU0@S8F4D-#4V
M0T1R=:*TX3=T=H*SM25%<X.CLH7!Q/_:``P#`0`"$0,1`#\`O\<<<<4IQQQQ
M2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<
M<<4IQQQQ2G'''%*<<<<4IQQQQ2G.M;;N2IZ$@3]:5V61!ZGKF,)_6I!.+#D[
M/$(NTE"\6"0K'I\5HD0%"HP/H$2,!HUB]2("9$G4*!@*%RV42:/PN-R"82QY
M;H[%HJR.LDDL@>%12%H8H^Q(%#H]/3JN4"`0C;6IM2*EZY4<,!1"5.::8,(0
MYSBDG)%\YZMEJD;F7RT+EE*X=G0[1W7V3%&JX=6-/%KAH8W=TCB"\C#6Z7E=
M[>@23E6]NZ-<HA,2<8Y&&(PK*7*L"E6):VZZ'27MF;M=>0W>2F\2A\580L)<
MN,EE:L4A7C5"0IT,=F-E1>(PU^6+EH?56Y,U2!4<XG"`!"!0(8,"A(W!ZD.U
M.]5[VI4^J%T2[6G36H)S*ZA%9U.Y:6V\]FIY"W(^,V,],EB/+6_!K.FHO*T#
MG&(DL@R--+ITK;W.0'2%&TB;D21,M.&6;1AQBLIBS5*V-X2'-ZEADC6D>69;
MZP6,D@I0@<RE"//8TP(B3?1A,3#['$FDF!P,.+W1ZK]J7:=ZY@2(P$#00Q2R
M.Z;Q%&C329AETF996G.&466'U@J1H',)Q8@Y,+%_HS1F#"(P2E=J5OIY:[+Z
MV\0+<7?JO90YR`4P4R>/[<6<^*%4J4%D%*WUWCL]/F$)D:EP(3$IG-+(HTYH
M5Z8O!1B</W(@YXUQOUU&M)3"3MJ&7'4%UG1Y5FR&V*HKQFKW<ZJF8!AJD4EF
M%41E0WU9L'%6)N+`G<QU>U0.Q4Z0I0^&Q^2&@$C,DJI^DTR]*FP%*$6<@!YY
M!CY<8SY=NV,9S[<^?;Y<=^_.WII0I2%N$<%+@&08P,)@`^$98R^P@#`,';(3
M`#Q@0!!S@0!!P((L9QCBE9)43?-/;-53#+PH6PHW:-56"T$O<3F<56Y5MCFC
M-^Y.)-*-`0O:7=M4A-;WR//2-N?X\[)U;.^MC<Z)%*0KMWE4A\DCATB=B'G;
M6N$:HC3FX)6RI]^J-86PP3!#5#PL"S)-Y:T86S&`,<RAJM<@+V-:6EL-)LJN
M09EBA."41,MRS:I;')O>6Y`[M*Y&YM;HC2N+<Y-RHE<WN"!<06J1KD*U,,Q.
MK1JTQI2A*I(&,I00:6:6+(!XSE2OW<<<<4IR++?#J<Q75B2LVO5*P%;M!NO/
M&,Y^A^OT3?FYE;8+$\#*3_NN[&3I1E4DIJH4R@\!2%T<$*Z43IP#\"P./NYV
M%[@U=A=3#=H[1_7$Z7PN-HK#V%M>6L%'ZN52K..`38-ZSX1Z:-EO($HRE94%
MA+<G=K$LIQ+/1A00>+/`0KTBQ6A,S'-H;IBGJYE?Y),Y&=;FP]RR`5A[([`/
MJ$@F4W-9[CDP]:ZG^`O&66"QO)YC#5\"1>@8X1$4R)O;D2=2<M-,4K`F[=7M
MK]WF9:#J#[/3BVHJ\*S')1K!1>5E!:E,`1C+4(V0QBC>2;;MTEE5!&<BD5M6
M`N5J3Q>L?`:``"4Y>!\CZ6-%TV]L<_H.+277*U(.H-<(-;E&SJ;PBQXFYB2#
M1^OH7L;ZZ$.&3$XS"%:)]0NC>Y)CE*5P3'IU1X1715-`D!:<FX2EYS@GQ>')
M8>^,>'';OC&._;'_`/;S]L?-]U0E1D+<>K!QG&#/+P>W.._R?^_&?+R_1Q2L
M7M".N?`:]JJY*MZI]YP"`7CK.[09(UV<>VEM;SMC65H!>LUS.H+34%;G.2OE
MIHE\?>HG:<*K&*NR)"^MZ.0MR%O:9`!,DSAJ;KU=+ZVI\PUH3L`[U?*Y<ZEL
ML+#L#3ERZ_1R8.2@00(D+!-[;@T5A)SBYFC*(:6E=(6]V=E!Q29O0J%`PE9K
M,IJ0;+"ZI+F0D84Z]16NDR=>\.IJ!(L&S.L^OY0FB)"94>4-0RN:MECTO-`:
MVF$JEK88I*6#RDP6`>>,[T]C\PBKM%Y?%VV3QI[0G(7E@D#>4ZL[FD/`()A"
MQ"K"829C.,]P&@]&I3F8">E/(4``:%2K?X18%COC/?&?]O\`;]'G[.>>5H^C
MKL98.NUV+.EW=\L?9=`E\`>[7T(GTU=%#S*B8!"5B1%:VJ[Y(G`\YTDRRE$S
MJPRRKW!SRK>#:G<UK0M7"20YM3D67.*4XXXXI3CCCBE....*4XXXXI3CCCBE
M....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXX
MXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE.
M...*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI4-?7EE;VCZ=$^J*,
M+US9(MLK3U]T^2K6\L9B@$?V*N:(0:R"0Y#]R3A95)TZ1>L&]BB<J<"'WQ]S
MGY%%T4SE-[:V-+82D:F]*E;FE$04$!"-J;B"T+8D(`''8!*1`0G3$A#C&,%E
M`#VQCRY\#KPI0AI?1V2*O0X9H5U3=(7U^,/RK"`E"[2F60=`?XD91F0Y(D4N
M9#,^L")2Y#@033<Y$$DW,K7EX;$Y*'!^08R#!81ASX>^,A[8%C./DSC..V<>
M?GC/%*_6ZZ]@(;/3A2>`008&`>"_#D`P8P(`@Y]GB#G&!8[]NV<>?*\51Q8&
MDN_5S:K2/Q-=:;(R25[8ZCKU8`$-BI?)#P+]HZ.;%.,@)^&Z^GIF+.CS#@/K
MA\#G*U>G",AK,"&W4\OC2!J4#$I),"82+``8SC.>^<>7?&?9X?\`EQV[_+RN
M%UIHW`)1J%>,^>\N37+M>H3,MAZ=GL4<2V*=UK;571ITD$3E,)D.0#$V."Q4
MD#'7E&,)B*1QUV<&%P(."J2F)E*FJHF4-)"0@)IA8?&4''B\L=O$'&/%COGS
MSC]&/9VSW]G.[9W*&<MD/*PH*.$,`A8[9QGPX[?)Y]^^>_GC'G[,^>._*Q>O
M^]-N4DXUA0_4(AS?KYL#/(A%7ZMYN5EQ1Z\;-)'R/,SKE;3D\>D;8VL]E(3G
M0""=43)AM4PCKWXA1<B0QY:WFDR"2G8P(DAI!JP0#`@SXBS1B`8#[G'D(LSL
M,.<A\\8R''EV\L\4K@VU>8Q)6221Z0MZ)ZCK\U.K'(69:4!0A=V)Y0J&UY:E
MI!F!`-2N+8K5(E!8L9",H\>/+V\['Z!-J2&8Z#$4U+71>_2+2R\+ETT,D#FL
MPK6O,0IZ0)E]/*C!9,,/!A)2<PKIEQZUX#SLL^5.`9).*&*,#8:^VLAL>7!R
M=TC>WH$2U>Y.*U46F1-K<D(,4+7%8I-$$I,B1)BS#U1YHPE$DEC&,0<8Y(+]
M3NP*3-FE%DWU)&MP9$NZ&U]T[10)N=TZM"Z#J=Z1PRKJO?5#<O(3*TB>:Q"K
M$$Z:<&%8"H8Y*U+"<B3J2LY4J>KCCGC.<!QG(LXQC'MSG.,8Q_#G/EQ2JLV_
MU@XN#K&Q6#N)YBB(Z.:F,DAC[6?DX*<B\-PI3)D#U*`$9P60>K9J3JM-'&Q=
MGU@Q(5,I"G)$0)0>$<LFO,G;DY2`0QE]@A!GOGM[/+MY]^V,8[8[^W./EQ\\
M%'5`0N^M_5W6SI_]9307=G7"IL5W(3Q9+:%MM:PN4YCLZKM.>(D`<R`=>SN)
M31M0`/,,7MP7@9)0C$V0YRBIV_R$R9+D*T'D`'L-\L^6/9VS_JX[8[^W&?+V
M>?%*L<J)BR!;!J/609R(C/8O.>WGD';V_-CV_P"W?D5^W%H0F$Q":SJ9/[9&
M(=#V!ZE,JD;J>6F;F&.L2$YQ=W=:<(0<8(1HDYIO@QGTJ@S!25.$Q0>2`?2T
M_P!T('6,">9W8T\C<$A$>294/<LEKVC8V!L+[=@`4."XXLD2I0+L2B;DV%#D
MX*!`2-R)6J-*('"AL=+KPW/GFC,QMRII)6G3/N[;9JKJ.Q2UVA\AUD;=R9BJ
M.T[CKJ;S"$+B4JN(:TGRRN6(,,@TP$DD=RGFCDSLPEQI&QD<4J1?I(ZZR6PF
M"W-TK+C+E&IUNQ-&2>Q.(OQ`B'R`:S0=F.C&ML/=TV3SPHGIXBBMVM*0HB\$
M^@=;""0H)`K2G8Q,[)M?R$S6(S*,/;`,Y_WO'EGM[/+V9^;&>?IU^DC40F1Y
M&(D(?1%]L!"`L(<>'MC```P$!808[8`66$(`!P$``A!C&,90RF3,Y3,IQZR4
M;DPO/;'?_5\LYQG/S9^3M^GM[<XXI57KJ&LN=>GK5[;=H&)L=]3]S=<9^X.*
M4PM*J%5UE6$UZ^7@P>LF'$%`0R2M[6<4[B!2<%*("$@XWO@C&.6OB\_<XQY]
M@Y$#'?/?/8`L@QG.?E[X#W_CY5KZV;V@4Z47JVD)"W)=)%=01-D08RGR:ID4
MJV"J=CCY:4!_W!BW#JM3&)"R^QXSB\>KC`=@(@VE09[XSV^^'C^08L9_]_%*
M]N...*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XX
MXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE
M....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXX
MXI3CCCBE....*5'=U7M9I9MOT_=E*9KC&<6RHAS?8M+B+++$H%=-*RABN.IT
M2<\P0<(\O4X@S-'SE@18$G2.Z@?W8?$6.*73S=-@N>HJZMUA.&B13V-('Y2U
M*!9+71U_%DQ'+8FYD"%D:1WA\L2/<8=4AF?3)5[2>4/&>V!9LU9QC.,XS\O\
MN/FSC/R9QGSQGVXSYXY56WYZ;>R.K5SV1M/H77#E=]`W/(E]C7YJ-"5#:BM&
MM[9=1G*IA<VMC8[+&IEE[#8AA9+G8U*?""-^,F8SY1`S5>'A>SMJE20.6R10
MF[(,N&.W@[>9OSX[8\\Y[8[^S'?/R_+R(+>UX>-KW*E=#HL!<LE&[5SPNLGT
ME(3@U2Q:^0Z0L]E;-6"I+/!X`-$9JV.*V02H8,DFO<N9&P`O6%H/#%"V7MLA
MNW+I-"ZVE=IZP4E7T@<(%8$D#&!PO8R:V2S>E13:`-!,M1K55.-5=N@\,$K<
MCF,V9*Y0F7M2(2%*C.&5FO5727UU=%Q,F=F"U7Z9'-Y[<;/'C8O8HV=Y2+R"
M"7$DN5H+0;7-&G=!)B5#BB0&)&Y6J**--19"0G**4JY1=>OU';)UF[TY?E40
M&W*O?RR/A&!6#%FN11TT:+`L-BTAK<DQ@6]U9_$$QH>&WU-V9U``*&Q<D/`$
MS%>#<CI.ZTZ1TW/+[AO4+VOTZH6#I/6%E;/RZ';60!J^$%)3?%X)3,2O&,RJ
MS$\HD;^I01Z'Q)HG3Z<[N*Y,SM[>5@T2@CX$6U+V^U^`4^:C;^;55JH;R"`)
M:SV!F"W<K7]S3)A!&!G7PV[SW*PHLVJ0@PE/<*YM"-NR4@0C4OI3P^$S$N[M
MEK_V'W=U:@75-A=?:_P*HV7*G7!PK^1RB2:E;$;I21V6M9=EK)?)T+5BLIO#
M*[SEBI*F[F&M=6Z52.6/\?E;JXGL?IE*B=9NGMM/MNT+7?<.]+>25:[+L+8?
M1#4V02NI:OBX33SF9=?68*TCC;;,7!,8E7.4"8!2-+$U./@I3)U+BB-,Y(9!
MY#U$],EK++];-P;\L0F)EH0'Z_;96.YWM3%C1QH+(`5`RW"7I%$UJ0]8D2$M
M;#*Z^?VX$>SA(G,:C&(DQ&&Q.Q:W`&@QW;\A$$.0C",D01A&'.0B"8$>,#`8
M$>,A&$6/'@6!8'C`L9QCHJUZ`(2I%.!(@X[A'C.,@[?)G';OX>_L\\X[_+GM
MQ2I/]&-R*ZWPUEKW9&N4+G'4TJ*=&690"0C+^NRK;/B+FHC=BU?+"L%)L@?X
M7*D*YI,592I2'E`%ND"`D+:[H\YKJ;K]47;+:Z][)I#1>U%VN&L=+32151--
MAXC%X_(;COVS8DKPT6"TU&Y3MA>(W7-7P*2$.$1-L!O9'J2S"3-#F='%B2/E
M!,,[`Z9LXDFN5F=:*JXZI$G:XU5%3[S0%I!Z3X.:Y]/J:M.%6,IR0'P@3'O\
MFHB)R-6(D>!+%"M0=G`30CSC%+I<T:@*U)UA]"62K->*1K66.2\`LJ<NC].H
MT@G$E=SU0\>D5K'60R-T<%JPX0SE*M2<<<,9@ABRI6+UW:;[6[)5"YU?/-\-
MH[+9ECRCEK8T['KH7?,;8YFUGC/:)5&SE,3AUB5_)&?)ZHAEDM:6#%'EF1KE
MZ!&(UI<'!J6?.T>U>LR4VC'=/=D>H)?^J.P\@PJS3ZYVJS7J[:>V98FM*:8[
M$4E=LN@\=E2&T&8DD3@\51;+7]?2!O\``O8#)^@$K6MMHZ%Z[DJ4!8@H<"[`
MQW_T>,_\''R]L^?E\WR?/S';;C1J$W=6#Y7<T2NS<E4*6U_CLJC*P]EFM=SN
M-*P.L+LNOW])DM8P3F$/I*9Y8'5&:6,1A!K8L],U."]*<I7=^OG0\T\J2<1R
MWK@=K>W6N*)J_A:(3C;B:(K$CT#>#,%"&YUQ2S"Q1.C86M3G$DG-+NCKY9)&
M@919B!_*/P(\?,NM%KY.;XT0G+I3C(HDE[ZTS2MMO:0CR+*@Q=(K`USDZ>=*
M(>A3I`&K%;E/X$3-H&V)"`B,5N$D2)_`<$S)!L7E.]7S?N2PQ?I5#-;HS8/4
M!UT/35YLCLC<;\"%:H-S2I3J#ZCV`21Z&'J[.LR07S"T1,R%5$.:8>WLK]F0
MD*I@U-R,M$7Z2C4+:^\P'/VVF_>W%M.*T@05,%I>?..F]#-98SO6/@]GKO7Y
M5'Y4](DP<^IIE]@V/+7DY,`)JI1A;G)X%*[:UIW!AUEUW"+-@CX!RAD]C31+
M(RMP,19AC4])@*4Y"DH?A-3KVX8C6QS2&@`>B=$2U">`!Z8P(<GGW9(LU`,.
M5^,]R\_^5]OEGY\]L?)Y^?\`!\G*X$SU&V%Z?+RXK=282[7+J^\K#WEYUO)E
M82K3I^2J"@C>Y+2LBGKSE).HC*591CM(ZVD#XGD2.1J%#G%W!9AS<"\=6?9Q
MW!.;"K&BZUUGOO%QW9.FFK:T;KRC96O==*IV^M[BZMK7(+%F;D:E2X$VM+HN
M`@8D#N]._J)K4RIS7E2C3FJ5*W-53AN=O5I#J+'O&Z-;==$;W3O\PDDM8ECE
M%:GO9,OBQ3[CQ^D2IK.V"_<V@S;_`*(8EI21^\&`$I3SB[<@<9P''?MW]HNW
ML\6<]Q=OT=\Y[<BJZ7'3@%HY"IO/+;F;3<FW^P*ID?;ZMQL:#FF/-Z)C1"*A
M]*U,VK3#%S+3E7EJW!-'\+`IGJ7/"QSFDF3)W1S);FN5?BE....*4XXXXI3C
MCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*
M4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CC
MCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4
MY_,W'<./9VP,H6>_LQ@!@!9S^CPX#W[_`"=N_/Z<9QC.,XSCOC/EG&?9G'S9
MXI5$?0R"CCSC=]<R!,%-.*HV_P!N(!8*,T*@"LB4IMA9[)2E:H"L(5&0OD5E
M$9?VY0/'HEK0YMZU+D:4XH6;+%`5TB6$H@Y(!G(@EX[>'&?/.,?-C/?&?GQ[
M/Y,\CLZI6N4DTVV4>^IC648>)/KM;C?%&#?V'Q9$L<WBK'B&(RV&#;H,49;D
M*Q6]QUBB91$&V&;V<`'5/%&^-V(6C<`Q^0JDV?6KUSQ.0QF+RR+2)EDL9D;0
MW/L<D;`Y)'9C?V1Q)`>WO#*Z(C#DCBVK218-3+$IHRS`Y$'N$P(P`4J0Y34+
M1\%"!@LO)P2?%D/@QV[X#WSC&?GQCR^;RY%=N)K[7-F0685S9,.8)O!98WFM
MDDBLB0EKF=W28%@XG!Y(ONR52-2`M:UN:0Q.Y,[D2G<VI6C<$Y"@$IRFWVG#
M6(01EX.$5X<B\>/E#VSGMW^7^7&/;Y\CAV$L%$J)79P>#/BP9[18SCSP+V9_
MB[^?R\4K%OI#;03"O[;EW3*V-F#A83O$(.HM#2^XY>:8IE]H:],#@E8954=@
M/:L6?KBM?7-8X,#:!_$H4/$ZJYV8Y$X)R5,?=3S96=@&AI)3K/1A*QV`//;'
MA\NP<YSCR\_+^#'M\_T5/+6LT<"WFZ;-FQY:%%+8_O;74)1G%`,$I<(3<D0G
MM>6HP#,3B":%M<H>L,7.`,]TXS&5$-0'(2@YQ.5MOM_`Z@J>P+=L9Z]0A-=1
M5SEDE4@SZ56>@;"0Y`V-Q`<^D6/+\N,2,+&A)P(]>].:!$0`1AX<<4KIWID0
MQGL[?KJUOCDV970ILJ_3'5)P-R$84#H[%P"X;3LIF&(P`TRD]L9KEAR55G&1
M>K^M93&EX$(8AXZ](E&JB5%M^O<S,3XLK3FPK$T[LM$$SQF)Y!0,K71:...0
MB"$P"*65J."R]G-\`2536]IST@SDOHQYEEZ.6MT^U_TT:I->#&./;([4V%.M
MNMBF92:(Y9';$NU<G<F:`JA&E%F$G575S=7U8J4@>Z=.OBB_";`2AX#C`SJ*
MPE=H!N*7U!VDL9.JFUV:^JG==6`A2-OI&YXD@S$Z"VB=C$I1R=KKZ4L!A%*7
M.]K0(T3$>FK>3K5A@?6@EJ5/]6R5LPR$B)`2(W(`8SWP'.?#X<>P.>_EW^7M
M[.W\?7%X)6G"`X7A*P;DD61X#C'M[>?;MCMCR]N,?_+SQ+@NPR<AM($2O+$`
M9)9@!EGEF%F%F%A,+,+,*&(HPHTL8#"C2AC*.*$`PH8RAA$+A=I7TG6HU'=:
M$61!%CODSY<XSVQVSGM^C]'S9XI47DB3-M5]6O36QT82D['M9'+2TEL\L)^4
MY"Z0MD;=M@-=Y"M)R("9:N97V#6!"T9IP1K"&V7Y2HQ>A",OEE(-1,^6K`<%
ME9-$3@>`^''MR'OVP+Y^WZ?+Y^_*D&Q,V,F>WW3&8&A;X7D/4CHR8EX+,%@S
M$?KF'VI+YJ<+T6?3@2EQ=&L3K1`"(D12T"=9D"50/.;;Q=NM&6<(_&7@[U<(
M<9R+&.WW&,=\X[^WM[?F\_;GSXI4>VP==H4I"W'H"_+!OEX<=O+OV\LXQW^;
MY/X.5W=CH8K>-EM#(+$RQ8G<SZB&HQL0&E;L.BML)KJT$=JSF4!08).\3?$Z
M^ADD=W@\?HTZ=#G/K2@HD[(1V`=L+RA$,B,MG$XE+'$H=%6E<^2:42)Q3MC&
MPM",`C%+@YKSQ8+((!V\)8`X&I5'C*1HB%*TXA.;B5TE]7Y?L5?)?5,N>*/<
M,KYLALB@?3^K&7MJIAF*6$SCNBLW:F;Q]264N8)!=+.D0Q>K&%>,*IHJ#"IX
M7H_69BD484JR4#S#C/?OC.<BQGMV\A9SD/E_!G'Z?G\^>W''%*<<<<4IQQQQ
M2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<
M<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2
MG'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<
M<4IQQQQ2OY'D$J2C"%!19Q)P!E&E&@"86868'(#"S"QX$`99@!"`8`81`&`0
M@#"((LXS`;<G2+LZC)>_VYTL+,AM0)Y,]N$EGFDEUEOZO3^7/;LL"N>Y%5#C
M$4JV=ZN31V.&O5+Q09!)JR>5YZ7"RNVHHDX\Z??GYEJU&VHU3@X*DZ)"B3GJ
MUBQ6>4F2I$J8H9ZE2I4GC+)3ITY)9AQYYQ@"B2@#--&``!"PYN>G-SU57E>Z
M&S-))U+/MOH7N-1CHW(_6%TKKFM73;ZC59`#,E'+FBVM;4DN/0HP@\*P*6<P
MF&O8$1@<F-PE12D@F-S9KK'ZNP5"?\/RBRP.BE$!8C83Z+N>,.ZHI4+):+RL
M6$P=L1EKSO\`0(U;BYI$)IF!Y"I\!1H@2S[B]8NT+HL!;J]TQF@R3R$\#D1*
MMA0)&\YI1-2`H?P\^092^^",QR%1Y,$]6^W;/!DQQ`F(.41UO4`]1?3H"-5M
M,)GOG+'7:+:*3R.X:M-ESJ*E&"7/<IDC?=>8\['-X=AK`5RXX+Y*HD^."%5F
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MLH:CD9+2WE2@..KQ:)M+(2MWJB9*3Z)(G3$A3)TI(`8"`E*F3A+)2D@#VP`I
M.`LH`<>$(0AQC',3*WD[[TP-P:OVIA9@X[25O63`*(WAAR()R>,2B"V;(B(7
M7M]K&5-D2`-C4I8[]'A*)2G;QOKW7LADL>5J#RQ%"QL[J!KF!X%N)[7>#(S6
MS(DZKX1&[I((V8<-876H)*%6R8;F]MGO+:2V2ZN;+>Y*UQ9LD=RJ9YL(I)(Y
M1$S#O3(J%U!)C9'TNLBP:]^J1L8QC%R4]CRQ[5M%9SWSYYR+.*A\Q9SWR+./
M+(N^<<X#8$C^J`F.)RB$7+KS4FTM829B=HI-8DYP:HK!CL[B3N@RVOK$\,<(
MF,&?G9H?VY2>E7HC&`L]46<H`!,7Z/`06H@Y\6,9^7SQGMW[>(.<A%V[^?;O
MC/;/RX\^8G;U[2L&D^H6P>U$A:\OR>F*V>Y2T1L.3`#ETR-]`R5_"BSB0C.)
M.FD\=HW%BCBBS32A.WI2RC!@"`6D[72O&/'=H48<06Q'>KP'#-)8F4C@"1EQ
MYN;A4<.R17C#M+M5$XXAFQ<SKX.#1S0.C#AF00,^/'C6OP+WJOWIHV"71EN5
M5.<5*Y*2EU=Z^R!5,S]FJ)B;AC($3%`TMAE_7';=%,@T:U/#P2E6"01=I`%C
M2SQ^1-/<>43IU<:'ES@T0YC>;.765*5J%FC%0%TC<&;:DTA=E!2)NC<;@X(>
M-=(WU8YG!:DR1D4+B5#B$Q.G5FX!DS.0%`ZP6!*7I^O;8%Y565M9<IQ$JO.U
M7;(ECLKD:X@LS,"BAYH?%&*LKI/DJ'06$L>&]A;6=G(480B5J33N90V/HC`+
M?B!T6LB$H96S"P6>FPN"I3NK*N3F`.2.\8D:`U+((H^MYX"U+:^QQS;71"J*
M*.)4XR#(<[FSAGMX%BN+I[V12W^$211Q.RD]Z'6(!"RC@7`&K+,@&I#A]O<V
MMJD%W>OB$R%@;J6&*&21,^\$B0@1ET7)2X52Y&H@$FHD-<]@QMFVCCL=MI6N
MQ%%/],L<MKV@Z0GFK>RA\TC9LXP6AL6X)MEDIMW:D4JDC"VIX7%F!I?'($<8
MAON5JP3BO\1DXD4W#VHOLDAFU"T,VRN-6X)P#1V#<$%<-/*`;BCAA+"XNMC[
M`I(]*GQ"F+,`N4H:]K>6/*A'C):,CUL82\=::U=5+87IL7-"]2>H-()G?^K\
M_(/2:U;?.:4URN"+?`:<!CS4MYF-^`_NEOD1:\$NS=+O0@G<JBH5;\(4G=$J
MUA;+:$0EL4GT98YG"9`S2R*21M3/$>DK`Y)GAF>&M:7@Q,O;'1(:>F5I#P>8
M#231![X$`>`F`&`-Q+B)YI+<-E-$%=XFX/NWS"2J#^%$Y#*'7-0ZO&2'1E%V
M.Z@DN)K4/E<P*CR0MWLFZDS$<RC\>&0JRK(A*B1'B8K*CHL(5#=(N<V=.HO>
MW5$LJ&W_`"J%O223UCJ=4Z"0M&F54R)O.P:V2J0L\N%F7;*V*UB`$YKE=L)D
M,38%!R@;!72=06A<DT\.,8#CMC_W^><YS[<YS\N<\\\<O5D4XXXXI3CCCBE.
M...*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXX
MI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE..
M..*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI
M3CCCBE....*4SGMY_P"W^WZ.5<^IEMA;^\6R3=TO],'01C2>ZJF&^YFC/4)V
M=U<&L19TI8'EX0A,5(ZNK-*'([#-28]++I2,J$IRU8$F4#Y,GU,]I5.H.G%K
M6NQJ2DT\7(TD`K$1N<XP"P)P88T,SD'MG&!YC*/+I+AE9QD)A3`,`\>`0LXP
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M%'F1`F`2B9F%F0)VQE:$1(`X`4E;&M(E0IRPXP$!*<&,>S/,3NJ<ZIW#J9],
M&.+\J_4(A2N_]IHR#22?@LZ4&-FO-9-;@4:+Q&B=6B.S&7I@>#!?JR1]SG`Q
M>MCP&3FA)<UIDZ3)@R\8\`,9SWQCMW#VSGS^7'MQVSWS\^<\D-O;P6D,=O;1
M)#!$H2.-!DJJ/623F68DLS$LQ+$DRJUM;>QMX;2TA2"W@01Q11C2J*OK))S+
M,26=B68EB2?I2FA4R=J&;A*7GL7GOV"'/;/A[]L^7?'LSWY7[ZO]4-@-&MQ1
MJ"<%!:]>+4D28T/8LPATB4;52QC4DF>0BSTSVR-YY`P9"8`X`!E9P;@.>6C)
M7,64ME48`I+,R:5[,YQ]SC./E]OG_%_!WY6TZQ*M38VO:W72)G`S.MQ;:I?4
M*$I2^PE"E=>5FQ]GEJHK&>X0EL-7M\^DBY49@*="C:3E:@TDDL1H+U9%64JG
M>7.15A73^\@5%N[Y!(<\.I:[*82T#DYQIK7+@+!(S3T@E051YV%&4IYR;)V!
MY(-,*\`Q0]?5`QJ]3HS!HL%+E5&IWO'H3$)V$>3`I2XDLVBK]S/$M&$82`)#
MWMH841@E>!IO$J+#D/ILDC!-JTMR)G;$#4VIP)6]L1IFY`F+SG)9"%"06D1D
M@SG.<Y`6F)*`'OG.>P<=\YY&3UH:<EEV],S:U@KY")QLB"PIDOZMT)"8:M>X
M3S6>;QC8"-,S8G*QD\]?(EE<9CJ<@C(3E`G;*8HPL1_CPI71E&50F7X)R-,$
M0S#1"'W!COXQF"$+OWQY9R+.>^/D[]OT<SV!0*?X)])ZH7YE9%V\(<B[>'OW
MSCVYQY?/CS^;Y<0=-;EAEHU]75K1-<F<(I9<0C%@1U84+N4<S3)G12%!V\6,
M"P(DEPPE/"/&#"3R323,!-+'C$J(9@R9;<*/60=_0=O1=PX\\`[>'SS[/9W^
M7]'%*KD]5C1\C8W6.T*Z94B=-9#6@_="I1\R`(%,;N>`@4/\`<4:GT)PTP71
M>2=$70198_3L4E=4HRS`&9#R/;I&;^SG2U?045NQ8:+3W<F!0^V(#(E)YBAK
MJY[FN?@EY=VS(51Z5F;XY8A#O`KPB7C$9'7ML(FQ.`ISSU$AL7["RI!G"H\H
M1?B)'Z<';./]<LSTH>W?/WP<?_/V\@WUKU0;=Q.DAM93,;9RUD^TLW_WV0:]
MF%%>B&$A%:KE:ZNOD/I#%/=CE\<LE?%S$0`-Z7#XE95N$^!M1"P[0X[93R1Q
M8E8,4Q/#!)+;@9Z;J$Z6N+*91Q=)T3O!SK*%*E22U1?:7#;F:*'%\+8QXS@X
MDFM0,]%Y;G2UUATZC+>1W*1^YC\))@I1D+,U7!@#`8`)@!!&`8<""(.<""((
ML8R$018[X$$6,XR$6,YP(.<"QG.,XSSVY#=T/MKE^R>FK3%Y8YJ72PM?'0BJ
MG]<X'Y/<WB+E-I#I6[\OR,(3?6#8N<&-JS3\C.4.,57*#C3#C3!<F1YL["\B
MQ"SMKV'/=W,2RJ#Q*$C)D8CAJC<,C9<-2G+A6YPO$(<5P^SQ&WSW5Y`DRJ3F
MR%AW\3$<-<4@:-\N&I3EPIQQQS+K/IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<
M<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2
MG'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<
M<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*K*?5#;D[SR1:
M,ZUM8U19-G6;(W!6'!O@2*7!:Y0:L&'N#!@<"4(03Y\4!&/'^BP?C)0PB$+E
MD^,1YHB,<88JP(RV]BC+,UQYE0$XP$E"TL:%.UMJ0D.,8P`I,B2$$EAQC&`A
M!C&.5FNNH2FB&XW36M)Y]=3QQNFV$SJO%D(T"=/%KEJ*2K/1%YR'(5A;<N4J
ME&1CP`Q*03@/A]"//+/X?9G_`.T+_P!XL]N1O"P&Q[:5V_K%DPN(9\XA%B'3
M+P@,S.Q\!(\8SJ(8(-6TVV$C_P!:LV#0+F<RMNN'!XP!SA7=Y&/@+9\25)JN
MGUXFERK.P^G5N/C"LJ%U1<UH:WVHYD9-$@CT/V^A+,QQ.1OP`F`*2-"6YJRK
M9C/=SL")0'2-,$X/A4`,)_C5VPI:-*0$2S`!`Q@(PB,Q@0!`\A`%C.>^,ASC
M(,X[?<BQG'Z>3F;%:_U9M31]H:[79&D\OJNWH@Z0N9L)X\D&*&MS+#DM:W+0
M8$>U/S*O*1O<<?$GA7L3^W-KP@,+6(B1XI;[BZR[\])F`R&>S=%'MP=5HA(H
MI%(C=<4G[%!-AB6^:2ED@M=QJTZ@E*%(VS:>J7MZ;(\;)JJ?W/ZY1!^N9VC[
M'Z5T"@DE2^IXGW9,!J')>%OBSD.`X#@SOD0A=@X#C'?OXA9[8QCSSG/EGF+O
M3UBZ_J`[TF;@+0&.&I^C!LUKW7]X,,$..W7N!,&PR+6M:\6%W-02:%4%7RQS
MJ>-2`)9B!78TLF:Z/+S#8ZI$5!VVQC=[<'`8M-PDZG4@XA-1R]GB,W13G8B?
MMAZ?!*V,E3./)`PBIXZYA-.1NKBPJI!-%2'!Z0@YM*5&>'/JE=';>UUCK&W:
M:;>;<:K)8JE-#$X8P6N[7'0S<::J.7#`XZ]WM]?4!7-ZA8I5'+T;*.+'JC51
MZG"\I6/)^5*N=8QC&,8QY8QCMC'S8QS^1P"S2AE&A`(!@<EB`8'`BS,#QX<E
MC!GR,`9C.0#+SWP,&1`SC.,YY6WB/6DMK3$M%#>JU6*4YE>5"N/5!MQJE#91
M)83<4Y*:')SCU13+7W*I^L6J;NFA32)'%2V5REU8S!^6B(3O4+;49QX>LK#M
M_J<[\Y4N;Y.YCTW-<'4H7UO4C1SDRJ]PY:QGB"8F<+LV#5-;BAI%W6)RRE`Z
M\H]M%)(UZXJ9Y#82QR2>E*4K@T5:W/I<;3R31>2EJFG7^SI#.KAZ>4N6A]`S
MND!?'53,K7U9+6YP$D$UU^EKZYN$*93#3%S[3C^Q*4>##&4:7$BH=E2_@_`<
M.&.W@\NQN.V<9QCM[!=NW;S[XQVS\_;/?D%5M=([7U[1NCF]1ZQ'BP%2@QX2
MW-)[EM^;70RRL/JYJ*;,EA3::2%>AEK6J1(E2!R"F&0`U*40<B.1Y&F%A':-
MY;LZ71=\6VTTQS9ZK8L$@)5MQ^1MM4VTA:U3@WM2!7:D,>D2B$.F4BIP)+>Y
MG#W=&5E,$R0/C0C+`O.+4J?&[]C6=(UNKJ]/*5N9VQ&L<W=P6*@$)$#4WIS%
MCHN5J#1A+(3HT*=0I.-'D("RBAB%GL'/,V.@9!I&P].2$6M+T"QI?]K[7OO<
M`34NP+"M%&=@;5D$PK<)V1%@%@Q;6((8YC+R(W!/PA@@!IA0`=HFZ3Z.6\^Y
M4G90;Z-T,U;U23N+>YSVC(/:35<5Z;`-J)2G<B:_E%@0A,17%6U8_#)2`F)D
M0>Y=,9.T@7QI(M:&YT^&2;?+:U-K(U(65F;T+4TM+>E;&IK;$A"!N;6Y`F+1
MH&]O0I0%ID:%$E))2I$J<L!*=.4624`(`!QA2JPO2I)3T#U<.H+K0TY$DB#N
M&</S`V)PFA1I@1"QFN1QHG!7A]&7A#%K66MP!YQ@.`I@$DB&#(<<M%\K$:8J
MCYSU_MX9.U$EF-D8B%CL3HH+,,&62:RJ*3@@<]QE`SDX]X8EQ(RO(`1D'X),
M.++P,5G?D;V7R6PNHE_JH<6Q2*`99`0K=.5"_P!D,S99=(\&51#8L!,,OH4_
MJ+?'<:@MLADH@6]D90HS/>AF?++@.;G%.8-WQU!J#ULFTXK^VRYW'I)%*V8[
M.C*8N,$KPW*V/LH0PDB,TMA.[943B?(I<Z-+"YPWU=L=T9SJ@<?1F,AHW0O.
M3D06\&GNTVS]X1ZTX)*:\@:;4QA9Y]J(G<U070R<;%+)"PO,J7VZ6;$UIL<K
M@$8CQ<%;&UF6.K@>L=E4O-PF,;TB`>SQ.6\AM==A&9;C>*%CW6]!0AC(2#)$
M%*(&>/-U$DJQP9C>YC=8S/B%O9&3#(C/=[U%6(0[X-&0QF9@9854QQAI8]4B
M"69([;4IG#"1%;L92+$Z,$8FEHU[7T\D"9N-3UO.)["F&?(USBPADF&5='#9
M":IP[I6C(UBHA(-8GRG(/5I52I$$*D?"[5W$H2JM=7[:4V:-]AU"R@;P)'RH
MUS/89DK<761H8FVLD-^!G7X/D+TL?W`AN*0)7$(PGX.P<,K!!F<1[W+H):]V
MS>_[$D<-IP+O<=I].:>($#H\8?3&9FUU7L:Z[HVH=54/R88G&0%^;(L467E+
M+4JCLY`9"UR@HOX3WT[]BI"^H(.RRZOZJJ'/4$OC=-:\QQ,W2IW0A^#F)1KX
MRH*]?HV5$7,P,P,?I%,FMV-RU-"AO9UB0;PM'_N;"EO<6&^6.PU`B5+=PK%]
M9N'@@DE60Q1Z`B+<R`O&-W*%U)H+OK9L1QT<H6'#-0(FCM)`CE]XUU+;6TTR
M2-#%H$<:WDRF2$"*=$UINV>20!=O=KDU1/6V?/,P`PP+:-J=WF`3B0',K#$6
M%`QUZOLAR.L-_=GI&WQ'U9I;5308$XY9D$F"%F,\`Q>FQVW9%_UK6M#2[9%:
M\8E=50^O7.SU#Y`C&^5!?(@UM@G<;A%S4B\MM?`K$(?3-XR'$"97@0<@4A"+
M`N0[Q'07:VH&#7B.)F&G=A(SJ'M7?]F5HP3>7AAHYM3-G5R^@C"`Y.&!OK!$
MK`CUC2Z1*6IO]551AG1D-!R5R()*P6DR4C.F%O-/2]MS5,8X*WVY:4)V'-:H
MVU.Z\NL:^?;PETRFC+7K,]F-1JOZTH-B4IX\!S3L0"3PH5*M"U%I32".>6][
MBL@N%ELC&ZV;RQYQ.`MREK:$1!LS%,LET]TJ:'U!81GFK*U>6N(XY*MTL^'F
M*5;"2:'.&10EY'961$.O-H;A)KZ2]6,1R:Q'`I.:2(]92P+<*(R=FE$LL&M+
M>UN@4486J0K;%V29896,#5(GA8!&C*12/,]>DH5?B.3'&%.`4`,%*TP"S35)
MN$^.W9=>%<Q.DI9L*6_))=5L1KN1VBHD,$5MTJ3/<0C#&MD"]=&%2!=\&/8C
MV]`HR@]7<`IU1V`E>L%]Q"#'E;W3T;8I6E1J];X"PO$QK*^*.O*;5G8EHV$Y
M1.WR:G9Y6T"BI#[.'2;ML2<T*J9+)3%7++")E^'F5I"[(L%%I5"'M1EULLA=
MH!>%#*8%1]36=<E?;&HT<#J0Q_0U7$Y'=!4P.:4BIZ=AN:MQ<L*)`E63N2M#
M.ULCC(3WA?'HPWMF4J4=Z*XQ-=]#-`K2):2S)*@D=))N>)%<0PQGB=!B(28%
M"Q#(RM61#=8PIGMY[9&ECL)9XYT$DD<MQSPQK((+>$YEMVT!$<ZM&SY-$RN>
M<TWOC5=N6&S58XPFXZ8FLMKM3:U?MEX0A%#$MCP1NPB,>WN#O3=(I&R.PH\F
M<VQ<^M1Z]"\-S<X$.!B`2,"DXCO%AV3UWE,>?I=&KWIN016+O"2/263,UG0I
MRC\??G!1A*WLKT\I'LUN:W5>I$%.A0+E)"E8<()24LX>?#R+*9:.;2[.HV1/
M<.:OH8BH=,;KULJ4FO["?[1=)#8EXUVS5T]6)+7HR`5V*-Q-D9&`@A-%FHE\
M=%YCNX'#<R0(R@+>OGCI^;#6\I.D<FJ+7ZCR6N+:2U$.JX9,\RF*6$P:X;(Q
MZWIM8,A5IH$QMJ=,1$FQ9%:MB+@S.CSZFO<$3^[,Z8\HK.,M_BR`@V37`.\,
M+M#+`\JK`'RD0!A`4N`T8WHC:XC*-"A8,6PTQ/'8U(.&O=#W0P2/!-;R3JMJ
M)#O8U5EM6BN@\($ZQ-=1-&\"%@Q>9.';&:_V&[QZ/P*\*BFK[+69RD4598G8
M\0D+M)&!F6*6YW>V%M:7=4M=FEK<$2Q"X+T!!Z9&K2J2#S"QISL`X-+MOJ-9
M(/:4RA4UC%UK*>-;TLY@]03RM)',V=Q<G]+'$[4X)76:,+*R.6'!0:#*:1O;
M-Z3*%8E3#/<`%(S8_8[T][-BMGLU@QIDIMD<6CJ$[.;*I'4KOD\FK+7H2:5[
M"&U6F0QU"J7JR9B]LZF30PMP2M^&0I88F>3U(2B18;Q3I=;>+Z_G[+)F*K(^
M\2+52"T.@;\62PKXV7+81LQ!;><UL:CL)IB#QZNJL=V9KD"B&15,GE;^U+\E
MDREV5+G(U:E28ABZII&&L9&%SDT:R%1N[>)HF!96",\\CJ%<,&6,@`G40FQ;
M'D30,(<RLMV`\*2LHW5I"\#*65U1Y+J5T59`ZLL14:B&86#2;^HQ1.D=7%7'
M5@[-<%+HA1UT"P8D9.E"]CQG+VWE10IX&^&+F;PF!=$8$0E"$19F%!8,`'G'
M[85=M.63(93$J\M>MYW*H.?E+,XW#IQ&9,_1)3A2:CR1)&AF<UJ]D-PL(/29
M`XD)\X5$FIQ=CBQ`Q&*5H%/R9";+2V.K2Y4?U9?LRSI*6K""0&TCA&-O"@&\
MXC7P@*7!0F#2?6QE1\&^JC-(^&_`8/Q<8T!T=O\`UUV!,DDRCT$BU4PVK[%K
MJ.-B>>H;8-"KEME-4O:0THZ.M<1JU*RK$U$WKG*5PBS;!L98IDJYN^#U)H&T
M3J+(2^Q+E$$<EAE%+*RO(@E.[CR307)4(N6<C.[.!WJ1HC,Q=<I,2Q?E5M%+
MA>4,]PZ22QB=MS#E&(V<E!&I&<KR.[`'2D4<;,Y=)L....;JI%3CCCBE....
M*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3C
MCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*
M4XXXXI3CCCBE....*4XXXXI3CCCBE03_`%0+K^X6MI@AM&/HSU3]KQ.4<U6&
M)0^D4IH')T1L0FBLHL.,F^C9S5L=DRL9??!"-B4JC`X+($8"03IY[(MVU>H%
M+6V2L]9D2B*(XK82<PXHU6WV1"RBXY,B5@2NV"LKG1")]0A%@(S6AX;E.0X"
M>'F6<MBL?G46DD*EC4E?8M+F)VC,D95H1"1N[$^H%#6[-JH(!@'DA<@5*$QO
M@&`>`F9$`01X"+%3/7&R))T1]ZYUK1=B]S,U"O!Q(?X?/5A2A6D:&K!QC;$+
M-P$DH8AJ&%.817MTHTA?K:<+>SRS!)C>C;0N$6OG&#XW%BDG>X?BD4=C?R?B
M6UU$QY%<RG+)8W1FMV8D*G!F(X`PK$I!L_M'#C,G>X5C4$.&8G+S):7T#-]S
MKR9N989$=K5W.219!W89@&W;R`/ZHL9CG#436UW4E'F1.(=173=^GA@#1$ID
MT>7RZ0PYI5N6<DG)C&Y)/)5#3SRUP0)\#"4:6:4M+2C#/DB6HW)&E<&]4F7(
M%R8A8B6HSRE216D5%`/3*DJD@8R5"90086<0>2,91Q(P&E#$`819QAW=U9B>
M[&IU\:LS1<H9V:YJ_=(NED2/&1+8A*2#$SY!)RW@P(.!N4%G+3'9<W!$+&!*
MV8H&<XP/.>2GGYJFH((S!S!X@CF(\=0DZZ5FG.+1`,3A])CP!,QD';/I`YQ@
M6!8SCOWQG&<9\\YQGV_+R5%/`(5`J[E-CSQU;(E!8'%GR9S*4N_8EJC<4B[0
MK?)$_.1W_DD+0T(5C@J%C./]"0/&!8SG'(?NG-<\HD;$^U?>#83#]J-=)*73
M6TE?FXP2<Q6DQH"!AEK,7D6<.->VXR>J656\D1B.;'J//@B4B@P]L6`+[?ZW
MMI&KM$JUUW:%9J9)N'ME0.N,X,0C4DK!5.<O?;@MM"!2FQ_H$T@@E2.D4<@G
M&E%JFB0N";(AA-&#*E8@ZB0ERW@O$CJ'7)''!J;70EQ1:,TY(C"SR=?]?GG`
M`-EGN+65G+>GV%V`:`D2R9R`(3W&(0YQ8H,R+TZ<M<`NQ1!*01*6HHW)!18<
M%AP'N$.,?ZOEC&>WG\GL[=L>SV<C%UIDC8F(;0$%IDJ8LH@M.F(``I,E3E``
M6G2IR@X"`I.E)"`A.4#&"RB2P%@"$(<8Q,O`I\S"9B23CP`R`&,^6<=^^0^>
M,^?S8[]_9VXI6)5R4XE0)5&,I@=L`%D/8&,?)Y9[XQVSW]N,?H\\<K/]6J-M
M4:U%V<4J"09,7U),8LTI@@\1[A)9NDQ"XDUHR\`&-0X.<HD#0B;DI0!'*5AY
M))6,&""(-K6\)VUJ49^"S2_"66(.,Y$'_@XS[<_/V\_+Y.^/;VY`C&*Y/ZA'
M48KFEV-$H<]<-'K`B.QNVLK`'&(V_P!V1G&9#K1K$E68$86ZO[;*`H[NMEF]
M`H2,L=C<48'P21SD!"82E6<:ACSW$:JK6*R1=\)R*-0"%Q]^<LDEI\N#TRQA
MJ;'5;D@K.2B<JG!(H/R27G("LF>C!G(0XY\38"YHKKS2MG7;-5)2:-UG#7N6
M+L&&>C$N.;4@Q-;,F%_PE[\[C;V1M)QVR>O<$Q(>V1]\=O>0`^?_`">><YSW
MSY8^46<]^V,>W/*I'4OV5F'4JV5@/3<U`=$T@A#5+RG*U[#;#LJXLYR.-F""
M\."EP29,(6UQ32<T]P<598S4LJL,;:TM/K!C8T'N6IQG$UPRS9T&]O)SR>PM
MEXR7%U)WL:JO.55B'D/,$&6>IE!T6T.,+@]@TD:[[$+EA:X7:+DTMU?3=Y"B
MISLB,PDF/,J`C/4R@]V_4^%62N1MNS^Z-B)CS9+>UA'1QG=U!F?$YEMCR[S*
MR'),`7F:B53R3%,Q2CO@.3XLI(+[X(%G%DSG4-!TG"-<J;KJD*Y1"10ZMHP@
MC;3@T61JUPDX1'.3VY&>PYWD#L>N?'@_&`A.<W!48$(0""`/;W*\'L#AF&VM
MFS!Y8XRT[@YZ[B5FEG;,Y$@RNVDGB5`SJYL_AAP?!['#W;>311%[F3//>7<[
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M$D]O<(T<T4@S5T;G!YB".!5@0RL`RD,`14DHK<+;'HTV"W:K[JQ%^L;692Y'
MI*LL=@]8=AL4=3&"+PMJMS6"++D46((&2N>J@?E:&80D1@_K?S\'92-SK9[I
M&_J<V.@K?9-)6%'+$ASCCP!=6!;Z4Q`K#CN:V/C8H"0[1UY39^Y5LSZA;G-,
M+M@Y*'&0YS]2W*;JV^8.[5M<,$C=B0=[`'#C'9.W%."$1Q81A(7)!B\"IK=D
M?C$-O>6I2B=FX[.#T*U.:'`\5W[9Z']WZ^SE5=73+V-DM=R(K)A^*[F,G6,Z
MTQ,$6#<,;=8")$N:I4RC%V(31JU(PZ)1%A!Z])CA>(W$92'&,![RU1\:PE?Z
MNW,BKB=E'\'$[Y)>0H,Q'&2LP!5%(5<S#H[?']F!NK*.3:+`T_JK5I53&<.B
MS'N<#R`1XA;QC,11,RS@%(T*HF9SUZA'3PE]O35FW%T[?XS6F[E?Q@N)*BI=
M\($U#M%52)4<Z%4A>Y#/W<$6&]Q--<JPM=G3GR>MGPX8!E.D:5G(4-<'J"[0
MNEZTM':[DE>S^BMY]+[MKG:5UTPM3U%JM":1R!(Y?$+1(IUQ+.+B^P47=ZUE
M<T?(%,*K<GA*_C9T9:QJ:UBX#8.1Q!U9>IOIZ),P;S:7N4S9FXXY&ILEE9G*
M#*'3T(@A&KQ+(BBFU./1@0Y"((D0(L6?@6,C"1G.<8_9;O5DZ/V^$"0U]NAK
M/+Y(VI%!BA`FG%:1Z=J(6Z'A+*.>(+/J\E8YW"7S(<8`6_P\R-OA6"_%@\&<
M!#S*BVHP9SNY[EK"<?AV^(0RVDJ'(<&,JB//CEWLC`\X.59L.VNSTC;JYO'P
MRY&6NUQ6WFL)HR<N#F9!#GQ_$E8'P$CC6)&JVU$/G,28)C!I2@DT6=DY1[:\
MMBC!Q`PXQC`TJH&/]*W.2,P(D[DU+@$.#:K*/2K$Q)I0@XDT2;5LL3C"V1R6
M2-<;CC.C,6.TAD+JB8V!J2)R\C/4N3RZGHVQ`G*!@0C#52LHL(<>8L=^0;JM
M._J<)HDK]**?VEZCNOBZ1.(7)R3T_.[N1)E*KX2PXGFJUDRK.8R%V-59\1)J
MA]?'-3D(O6<FY7^)2+MN/R7ZG;I)8W/[K3.TF\TVBN`"C[_MB_SFYV=0M2C.
M]";B)WM8#'5B(1H\EJ##_P!R['@+P1DE,`TLPC&2^T.!HI9L6L"!Q[VYB=N;
M/@J,S'@>8`GP<]9<FU>S4:EFQW"R!Q[R\AE;@,^"1N[GAS`*2>&7.*S*8+GV
M>ZG+JHK;I_)W&)4PH5JF6S.HU,XRH%4$-;@''('QLU78'D;:KV-N!/@M62UR
M-`0GIZ#N19#@]25R5C;2<SO4+2>K/3%U6::\CCRT5G3M<)W)]E]B63)DHG^:
MS)]4#<YA9-F35TRF42ZQYX]B.<7=>9@2M<K,2,C"VI6I`T,Z2#4?63W8V(1I
MX/T^]#W1K:B6TAF:I0Y,#Q8*5A1IP!2HQ("61NA=31E*@3A3EI"'62NK4DP7
M@'JAQ.`E9^E#^CWNYN;+VBSNIILL]D-J-3E8DJR(O;=)7]N*&:`PYN;!MB-+
M459@4!$8`X^(L4K=!E=@Y<"3^QQ6`VT1N\X\#P^ZQ.0C(7#QO:8?&3PSDN9U
M0MI_"T1H2X!"L.<:U]K3?9Q;-X7?8Q*W!;N2&2QPJ,G@6EN[I8V?1GJW<49:
M0`A6!R-?"VKZFNP/4/G*_33IG126YC4@*,03RY?1+XJ]N\6.-"C<%Q3F>62=
M4%7G!'DMRECWZO.)0F,$S,+,W'*L('B8OIR].6L=!*Q^#FWU"771+D"'-I6E
ME#A.:YFI^QQ$2B1!X<J&&OF%1G.&MKQD"MW5@R_OV3'$U.G;LI]>M9:-U7@A
M%<T17;%`(T$9:EQPW%FJ7F1.99?H\O,KD3@:J?).\F!SG&7%Z7JSRB\^@3>K
MI@@(!WQS(P_")4N?NGBLZWN)E2L>A2MI81M^%#91MQ&?,\[^Z2#/,+J<OE85
M@$\=W]V<<NEQ'&60I$44K8X9$WX4&'0MQ7/\&2Y?*:4<X4M(9''''-_4HIQQ
MQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*
M<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQ
MQ2G'''%*<]1C`6$0QB"```Y$,8Q8"$(0XR(0A"SG&`A"'&<YSG.,8QC.<Y[8
MY[<>WV\4KIH.Q5`#--(!=]0#.(%D!Y(;.@PC21ASVR`TO#]XRQ8SY9",(<XS
MY9QWY[?9#T'^6VHO>9!_I[G4]VZ":5;'%J?W;=7*.L):KSG)K\\UU'298'.<
M9QD2>8M*)ME:0>>^<^D3/)0\"["QG`L8SR(.[?J930R?>NKJA?+3H)V4#$-*
MC:75JLF&I<B[]@Y8+#0.#_Z$.<X[%))JB[`QX0B!GL+FNN),4CS-O:VEP/`#
M=20R$?[+0-'\LH]7'27L^/PZFL\/PZ]4<RF_FM9FZ-$EJ\(ZS<#J\<ZGV1%!
M_EMJ+WF0?Z>X^R(H/\MM1>\R#_3W*6%V_4PNVL)]=74I8=$WBV$C%ZFUNR1=
M4,R4E^>0!PD>4DJB!AV<=L9R9+V\K(\_^3!YXB%NWIO;J:Z^NG6]J1:4;:4`
MQA4RAK@94ZAH<`[YR;]=]?`E4?*)SC&18,5KDO8'W0@A\\8T=QCV+6N>_P`$
M=%'.XE=XQS9^Z1PO'X\N^\7343O=L-HL/S-WLI+$J_A2BXEEA'-SSPVLD(_;
M\(\7'9D_9$4'^6VHO>9!_I[C[(B@_P`MM1>\R#_3W-3.%"VB,,)`@:AG$BR`
MXD*%`(XD8?(0#B<$^E)&'/D(!H`"#G&<9QC.,XYY]0;_`,&MO]7(O\CF!VY2
M^3X_2&Z/S/7ZNFM/W3[GR-!Z;)]EZ_8<=LO]D10?Y;:B]YD'^GN/LB*#_+;4
M7O,@_P!/<U-'J#?^#6W^KD7^1QZ@W_@UM_JY%_D<=N4OD^/TANC\SU^KIIW3
M[GR-!Z;)]EZ_8<=LO]D10?Y;:B]YD'^GN/LB*#_+;47O,@_T]S4T>H-_X-;?
MZN1?Y''J#?\`@UM_JY%_D<=N4OD^/TANC\SU^KIIW3[GR-!Z;)]EZ_8<=LO]
MD10?Y;:B]YD'^GN/LB*#_+;47O,@_P!/<U-'J#?^#6W^KD7^1QZ@W_@UM_JY
M%_D<=N4OD^/TANC\SU^KIIW3[GR-!Z;)]EZ_8<=LO]D10?Y;:B]YD'^GN/LB
M*#_+;47O,@_T]S4T>H-_X-;?ZN1?Y''J#?\`@UM_JY%_D<=N4OD^/TANC\SU
M^KIIW3[GR-!Z;)]EZ_8<=LO]D10?Y;:B]YD'^GN/LB*#_+;47O,@_P!/<U-'
MJ#?^#6W^KD7^1QZ@W_@UM_JY%_D<=N4OD^/TANC\SU^KIIW3[GR-!Z;)]EZ_
M8<=LO]D10?Y;:B]YD'^GN/LB*#_+;47O,@_T]S4T>H-_X-;?ZN1?Y''J#?\`
M@UM_JY%_D<=N4OD^/TANC\SU^KIIW3[GR-!Z;)]EZ_8<=LO]D10?Y;:B]YD'
M^GN/LB*#_+;47O,@_P!/<U-'J#?^#6W^KD7^1QZ@W_@UM_JY%_D<=N4OD^/T
MANC\SU^KIIW3[GR-!Z;)]EZ_8<=LO]D10?Y;:B]YD'^GN/LB*#_+;47O,@_T
M]S4T>H-_X-;?ZN1?Y''J#?\`@UM_JY%_D<=N4OD^/TANC\SU^KIIW3[GR-!Z
M;)]EZ_8<=LO]D10?Y;:B]YD'^GN/LB*#_+;47O,@_P!/<U-'J#?^#6W^KD7^
M1QZ@W_@UM_JY%_D<=N4OD^/TANC\SU^KIIW3[GR-!Z;)]EZ_8<=LO]D10?Y;
M:B]YD'^GN/LB*#_+;47O,@_T]S4T>H-_X-;?ZN1?Y''J#?\`@UM_JY%_D<=N
M4OD^/TANC\SU^KIIW3[GR-!Z;)]EZ_8<=LO]D10?Y;:B]YD'^GN/LB*#_+;4
M7O,@_P!/<U-'J#?^#6W^KD7^1QZ@W_@UM_JY%_D<=N4OD^/TANC\SU^KIIW3
M[GR-!Z;)]EZ_8<=LF/8/7\P(@#NJH!`'@01@%9<&R`>!8["P,&7[(!X%C/;.
M!8SC./+.,XYCY,X=TW;$4GK9W'=+I>O4A/">XR%)1SHY&^LEY*.$-P4"$MR,
M1>?#Z7)_I0^0@#"+&,\U=_J#?^#6W^KD7^1QZ@W_`(-;?ZN1?Y'+<FUIE&F7
M"[>1?>R3:QX,^#0$>/U5;E[)#3KHGP&TF3WLMT9%\'XKVC#U>+Q<=EMC5KI"
MX[=JHT;\O9_HZCS[/X7/S_CYV-$ZTZ8T%&E-B$,TCCRE$`H"1:V-U&$N!'H#
M!&DC`O&(U9Z4HP8A`.$?DT.<^0^V,8QK`_4&_P#!K;_5R+_(X]0;_P`&MO\`
M5R+_`".65VDMT(9<#L58<S+NU(YN8BV!\?JK&3;RVC8-'LOA:,.9D>-6'-S%
M;($<W\/%QVQR:_->42<E(DN2FTJ1.6$DA*GL>"$)B2@8[`+*3E/@"2@!QY!`
M`L(<8]F.?I^R'H/\MM1>\R#_`$]S4T>H-_X-;?ZN1?Y''J#?^#6W^KD7^1S*
M[<I?)\?I#='YGK]736;W3K@?_)H/37Z/T7K]7BX[9?[(B@_RVU%[S(/]/<?9
M$4'^6VHO>9!_I[FIH]0;_P`&MO\`5R+_`"./4&_\&MO]7(O\CCMRE\GQ^D-T
M?F>OU=-.Z?<^1H/39/LO7[#CME_LB*#_`"VU%[S(/]/<?9$4'^6VHO>9!_I[
MFIH]0;_P:V_U<B_R./4&_P#!K;_5R+_(X[<I?)\?I#='YGK]733NGW/D:#TV
M3[+U^PX[9?[(B@_RVU%[S(/]/<?9$4'^6VHO>9!_I[FIH]0;_P`&MO\`5R+_
M`"./4&_\&MO]7(O\CCMRE\GQ^D-T?F>OU=-.Z?<^1H/39/LO7[#CME_LB*#_
M`"VU%[S(/]/<?9$4'^6VHO>9!_I[FIH]0;_P:V_U<B_R./4&_P#!K;_5R+_(
MX[<I?)\?I#='YGK]733NGW/D:#TV3[+U^PX[9?[(B@_RVU%[S(/]/<?9$4'^
M6VHO>9!_I[FIH]0;_P`&MO\`5R+_`"./4&_\&MO]7(O\CCMRE\GQ^D-T?F>O
MU=-.Z?<^1H/39/LO7[#CME_LB*#_`"VU%[S(/]/<?9$4'^6VHO>9!_I[FIH]
M0;_P:V_U<B_R./4&_P#!K;_5R+_(X[<I?)\?I#='YGK]733NGW/D:#TV3[+U
M^PX[9?[(B@_RVU%[S(/]/<?9$4'^6VHO>9!_I[FIH]0;_P`&MO\`5R+_`"./
M4&_\&MO]7(O\CCMRE\GQ^D-T?F>OU=-.Z?<^1H/39/LO7[#CME_LB*#_`"VU
M%[S(/]/<?9$4'^6VHO>9!_I[FIH]0;_P:V_U<B_R./4&_P#!K;_5R+_(X[<I
M?)\?I#='YGK]733NGW/D:#TV3[+U^PX[9?[(B@_RVU%[S(/]/<?9$4'^6VHO
M>9!_I[FIH]0;_P`&MO\`5R+_`"./4&_\&MO]7(O\CCMRE\GQ^D-T?F>OU=-.
MZ?<^1H/39/LO7[#CME_LB*#_`"VU%[S(/]/<?9$4'^6VHO>9!_I[FIH]0;_P
M:V_U<B_R./4&_P#!K;_5R+_(X[<I?)\?I#='YGK]733NGW/D:#TV3[+U^PX[
M9?[(B@_RVU%[S(/]/<?9$4'^6VHO>9!_I[FIH]0;_P`&MO\`5R+_`"./4&_\
M&MO]7(O\CCMRE\GQ^D-T?F>OU=-.Z?<^1H/39/LO7[#CME_LB*#_`"VU%[S(
M/]/<?9$4'^6VHO>9!_I[FIH]0;O3%)_@]K]8/$$!";U!#E2>,6>P0$)\$9//
M&+.>P0$EC&+/D$.<\S9I+IH;N[$^I'U-J+:#VT.`@X2RA^@Z:O8<,(NW8[$J
ML7$49CR,8S@63$*E9G(<X$``O+ER+:R[F;3#A>^;AWL4LLC>#\5("?"?!XNF
MK\'9&Q&Z?=VVS_*9.'N<%Q/,_'+\6.T9O#XN&8_7LOOLB*#_`"VU%[S(/]/<
M?9#T'^6VHO>9!_I[E+RDOJ8#:J9^I+KOLVBZ3;#A!RK:H^V.%OS%*#RR,`B4
M":'Q$H[MY8$5)W0D(N_^^!QC.9>Z2^IFM`J^]276ROM"_P!W($$2I+(7MNKV
M'J1![9R$$>KA`S//H!9QVR2NE[AC(,^$8AY[YSN;>^QNXR)PB*!3^-<7F[\`
M_$6%Y1SGGC'-XZE%EBVU=YI)V:M[2-LN_O,3,.6>7/$MK+<#+,\#".;+G'&<
MC&Q%!B4$),7;4652HP)29-BS(/E0H-&+`0%D$X?LF&F#%G`0@+"(0A9QC&,Y
MSC'.X_;[.8GTGHGIKKD4F#2&L5'UNK29QDI[CM<QHN4#SCMV$JEJU`ME"TS&
M<8SZ56[G&9%W%D7BSG/,L.;J+?%<YQ$K\.]B9G4<./?.J%N/,="\/!4IMS=%
M,[M8$D.7>V[R2(.''OY$B9N/,=VO#P4XXXY=J_3CCCBE....*4XXXXI3CCCB
ME....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3GKX`_)CMWSWSX
M<Y#G.?TY#G'?^/GMQQ2L4+OT6T\V/+4XNW6VGK"6J\YR:_/$(9D\L#D6,XR)
M/,6<ALE:4?GG.#$[R4,(ON@BP+'?D05V_4TFCD^]=75#+;DH)V/&(:5&TR5-
M94-2Y%W[!RP6&G<'_P!"'.<=BDDU1=@8\(1`SVSBQ9QS"N,.L+K/E%I!(QYW
M,:B3SBZ9!^IJU5[@>#XAF;S#;2=VYY3"JS?JGC"3#]3BJ*]V_4RFXL)]=74I
M:E-WBV$C%ZFUNQKU4,R4E^>0!PD>2Y5$##LX[8SDR7MY61Y_\F#SQ$+=O3LW
MDUU]=.M[5FY(VTH!C"IE#7$U$ZAH<`[YR;]=]?&2J/E$YQC(L&*UR7L#[H00
M^>,;2+GKX`_)CMWSWSX<Y#G.?TY#G'?^/FCN-DL.DS,$D]LW@`82QC_RR#>'
MSHJ)WO8YP6?-K2:[L6/,H<7,(ZTF&^/I`K4(!R$1AA(!`&<2+(#B0B"(XD8?
M(0#B<9]*2,.?(0#0`$'.,XSC&<9QSSS:@W?HMIYL>6IQ=NMM/6$M5YSDU^>(
M0S)Y8'(L9QD2>8LY#9*TH_/.<&)WDH81?=!%@6._(@KM^II-')]ZZNJ&6W)0
M3L>,0TJ-IDJ:RH:ER+OV#E@L-.X/_H0YSCL4DFJ+L#'A"(&>V<:.XV1OX\S;
MS07"CF!+0R'_`,K:H_EEJ)WO8WQB'-K.YM+U!S*6:UF;J20/"/UW`JAWQRR1
M=OU,IN+"?75U*6I3=XMA(Q>IM;L:]5#,E)?GD`<)'DN51`P[..V,Y,E[>5D>
M?_)@\\0]7;T^MV]=<K#;BU=N6)M2`8P*).EAZR80S'H^_<P,R@HI/&@DYQCQ
MA,/<R/N/NA!!YXQH[C"\0M<S/9SHHYW"%XQUR1ZX_P#BJ)WN`XSAV9O,-NXD
M7GE$1EA'7/#O(?\`CK#SCG@`@F"&66,LTPH60FEEC`884(.>P@G%ASD90PY\
MA`,"$0<^6<8SY<\\P*U%....*4XXXXI3CCCBE....*4X\^V>V,BSVSV#CMW%
MG&/(..^<8[BSY8\6<![YQWSC'?.'/&<YQC.<!\6<8SG`?%X?$+&,YP'(NV?#
M@6>P<B[9\/?Q=L]NW%*ST'TZK[+JT-\B=JO_`'`<Z]F;%#O+Z['G%:%,Q4B^
MLT=6F.XHD%P#?7UZY#$,5;\%95Y?,Y!AV]0+-7@Z1;-1MKWHN.&M.K^Q+D"8
M+E+7%!(J4LE3B2.2)AS*5B!BR5&Q8=5"6-!&_G819.+^!P"<2S#$N/2\D,4[
MB:BFZ&K.G9AILXR`**P<+I+O,486`EQ>_BEW&YIRP0/Z]1MQ>O94=&*O#5/B
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M64V-`WJ36A&5J:OHQ+9C)8?BH66)OTSD<Z:F..JTD7BB9%,6LM(\K'4?IU9#
MD0>E282`,42K,O5.UWIB0W!/ZOI:36G.+PZD$VW$?AS&12FGF^)02'RQR<]>
M&=&9!G)>9-'5&GDDJ?I7!Y&'ZS279WR@79=`DE'8Y7!=[]&H9*(,IA-L;15+
M`J/ZA%U[OPVOXM5!IS;:<,GK)#%K-1\E&W6:VIXVY!D**3Q%(\/B*11-N@KB
MZX<`D*7A&8GK2SPPHBF\0R`,)6$J(,Y)H]RZ;P+&0EN)#*BR.VLA<U;2#<CP
MS`6CB1L3B,X$JW#BXCB7.6YA-M+$9E6%A#9B9KB-)I#O2L>:2:08@=7-6WW;
M&8IZ]AEN4)`)P\/<9C<)BUQSQ[ASQ9;_`"LU<2W-%?$,\+EI3XM3F(@`<2UA
M[2!,)Q;?1&*<*1Y(_N]Z?W";/)-`*:2-VV:V%1PB33-_U);Y[=D4B"0Q<Z-R
MI%)71!!&9:SNC4L:5)3DG5M0$P!#)PC6K1>G"G^GK#?,1JK>"FMDY@TN#3!8
M;L@V7%(X_$T93HX-<;Q,7&3*F2/M^3V\AP.:DR\+<WI_3HRCP)@>`1(<A#C/
MG0C?*B*0K:V*]LIP=8`]K=NX/MA`[&1U)+[<4.Z:&)'M"1!#F.#6_3KBQ2YJ
M/4()#"'B6O4LK,EP<'Q'*8N>#)2DS%M8K&98XYI%A<RSAYC)I+1I&CQ$+(1&
MAD=V34W`Z`.#$DX-A;85<I#%<W"6LAN+M9+DRZ-4,,,4EN=$S"&(SO))&'D(
M4[D(`)&),2:.GK<<JTD5T-E564Z5!$%^6F4VFW063K:\CKM@2<&6MZF9#6..
MM;A@U6C(,2KG$@PA0K2IU."3E!(!]VWYI!L[KC*E<:L&I9HH;BY5&X,T6!%X
MA-'JL9A,I7'622,T6A,W.C+:VRB0*$S\D;L-#<`:XU\3KVE&0K4HQ^*0:Q=^
M*0MBG3WT^U=EJ:M*+U'N54B&@ZABL8CU:W"X;0V])[*;9I+)5A8^02(1,]%+
M#6BY81B'N<K<\Q]J35S*T18"W53S*1]3^GI%=>U,O<G*Y76N[4NKIESVJ8\Y
MM)RHB-QO4*?0&16N2*-*I2>UQ1P6LT>?"8HD:1'9D:A66G7JT/K9IX+PM,-"
MZ3>9NPB*2!H@HS@GE?5'J++G*D4&ARLB,RN=2R*M9`P[!`A5L3S=U@:*8-`%
M&=G>3REX0[.@-Q%!:".1DFC=DE.I)XUJ'.5Z^7Y`Q0HN<4=<4,-LE4<@KLB5
MU?.8\IGJ].K*0'-\-2.S"D525Q+6GD)1-S02K7^G.)#A-G!I8A=@)M.MAB%5
MVM<SKB25-(*!HQRV(GD6N&/RBN9.96K9)8O%#%T=97Y@*5.ZU4ZRUL]0+'A$
MVJ4Y+B++J6H1^K&RE5AU3JMB\Y5RR=FW3-0F]3/8C9YF6'%%.<BA%'79K[8U
M,,CW"E$DD*E&SVA`'>8,TN9X6F&@:BSH\3A*^IU):8>.&R'>'72%ZSR+5J,3
M^XMA5"+3;:.F6*_+%KU7$7.5S_86^J1M1CA1L:D4RE<MCU5PACK![PM>'E\<
MCU<LE#J-H82VQ26;SSDF'A6?EF8"N50M&'U!(]"D`EF+L\C!E71&(=$F;2HP
M\&'8*$ED^Z>H*DI2-GA5RZI"(D*@EW,TDDTBO&N[A6VW,I+W,+U$S**0NB$0
MJ*65,ZAM&(US.QX!!Y_)Z^ES#"ID(18C2PQ>3NC.E9GP1Y(!'I`-RP\:X@(C
MT05!(1&8Y-(M6]FXB<)/*]<K[C1P6Q0]B+?J;L9JSAF2,ILE6.WB61LH&6Y%
M'2#WY>LP/)+>S$'N2X:9&0<<";=YZD>N[C9UB6W"7^T[0ENU%ZZ(3`&LMR,;
M5`:2UC!K59L#E;VB26@_2]YA#H@<<1DR$0%[CL6B;/%8(^N:R=')0)CP<SDE
M"Z1:_3/72-,TLM6S)Y:?56N"Y72O-CYS3#*^.NN-I4=+HA=N(XYM5RS*(&U`
MS1N6NA2*<O4FC#7.)8D+70Z*IP"1DK[\>%6LI8QW3R1HT:L\:QOIURF-"<F.
MIIE"RI$IWD6K=2`R#.LR'9[#I]XT.(2S11/"DDD"PRB,RW+P1,=#$2O=1A+B
M*WC.^@+<FFSF&=5&54#G2%K0/BV$S%&R.L8)FS8]*HK("&=QA:AU$Q$3!"Z&
M-P4"J)GOH1,A,F)4#8S7D.6DM>)QQZMSBG)5=S]@:FE-P[.P6LK6L^-4S5='
M5;IOJO&Z]`UO,!MNKZ(D+*C.:[7>3C$A@(5()`VR&UFYY949AT@EBAI6'E83
M#",R*L6>XLY[YSWSG/?/MSY^W/Z<_+S4W,4<,I2.3>A2REQIR+([(Q72Q.AB
MNI-05BA5LB""8W?00VT[10S"=4:1&D!0JSQ2O$S(%8L(W*;R+>*C-$Z-IR8$
M^....8]8=....*4XXXXI3CCCBE....*4XX\O3%)^X?6#Q!`0F[XRI/&+/8("
M$^.YYXQ9SV"`DL8Q9\@ASGF;-)=-[>[8GU(^IM5KB>VAP$'"64/T8,KV'#"+
MMV.Q*K%.BC,>1C&<"R8A4K,Y#G`@`%Y<N1PRS-IABDF;WL2-(W[*`GP^*KT%
MM<W3[NUMY[F3X."*29^.7XL:LWA'@\-83<<LJ4E]3'[=3+U)==]OT[2;8<(.
M5;5'POEOS%*#RR(`B4`8?$"CNWEC)4G="<"[_P"^!QC.9>Z2^IJM$Z^]26VS
M(;AO]V($$2M+(9657L.5"#VSX0QVN$[.\>@%GOW)72]PQD&<!&(>>^<[FWV;
MQ:XR)MU@4_C7$BQ^+G1=<HY_#&.((J466P^T=YI)LULXVR[^]E2+('+GB3>7
M`(!YC".((YZH8>7IBD_</K!X@@(3=\94GC%GL$!"?'<\\8LY[!`26,8L^00Y
MSS-FDNF]O=L3ZD?4VJUQ/;0X"#A+*'Z,&5[#AA%V['8E5BG11F/(QC.!9,0J
M5F<AS@0`"\N;'.DM)-1M<24P*0URI^N%27MZ-[C\&9,2@><8[8$JEK@F72A8
M/Y<F*G<XS(NXLBSG.<\RB\`?EQW[9[X\6<BSC/Z,BSGM_%S>6^QR\#=7K'QI
M;Q@9<W-)+JS\/^B'@J6678R0:6Q'$V;FU164(7+FS`GG+YCG'&W4Y9&J,M)?
M4Q^W4R]277?;].TFV'"#E6U1\+Y;\Q2@\LB`(E`&'Q`H[MY8R5)W0G`N_P#O
M@<8SF7NDOJ:K1.OO4EMLR&X;_=B!!$K2R&5E5[#E0@]L^$,=KA.SO'H!9[]R
M5TO<,9!G`1B'GOG-B'CF\M]GL)M\LK59F'XUPS39\W.C'=>#/A&..=2RRV+V
M<LM)%@MS(,O=+UWN<R,N)B<BWSS&?"$<<_!6+=):2:C:XDI@4AKE3]<*DO;T
M;W'X,R8E`\XQVP)5+7!,NE"P?RY,5.YQF1=Q9%G.<YYE%X`_+COVSWQXLY%G
M&?T9%G/;^+GMQS<)''$H2-$C0<RHJHHZE4`#Y*DL4,-N@C@BBAC7\&.*-8T'
M@X(@51P\0IQQQRNKM....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXX
MXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE....*4XXXXI3CCCBE.
M>O@#Y^7;OGOGMW#W_A[=N_\`'W[X\N>W'%*Q%N_0?3'8\*@5U:ST[.W!4(0S
MI"NA34VR_P`0\9P(1,SCY31*TYF<YR+!A+R`6!?=8SW\^1!79]3.Z33KUQ;3
MDZN6A74\8QID*1^1VA#$OB[YP#X$GB<Z3>A`+/;!:><I\X!CPA$'/;/+&_',
M*XPVPN\S<6D$C'@7,863SB:9!^IJU-[@6#XCF;S#;29VYY3"J3_JGCT3#]4@
MJB9=GU,UNA!O7%U,V13-ZM91@\)&U4M>*CF:DO'?)>/@^1%2&(".%CMC.,S5
M(7D><]LA#Y\B%NSI][MZZ^N'7%J[<L2:D(Q@429-#UDPAN/!W[F8F4$%)XR$
MK.,>+!A[F1CP?="P''-I;SU\`?/R[=\]\]NX>_\`#V[=_P"/OWQY<T=QLEA\
MN9@DGMCX`&$T8_\`+)[H?.U$[WL<8-/FUG/=V+GF4.+F$=:3#?'T@5J$`""8
M(998RS3"A9":66,!AA0@Y[""<6'.1E##GR$`P(1!SY9QC/ESSS:;7?H/ICL>
M%0*ZM9Z=G;@J$(9TA70IJ;9?XAXS@0B9G'RFB5IS,YSD6#"7D`L"^ZQGOY\B
M"NSZF=TFG7KBVG)U<M"NIXQC3(4C\CM"&)?%WS@'P)/$YTF]"`6>V"T\Y3YP
M#'A"(.>V>:.XV2OX\S;RP7*CF!)AD/1I?5&/URU$[WL<8Q!FUG<6E\HYE+-:
MSMU))JA'Z[@51&XY8]NSZF:W0@WKBZF;(IF]6LHP>$C:J6O%1S-27CODO'P?
M(BI#$!'"QVQG&9JD+R/.>V0A\^1"W9T^]V]=?7#KBU=N6)-2$8P*),FAZR80
MW'@[]S,3*""D\9"5G&/%@P]S(QX/NA8#CFCN,+Q"USW]G.@'$N$+QC_[D>J/
M_BJ)WN`XSA^9O,-NX47GE$1EA'7/#O(?_P`E8><<\`$$P0RRQEFF%"R$TLL8
M##"A!SV$$XL.<C*&'/D(!@0B#GRSC&?+GGF!6IJ3?I]:BU5LI`]J9Q9+3.Y,
MKHIJH]5%8G#+VI?71*]GVC.9'%GL]_LV]V%Y@C:4RH&A.O:V]0<W+7E9DUK;
MQK%RM*0#^BK0J.3V6W0_1FS*ZU;IJF[,I.F'T_8:YF^^GK]T2YHXM<(X1'Y[
MK#7#K!)\V.KFWFEF',)*`F)H3CSGU>>G8']<CQMUXVH74##;JKA=3-,7G7E]
MI:V3SR%74WSM<RC-JB3N<OAZYL'`)W`G5,L1OCH:I.R<Y*2#L$)@>@"$)OI?
MTOVV;FJA%A5I!J8I:GJ\L.VJ,N97#JW03XMGC\MH5GDC3'R8X*7SR6.1#3*!
M2AQ<YDG=%[HI4N02!,2MB28.2';-)+#<6ZR1@R(LQF&E@TDF=P8LW6,/HR:W
M5M-PHR4C=@@O6^BFPCD5FDT2M-&ER;E0CI)+/G>-;:I8X%D,1#6:.4OD[U2N
MY!4RUE=#^D/>#]-FBL)9<>N]5V=-KSMZAJB@\[DDY&LN*0T,NRW6H_Q!WBL$
MD+8U1QE68RC9,S$3`ZRQ<`UN:D!:X!!"OBWV`1<LAE92ILG->4E'D.C<;W$N
MFPK;G<QDL:,C#]=\AJ(3Q'6*&U6K?F)S(5MA&":U1$RL]S$$GX*E*MW=B6@C
M/+6KJM4@E>&R_-G4[6\71`-C+ZO^'P%!K8X3<R.F76ERO>HGKC<8K<:T=6-T
MKD8L'3!1=$7L1='1Y4NT#7)EYR96FBB=]XK5>JM<*F51R`%1URU`C&EIJLA!
M(/A@BL(I=*F]&Y](4BD'J0IT9*E9K4L<C&[+";'L!*)CB9S_`/TCC)E7"(D5
MD)DWBRD+K+R=XD#1"8*28&>8S+DFZ8P:0ZZM3-G3Q[-P0QR1$S;^.X9(S(99
MANX[1[<7(1L[5Y+@W2$1&!S:A%D4-K=\N(WT7MAY%)I(RXM"FD+""<5?7%5S
MXI';LFB=W2^Y*S:[<@)$7^LZN'YW@\>50I]85,@FMHH(M%HPZ/3>U+G`\T\!
MPNN'?I.;+QZB)-<4@5Q1FE43J.;W\ZT4J:[$'/P4U7<M70^62W$S3PTVF0/2
M!2V.3ZEKPZP2YJY1)$<_I&X17=,'D,:ZO%[-;8J8)36-16!%R0TTY1:*O+C<
MD98HM,J2IYGI!@E9I,`L^,K)LBE,+C[*.P*\G*UZKV2/#<F6D,342'U7/64I
MZD]QSC7O%%3*&5_)79-6CW3#/;[@Y6>7+&"KGV2N4E4,+97Z*>I:4%(VX3PZ
M1^/6*X5\MF+'$E@F),M,P`*O-+?</2P47&K=S%=1E!UZQN@>]9=07,1$$H1G
MR@:B":'.RF[DW:WFO=71C#/./=#*NX5N\8:PF?)V!:(KF+T;S)CW*+H\VXAE
MU@11YO\`U\)Q3D=A;]=3K%T]U63FJE5JJX^13T5D$8@E6.TR=)79*)\4R),V
MQ]B<$L.BK`[2":N+0E&@`IY)3?2$EI5]UU6FU=LUG3;=*ML7#6ENAI<CD1=C
M7,.%%1QVL5XIA[)@4CB#6G2QR5L*V)N-B@9@R)R<4C$4VE/*MO0KNEH]U2+K
M;K<V,LZ1P6NY:S;2H:N(M>KRGNVJ]BQSI3+:PMM=R&+RJM;"C=G1EU:2F,8'
M(M+,%#9(T;T]-3PA.;E*<A+]*`]52UH;(&J6/E%ZWV5(X'?TGV,H]7,XW/D[
M=0DUFZ9F;Y>U5XS1>P6,E=%71OCK&%O;9FKD2F/NS:GDJ!:<^EIU2:I7P0-&
MV[D`$K9AS,RF-9B`9%'$Z[8(R!=.5R9!*H@TZ:XY-E`\3[J<:;AR4D-TZ-`E
MTVG?(H.K>V2QM&(W!6]:5;A1:%-'$-#=3Z_V5OR]*VFK=8DE9ZIHV^[2C<7K
MJ=P*MI9-9#54B8&F.Q<<[LED=X-&TSVG=%`7!W?421N3*`$GF*T1`1EC[3F'
M3M:W^7292U.37I/64+75-6SD\;@7S"+L!([NN;$B=X)%V&<ZP0);$F=I=8JS
M_"[XX2(@AMKU`A6O4N>B$BL"5!@=5^P4PJAQO1R8&F+N!FP--6W1\S3OJ)P6
M)4$3N5>V.,G6L!2=R2Y(?$1S6G`RGN8G-`04,X*YO7B$$0.RM:=P';76(RFN
M%]+TI>U8R6P8-<1%=7(RR)3&&&X:V3.""'V`A)AS_&3W41#2Z+F210^1F.D/
ME[(<)M>VT1!BGUK&AEL"D44T>1USM)+ED`,O<4;1&9RN875NI5`'`QMF6K`M
M9\(,-O;W4!#;RY>>XRR&1!Y-&YBB-V4U!2Q@N(\@-)B?46'*]/=;J[LN^;EK
MR^392LB]'T%M!;DB2TO.(>2YR)ZUXBY[Z%GB\^5L<YAZUD?U*%4G22%&V.C<
MXHCD;DA4>K&8$/(%XZ?5>79`]>;SU1E4FKFH[6B^QKQ;A&TLA:WH[7PC5<;0
MJLN;O4WK"#M@)E!7-ED+,='D+%!_KH&_*TS'ZN<-<,QIPVHO:^949<L\NA)!
MZOGSE9T*N&OIS")E'G-KKEZBUY(CFZ=M*>.5T^PA0P-YB!0<A96V/.C6A94`
MPHDA'H""`E]XD=2FVV^40`3!5U%Q6D:\JJTJ3;=58U&I@BH=VK:\AD*+G;'\
ME?.'6Q7&06.Y(FIX=IF9.\R!M=&-E.9C4B=$<E6^V\F'"+1.I),C9$1G>@&6
M`HYE7(",1+,LB*2S%P43,!UKLY<%%MNKM"S&:3(K"W*%4W%FT4K7"9`0+;I=
M1RQ(6=FE!CCU!98^4-_2^FBP#Q+5FR&MS11".#4=93!L(O66D;!9Q"M@;*D-
M/0I1'8RCKL^?I9(W63&G&*S"&RA@87..*?"M4*3FLI4M(_%..E79L'?(3%C;
M?UB>5LEV??\`4.P344K?&F.TK=<=C0IY\"V2]2>&,J)R;U4%#]<"!=#"9*/X
M7_ZB4R53+1!1CX=/>H?:$RA4JJQEKBHJYJ1WAVOE?1"MX<W3`UIK&&ZX6P^7
M3$FR,/,AECM(7ISE4]DCRYV))9HO?WF1A68"C-9C""C`\\C'5:V!B]H.UJ(X
M;4IKL_;?3K<MV:QM<O(0"G]C4\\T=)HLUK29=EY8XC]93\X'L3@@7YF\=DN$
M;ZWRC)J0M/FYG@W>KIF'&/7(-Z<B97,NA68$QK&L8CUC>%7?7G(`4N9[,G0A
M2X4%H1+,O*&TYSS&X,4;N-4*PK`L`D7?%)9-[G,JM'R*6=-214XDN8%@.+7/
M24.I\6V"J*5L"RS:>PE^NW8",4.D<)765JU(V6`H,:'YV5!7P>1-T)RL9Q$2
M5JDJD04S0I_C*.DK<#5,B*XA]XZWVE/FW:.)ZC6-'(;)9\B+JBU9ZU/C_#\2
MI[E\`CC>[L;FS1QX-6J(B!Z<&EW2&1<;>MD)2I"FX!8'4JM:=,KC&T]95-$H
M^KHI#KLC0-"FV)"L;J[:-@&C8QJ/,D5@V5+I(_S(N9M&&]UELE='17(69P<3
MW-)E\-3NB7X"KJ(6ZNFEQ39P@-*O"F[]LZ]W"F4>DD-<I3#13^N4\P2-D1(C
M3_(5R);7;JFFKJ!W;7S+K(`'IVM>T2-K7HL*#/6;!\P`DA3AF1O%9?ZYVTL<
MBW?;F-6E#L(R?Q@"*Y'V:U!%BF,8TC4F^5DS%U))H=LFDSDY+"C7"RLL);AJ
M4,O7NW>HDHU"EL5B\EGD-G>9<QN[PD-CS-8<(D;"<P2!5&G9GG%86]$8+9D)
M7"7)?78\K?8V2SS%@/)?8RXKT(3\DXD\S)V\W4GFX!M5(Y1$8Q!HO3$;D\:@
MD<8)'9LZ6IDTRD1<ID1SS/;AFD]G[Z`QS(3$,+0K?0,429TQ+-'VY(DP/QX;
M<UUUR??R<ESW'>Z,PX/X"ZP-X2^0?4%+]\5R)`)R&DO^1\KFY`6-IWFZU"0'
M/=IO`-[[J4$NL(9,G*!2P!)`<<>7IBD_</K!X@@(3=\94GC%GL$!"?'<\\8L
MY[!`26,8L^00YSS-FDNF]O=L3ZD?4VJUQ/;0X"#A+*'Z,&5[#AA%V['8E5BG
M11F/(QC.!9,0J5F<AS@0`"\N6XX99FTPQ23-[V)&D;]E`3X?%5F"VN;I]W:V
M\]S)\'!%),_'+\6-6;PCP>&L)N.65*2^IC]NIEZDNN^WZ=I-L.$'*MJCX7RW
MYBE!Y9$`1*`,/B!1W;RQDJ3NA.!=_P#?`XQG,O=)?4U6B=?>I+;9D-PW^[$"
M")6ED,K*KV'*A![9\(8[7"=G>/0"SW[DKI>X8R#.`C$//?.=S;[-XM<9$VZP
M*?QKB18_%SHNN4<_AC'$$5*++8?:.\TDV:V<;9=_>RI%D#ESQ)O+@$`\QA'$
M$<]4,/+TQ2?N'U@\00$)N^,J3QBSV"`A/CN>>,6<]@@)+&,6?((<YYFS273>
MWNV)]2/J;5:XGMH<!!PEE#]&#*]APPB[=CL2JQ3HHS'D8QG`LF(5*S.0YP(`
M!>7-CG26DFHVN)*8%(:Y4_7"I+V]&]Q^#,F)0/.,=L"52UP3+I0L'\N3%3N<
M9D7<619SG.>91>`/RX[]L]\>+.19QG]&19SV_BYO+?8Y>!NKUCXTMXP,N;FD
MEU9^'_1#P5+++L9(-+8CB;-S:HK*$+ES9@3SE\QSCC;J<LC5&6DOJ8_;J9>I
M+KOM^G:3;#A!RK:H^%\M^8I0>61`$2@##X@4=V\L9*D[H3@7?_?`XQG,O=)?
M4U6B=?>I+;9D-PW^[$"")6ED,K*KV'*A![9\(8[7"=G>/0"SW[DKI>X8R#.`
MC$//?.;$/'-Y;[/83;Y96JS,/QKAFFSYN=&.Z\&?",<<ZEEEL7LY9:2+!;F0
M9>Z7KO<YD9<3$Y%OGF,^$(XY^"L6Z2TDU&UQ)3`I#7*GZX5)>WHWN/P9DQ*!
MYQCM@2J6N"9=*%@_ER8J=SC,B[BR+.<YSS*+P!^7'?MGOCQ9R+.,_HR+.>W\
M7/;CFX2..)0D:)&@YE1511U*H`'R5)8H8;=!'!%%#&OX,<4:QH/!P1`JCAXA
M3CCCE=7:<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<
M<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ
M2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G/7P!\_+MWSWSV[A[_P`/;MW_
M`(^_?'ESVXXI6(MWZ#Z8['A4"NK6>G9VX*A"&=(5T*:FV7^(>,X$(F9Q\IHE
M:<S.<Y%@PEY`+`ONL9[^?(@KL^IG=)IUZXMIR=7+0KJ>,8TR%(_([0AB7Q=\
MX!\"3Q.=)O0@%GM@M/.4^<`QX0B#GMGEC?CF%<8;87>9N+2"1CP+F,+)YQ-,
M@_4U:F]P+!\1S-YAMI,[<\IA5)_U3QZ)A^J051,NSZF:W0@WKBZF;(IF]6LH
MP>$C:J6O%1S-27CODO'P?(BI#$!'"QVQG&9JD+R/.>V0A\^1"W9T^]V]=?7#
MKBU=N6)-2$8P*),FAZR80W'@[]S,3*""D\9"5G&/%@P]S(QX/NA8#CFTMYZ^
M`/GY=N^>^>W</?\`A[=N_P#'W[X\N:.XV2P^7,P23VQ\`#":,?\`ED]T/G:B
M=[V.,&GS:SGN[%SS*'%S".M)AOCZ0*U"`!!,$,LL99IA0LA-++&`PPH0<]A!
M.+#G(RAASY"`8$(@Y\LXQGRYYYM-KOT'TQV/"H%=6L].SMP5"$,Z0KH4U-LO
M\0\9P(1,SCY31*TYF<YR+!A+R`6!?=8SW\^1!79]3.Z33KUQ;3DZN6A74\8Q
MID*1^1VA#$OB[YP#X$GB<Z3>A`+/;!:><I\X!CPA$'/;/-'<;)7\>9MY8+E1
MS`DPR'HTOJC'ZY:B=[V.,8@S:SN+2^4<REFM9VZDDU0C]=P*HC<<L>W9]3-;
MH0;UQ=3-D4S>K648/"1M5+7BHYFI+QWR7CX/D14AB`CA8[8SC,U2%Y'G/;(0
M^?(A;LZ?>[>NOKAUQ:NW+$FI",8%$F30]9,(;CP=^YF)E!!2>,A*SC'BP8>Y
MD8\'W0L!QS1W&%XA:Y[^SG0#B7"%XQ_]R/5'_P`51.]P'&</S-YAMW"B\\HB
M,L(ZYX=Y#_\`DK#SCG@`@F"&66,LTPH60FEEC`884(.>P@G%ASD90PY\A`,"
M$0<^6<8SY<\\P*U-....*4XYXSD(3"R1"``XX6`$DB&$)QXQ9[!`03G.#3AB
MSG&`@*`,0L^6,9SS-"DNG9O)L5ZD=4.K5R21I7B`%-*'2)J(-#1X'VS@WZ[[
M!,BK`83VS@63$BY5W#]T$(L<N1Q2S-HABDE?WD2-(W[*`GU5>@M[BY?=VT$U
MQ)P]S@B>9^/-WD:LWJK##CEDBDOJ93<6:^I+KKM2FZ.;#A@];:VDU[M^9)B\
M]LC#E(S%Q6(%G8QW#C()>X%8'C_A@\\R^TE]32:.P'U)=;TMN2_78@81JD;M
M)4U;0U5D/;.0X8*\3-[_`.A%G&>Y2N:K?N,^$0AY[BYN+?9S%KC(\G$"G\:X
M=8_E0:YA^N.I/9;$;1WF1Y$+1#EW][*L.6?CB7>7`R'.#"/%SU0YSD(3"R1"
M``XX6`$DB&$)QXQ9[!`03G.#3ABSG&`@*`,0L^6,9SS-FD.G#O7L8%"IJ+5F
MWW]E<O!E'*WR-#K^%G%C[9P>7++$/BK*I3XQG`LFH%2WN'S`$?-C32.BVGFN
M!:;%(ZVT]7JU)G`BGYGA#,HE@LA[8P)1,7A.YRM4/RQG)BAY-&(7<619%GOS
M*WP!^7'?MGOCQ9R+.,_HR+.>W\7-[;['#@;N])\:6\8&75++JS\/^A%2RR[&
M2C)L1Q,GFU16407+FS`N)]68YQ_BRGPU1EI+ZF/VZF7J2Z[[?IVDVPX0<JVJ
M/A?+?F*4'ED0!$H`P^(%'=O+&2I.Z$X%W_WP.,9S+W27U-5HG7WJ2VV9#<-_
MNQ`@B5I9#*RJ]ARH0>V?"&.UPG9WCT`L]^Y*Z7N&,@S@(Q#SWSFQ#QS>6^SV
M$V^65JLS#\:X9IL^;G1CNO!GPC''.I;9;%[.66DBP6YD&7NEZ[W.9&7$Q.1;
MYYC/A"..?@K%NDM)-1M<24P*0URI^N%27MZ-[C\&9,2@><8[8$JEK@F72A8/
MY<F*G<XS(NXLBSG.<\RB\`?EQW[9[X\6<BSC/Z,BSGM_%SVXYN$CCB4)&B1H
M.94544=2J`!\E26*&&W01P110QK^#'%&L:#P<$0*HX>(4XXXY75VG'''%*<<
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MWZ)9_P`PZ?X^(UL'^.:^#X_'J??EJA'N0K+Z'X^/QZGWY:H1[D*R^A^.X7ME
M\:P'TV]Z/[MZ?4?%3NR;*_%L;]$L_P"8=/\`'Q&M@_QS7P?'X]3[\M4(]R%9
M?0_'Q^/4^_+5"/<A67T/QW"]LOC6`^FWO1_=O3ZCXJ=V397XMC?HEG_,.G^/
MB-;!_CFO@^/QZGWY:H1[D*R^A^/C\>I]^6J$>Y"LOH?CN%[9?&L!]-O>C^[>
MGU'Q4[LFROQ;&_1+/^8=/\?$:V#_`!S7P?'X]3[\M4(]R%9?0_'Q^/4^_+5"
M/<A67T/QW"]LOC6`^FWO1_=O3ZCXJ=V397XMC?HEG_,.G^/B-;!_CFO@^/QZ
MGWY:H1[D*R^A^/C\>I]^6J$>Y"LOH?CN%[9?&L!]-O>C^[>GU'Q4[LFROQ;&
M_1+/^8=/\?$:V#_'*3V@767Z@M[[I:U4Y9EL1)Y@%C6>BC4M:451P!D5N#.<
MQORTQ.G=VUK)7MYF5*%,/"A(:`[`0"!@6`C%C.47U0AU2]U=![MURA>K]D1J
M$QZPZEF\KE:1\K2&S@Y<]LLV:F5O4D+),@5J$!1+>J.*&E2B`2<,6#C`Y,"'
M/(?CFP6-;/XO9X+?2X>]W?6;7L+6\\[P+"KS(1(\EK$ZR:H'R58V&17ON)RF
M^RVTV'[76T]UA:74<=O<-;.+R.*)]XL44Q*B&:X!71*O$L#JS!4``FU_QS6;
M?;('5T_+[7W]GVI_H7C[9`ZNGY?:^_L^U/\`0O,?M+Q;X2Q\]+]G]LCT9ROD
MLGOD^5OHULR>.:S;[9`ZNGY?:^_L^U/]"\?;('5T_+[7W]GVI_H7CM+Q;X2Q
M\]+]G]LCT9N2R>^3Y6^C6S)XYK-OMD#JZ?E]K[^S[4_T+Q]L@=73\OM??V?:
MG^A>.TO%OA+'STOV?VR/1FY+)[Y/E;Z-;,GCFLV^V0.KI^7VOO[/M3_0O'VR
M!U=/R^U]_9]J?Z%X[2\6^$L?/2_9_;(]&;DLGOD^5OHULR>.:S;[9`ZNGY?:
M^_L^U/\`0O'VR!U=/R^U]_9]J?Z%X[2\6^$L?/2_9_;(]&;DLGOD^5OHULR>
M.:S;[9`ZNGY?:^_L^U/]"\?;('5T_+[7W]GVI_H7CM+Q;X2Q\]+]G]LCT9N2
MR>^3Y6^C6S)XYK-OMD#JZ?E]K[^S[4_T+Q]L@=73\OM??V?:G^A>.TO%OA+'
MSTOV?VR/1FY+)[Y/E;Z-;,GCFLV^V0.KI^7VOO[/M3_0O'VR!U=/R^U]_9]J
M?Z%X[2\6^$L?/2_9_;(]&;DLGOD^5OHULR>>O@#Y^7;OGOGMW#W_`(>W;O\`
MQ]^^/+FLX^V0.KI^7VOO[/M3_0O'VR!U=/R^U]_9]J?Z%X[2\6^$L?/2_9_;
M(]&;DLGOD^5OHUL#[OT'TQV/"H%=6L].SMP5"$,Z0KH4U-LO\0\9P(1,SCY3
M1*TYF<YR+!A+R`6!?=8SW\^1!79]3.Z33KUQ;3DZN6A74\8QID*1^1VA#$OB
M[YP#X$GB<Z3>A`+/;!:><I\X!CPA$'/;/*MOVR!U=/R^U]_9]J?Z%Y[E_5'W
M5S$8`.;]K[L(8<9_['VI_9D6,9__`&+\W,&X['4]UF;B#"Y&(XN7D63P?Z1;
M=7'ZF\!_7J;W9C"\1S-YA]C,[<\IBT3_`*IXU28?JD%2\E?4L]W9FN41^VM5
M!KK!OE(B:QF8YN(GQ_ZN8>.1@CP#O!_Y?Z]C"<#_`/U7P^6)(J2^II-'8#ZD
MNMZ6W)?KL0,(U2-VDJ:MH:JR'MG(<,%>)F]_]"+.,]RE<U6_<9\(A#SW%SL1
MHWFV45]$^B]S#YDS"V"F\&J5[D<L#"XX!I6.,JL`MA>SB8CA+\`(P*6L62"B
M4Z8):4S_`$Y&`F_=<B<^.,Z@'Y5XG[IH%]&<UV$=C".^6XGM;>P(M[R:T<7=
MQ<R`2P!"VB-HY4,??KI9AJ/',#P\EVAQ3L>;#XJN'8C@U_<W4EO'>*4C6^ME
MBDEFB5=-Y?QKJ#P.2&A;O2O?G,@6FZ1T6T\UP+38I'6VGJ]6I,X$4_,\(9E$
ML%D/;&!*)B\)W.5JA^6,Y,4/)HQ"[BR+(L]^96^`/RX[]L]\>+.19QG]&19S
MV_BY2W^.,Z@'Y5XG[IH%]&<?'&=0#\J\3]TT"^C.2>/L=8Q$H2)L+C0<RQRR
MHHZE6T`'R53#V:MB+=!';X?C,$8RRCAP_#XD',!DB8BJCAEX.'ZC5TKCE+7X
MXSJ`?E7B?NF@7T9Q\<9U`/RKQ/W30+Z,Y7W/L<^&P[S\_P!EJ[W<=C_BN/>A
MV7\RZ?X^(U=*XY2U^.,Z@'Y5XG[IH%]&<?'&=0#\J\3]TT"^C..Y]CGPV'>?
MG^RT[N.Q_P`5Q[T.R_F73_'Q&KI7'*6OQQG4`_*O$_=-`OHSCXXSJ`?E7B?N
MF@7T9QW/L<^&P[S\_P!EIW<=C_BN/>AV7\RZ?X^(U=*XY2U^.,Z@'Y5XG[IH
M%]&<?'&=0#\J\3]TT"^C..Y]CGPV'>?G^RT[N.Q_Q7'O0[+^9=/\?$:NE<<I
M:_'&=0#\J\3]TT"^C./CC.H!^5>)^Z:!?1G'<^QSX;#O/S_9:=W'8_XKCWH=
ME_,NG^/B-72N.4M?CC.H!^5>)^Z:!?1G'QQG4`_*O$_=-`OHSCN?8Y\-AWGY
M_LM.[CL?\5Q[T.R_F73_`!\1JZ5QREK\<9U`/RKQ/W30+Z,X^.,Z@'Y5XG[I
MH%]&<=S['/AL.\_/]EIW<=C_`(KCWH=E_,NG^/B-72N.4M?CC.H!^5>)^Z:!
M?1G'QQG4`_*O$_=-`OHSCN?8Y\-AWGY_LM.[CL?\5Q[T.R_F73_'Q&KI7'*6
MOQQG4`_*O$_=-`OHSDV'23W!OW:R+;`NEWRIJDJV!/$(21@QLBC#&0HB'IAD
MBYQ">6RI4X%V3E+<D&`2G`Q$A+$`O.`F#QG`Q/9#%,)LI;ZYDLFAA,880RRO
M(3+(D2Z5:!%/?."<V&0S(S/`[S9WLI;.;3XO:X+AT&+)=W8F,375M:QP`002
M7#ZWCO9G&:1,%RC;OB`=()(F:XY0-4]=KJ8EJ5)8;GA>`%J5)0,?N*5KGL`I
M086#&<Y9^^<X"'&.^?//;OGSSGG\?CW>IG^6B%^Y.M/H?G)3MOA`.6ZOO,P_
M:/;+JS^X1_11[)9`(O\`9'B`?\J8GX?_`.%J_P`<<H#_`![O4S_+1"_<G6GT
M/Q\>[U,_RT0OW)UI]#\\[=\'^"O_`#,/VCVR/1G[]ZAV2_C^R/[TQ/\`DE7^
M..4!_CW>IG^6B%^Y.M/H?CX]WJ9_EHA?N3K3Z'X[=\'^"O\`S,/VCVR/1F^]
M0[)?Q_9']Z8G_)*O\<<H#_'N]3/\M$+]R=:?0_'Q[O4S_+1"_<G6GT/QV[X/
M\%?^9A^T>V1Z,WWJ'9+^/[(_O3$_Y)5_CCE`?X]WJ9_EHA?N3K3Z'X^/=ZF?
MY:(7[DZT^A^.W?!_@K_S,/VCVR/1F^]0[)?Q_9']Z8G_`"2K_''*`_Q[O4S_
M`"T0OW)UI]#\?'N]3/\`+1"_<G6GT/QV[X/\%?\`F8?M'MD>C-]ZAV2_C^R/
M[TQ/^25?XXY0'^/=ZF?Y:(7[DZT^A^/CW>IG^6B%^Y.M/H?CMWP?X*_\S#]H
M]LCT9OO4.R7\?V1_>F)_R2K_`!QR@/\`'N]3/\M$+]R=:?0_'Q[O4S_+1"_<
MG6GT/QV[X/\`!7_F8?M'MD>C-]ZAV2_C^R/[TQ/^25?XXY0'^/=ZF?Y:(7[D
MZT^A^/CW>IG^6B%^Y.M/H?CMWP?X*_\`,P_:/;(]&;[U#LE_']D?WIB?\DJ_
MQQR@/\>[U,_RT0OW)UI]#\?'N]3/\M$+]R=:?0_';O@_P5_YF'[1[9'HS?>H
M=DOX_LC^],3_`))5_CCE/CIF=6S>K9#=JFJ9MVSXO(*]EY%DF/S2WU;!H\L5
M"CM6S*3M.2G=H;2'!)A.\M#>I,PG-#ZP64-,=XB3C`Y<WN&8M:XK;M<VRS+&
MDK0D3(BMK5(W.061QIRD49YYY@\,LB>1;>]CK'>QSC-O@>/3X9->7.&PXI&V
M&W%Q<0"VGN;NT17>>TM7$HDLIBRB-E"%"'+,56JMQ[>.><>6<9^;..?II7YE
M5VTNHJV$;#6,D(A#X_-UPQ-UF\#!$6]=,'-QC;-8#W5RU:X,\;2N3DR&"G$>
M<V1$E<TY)S@,"4Y($T"Y+@SB(8#/1*6Y$&"3D2UX;#WMG1AA<I$L=V5*I]24
MO+0DPT94NK.F6?[C4.K>4I;TZO\`W*<I+4?Z/DB=:=0!#5E*0^"0XFTXE8<3
MUK:Z21SJ&OJ2-J$CV1OJ3M4[.K6\-3\@?T;*Y5UE=!C\%X(7*7U:>E4H\QQ0
M>O%W)9'58^O9SLB2(U%ZI9>Z8ZEZ&II4KEJ0$@K%AW&1U<GHUE87M)*!N<7;
MJ@,@SJ8ZH(L>4C9,N*0R$`7&B59*AK8OM2EQ-$-GHIH%O,2AAN.5M"6MX!+)
MA\[1"*4".Y!@A9A+K#K++NP"L0E*X;LX\,<AQN6*5K6PED@Y*)0LTV[2]A$I
MDB[^`B6908].EHXC(2K2-$2IKZ?HCD29;`IVB4N2M[0-J=9"I4D4.2^->FS)
M$+<0I:"CEZV.83J,R%&C`>I8L)S\NQ2/!!V0>K5`9X^C2EL4%F[X8N1M[BA+
M9(;)W@Q:W.^5^&EP1@;&E4-6WNN6IUPUKD^#4CEEK<\(CC_@Y=ZO-&Y=6N-R
MRU&27V"TWO,XFT;$QFRF]I=92PN+S%ZZ6:*ONJ5FM,.^&GYR:6R5/L]DCI:I
M"$&$T?DAWB5R=R(D+BM'CK9!U&Z_J]B8HMK\1L5"FV)UMH-5#+)5TEBS%.G2
M(ZF7E:UDV*1(G&"OJ!(639T9GR!I1,K7V:S%1+DRR'/P*$+BZ6UQW:DI&K;+
M:+B2.R?_`![5;1M<S%+F.200"0-91-$[@1$2D3!"`@SN'!]G`[,-HM4"2W29
M<C(N'6&(-!(D>^*%+J19$7.0&,-$7!U'*)/$:DF6%1*<1R0YBR1U`PJI1AA>
M/K92OI@/2%L2F1>I?`J=\,+_`-(!G/7EN8P?=!2YQY\YZJH^TT\4K*:)X<[O
M;';[;,'>!_6ND52IU<D$$G1=;2,]<QQ].X.C-@B:')V1#AQ3$_"JA4C]0R=E
M8F`;*K<O5$KRR=5;6H2/P&P(BZ35VO!L;VL#;7:^NWR+VOL<^7LSR^5J%+J>
M]1ZQ(TE=TK*I3Q6-.9RAY9F]U:;`;&T:IN'CS7N]Q-8ZYM]80?%G0VTF75G8
M2BF*Q8>]I8X<R2VX]L:\OUIDS0]M+VADK6VMD/B;O&714@`G>P/;DGPVD&M@
ME"XF]'B^T\UNDIV>2UF^[+V;6TUWO=6&\DG:._::.-1$.5;C6$CN/<BT8`D)
M,=E\,V?BG:,8VUQ#]RDNA<1VQBTXARB`262Q.[&0\G,^EG:`;P*^9C4"3#8^
MA[<(K(-O?6)(5$&#-9U7R]:A:W%<Z1^35LQQ>0S,B5L"5&:[1-N9FV8L'I7J
M1)VYL&N5'MN%`5J)24#FLAU-NYABSM-4L=;YE&F+%1X>'"N';$],;S;KK)YM
MV&DGM\?1GN6,(X5'WE3,EH$@VN&NB$QI>7`!YA0QR7N'5B8,6,\2"/MEUL<%
MFFR6RUSV3#D+^S-Z2P8Q=&HD)H.*1V7M2"3`9I4OC5A1MTG+DF?O7&<E&O3N
M34<IDGI""5&]3RIJWPR#=R-J(F?&DW3X<BSJ/DT$C*F;N6E5`K*MDU>V"K>G
M\'K]16S(U!1R]L(3JEPXZ`M4YMOKZ;#.?KY,:VS6$3+L['J$4<XMQ*SLPFO8
MXVLY"N12>WMDE<SH)8Y!+%(8HRKPUFIA.RAEW38[)I,CPF;=!0-W:-(+I%/!
MH9[AHXQ"Y1XS'(F]<,LM1BG:LW3FKU5RM$:2RJN6FKX=;\ID40=TTA)A$.G<
MZD5=Q[$R)2E@-9G\4BB[J<\,(,+54<CP2).^F(60PU61U(;`IX0M;6TZ"S@E
MR>F@4@96TZ&2@EQ>8^$O)HG]G;S6D"QV8@E!R:)Z;B%+6$O&3!*\`^ZY)^DZ
MB$!-JE\KYPAECL^''7NN80GCT4<6,BO5EDUGNG:6TZ*./[,I>DPU5)2N,6"1
M5,D,);S)66PIW1$3'5K8K+`9W+/.K##5\NS+83G:AQ?#U.Z5@,TQMB>Q!\FU
M+SW:.DQUE#ZQHYSCZY.*/T=5$B`BE:0\:MK>Q'HF]0S1)"N0!PHOIC6UT<L\
M<FS:3KO[X6\BW(@400VD,MIO6`G61I[EIHF=1'I1%TQN_%[385LRT<,BX\\1
MW-GOT-N9299;EX[DQKG"R+%;B.4(QDS<MJD1<@D6].ZNVG=J6R'".**VAK34
M9\81V$]W9:T'HQCC;E,G9Y8XXS+'>SG2/H0OCB[Q]W;@LPC2W$I6B,3FIPG9
MP7SK&5UQ+8@LE)2Q`2]LT.E!T->)W"59<XJXR0%^#)2-GM",A7P9Z`X%&%J&
MDYO>C0NR4TI2@P>28`8LH==-T9SKI6NS"").SR&W[T>:/<FZ?.[%"+#1$`KZ
M9324SLZ6(K0:Y60ZO$L#)DV4+P)E=7/+D4O5JUZ$Q1E2?VVOWHCC_IZ*E7AP
MV+9;-Q%KAASQ'J_EE?1;6.U%5Q7,;;[C:UL0DME,=ULZ9!JS8PE9(ZP-R0YK
M:8V6TRZ+MR`YL%L);S::#$9LL.M;K#6Q"QLK?=2R1W,=O)86\]YB$NJ-T>".
M\:6TBR*-F=<B1I`TDV%':8!-8Q$W]S;WRV-W=S[R))('G2\EAM;*/2R,DLEJ
M([F0MK7@5B=WF$<?1U1Z([$7C`XK8%=(:Q7()^[S5@KJ+R"ZJQAEDV2^UZ<0
MFE;/7E=2R0M,EF3D@5*DJ4I(R)E)BM2J3$$_Z12G"9BX*'R\#:G>3(C+"V98
M^F1=(\&Q=_+:%4H)/$F.C"9U$W8;E,F)4@&F.CQ"HQY*4@&G&A"<`0,22:\;
M;:Q5K`M2'"S8=?TDM[3"U[BN"N6&#G5@TU7/)%.)E$I[#$,ZE$@7J9TQ-C!)
M(<U&OV8S&5A[@W^M(DV#<J,#!VJ;U.X6ZU`Q,+_'[R53=1%:4@,LK%-*HF#5
M%E'5NR#-?LAOVNH08:&1H[VF^&Q:Q&8<DJ-(B6R!Z<5<Q<D9Y*,O!;%]JH;V
MX08&+VS.(&WBD'^!-#;\OOHDD#O/<<L1L.BLKQIA#:Q)+-);AGE8)#EKAFS<
MMI"YQ<VEUR)9I$;.[66?D5E(T>E(8.2L+Z2\M1$TMR[1QK-DJ+KEB4<:\L)G
M2+U[Q7\]:$#6C3.+HO=H1+&M"V-RU>H:T3BY+7!G3)6YO6N:16VHURTXA(K<
M4JI`G.-5ICR2^4QZD;&?P/QI[&9$"6.J9=<Y1]AEN,$(E$&A:9`J=U,$.D#8
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MB.)PO(2#.-19.*PJ`3DP&!<<Y)IN;OT1M5#[.B)F+2/0/FU46NNK4$Z?$CLT
M5S6S+KT&I'*!M"$I\<R(ZJ<96`,E&W1M.&/JTH<KERH3V,98HR^2G"+K$+RS
M2;$[`8==$KKMEF,ZJ'BCE'?E(SJ0R-#(-.6\B<J2I!J/XG;V5M=-%A]X;ZV`
M[VX:+<EF5W0]YK?@P02*=7X$B@@,"*D&Z47_`(R+3+_CL;?^;,HYG#]5L?\`
MA+Z>?\05F?\`26P\P>Z47_C(M,O^.QM_YLRCF</U6Q_X2^GG_$%9G_26P\X5
MV3_^T#9[_P`/S?\`,8A7T3V#/\C8I_O>3_D+*JF''''-/7=Z<[DHB@+6V5L`
MJM*?CB>020+!(I>\*G9^8HA$H?"H@WB=99.IY-Y4O:HM"85&6_`5#W)9"YHF
MY)DY*E",Y<M1I3^F^9FZ4;(0+7N670S6]#YA,Z6V5UTL366W4E<.S.RV8Q1&
M>N46D*:7UZLD?:-'R6,R2',JW#+(Q%LD@;!.#2X'E%'X\=FY:9()&@0/*JYH
MI&>9S&?>ZDU$+F0FM-9`74N>8\8D`D#,^`>V7\>-<"N_4C8'7J1LL=L:`*%!
M4J:HB^PF9UTYMMLU?8+//1KR8:O@%H5R?(H3+L216U.S<U-[4[F/2IS:7-O"
MUX4HCB\?'F.KVP\!#4>)73%D-RJ]X:LGU3-),.D#I()E&6Y]?8XXGH8XU-RQ
M^3NK8Y1QS&Z1M>W)I$V-&6R0+VM,Q/C*X+YE]$MN=,J#?]EY!!8\Y1+7NJ*!
MJ6UZ^A^Q%NLRN][\WUU^LIRG>OUI16M8UA1#$"Q=(WESC4S@U9GE1V$UX0A>
MW]T=3W-Q-QUC6O5$@*.OJEBUDR?=AEG232V;:CVA=-*V%#VVS(`\+-EA;#LE
MSZZO\HDQ:T+_`&"E4J:MN=ID:N%GFP5!'&Z.O;BE:0(L:H7V):F1;+>"(QAW
M(,9D$D!EU"-7EW1B8#6F\E9@R*H61LEHU/G^#GD0">;@5SX#,Y9>+CXN>HHE
M>O=UH:FB]Y*:SEP*LF=HR.EHU*@,RXXMSM"*(F=:]0XML)(,=R7,OX=1-S?A
M0A*)>G\AYC3,8ND$>?FUNX@96MD$N+@SG5S89#NT/K)%G=I/@4P(=6B428>2
MXU&79L-9`+VN220>,@CD>7ID[S(!XR%F0KA8SC$[QG65JUVL)NL=WKS89J41
MS="XKTCL8C<\A8DH:WN[5&*ZSN\V/>W`9*-NVJKZ018[8*$/[;$1P=7;LSF+
MLJ=6A4O,=EGV*EZQ5(U7<ZZ;J&_=*QX\EU7IO3Y-+YQ/ZV47I8K/&;$F,YEF
MU-IR03BYM"C9:J4\G3L>JY254]IXL0W^EE-A(PC"3QR[%0K9X7J<+K"K*`,S
M)D(M7?!F2,J6D&2NS$JBB-P/-4GP?3SY>$<.O(DYY99^+*H/)=K]:<070YK'
M'396[32HF:[DS171#M/7>-P9W6/+>;F>-4?:%#A"W^-K&%>FFC*\)P9B*C*9
M.\K"%!_HB^1:_:N6ALLFL9RKQSJ9@CU2L46D=@3&Y+FKND(-'FR;2/,1B>5$
MSLEY8XZ-8_2/P-3:A"O"I5JSDY1`##%!(!RG4UU1:8KR,1F"+#=RX(GB>O&G
M]8)[HUVF5;0&^'Z2ZF6O?T\4QEX=)&ZO3434EVM]PLI\X+&M>%Z&6Q,E8MB,
MM;"B`*<+-;=[I-K.P[KN==8>&*TMF$M9IX+)5S%6MC-D2!&+\46K+RIFVV!%
MUD:?E#Q&59[&A=4$"&+,@$)U3-D9)$2-'=%QB3QSA;5$E1X%A>0G1(LDR+*[
M*`2BQQLYR!=ET:BIU*I]U/D>]&8*Y9YY$$C,]&0)\?-TY#$.;5+-H*Z39$L1
M-\J9J]D2:*R:Q:Q=4UH4Z4]+DR56W)VVX(5AVKQU+="5A&6HY*_YPY&9&4B"
M>86+',E:&Z>>R^R4`C%CU8EI\YIG<YEU9US'YOL!4E8V#9]@09,P*I'$:S@<
M^DS"_3A\2AE4=((1L12@2E8\($@1`-4E>+)='U'(Z\:82.E9DZ[1LER.*+:1
MN=FRG)A5E>ZP7LY;1SYBG3E8>PT$)C65JZ15]Z@MC;)&H=$4R)?'2&!N8)57
MZ9&I*S\[5S;S4&N*@U29[YA.RTJL?37::V=H:[C]4FU(T5M93O,U-+/T5B=@
MS"8.YDYB3:WR>F&@;ZY0V+N*\;.X+"D.%"H17H/)+C$A"Q6V"S)<-%P4S"2-
M8I2LJIKAR2658N)DRC24AB&C8@2^7`<=67`9\`,\^<<YX<_`'QU&.M@4\;6]
M8[.,%FR!H;I0J@[@\+(A(T[*AFZ%48A6PM6]F-F&<F7I%Q)J)1&!KL/A:LL9
M&4'I`^'G[G*K;19DK@N>:PLQG0M+;EY=ESQ74V:D+2S8=#F/+PZK7!A3)6QH
MP]IU#+EU7')V_#RG/:<J<.))J8$SLGZND5GE`O\`&I;';[#:,SK%SJ.4U$RS
M&(%:2872/;`[:!_V>9X$J,^O$O8T*A8LC+8:I;\$8683O2B;A29,;,<HLOK2
MJ;'_`'6F1V<ME76`67(^J\,V"R">D.,>.@6[<#9(UK-"'=E4S%>TF,]`/:=_
M=E;,!,K98;\-J%U:)G%>I6%C\%YBF8!PU0`\JL=_F-$:JRLI"'49#J1>8%M)
MSRSR:GS_``/"?QO%ET>'B!GPSRXU#3#-?K1F:A03B/CAB?%46/=#0[V>4ZUR
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M/-Q`_7P.?-QRRJ)GCCCFWJY3G]"?]]*__B`_^+'/Y\_H3_OI7_\`$!_\6.*5
M?SC_`/\`1JM7O^+"@_\`I8)Y`QR>>/\`_P!&JU>_XL*#_P"E@GD#','8[_$\
M5_W]B/\`^MO7QMV=/\\K;_<EK_SN(TXXXY+JXQ3CV\<?P_[?\O%*R(2ZJW@N
M@J2S4442+*^<*_*LA#,$C\VJ616T'S(FO4\=3GD#,-.LE1-E!,:35F62*7J'
M$>,D-QB7`E&.OIS4%G5M)YU#YG!I*SOU9KL()Z3AI6N#?%C3!8"F4.SXVD*V
M5,V+\YQEK>!K\-3J#/I&U8J+^ZYEHAVGJYOU12ZJI8E/TS:A+37(CL%(Y)DD
ME(VO2OY2HAU3H4\G`W)*@3Q`H$03DD8^NPM=@,R`W%O@`9#D[(NI=7*UFV$;
MV.,W`F4VS,;(GK0>^%U\_@=%-LUDW0=ZKZ=%.3RJ2)H5"%J(XJ&N*)MEJQ1%
M%7J6&"-NY)2L,=-]C:2./N<L\>_G1,@8&,"RVRV\S-O)^,B//K3=JRE`[*B*
M0TY7"-D9H(C]W7LY^164TVK*[7ECV]Z]]:1QF"T.FWFBM-U+OG1UE>)))Y&0
MI$,LBDJ;TR)8X1:3H$;DJ*0MJQ?''Q$D<EQZ=.L(0MRI4@)3KUIZ16E5D(T9
MIZHY*J3*2BAD*"3!\R>Z9LB-'U@CD$:4LJ^X2AG05L=!_!SJLP"=KZV$4\-:
MX"=?&U.)>VJT'JKRG2GY2A*<L%^IGE&"S_9^HDWMCY'E;DR6+*8Q#)SI?*X;
M#7M]0',T9)UVIU\K:R#8\C5.;BVQY^E[V[)I7&%R!"("I>TMZJ5F$*DY8`]%
MWILK#[&G>LKXR+[MF#90C:WM;S*;P>(\]VC-RT-U.MG>MK75D<UB`]1AG<2V
M1"%6K+&ERE3)C5)Q!.%@LB.\Q5YHT?#UAC*L[R[PRC,VKRK&!DFADG,4,A8D
M.Q81@@,ZX4^%[-Q6T\L../=3*Z1PP;@6YR7$8;>29F+3;Q)K,7-U$$TF)1&9
MB&*Q2=/69K=8]5.B&/O2^M)5*5LD=(B*'5+:L)M^:-TB9<*,.36^1"OG-\D+
M*I2G(U:,9;@@),PO2J4.2PJ"#0!XK5U.3FX)<Y0B()F1(^,L>D\J?1S61M,"
M9F!@AA19TG<']]E)[>VLI;.`T.5@'(U,(D030&X+$49X<RTF^KS)+]L>P+*<
M9V5!Y:PW[#X,[U>SUC"+DI]GN1Y2KVZ2Q5]9FB/IG:8,;<TMC*N4ODB/4G(%
MC[Z@_E*5IQZWK^/[%UN?L1=UC3HJZG:OKBJ>SJH4."IVA,ON@"6<1)DBB*3/
MKDN)BD-=WP`&?U]P+P4`@H)Q2+![N:G,<E?D=SC`AD6:TBWZVF^66(M)&UPS
M#*%8CH9BJ$ZAK!U(1Q5D=JI;#9=KJ"2UQ*XY')BG)7M[D1PW"62Q]]=27"[Y
M(U>4`(^Y==W*KD!XY8EZ)L'7ZVJUD[+$GR*B?'*3Q@N:1197+@BM%@ET2&<I
M3&2.+/\``37YM?&E$K1JT3HI1FB^"5:<PAQ`GSDD1O72"(RUU1A<6N)RMT;A
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M@94F&%OR".G8$2:7Z)[$@'Z0L8,XQD`_#RZ55#/HH^K8^-D.DRAN9V%\6N,"
M(<9JP)D,AB+9.$N#7QD;CD1:A#'G9,I>B3,@^"3"U@%(_0I1J<R@I^H]6`R+
MN&KC-Q%+[B+FA+OC*UF>VM[,ENLT6I1.Z/;<LGK:UM;HU2EC<9"[+D3%(GJ7
M-B]O$>^LJEO4MBS@T3ZAS3#9-"W=A0VFR-C;;VLLSG*!B>6UK%,H'2FKC/1$
MMA;@6D?4Y#LGDTD;1/K>T/`LL2MERGR]>A<B@(RJ1B&,L6(PC3IAU!'G'?RG
M<]YK"<-/NV60;4"@8(RL*K.![*((U;:?>;V[W;2QV9]QMU-T-\86E4MO,K74
M&=#&1*4WR,C"*O&<9QC.,XSC.,9QG&>^,XSYXSC./+.,X\\9QY9QYXXY[F"P
M,TT8<=@C--&''EWP$9HQAQG&/+&0A%@.<8\L=NV/+MSTY(1S#P5!Z<<<<4IR
MRGT"/^X;;/\`]H:T_P":\RY6LY93Z!'_`'#;9_\`M#6G_->9<BFVW^;E]_MV
MG_.05TWL/?\`:#@G^QB7_MEY5,5;_P!N+?\`UU;_`/E9_/S<_2M_[<6_^NK?
M_P`K/Y^;GP&W.>L_QK^GE/P%_P!E?X"G.;,5>2F1P:S[':DB,R(4XW0YUL!R
M4NB%$:T(9Y*@0N,&I4*HTM2[#72(P",XE`$TQ$5GUQ3@"<.1<X3S+G6O:V6:
MR5]LLW5P]2:)6?<<2JJ,PJ;QTF/*"HOB%V:7,91\+DR%.X%C3/K!Z9H1Y1M3
M@>!69XC?4R?]TXO6ZP/+E<.T<6[G)9`&<.L,C1!58J&+2A%TET#9Y%TSU#68
MU/BEO8&3!K6WO,0Y;A,4=O=2R06[6UQB]C;XB\L\4<\D"08;+=W&_2WNFA,0
ME%I=%.3R],SJE;/KIZ>6&21%T,5QR%P6PY$JCR93*F:/0VR8>R3R'/L@?6!.
MN:F)&Z1J0M:L9KLJ1EI%1IS<>8%8E/+!^Z;:^W;7C\WQB6U;.&Y^<ZZC=M)&
MQ-&GAX5?N<RIE2O[3+5(&=$N]1:BVY81\-FK?0"C#ADYGD86MV3*494Q;;U@
MH?\``=P$.L*LHF53[ZR9"&5M[96+P=8,F0:E0O7*:1RU6M^<D[&1$%S_`!EV
MEC$X(6>9>!EE#LV&0MJ=!DJ2?Q4[U9*VK?*56N8]@A2%92NH\5>)2D5P.4N;
M1/-68HY0Q2PQE-*I6C(7U=:1"LF9O"V1JANC9-S')0[PB6HU>3<[GD&"E\AB
MK*KR2$$PCW*)6E"AAF#))(!$HXQ*N;2'4A[WF`VO[*,=NLDG8]@EF@M+,311
MXDXY9>W$.'/</"XB?DEK9F3$)60QWTTPCBM!N;I")X1D<*FCB4RJ&Z&S%Q(D
MBDA%&SVZ)R->1(UBH"TQ*CCIZ-K/*?UBDIM<34R5G&M4'E-S@:26,M`L$1S&
ML*/M:X[$:*KK^$/SM-GB3MD/^#E3:X-*1B?WA<)K;TDS=7!&4@A)1SD$2$2J
M4FM9!2L.4Q@L'XR7B06%]1="SJ:?CCF9>48KF):N7113X75$K8HU**VL6X[0
ML*:*KSH5O-5I(BV3%CB\F9(*2M7IXJZ&QG$D8&I<Q-9Z'!^15>=62JHY:BZ;
M.['M.PMC)<M)68UN<!G,`^OJ_P!KJ>A6NAG-DVV6N1S8WS#,M"UYLQP*8CW)
M**3NSLWFFY/&FDI=J&RPEFAWN)E5,D:S+N=)TF(/*5;4P72V:!F!#>`%P5.P
MQ/:GLAP18@MCL&DLR65Y+83?=031\H3$&M+%)X!!"\QGM\KJ2&&56B`)>1;=
MEN!#B^TE8[**)@2L)TQ,F-?QFR6\NNB7*?#;&"6'OZ=J1R8,<;%>8])`&1EY
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M8$N'*A$'X60!-)]J.R);"[T;"Q7ZP3O!!(N)FVEN(^2R7`O3;BUG401R*+9H
M8YGN9I`!"C/($6$H4=D068<CS'I!B.EG"3&2'X"=_@`"D"K*$24;YE%\$@5!
M78RARF$LP?A=C*/)?K6,E8R%GNI%IUG7K;8TRD-&-B1WAL"G[;!BM@:I7W*K
MBEF(FASACH52Z20CL46'5J?&YV$1ABR:D:C#7%1@*1.<:'M':'<U??=9Q^MV
M$R<Q=CS>>S=TSJ-GKVAKATL=;EGD?E,$<%\;B)B!@7R2((6YX"N..8TK8U/#
MVN418&0+EJHSLYQZD4I,LW5E<!ER_P!%Z\->HQKC4S]$ZN2.LGDVNL3CC1(E
MB6?)HNXS(M`]OS6X/493NLF4(B,&-I3JS)TZ?U$BPL.&*TR/=2N-%N(9DC`7
M>2J6E=X]18QP9@,`VLD,%1LP1LY\5V]FM\-N;39_#K:4W&-38GAMS>R22M98
M=/%'A]M;7JP)`F(8PHFDMS+$+2.)XI)KB$QO&^!$8J6Q)9:$0IEOBKLVV7.9
M3&(9'HI*T:N&N)S_`#%>E;8XF7E25.VFM*9S4K4V27!>22C]7-PJ]*(C&1\[
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MKC#KR5Y;UK61%,<MQ;Q;@KRPC'%W:"Z_GQCO'S`DO[27!Y8-U831(U+B$I];
M`,XE[*8)N1K'$);HG2#$WI%2X(<I$QYQ9-7M@K7@B.HH!/5DB5-!,@31Y'")
M6J?U,?4$!4D/Z9C3LYCLH83TPP*2'HE&-K.3C`>6K$4,(\S$LG52B\)DD$.B
M)FS+BB@DQTC*>++F<VCYUVW?6^M<KNV268DN-W8GU*WN[O/F^VD$+C\;4.LA
MCYD1BJ%NEST:'!9?/>G.JI$HD]P>962DV$E5BQ*M`PA3/4LK1OKH\EI-NIU?
MY#(ZH7BP8X2_LQL!D<>A+&XRE<]HX`[Q\TQJ@C^T#;S$U:V.%%D4XH5)+ER8
M`54+(%"!A(<W93FK`&,E2=07(UC3[7=D..*YFC['@F""U2VC7%R)YGGLS.]R
M\368W=K!.NZEBUF\3>HNY:9)(Q$LLIN?$1VNI*WM.)019S5)7AA:(5A=+Y.V
M)HK-LU\XDRZ.,;>J<8NO4R;)"9H1+@#-<R%S<:5X#5Z5,9UJK2*V]6J0."16
MWKT*@Y(M0+TIZ)<B5IC!$J4BU$J+)5(U:<X`R5"5244>0:`91I8!A$'$K<JZ
MBK&5';.2U6DMF`3"35EN#"(3,V1V;8J[Q5VV/W:C&SD<=2'*.R/+LS$Q^$L[
ME$7PYD4C7X?UA0FCUAI,.7$X1[9W&S[";)7'=L?;'AF9[,EI4E1MD@$A&]IL
MYCK"U+!.IC:I5H35JMP:UBXTU.J/P=ZT$TTS*@9V,8MW;V448:VN]_)[@&31
MDO?PL965L\^\E3(KD0!(F3'(U(MF\8VIQ"[DAQO9T87:$8M)#=FZURYV^(VR
M8=!+;B(`"ZP^[9TF$I8R8=<F2&+>QJ,>....:ZII4IG18_\`&6:Z?^JW+_T'
M6)QQT6/_`!EFNG_JMR_]!UB<<ZCL5_DF?_O\W_H6M?GS_2M_[1<(_P#!N&_^
M];05#SXP?OA?](#_`!<>,'[X7_2`_P`7-GW]@+HY^9WK![B:S_9OC.@NC>,9
MS]AWK!Y8[^5$5IG/E\V,1K.<Y_1C&<Y^3GVQW?L)_)[$?2[;Z-?F3W$\4\N8
M?Z-<?2Z_8<=8)XP?OA?](#_%QXP?OA?](#_%S9\AT(T:%GMC3K6+'EW^ZH6M
M@X_E%&<8[_H[]_Y,\]OL!='/S.]8/<36?[-\=W["?R>Q'TNV^C3N)XIY<P_T
M:X^EU^PXZP3Q@_?"_P"D!_BX\8/WPO\`I`?XN;/O[`71S\SO6#W$UG^S?'V`
MNC??./L.]8/+_P"HBM.WG\V?K:[9_B]GR\=W["?R>Q'TNV^C3N)XIY<P_P!&
MN/I=?L..L$\8/WPO^D!_BX\8/WPO^D!_BYL^LZ"Z-XQW^P[UA_BHBM,Y_DQ&
MLY_V[^SG@6@^C0>W?3O6+/?[VAJV'_+X8SGM_'QW?L)_)[$?2[;Z-.XGBGES
M#_1KCZ77[#CK!O&#]\+_`*0'^+CQ@_?"_P"D!_BYL^\:"Z-YQWQIWK!Y_P#U
M$5IC/\>,QOOC/SXSYX^7C[`71S\SO6#W$UG^S?'=^PG\GL1]+MOHT[B>*>7,
M/]&N/I=?L..L$\8/WPO^D!_BX\8/WPO^D!_BYL^_L!='/S.]8/<36?[-\8T%
MT;S_`.9WK![<X\Z(K3'L_AC7L^;/LS\G'=^PG\GL1]+MOHT[B>*>7,/]&N/I
M=?L..L$\8/WPO^D!_BX\8/WPO^D!_BYL^_L!='/S.]8/<36?[-\9T%T;Q_YG
M>L'N(K3/_)&N.[]A/Y/8CZ7;?1IW$\4\N8?Z-<?2Z_8<=8)XP?OA?](#_%QX
MP?OA?](#_%S9]_8"Z.?F=ZP>XFL_V;YXSH-HWC_S.]8?G\J(K3/_`"1K/\GM
MX[OV$_D]B/I=M]&G<3Q3RYA_HUQ]+K]AQU@OC!^^%_T@/\7'C!^^%_T@/\7-
MGUC0;1O.,9QIWK!Y^>/^L16G_P`XUY?IQGSQ[,^?//V`NCGYG>L'N)K/]F^.
M[]A/Y/8CZ7;?1IW$\4\N8?Z-<?2Z_8<=8)XP?OA?](#_`!<>,'[X7_2`_P`7
M-GW]@+HY^9WK![B:S_9OC[`71S\SO6#W$UG^S?'=^PG\GL1]+MOHT[B>*>7,
M/]&N/I=?L.-`KI0C!GJ1:98P,&<YNQM[8P,&<Y_ZF91GRQC/?/\`%S.'ZK9$
M`.R^GGB&`/>@K,[>(80YS_URV'V8%G'+FL3TRU$@<E99E"=7M?(A+8VN"YQ^
M3QFGH"QR!C<0%&D`7M#NVL*9>W+`DGGE!4I#RC@EG&@P/PC%C/W+<U8UGOYS
M9GJ\]?*5N-XCK>I:F!TM"L(9.W!D;%JDM8L;FI9)F=R4-Z%4K**5*$J4PH@Y
M06`XP`C`A%CF>UG9"L]HMI,,QR'#KFVBL<->Q>"6:)Y)'>6YDWBL@"A0)P-)
MXYJ>/$9=7['VRMQL;8W=I=7<-ZUS>M=*\$;QJJM;V\&DB0DY@PELP<LF`YP:
MT[WI"OWTK^E+_P`7'I"OWTK^E+_Q<VXWQ;G3V_,;U&_L[5/^RO/473=Z>H<=
M\Z-:D9^3[G7.J19_D#$\YQ_#GRYA=O%K\0N/.Q_-U^QX=#Y6OO&^4>WC]CPU
M'?I"OWTK^E+_`,7'I"OWTK^E+_Q<VXH>F[T]18[XT:U'^;[K72J`Y_D%%,9_
MC[=N>?BW.GM^8WJ-_9VJ?]E>.WBU^(7'G8_FZ_8\'*U]XWRCV\?L>&HZP:7C
MOV.+QW\L]C0>>/FS]UY\\>D*_?2OZ4O_`!<VXWQ;G3V_,;U&_L[5/^RO&.FY
MT]LX[_8-ZC?QZZU/C/\`)F*8SQV\6OQ"X\['\W7['@Y6OO&^4>WC]CPU'/I"
MOWTK^E+_`,7'I"OWTK^E+_Q<VXOQ;G3V[XQ]@WJ/Y]__`#=:G[>7SY^M3MC]
M'?.._P`G/7/3?Z>F,^'[!K4CO\_V.55>'^=]:?A[?/GOVQ\O';Q:_$+CSL?S
M=?L>#E:^\;Y1[>/V/#4>>D*_?2OZ4O\`Q<>D*_?2OZ4O_%S;C?%N=/;\QO4;
M^SM4_P"RO'Q;G3V_,;U&_L[5/^RO';Q:_$+CSL?S=?L>#E:^\;Y1[>/V/#4<
M^D*_?2OZ4O\`Q<>D*_?2OZ4O_%S;C9Z;G3VQC.?L&]1O+S\M=:GSG^3$4[Y_
M@QY\?%N=/;\QO4;^SK4_[*\=O%K\0N/.Q_-U^QX.5K[QOE'MX_8\-1SZ0K]]
M*_I2_P#%QZ0K]]*_I2_\7-N-\6YT]OS&]1O[.U3_`+*\\?%N=/;V?8-ZC_V=
M:G_Y?K4[<=O%K\0N/.Q_-U^QX.5K[QOE'MX_8\-1UZ0K]]*_I2_\7'I"OWTK
M^E+_`,7-N-\6YT]OS&]1O[.U3_LKSQGIN]/7'MT;U']O;_P=*H[>?Z?K4[=O
MT^S]/';Q:_$+CSL?S=?L>#E:^\;Y1[>/V/#4=>D*_?2OZ4O_`!<>D*_?2OZ4
MO_%S;B_%N=/;\QO4?^SK5'S]OQ4_VQY^SSYY^+<Z>WYC>HW]G:I_V5X[>+7X
MA<>=C^;K]CP<K7WC?*/;Q^QX:CGTA7[Z5_2E_P"+G]"3"O2E?Z4K_?`?^5+^
M^Q_Z7-N%\6YT]OS&]1O[.U3_`+*\8Z;G3VQGOC1O4;&<>>,XUVJ?OC/S_P#<
MKQV\6OQ"X\['\W7['@Y6OO&^4>WC]CP@RC^<9^IJ=7LX$'M^YA0?W7BQX?\`
MOL$_\+OV_P#?[?+D#'B#]^#^>'^_FPT+HNEBJT:Z8*J2M2ZB9$J!"S5>7"(X
M"OFE$U*\+VQ(W0\+=A@1)FY=C"Q"0G0%EI56,*"`@-QXN<!^PVU)_-CH#W0P
M/Z#YCX)ME;85#=Q264\IN<1N;T%)(P%6<1`(=0XLN@YD<#F,O#7#NR#V,K[;
M/'(L6M<4M+*..PAL]S/#-(Y:.XNIB^J,A=)$ZJ!EGFI/,15`GQ!^_!_/#_?Q
MX@_?@_GA_OY?T%ISJ0'/;.L5!9\N_P!S3L&%C^4+#G'?]'?O_+CGMC3?4G.,
M9^QBH#SQW\Z@@F,^?SXRQ8SC/Z,XQG'R\W/=&L_)MSYV+HZ.OU=-07N"XMY?
MP[T6Y^E5`GQ!^_!_/#_?QX@_?@_GA_OY?V^PVU)_-CH#W0P/Z#XSIOJ3C'?[
M&*@/XJ@@F<_R88LYX[HUGY-N?.Q='1U^KIIW!<6\OX=Z+<_2J@3X@_?@_GA_
MOX\0?OP?SP_W\O[?8;:D_FQT![H8']!\\?8;ZD]\X^QBH'R[?_Z@@G;S^;/P
M%VS^GMG/;Y>.Z-9^3;GSL71T=?JZ:=P7%O+^'>BW/TJH%>(/WX/YX?[^/$'[
M\'\\/]_+^OV'&I'?&/L8J!\__J?@G;R_3\!=OXOE\^WLSSS]AMJ3^;'0'NA@
M?T'QW1K/R;<^=BZ.CK]733N"XMY?P[T6Y^E5`GQ!^_!_/#_?QX@_?@_GA_OY
M?V^PVU)_-CH#W0P/Z#X^PVU)_-CH#W0P/Z#X[HUGY-N?.Q='1U^KIIW!<6\O
MX=Z+<_2J@3X@_?@_GA_OX\0?OP?SP_W\O[?8;:D_FQT![H8']!\?8;ZDX_\`
M-BH#W00//_(Q<=T:S\FW/G8NCHZ_5TT[@N+>7\.]%N?I50)\0?OP?SP_W\>(
M/WX/YX?[^7]OL-]2?S8J`]T$#^@N>/L.-2.^,?8Q4#Y__4_!.WE^GX"[?Q?+
MY]O9GCNC6?DVY\[%T='7ZNFG<%Q;R_AWHMS]*J!7B#]^#^>'^_CQ!^_!_/#_
M`'\O[?8;:D_FQT![H8']!\?8;:D_FQT![H8']!\=T:S\FW/G8NCHZ_5TT[@N
M+>7\.]%N?I50)\0?OP?SP_W\>(/WX/YX?[^7]OL-M2?S8Z`]T,#^@^/L-M2?
MS8Z`]T,#^@^.Z-9^3;GSL71T=?JZ:=P7%O+^'>BW/TJH$^(/WX/YX?[^64^@
M1G&8-MGVR'/:0UIW[9QGM_U+S+V]LYY-']AMJ3^;'0'NA@?T'SLN`4[4U4$.
MZ6L:S@->)G\Q*:^)X1$6*+$O!J(HXA&8YE,J%&!<-*0I4$IQJ0F")*/.`7D(
M3!XSI\>VSML7PNXL([*>%YC"1(\D;*NZFBE.87CQ",!EX2.FI7L3V)L0V5VD
ML,<GQ>RNXK-;H-!#!.DC\HM)[=2K.=(TM*&.?.`0.-:M98,OUQ;_`*0O_MU;
M_P`,'_[V=^GGYO&#]\+_`*0'^+FS)%H;I((0A"U#UHR(0A"$+-'UQG(A"SD0
MA"S];O?(A"SG.<Y[YSG.<YSSQ]@9I'^:%K/[CZX_9WGSD=A+LDGE]OQ_-2?/
M7ZQK_2\V="J#L=C68`!_^(V/@`!_T77ZO'PUF_C!^^%_T@/\7'C!^^%_T@/\
M7-F1]@9I'^:%K/[CZX_9WC[`S2/\T+6?W'UQ^SO':)=_'[?S4GSU5]][LY^1
MN-_O&Q^JZ_8\-9OXP?OA?](#_%QXP?OA?](#_%S9D?8&:1_FA:S^X^N/V=X^
MP,TC_-"UG]Q]<?L[QVB7?Q^W\U)\]/OO=G/R-QO]XV/U77['AK-_&#]\+_I`
M?XN/&#]\+_I`?XN;,C[`S2/\T+6?W'UQ^SO'V!FD?YH6L_N/KC]G>.T2[^/V
M_FI/GI]][LY^1N-_O&Q^JZ_8\-9OXP?OA?\`2`_Q<>,'[X7_`$@/\7-F1]@9
MI'^:%K/[CZX_9WC[`S2/\T+6?W'UQ^SO':)=_'[?S4GST^^]V<_(W&_WC8_5
M=?L>&LW\8/WPO^D!_BX\8/WPO^D!_BYLR/L#-(_S0M9_<?7'[.\?8&:1_FA:
MS^X^N/V=X[1+OX_;^:D^>GWWNSGY&XW^\;'ZKK]CPUF_C!^^%_T@/\7'C!^^
M%_T@/\7-F1]@9I'^:%K/[CZX_9WC[`S2/\T+6?W'UQ^SO':)=_'[?S4GST^^
M]V<_(W&_WC8_5=?L>&LW\8/WPO\`I`?XN/&#]\+_`*0'^+FS(^P,TC_-"UG]
MQ]<?L[Q]@9I'^:%K/[CZX_9WCM$N_C]OYJ3YZ??>[.?D;C?[QL?JNOV/#6;^
M,'[X7_2`_P`7'C!^^%_T@/\`%S9D?8&:1_FA:S^X^N/V=X^P,TC_`#0M9_<?
M7'[.\=HEW\?M_-2?/3[[W9S\C<;_`'C8_5=?L>&LW\8/WPO^D!_BX\8/WPO^
MD!_BYLR/L#-(_P`T+6?W'UQ^SO'V!FD?YH6L_N/KC]G>.T2[^/V_FI/GI]][
MLY^1N-_O&Q^JZ_8\*0?17$#/4LUTQ@8,Y]5N7RP,.<Y_ZQUB^S&,YSG]/;V>
MWCEZ:$ZC:KUK)FV:5YK?1<&E[/A:%IE,1JF$1V0M@7%"I:W`*!Y:65*X),+6
MU8K0*\$*`84(U2A,;XB3C`"<EN`X/)A%G);23),SW+SAD5E`5HX4TD,2208R
M<^;(@>,U\V=F'LE6/9,VGLL>L<,N\+BM<#M<):WNYX9Y'DM[[$KMIE>%54(R
MWR(%(U!HV)X$5D1SB,_A$:LR#3&NIDB4N42G<7?H?)VY&[/+"K71^2-BEH>$
M:9\CK@TO[.>I0*SR2G-D=&YV0C&%2WKDJHLH\'+N.;^N/U3?::^DFA-$['7)
MK:VW95E[2;JF7AI?"K=D&+AOIEK+4U-92MYBF7)@N&0V?"HE"C$<&98M'KJ.
MIJY)&H=GQIC35'I"Y3`IP0]J0K>KJ[V90N;KB[@+$MJOI&0+8R44\FUD0'GV
M[MG*+8VPIZ3``)W2-,G8U=?QRL(C;+M2D9)0OLFDS<P1Q$ABS))5[`_6RLAQ
MG';/B]O?R$+&>_Z,XSC.,?HQGM\G;MSAMA5U!;9@TLK*S(FPSROIW'W.*S&'
M2MM3O<=DD>>$QB1S:'AL7!-3+$2Q.:,LTLP/?_4&`0#"RQ@4JF5.^JSU*2*J
MG2>D]BW*V8)%-RG.GUVZ,FTD>:ND,:@I6C]6735227:[D498$DBK?;=WS"0Q
MY5*W>G51LF:VEN;H.X0($SCKFCY3;FXO4SHN:;?3=IG=F-T^M63=+233QJ.I
M"<R&HM3Z1M;5S!]_7'1[;,*/E[JF9HS?[*AI1<W3"`3=ZB2-_<)=;%9*9DC5
M2AMM?ZZ:KZ]ZE09;7&N=4Q6IH>Z2!9*WALBR=6`]]DR]*B;U3_(7AQ6.#[('
M@3:VMC46X/3HO5)VAL;&E,82W-Z-*1W_`)`'/?\`UO/&,>0QX[=O9X>PL>'/
MR9R'MG./+.<XXI5*_;?<OJ.6A3M#U];$ZEM9.E@:VZ262VQ>CM1KN6,FWMEO
M>[`6J\'8ZV'JOXO,=72:KJ*&5E/5L-D[3`B'DJR'XPY$[PU='T0)%^K+K->F
MU>].KU?5?7T#LJ.,>GNW4T?(]=5R;5T94(9&W6YK:U1Q8*::JKVZ3G6+ZF].
MZ.-,[ZHRUFQQ9+7,D'K[6C&"QQD`<]O];';YACQW[?/V%CQ9_2+OG/GW]N>>
MW;S[^??MG'MSV\^WR=^W?R]O;OCSQC/;.>*53)T[WFZH#!<733H`AVDYM-/6
MOVC7K3?>M361*)CL6W6+%Y+C:YUD5I,%2V:]1:P]=)`C+B3"9++7K-MCB2*M
M+W=>)@5,U3NW_9SU..J(;JM:%D,<SFLCMCZ^]?V_8>+NO3XG=:H.F^1-[>FD
M=NF-0JP'.+3-HO\`(K**-<72FK7:IKM<(ZW/&+@>7:01A87&4=QOP![XS]UY
M?.,><9_^UC(NPL_I%C.?+'GY8X\`>V<?=>?_`*8^^/\`[.?%W#C]`>V.WE[.
M*53/>^J5U/$,@U]CAEI$'W&NU6U:M>-T=7VD]@RZ.;BV)8NZ%^U"X-4JF$JK
M&$3+69LL'7ZO8W-7!R?&>O&%(^IGJ6UVI3PYJ5M3Q]-9MGO'KE7UCP,K:?8*
M+-S;U#>JBQ63L#+-)9)LQ+(*_P`(GJ23:5Z_1J#L\!`@,K3:F.2QVL)MG+.U
MO<:9$K4W5'6<FKA,H;$#9;?2557B&T'VZ$D4:B+2D\%BM9O\V+`?A\=8)"'^
M5RB*1A6=D_)(VMC?YQ+'1"7@@)H53\X",.,`8`!?/\@#GO\`ZWGGOWP,>,_P
M8S@7?`?+_5QV#^CBE5TZYVPWY?4^W=R;-7&?J!`Z2UFTH/#6R?31ZNX%>;`[
M"4%2U@W(\X;(N%5;5IM=8V4[2NNT%?1M:N-:'&0N;E*W]6BBJ-N1YF]0*F97
M>U\:<1>.06F[`;4B#9M\=6S8.`R2P:G3&@@4#2,:UQ96!>UB32;"I>:3'7%6
ML`).F-?0HBAK#`Y*E?R'&<9QYXQGM[!"QV[>SP]LX\/_`/+V[_+SV[?+\WZ<
M_P#)[,_Q^SY.*5`&Z7=M-`[.M^BJCG4:J>Q:1.)@VNFFS9J>[2*B+/JN%:FM
M%K%6>59;.E:G^MXY/+BQ(ZQC4U/LP59UH%G;*K?H7);2>$SP/KEV#:_44F]3
M7FTZ\ZY6K"+-U+V(G](QO:R)6*VQIEJN6V_5P**=75*SQR6+&VTIS'4*^12`
MMN^`7-/"7MF1H3"5Z1U\5CPY.2>6:4<#TA9Q8RC2Q"%X!EF@R`P.0XS@/W0!
M"#G.,8SVSGSYQ:`0*'U9!H?6M?,""*06`1ACAL-C#4`PMKCT7C;<G:6-E;RC
M33C`(VQM2)T:8)AII@22@!$8//<65*JWLLMLV,M73BF2BV;AI)A<ZBZ<<?L:
M])9$!6#+ZZ3N&H'4Y;I^;+\3"*/\)32Y',<Q.O'V76-$WMHC+L\,#C,&I<^&
MMJ@RP/HA9UOW)J32-E7NRC9+0E,54JW_``=%7""*)`B22%[:XI.E4&=19<(0
MKLB&(([8*J&*_"=%5$G-8L@`%`$`<ML@QG';.1?)[!CQGR[_`"X%C/R^?GY^
M7?OVQV]L8[8[8^3^//\`'G/GG/SYSYY^7BE....*4XXXXI3D6G65H*+7?T[=
MJG1P89F]V)3&OE^6_19L"F5EQ*2LUS1BF9N&$N[6GK.21]?*ER9Q/+PWQEY)
M?69P7B3Y,9%:D!':4OF)FY>RI^K-4,]@)6ZOUBB06I5=7$KK7LDRHZVC@[-E
MZ*+8DTSGQ47F)K&S,N%65`LEL*H2Y6)*@P:D]9]:*4JN3MC=6PG3+D^K-$:%
M(IY7M:GP&EM@[:B4UKR>7E'[HDMK7Q7M:VXRI[<LD^XY^2OAE=-KM*)?!XLN
MI%HK%L=&B=.%DK\/2"'"[1N#;WJ4P=FD%B2?8235?2\VZE&XE`)YY%=%"KU?
M==*-USEVPK)0#?\`N=0YB=9K:@=II-&Z_ACC:*MC^"X]'B8]EA4-+W*ETZ<I
MAV#J'TNP-$"(NNP*J!*Y^FR_MSAK,_VALQ3C/!'.Q`U3$YG,KBC%2,,?@C)(
M;&PJ@B=WG"6/,)TP;7ID:GEU$P/Y[9CKU";0TLV)JN@HM*H?JWLPU6/8E92*
M&*KUMIVJ2`UU'K0@&P+I%+9/LI@B<FD\;+EA5(V%6S:UMZ-`H?W4]PC3[E*G
M3JT9JE1":\]37JM77?\`T\HPYOS'&*WOK7[2"6/"PRAW]X;+^)O>&R0_:>SV
M"502C9_'X9--?WS*-9%8^XS:J*WBJF/(,VJR2Z+S`2Q#CW1>^'58I^ONGE3<
M*GLYDB$^+.*6?S#8O7NUY.^W!L<W[COU=VCJA-7B*Z_V%.VM/6=+$L<GC3^S
MB@LA=E4U-EJFUY3"H>?'VV?*INHM'(30SFDB6ND"C$4H2I=S\QEGIJR4SQ0#
MXPZ(&TG'6MOH68H*]CZ.15E*DEJEQLE]+B3/F`2Z`RV%&,3\<T&.&)$XUMA2
M,KNYSU]:7F6AL9M^O,*?+K6EH,4(DBNNC(Z78#7#+/>XF@K><.T)/E;&FDS3
M%I2[JVE4I6(S2<J&=[*;E*K_`&O6P>V5X=7ZKFFXYY9^$%96'U288_Z[8UQF
ME7UQK]"(VYPJ+ZUK3[V^"$D,V./NNKV5JM)M>A/3\8TNCTXYCP61K'AO'BWL
MUKMLVY[B[B[7-3$>Q0*N>J]IK`T-V,]R[:Q[92NJQ?TVCS',EM)TQ'WA!JW.
MZH3E3N3DR]RL)&M0%L[Q:RMY2K\QAJ1BN<8!C&>^/%W\_+Q"\/G_`.CG/AQ_
M%CR^3V\\^'&>^//SSC.?NA8\\=O9G&>^,>6.^,=L9\^^///=2J<U<]3;K!N<
M<WZ?9HR-[7(:R9%^5-;I-8+1DLQTZ7_9DL-2K)/$6EMIR-1B]HY&-5WF67HD
MBCG;-Q3&>.L$:I7'`?6"\/D71>\[ZE'50:;*U3BU0V.ILRH9:$]7`[]M#0RW
MZ9(W6D96SA,$<:WE4`C-16]*(0%OI?U:01^5P1GUY)F9KX79J4**(1]VCP[B
MG@#Y_P"MY_\`IC\O_L_=?<?_`,GA^3YL<>C#Y?ZWEG&>_C'WSV\\>+/B[C[?
M)@7?';R]G%*IBVYO+U%+]5=1JDZNO"TYD2UQ/K/P$R"5SJ<LA#KKI%=6'VP&
MG5*8UYLPT1HE!:$_N5WBZ>D%39%W=VE2%1(5;U'DL;L2"G299DW"-]-YL[4Z
MN5I"[2L:P*^D+CH%&8!6\CTEE62=M]9;=JV%NNV6Y\\V")BD:04I,:,DKS/R
M/K`%F"(F8ZJT#-)H'(G*QD2PJS#7555[4K4^,E<11JB#3)9S/K+?4+.`XDAS
MG=H2MTG$_DZD)IYV<NDIECTZ/KH:`0"S%ZY08242`>"\<_\``'&<9\_+YQ"S
MC/;V9%C.>PLX\ONA8SGRQY^6.*5!UTY]AMJ)K#]+G[;G9E4OL_:I+LG.T](&
M:<.<5!]:]>HF5IC\3-LZ(I$L?JUP@9"`^=N[C9Y:5SN)RFIL=@[8T((IA&/Z
MSI0$^?-R]S]@D%#:XVIBM+*KF0P`RRZVDCI>CM(()IQ4,CC+#3UA&.J:,QMJ
M46,%$C;UF6MP+9I(KE2XSTCGDDHF;#PXQV_UON>_;[H6?;\_?/W7Z/%W[?)V
MYY[>W]/M[^?R=OE]F/+V8\N_?/MSGBE5RXIU`MF(71<9N\FUW?:`EP/HZ$V]
M"'S4E_JAYK'839RO9M%(/5L&E+:DA;2]MD0VM-I>O9A7SVP2JRZEB<]<5]KV
M$YK5+$<CX!/J0N<BPYK>TAI^D#')@ZJ6HY,TV$B[;8;/LXQ,*B8:CPR?NU7+
M#8@YMG[C!+^Y/K0]H)+)UT='0KC82%W2#<A'"S8_G-=PJRV5''9W'4$H9$$J
MA,W1MSK@XY.GE=<3!DGT'?"\`.+'A;&IC'&.0-HLCR66X-J8PPLTL(BQ\S[8
M\\>?GGO[<^WOW]O?OC'?Y,>7MQV[9SQ2JV<-CUH9)9$ZIFG"<0B-<4Z@`T4E
M(+($7UNY$X.X,F')S1$%I8(,#@M,-"<)+#_1KE01LN,#%W;J1U!Y[(=G+5:+
MQL>2(Z;4PF72%F;++K-B@#M6L[:]HD=0M5>98XA`276$K"8W-(3\)0BQK8NN
MP#$*YBL1[=(&TO2MC)G?[8_3_.%\F>_S_/\`RX\L^7ESY[BT-CNFRB=4*9R1
MY4(U64B\H"M+E2WK4[BA/RG48,)R8C7I$JQ,/(,Y(4IR3B_"86$6%*^CC.,^
MSS\\X_CQGMG^3..W'''%*<<<<4J"SJ\:;5A>%IZ#SUWAMD/DBE^YE(T#:BZ#
MVA>430K-<G&*7M*I''Y"S5M.6!A;6<V5`9E2^8C;43\29AO;C)&6BRF1\C>F
M&^N]]'[CWGKK19DR;]:J1J;=>HJCJ&7:_N"Y^@CGJUI7^Z1KM.F:>O;'/)18
M"6QY[&E),0EMC7(_GW>T*%I+=2S%EI&_N5O/.._;V^6>_EG./Y>V<=\?HSWQ
M^CGCP8[YSW%WS_Z8\8]G;R#@7AQY9^3&//S]N,9XI50'9'??J:ZS)Z-369LZ
MZLKD_P!$Z8V>SN"'11J=HCL7.-E-F&V*[%PA_GK6ROT-UH1:I5D^Q%KBY$Q<
M6E[F8Y1\+O*J22!8T)$G3%X[D]62^X!U8*XDDNF-3XJJ`W=(&*OZQI*Q6*W:
M-%3FV$+8JN!7E@M=((H]-(W<U`X?93(W`=P61-)4C3XF]3@C$:2R./)K6MOZ
M*ZAW[;D!O>Y=?*TL:VJR`S%0V;RAB]?=6XB-OPI3&4RXO"@IND22+R<0Y)%T
MDG0O26-R`PQY9"4#B88I%E?@L.._;Q8\7?O]V/R[Y[YR'[K[G.<YSG.0]LYS
MGOWXI52:-=1[JN..WNST,A+6ELN#U]4NR3S0M-RZ@9\RR"XH%!=6VZQ]5MDF
M2:16BF6,ADNP%K9;VZ7QJ2V_%HD/$J<ZTB%5PB>1E&G5Y:]$.T[JNB[][+#M
M>Z+,V`;WJ$Z'?6Y9L^UVF>K3<O?"JLM$ZR8_&JDDS0PM:/,1F"@^/.\@C+62
MC=A(6U&Z*G5V:%#NOL2>`.,]_/V=NV1"SC^'PYSG'?YQ=O%G/?.<]\YYY"'`
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M(NX2*NHE`X>KM*5TC83Y=L<C958(H0CLQ/3RIKC[2<_!F;L\V-Y[7D-L^,+H
M;.V,F11EQ5,JU:TJ5*].0<JCK\UR=E.R8@5)%!8D#ZRM;B7@HX`1FI`%G!-(
M&:49S+``XQG&._;.19S]T+/F+/?/MS\_LQ[`_P#![<4J#R@;]V<M6YHI%V79
M62S/6",O=^2DO8Y?KS#(Y(KYA]>5QK"[(XLN*S!&6+M:2'6?9UG1I?-()!(L
M=-V>.+8<SIR9=")%,C>W=P*\E5[4CT^HJRKH!L,?([WK%XD,LNVL7`^M+):B
M-5K\>#I_8E90\$=*8TLA=,-DB;6,HIH9XY,%S`E"C("C3HLRS8#C'L\7R^T0
MLYSW^?.<YSGM\G?OV^3MSSV]GM\O9YY^;MY^?G_'W\_/VXQGBE0:QJQK;H_9
MN`ZMFRV-:U0^%)=74U:TC1FI[O+J=V8.MZ9S1=LN_,S@6TNTMKUA@)A1;:%W
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M>A]<"7Y84K/V$V[55E!"*N[+K^=A&C4.`!0R:QF5!$A2.1C.J6ARPNKA@21,
M[$FM9ZG'<@EQ*,0F&!5`$5CL/Q!\_N@^7M\\>7\/S?Q\JY;VZ"W_``C8R:6K
MT^(-:FNC?4>@%4!J-BT^0PRH8'8M^I]T'6<3.OIG$V%E1M$R3J8&N7R*1Q-8
MF0,DB3O*A;(#'584W9;^GGZ'];K%K=4Q>.4[<!<UM2[R)Z#9(^A:#*/=CW"4
M-1^C#AK5,"KN%F(V+'(=XDJ]LBE.,#TZ'"DJ>[WU6_E1][/4JW;@8,YQC`@Y
MSGV8P+'?/?SQV\_EQQXP>?W0?+V_=8\N^>V._G\N?+^'RY5P?ZUZF=3]377M
MDA$OWVF>JU3V304+E\VG]AG6E65PT=,:DL1WN^R)^%K-B,::']GNF4-\;6M3
MY!;!L5B*B[,_P^1U75;?&V$^/#6E\ZSURZ.*K3HB6;^RALL36'4&36E*;KL6
M$2R;V)-W"\T3G<LBZ?A['.V:0-$?<=9C7(#L29*ZVF3HMPUHV1<V6Z!0]*%*
MO/\`B#[?%CMV[]^^/9W[=_X._E_#SA:JR*\0R..0]=.X8CELP725LB475REB
M3R*4.,,0!=9>@CK(:O`YO:V*M@P.,D2-B54H8D`@K'4M(G%@S-3:1'=:*`T*
MQ1YJC^^MO3*T-)7.#5],4Q,*B4NJNWXSNY*)>R22^&4=\2UPC\[^Q0<XK&"9
MD2_32PK&:6HIHEB(J<8DB<OZ\8U.WXJ>UKP4Z]U+<K5933N_UE[<K.QK6<FN
M8P!:=L#J++UVGTNB$CF\ADQ#=!WZUSHFS3+(DK*8X3HH"*=)G=,W8/3*5;=5
MK4:!(J<%RM,C0HDYZM8M5*"4Z1(E3%"/4*5*DX8"4Z<@@`SCCCA@***`(PP0
M0!R+''6Z>P=W41Q(U3&*N2J81TZ7Q-,WR)F6J)/%$V&T2B31XE,M-->X^1AY
M:,G/36!6V%8=&[(U0<+DOIH9]$:]V2F>F&TM>6"T[XMSE.X8\Q2ND/46G]1R
MZSSII):,'';`.CKC`S7B3,=8*K15J_@9-8,E>"`X]<<H&@C\*.1M08AHK3/4
M7EE"Z[$UOJIN)K!:VA'1RF&D[M.AM='EV#)[\D<BU38#%&K[0.\FX%B-"6)4
MC/)`ME(I/7*\A@<D),">\V8HC[:)2KG?C!]\'S[]ONL>?;V_+\GR_-S^2E4F
M1IU"M6H(2I4A)JA4I4'%D)TQ!!8CCSE!QH@%DE$E!$::88(("RPB&,00XSG%
M*"11;KU.U":H(FU3O?`DS8_;0I#7B-OC1:MY9L@=J0=RUJF-SQB7VW44IQ1A
MD%,F[*U06_K'MEL9PM[F.Y5TE1/D!<6BT##`3B5Q+=>-NC+L4I?54QES(QEW
M*@A[9`WM0MH.$L^2]6,1M>K>,4"OD:=>I;?K^5&2\FQ76?8-4B8\LH$ZE=]5
MGLIKK=+FM9*=OREK8>6UK`^.+36EJ06>.;>RFJ249;NM015^=E25K,5J4Z4#
M@>46D&I/)("=DTTL(NZ?$'';N(..^>V//'GG(O#C&//VY%G`>WWWE[>5[Z(A
M^SLBUJ@=*`E.Z$4EJ1KT3A\K6*==(_K`\0"#QNWJ99;[10>X(PPM;I(CR:Y2
M2MD>PFK5JA/#4SH^LA@EP2'('%+A0[[P!\K&.16.[HR=HJ.RY<ZQ"9-,\LBP
MOKQK-@Z@3XJ+CTW98[*&(<[D+?I\P,64<HV;?K00V##'U"PP*N'ZUS)9)U:E
M6%"IS"CX\AEI,PBQL5<U#8D;9,5(&@R/N"I[>$T>9DR%Y`L$VJU#N_K$C&V$
MIU)AB]X5)FQ($Y:>40/E'B#Y_=!\O;YX\O/MY_Q^7\/E[>5<]=:+W%3,535[
MB"[7(HBS/#.[;%PZ[5:H58(9'#NJ!0$[U[.U[CRUW.0LB.,:ZL%LR*;'5RG2
ML9M=%1T=C@6W`).83]B.MW4O.A=PGV"_;9L;LK1UL5:IL<@EQRAN.M`6T*54
M_?N:)&#8!JLI#4:FJ4;_`!V=NFA#/%@M%626(RN*,SI8,=>V42E6=<9QG'?&
M<9QGV9QYXS_'QS&'3%59:O6&G3+@CLZBUAE1<Q$_L]ERLR;SD(6YZ=D#.Y2&
M3*V*-/3@K?6!,U/I)<L944Y;D3DE:I[A1-$+\K49/<4IQQQQ2G'''%*<]1C"
M6$0QB"```Y$(0LX"$(0X[Y$(0LXP'&,8[YSG.,8QYYSVY[<XK.H3$K*A4MKR
M>QUHE\'G4:>XA,(H_HBG)CDL8D;:I:'UA>&\_`B5S6[-BM2A7HS0Y*4I3S21
MXR$><<4K[H')`:+`2UJ0P61!!@(%2<><B$+`0A[!,SG(A"S@.`XQWSG.,8QG
M.<8Y^SQ!\ONL?=?ZOGCS_@^?^+E.ULZ6[;`:^=W&AM7GS7:X5'7Q:66+7'4E
M&M**TJ[TN8MF&]TC<MAPY-")+'PTK$(V@3/L5<Y%&I!5#84C0.ZQJ<VY'ZL=
MZ2BZNNNRRS46*(I!L.FC#,KM:-#GB_5URF9UV3ZO^H79]7,J':5GK+7Z1!BD
M2E.G+!7$L8I0J==8:_?D,K?;3:+)='-N2LQ2E7%/&#'?N(..V>V?NL>6?/RS
MY^6?+/\`)GYN>?$'OV[X[_-WQW]G?V>WV>?\'*DFUT_ZN\7JNT))7]G;T!F=
MF[P[_1FO6V"4%$WR-TQ1FOLENM/JE'FYJB>I5T6X^-&P&1Q%9'YL_-Y,+GR)
MGBC6[6S546$<_2OC\#W*ZH4_W'B</CTLVM>)\PNW2P^NRA4>M<0QJHR1B\-2
M(K9&[*C9BQCZR*E](3%C=5;K(H?'U]D0]:V2C"%BC43E!CFYIXPI5OOQ!^^Q
MY9[9\\>6<^S'\.?F]O/RK5Z%M2*E[@L2H4*%.<K6K5B@E*D2)DX!&'J%2H\9
M9"<DDL`QFFG&`++`$0QB"$(LXJ#:N[*]:=JI:V+.V)(VFDLB@MR:(RZU:U(U
M*EP;`B+=]EDF;MRJ^H%O0T!7S5<E7JM?"EF`Q^G!W\L:$*5MDL5N=6KD"T@G
MA%]M6[U\*+#NJ=0/=UZ6V=HWU_Z>J6HWS6U4ZP\2DF[\2G2VK[JK$ZHGM,TE
M3NFFYO5PH,[4`'8LMK>MXXQO;PK6R!CF*E7."S"S0A&68`P`P!,`(`PC"(`\
M8$`81!SG`@"#G&0BQG(18SC.,YQG'/YB5)@X-R(\D."3`%'9R:7C!1IG@\!9
MF<BQ@L8_2%^``_"(7C!X<9\0>]?_`%RLO>!1U'%U>V8MW0CE9M4F<([&:P:=
M4J]-T3.U;:=5ZZ=(!8[]LB])HM*XO>;S>JZ6H7MCALTL&2$O*(BOG.BXA"4*
MR:(,'MLJ^OUWLCJ<Z>Q_6/9R03O<?J2=/O8*C[)CM-S5RUV=:@KXS3=TLF42
MK8=N0J*SKW$(1T%.TD@:):]MD@PL$Q(FIG=C73PIE*MS^(/GCQ8[A]N.^/+^
M'YOX^,9QG&,XSC.,^S.,]\9_@Y3LEFQW7%0V-U0$%5,FVDR$S1JU7G7\,IUO
M:HM!:V;T&U,#96A)4S)):%2$V#9++K0XSY?5G[E5X;9L5IC92)?+X<US`UJB
MI\I_35MG<%\;-?V/:&>[-R9Q>S=QA,Q\JU&E<$9)K7,=E%4BJ!YV/G\]I:FY
M975HQ),.=,=7$F5O3:>]HTZ.;^\092OCC2X*E*FY$X(0KRFL2Q*%R/2G+B4`
ME).%IJ),:20H5EI,F84&)B#U*<DY0`L1)1IY)9@PC.+"+]61!Q[<X\^WR_)G
MV9_@_3[,8QG.?+&<\KR6+!=K7;J.D]0IMJ-Z-J^C=AZYTM96]499"2U7S5&5
M-*RMKZF4<I9GKA<V2ZN%NRUN1B\3++-FY:S-=:T)7YO85$<SZXJ^$X6QLU>,
M*IE+-G?;F%)J:;>FJ^7B]HZ;GU7E/-[D;PM41V%:C%SM5B!7.F9A@*;ZX)V*
M!DK("EC/P)*2G11'A.!^5*L8*5J-&$L:M4F3`-4ID98U!Y)`3%:P\"9(E`(T
M8,#4*E!A9"<@.<FGG&`**`,P00Y_1XP9SVP(/?OV[>+'?O\`-[?;RO'5DJW+
ML-SB1$]0;#3U458NK<MV&B-WZX,C'#:(V`:][:N2/+#K2ZJX&B)E59,=(?NF
MNZJ;15XM&/PR(P>M[30VNR3.6.KA(/HU;&NH0@*JNP93?FX;ZY_N?].VU9;7
M4@@E;I8FNL.W]G'F!;5U\]-B&DVZ2(XM#:,3-SF]PU,_H7&NBQAL!8O1."G+
MD)2K!?C!G/;`@]^_;MXL=^_S>WV\\^(/M\6.W;OW[X]G?MW_`(._E_#ROY5D
M6Z@2%35,[EFP&XCVJS#.G59\O@#_``:M4T563JX-I'>OMK8&]-Z*DF^1I(M#
M*&3-[L]P]._(G"NP#Q8*Q>B7J<N0O=BNS=VX&B&UDRNVT]?2AIB5*PNZK(#K
MZX1=0QSYZZA%70.SEL1>[(J<Z%25W:-:B+"6N$ACS5)H,S0AS+GB=2HRG3.:
M92K`'B#Y?=8^Z_U?/'G_``?/_%SSRM],;*ZE4,M&#UTTO5]/;3$YLZQ2I9<^
MUW,7/-MD-F[MM0-S<;VS7&K,O@4G:4^MK%5IA3M-;,U8:\1"3.5Q1Z2RQ]--
M>&.Q^'OV^Z]O<6/XL"S@/RY_X/;^'_W<4KVXXXXI3G4%PTVP7.B@2"0KW)`1
M`+:K>WF\+:%"+"][K.0%R)H;7`*Y,J`)J6K"P%K\$!*68*QC*500;C!F.W^?
M"?I1&XLG(5260,D?3*E'JB90^.[<T$*%62QG83$'.*E*6<?DHLPW!)8A&>C`
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MK:6F63-CC]RD[@I38^SHX@WM4+2;HDTL?926*I$K`4022SOU-D2"+@6$GX+6
MRV1`><.H<(#"/[P3IQ1Z!;A';@)+GGK[*3I7=#T:P2>*5<Z*5D:O).D/?J]=
M+-!$$ULN<*@KTRQDRGH^IF'P)74:8RXBD:'%$I&M*DDP,&<XQ@8<Y%W\.,"Q
MWSVSG&>V._GVSC.,]OEQGYN,&`SW[#!GPX[B["QGMCY\^?EC^'BE>W'/7Q@[
M=_$'MVR+OXL=O#CVB[]_9CY<^S'/B.,HC;.L96]VD#(V+Y&[C8(^B<7=O1*W
MQ]+;5CR8S,Z94I*/='8#0WKW0;:A+4+0MR)6N$1A*F..`I7W>.?SR:4$L1N3
M"\%@"(0S,C#@`0@#D0A"'G.`A"$.,B%G.<8QC&<YSC'GSY*:1L"SX)]4>VA3
M\/(SW%D]7=$!_P`+MZ8L@U0N:_1*!_"*,@M2G,.5(O3D%`/)&88$)I>1*5]K
MCGKZ0';&?&#MG/;&?%CMG/S8SW[9S^C'//?'GYX\O;Y^SR[^?S>7GY_)Y\4K
MSQS@[#9E=2F22:&QF>PR0RZ%F%DS"+L<J87>1Q0XT0P%%25C;G!2ZL!AHP#`
M6!W2(QC&$0`XR+&<8YMZ0';Q>,'A[]N_BQV[_-W[]N_Z/;Q2O;CGXW!Q;VI$
MN<G-<C;FYL1J7!Q7KE1"-&@0(R1J%:U:J4F%)TJ1*G+,/4*5!A9!!(!FFF`+
M"(6/T@-*,#@0#"QAR`)F!`&$0<@$'`@CQG&<XR`0<X$$6,]LASC.,YQGBE>_
M'/7`P9QWP(.<=LY[X%C..V.W?/M]F.^.^?9YXY[<4IQQQQ2G'''%*BZWTWHV
M1U#L.BXM6>F#3L+$K_L"$TI#9JIV<C%/J";RG1$_=FJ$N45>*RF2LB/DQN!*
M793.<N>$>%+@4U`:!&IS%!G%J9ZOM"R>\;$U?V$;C]9]@J\L936JN,OITPF]
M9N3TPZQ0C9N9Y+V";:W8*;9E,>CCY.$B1@D4I:I)(6:M'N9-S2!I7$)4N9^R
M&OT"O]VUU4S.7.<96:];'U]LE$DK2M8TXI!+(<SS*%,K"]E.Z94<9'W0RPE)
M1P6OU1T.<RFU,C6@$880?BQ,.F#K[;KW.GZ03>:R)DL/=*<;>2^/H'6/@9W"
M6R72UWT%F%9X7M3>!T0Q$->+G-U/,2N!,Q:YR$6</2=$F^#`J5^9MZTW3=>:
MR76XUW\YKH@ALBMJHP0126P&9LYS&YXT^RZFBX[6(JM#94HCUP,$:>UM4S.-
MQ-UB%BF-YZ&(O;LX8PES]I9UA>GLVN%\-CI>#NSJ=;*_DUIVP-ZI:^&5$WU_
M"9TR5E-I3$G%VK-$@LYLAE@R-FATL,K-3+1Q^0+@-SD60>`[!>/NM?0YH'6=
MAK-CCULV/(0U/L+0-[1=Q60#6V"NBM/K5![-@58P.7.-04K72Z>(`-5JR-?)
M9G-E4@G[Z\A)<`OS?E4[%N6,-^=`9OS7^X,AHR];`F=X;%TA>5,LF;C-K1K(
M+;+XV,JK8)W=)C;\6K`%N3V30=SKLM@K^3V,^S8Z/0Y.RQ%O0(FML#E0I4AC
MWUH.G!'*[)LYZOYQ;V(=A3VKU;"HI2_@6<QRNK(NT3FR,RBF_P!RW-LQ.,P6
M#2"/3:5SF2PMJA3)#Y`PR1<_E-3RW*%';4]ZDVH4$:9@X"LTZ4J8C84-J/#;
M!H7/YNHDMGV7KT5M'6<1AQD1BKX3+13VEE;?+8^_QS+K&C2W%*VG.I3N++?B
M/^U^@31EUAS,+)V.OF<[!.%R67:TFV#GD/U<G[_+4MG5?75)O$'=:HF=`/&O
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M<XRY)F=Q\9R;%5GZ)U2?N:T_&F_:6_E4OU]HS7FAJ.N=O#3`)C`<:=['2&\J
M$EA38CKD=>2:1P$]>"IGQIE42>(]+X0TF8ES2MFBQRDAF65B:#0&_-$WK1NS
M]AK[M-&^`8)$Z;!O\_C;S?ID[8[80W=#;`)>T\<##T!D;L&.M1\3C**'IH6U
M1AB0Q)N9PM*#'A4KKJQ>KSK91E][44O?Q<BKA#KC,]<J^89.PQV>7#(;DEVP
M=)S"]"V>'514T"E4^*.@\0@[\LD!Z="^(PMJ0YY5J&A.$L@_MMHZI&B+]<]7
MT"SWXU+[+N)EKEY@B(F(6,&+JC;?A*RQZIBT@L0Z'E5["+%LB#(%4GA%7S:3
MQZQ)*U`+.;(P>-2E*/P<M?H;55=$(M"/W#MK?%C79L':T)MZUKEGT0U4D;E8
M1E05@XU%7L5Q3;E0V:898Q7,.D2Q9'76&P=DG3-+7$R3#FF1J\H1\RKGH;ZV
M5?LO4VRT=L^UWN05Q'J"3/[59+/1ULN=ES+6JM4=4UE8[];%CU));KATA%&F
MME.ER.J;!@C')'E@9G#U%NRG4DJU*S5M_=J!1C3T>W]1KH?/H*ZKJW111[G\
ME?:;@9J6P[DBE.YDTRE$@ACF^PR*Q9?)%3Z_N*V&J3RVMD5"`DP4H*5!X-&N
MH94\7@`YYL):.M;0SN;[-F:)R?7"W);L?73PXP*(M$N>8.LFR"JH>E17*XM[
MF-3#Z@2)'*83Q(4`,*2/[ME4TI.S9+JK(IQJ@WZWSO8JRYY+T#C"'[.PDKCE
M6*+$=I/7-NL%OQ-X>XNS0UCJY>%$ZQAC8%;61#T3>XQ]'DI44)Q4'KS.GK)Z
M?#I>L+BT2NW9JRY0=7MBJKFK=^A,/J^HG")7(QM+614-CY3P:.)T$B=*4DR9
MVF\29Y`0MC3Y(7D()VT2=H969M2J5]\GJ9:WI$]DJ)4FN"(BK6WK3JAQ;7&C
M+?=9&Y)*8C$(EEDVLAB<:A3S)TM,P]LG\;#)+*=FE#&6)6YM:1T7IE+XQDN'
MVU74NTQ0/ECLSE;2EK252AL=;,)FZ5S:3?6(3:ECK%+Y^T1FTU4++KR=2)AB
MLF8)$&.0B22%[>&ET3J6)"YB`H)(Q\NWI5UML%(YN_OMMG`<':S+CD1(#:FH
MNR"X:VW_`%W1<=M&+H&VW(A8[(@E`'FE8G.J_G@&5!*X2-Y7LB@J2QY8$H[L
M6QNF#2]C5LZU:LF$^8V%;)KUEC:8Q&1E,MCCO=<:+8DQS,`]B4(0`K=:@9)%
M"TZQ"J1'.3*E22-(\,IRQM/4KS%NJ9KL\.5CIGY!:L8(AUJN%9L;.?16P"ZT
M'8N)T;2MTV9*I?2Y=3$V=6,>K5)=<<;92[RN.%,:1$I9'[+Q@B1H4A?;FP^[
MM::Q6?!H9:+9*B8A+J:N&XG"?1&&6'8X(DRT]*:?9'Y?)H]7$)EJQCA*-GM0
MV3R2Q7Y4SQJ*M\>$%<:?AS"<DQ1M#I:!MA(]!LK::82>96-;S_:4FDC]4E"G
MN**1+:4K.HH^Y4C_`-2*=\I.PJQC50-CS7MCP60#E+6J?9J;)`2A,K91QK-6
MWM4H=<0'3#_+)>E$[:LWEJ@I5IUC<M6F1*]_W/OKDE*A:Z(51RR9MPJ[;3&Y
M6I$-O4'KW,YS0*QF$>A4KK2W^H32]<([V:6$B52NQ:6J^XK'31YT@UE0>"6`
M92#(S/$_CL+NE]@V:TDCA%\R-B22@,5>I&J8#5BO!R$\UD?"6_M'5S93&RZ2
M\G9-!WN$M%3;&VA0C-]<:"6-#Q+$]6"9&MSF1[1+8?$3VQ*[R-4])VI(U"DK
M9EH;T"LZ1?#"MS8F3!U\Z2]=3*TK4LXS8:R7$ZRV/8^MY$0HC=-/DC(A6Q,9
M3QJ:0%39ZF$FV2N9JZ<FB.CIZ-NDE-8:R960$0)CS@C/RK)SQK;56H:ZE[G8
M((ZU2>PCK'N:PX_.9(R,2J7PD5Z/H7^<1>*/I#>0XMD:6J`@)&BP>(Q61CNO
M-4&B$8)2LE>...*4YAAMULU+=<G[5]NB=8/]P*+WO1ZIX^!PPF.?7P\'%T'=
M%IM.(PY36;0"",`DSO6J17(7V9R),RHXH0]E%!$\*&O',S^8_7_K=7FQ:6M_
MKW73IC>*@L,%J5K*JXG<EKZ512<AADQKX3LC=XTK3&+TZB'SV6,BYD=R7)B7
MI78W*YM4#(3C*4J.-5UAZD9TB:=J(]+Y7";!S5S?7,221ZO*OF<6D\@B%H.\
MZ@-CS2Y+UB=;K+):I75LGA++7;<O89,\S-H6Q6#I+)P%9(6WM:0=5NB89+K#
M03^M[I@]:5]9MVTFX7P^L$%.K9ZMJA*@=KTFT'9VYFL%TL[*Q97,=DJN*N3O
M7[4RR"1QQUAA"\J2X;D3CRUVZ7FK9T';:\C)=KUU%TL,::W>&Z!W#/6=/.8`
MWQ>6157$[%)6.3JDG1$A*FC\^/[[(DZV9+)DM/EZ.2M\B6N*Y?T73O3@TZD,
MQNA'*9(&XA'659EC`J5GMF?+*LKUCV(JUPJ6(/F*W328<<;[!/U_"]0AKGS>
M2!?EO5/,A9U1,B6JWP:E<GBG5RIFQ6XELK6G+AM2X%,CD;0"CJP=]?+$EPXY
M%*T;;3D4\(F\5O)RI)?'FN//;.PJ6EOM)5-0V$[MT!S%</"PD0NF%O4&L6(R
MF.0R"0&,PFDV9KOE6HE3G2!4:11QNK3:'6*D(95>:O-V`BLQBCY&(O>JT$\?
MG&+MS?F5GL2I)#8PCCTMB^<PE_31UV=F9O2.DDV*7R]O?WY\(ML[9>Z@7%ZI
M*X`SU;)8EBQT\L(>TL(?(#'V)F6Q)")$UY<FAOFR<HBP4Q<LQV$'0S64+62R
MEPIS`UI`RXHA&*72LX`")Q9=0VU("!#5N:A0J*5S2C*X7`PK-4F`2-"QLR88
MD>G<M6I7]-=MOFO9)$ZOD6HN^(U#%4.16-4D]F<2BZ"%7M7[P\/C1'W^NY`U
MS)Y0,BZ0!9DCZV0ZU3*YFF8E)XK*UT?1-#@O-:<-*\ZQM0+VF@DMO5V^578%
MOQFM9/,(L?8%(N`ZK1W-:DJJ:KE"MO5V@US>S4DA=(JI>GX^F8A8AM=150G?
MK$(C:,6<!S6UJU(H77XQ1)J:6S=R9WR+M49AR>0V_/K,AD)K)`].4HC\'JEJ
MDLD>H]$8.A<GE4>UI6$GTPFLME8PN9\<CL::VKKV,=.+7:*.D"<FU=<(00/Z
MUR,,Q=Q3MKC4U:ZZLJ86I5#)9L;CR]D9K!9ZLDDW>T,01R1&J]9BX&Z)RXV6
M,C<0DPI71SAU-9#)2J#?*?U.V%?(E=MK19I@;F_Q6OFI#>]1S*M[_D3'-*>E
M*JWFN'15W&[U/')4KCUUO,%EB:II&FE'UFF_"I0FCGL7ZF]82Z0UZW,=)WR.
M(S9DUC<Y%9JMGK%MAM9..VCY)HC5D7FJ17:)<Q<'Y),XLLC,YS`HM-&2(#7L
M[\K>E47<2GD//:XT&U:U_<XQ-&7,]1HZI<FEPK8B?7=9$HAM1L+$U6%'V*&P
M1FF4I6QZ*P=H1VK+4:-E)(S@!"F/M9RXUJB,1;6;[E9:KZH*8R-/7"##U'&*
M8U@P*#FV:/[NG1S#3*UI`KBK$L5"<#<X7U_9B.0-4I;SA9PYK42QDD`%1*<1
M&%*QN=>I_'W-G@STR5;/JO9I._4-8#6^W=%V@AHL#4^V)LZ1MTNF`!@LWD2Y
MK6-[>V$.PH=/$D>L2/(I)$7)^KX1$@3D%\H;^I]%EQ<;CI6K>U6+HL`ZNG&L
MJ"'&*F2V+8]?V=$)U.V&U6=X6W"EJQBAC1%ZSG)TW3SBQ8Q+84_,::&/D:)E
MDHA[5(.R8/TV-48*@-9T,5E\B9"!P)!'66?69/K`:H3!*R>7I^A51PA/,'QW
MQ'*?:7.0N9AE>(C,L;LE^#&MY`X-<<CB)GZ3L#I@Q*-0F'!UM=WY!9T$GL">
MF":W#>.Q[O,6RN8#`Y[6T<J6&7'$[!3V97L*CD=L5_RD8$V91')&C<)0U2AD
M5/DNQ/HXI7.*EZH%%W`ZU3'(U7USM<MNA50QD#B,BB,?:I(OB]\5Y:-EM\Y7
MMQ<L5":HO7C-2-MM=GFK#`N<9E,$<V!.W.:Q:RY<OD.&]U@QO8_86I'77R>S
ME+$[#J*IM>H97*>KPSNUG]ZHF6[`6S,ELDF-VL4/88I'8BVH,-Z.9EUVO*4%
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MQ5G$7Y7([3L1A:$39*&MI`GQ$&'=2H=1K/1EFHI@C(23%<Z6>!;79JI6..YP
M2!SE"M`0E-;%/158=5*0R-JJ%SE.NUD+IOL,S4JWUAKW79-8N<U9IK833N7*
M',^36Q*+OC]9N$46Q'4M]>D9PB8LIB!@R&]S4RA3("PQ[*:,].36R,3L^P2D
MUEO#L3)C)-&FR26Y/'R+00T[8>*;4'M,&BRQVRS1QB47;"H]*CV],F,R:D0%
MQ@:C,9"4U%=52[I;5,XFZ_HXA+;,B2&G+"32D^2-=F3!ELHB/12#;6LU91V%
MS&-GM1K$"$2+:B7$EB5)U('R"".BTH%(@%I194KIULZRE3%-+S/79C5+(9+Y
M1`HY2D5-=:UJR>C7'4EBRK@8K+?KKM>"U8P2FLI.@>H4M9@S)(I<9$2BCL7)
MEAQ_PMR6JJK+BMS5E7MN054I70NSX3%K`B:Q:C.;EJF.3!D1/[,:L;E.,*6]
M8)`O(PK0J0A4(U.#4YV,#+SS#)+TPM4F2&QR&0=HLBLRHF>WG,$HK>X;&B$^
M0Y(KE55;[@<Z;G[ZY5HYU$UJLRP%3@O5KY?*C"9ZZJQS="W/Z/.B'Q-B@<3B
M\'BR,UOC,-CS+%8Z@.7N3J<B8X\VIFAI2&N;PL<'9Q-3H$:<HQ>Z+UKBL&`2
ME<K4JC33QJ5R/CCCBE.<:FDQC%=P^53^:O2*.0V$1M]E\LD+D,13<PQF,M:M
M[?WIP-``P12%J:4*M>K,"`8@$)S,A`,6,!SR7G#["@<5M.!3:LITU`?838D1
MDL%F#(8>I3%O$6E[(NCLA:C%",TA606X-#DL2#.3'$J"L'9,(-+-"`85*BH:
M^K+#'2=2)>\0J85-24#A,4LF5O%R5K8T6LUS@\BUWVPV%,D<2AR!&Z$JVT$.
MUV;GQ'Z\86XY3.$DB3HU-EA-A4?([PDG4SH6(P"*SJ41"[&13*B;%>BH2X5N
M`J8(Z_J1KCS[8UJDA^N$44EM:1MIE\44DR2N9;-\R=P?DL:A3?)9:B>6!J^<
MQ],BMFP*]<\7WM'+Y@9%(C#6"P7VPX<VS.$,T"HVZ*"A_P!9[C"ZUB21L<F6
M+WQ.Y":\JF]P=Y!-S&]^E"U[(`XMCEU^?T<];#XBVQL,PLIN=$SS:3LY2M@C
MFM\?.<B;F8*[8;":&F`MFO9=-UHF>,59#'I*_4]6E>SUHE:%PE[=,R9/(I&Z
MNRE=O2CJ8ZTPQ\L!!+,V0QQF"U)8MUH[&75\Y_6/8<"JF/P>33IXK522I-D<
MI;6]JL.+J&:0#C+;#YKA2M'!I+)2&AS/2\)>=]=2:;1*+A=ZJGE>S:X$4MG-
ML%?N0-3/9@8!KPF885([CLE>C=@I)[74#9GJ--$3E\(DUF8D[$K"DJU/*4K*
M^D-'XC^DO1J:>RVPXC:^P-?O<H)N0@G,0D=9I5K`5>+.T-TO)1S-SJ1TL^1)
M42Z-Q9XBB*PI]-4D5*CR6%M!)%9.4@@[O\4[HY:S&Q6/1HB4V4TGM!MI@='I
M@9M?F(3ZSW(Z09YG,<;(FAH;%<5&VJ7*OF%<SNFO\*J291]Q42-[:Y65();)
MGAU4K+FF-PJHONT;(K&MFZ>O`*R=I1'72Q/K-68JQTDD&=F=DF,<:)HF4JR$
MSTS.3\W_``<BDJ*-"F[7Z_):W%,HNSN[TARM[8^;MVQV\O+R^;^#YOF^3F$]
M7:*UG5VQ\JV=2S&Q95/7]KF,=:DTH.@7J\8B<U=(T\*XA]=D<@$=M6PHM&E,
M81HZVCUR6+9#/5K&<:Q5\ACS>2C`GS9XI7CPX[]^V._M_CSCMG/\/;R[^WMY
M>SC(<9\\X^7&?X\>S/;V=\>7;/MQVQ\V.>>.*5X\(?FQV^;MY>WO[/9COGSS
M\^?//GQC&,>S';_YYS\N?GS^G/GSSQQ2G;'_`+^_\?/'AQYX\_/M[,YQ[,]\
M=LXSC.,?HQY?)[.>>.*5XP'&/9C&/X/X>_;^#O\`)[/;\_//;_;OGY/]OX_E
MXXXI3M_MWS\G^W\?R\\8QC'L_1\_R>S&/FQ^C'ESSQQ2O';&?;CO_P#W[X[_
M`#]L^>._L^3GGCCBE....*4Y&OU<]8HCM-T\]MX2Y43%;ZLMIUOOY[U_CSS7
MK)84J9+Q-IZ9,\"?:M2.K8Y+6:R<.K@2WQEYCOJC^2J6!3H598CLA%)1Q[?;
MQ2JGFWFB-[TU.$<YZ==:VGJJX4STF+%D\-0:;U/7D+8;,VQ3WE3<N;J?G;`"
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MGC469&R/1]J3&*#E9B=M9FA*C;4!`U2A0I&2E3%%B4'G'9#DPT8A*55-<[<Z
MN57:NPM69&=Z[NE=C:1]3>KJV=HY1JAOM6)[#K9_7+MH_/;\B3PO22.*/<5K
MUJL5L8+*E[+'WR5)AM9#W`QSQ[]4</X$:\;I078J[WRLJLV`FMKJNIPW;*0&
M571"R)/2!<?F_1WMV)Q2:1&8OC,2W14Q-M$B9Z>MAR9'1A71N,HJK@,A6HD2
MP\MPMM>`'ECPA[8[]L>''EWSWSV\O+OGSS^GSYY\(>^<]L=\^><]L=\Y[=N^
M?G\LYQ_!Y<4J$+I8YVDG&NEY--[J]^7)\=XG"FQ`'?\`@E.U_(R;@?*G6`O!
MMJ/,"):Y@X5`CL5:0D954[CJ&--^0"35<]2:+@7.!<+-;5WOL]45H^Q5;JIN
MEKS=?3.Z6&Y-`3>PGVE(@)T#?UG,%"5[`"]9FB6V"RL.P:_M5DNEN%D<=2VM
M'&!-BYI7.TT6,<0<;L>`A#_JXQC^#&,?\G/'@!CV`#YX[9^YQYX^;V>S]'LX
MI5)&037KQ+M8M>DS49OK"4R2U=KD3S/4E<FVA?#P_H$E6+M55TM@"ZI:\N!/
M0)[BIM=N$SW1'&XMP>&PQ/:UC#@"ROG4NSE7[C>4^9-S(2:\7M&[71H(Y&8A
M([(KUEKZF6"P7W5^%DGNVKTE9P.KQ-*N;[.-<7^2ODA=90Y1VS5,MCC4YK8X
MT,H.9^>`&?+(0]O/R\./E\L_)\N/+//;MCS\O;[?T_P\4JM4YUX]"I#6AFU)
MTJO;7K:G6^F[D-F\^-HTV`N4+,1ZK6I$Y97Y-LN+.G9MH)7=6P*^`/L>+@KC
M9K/-9BS(;NDSL@<6)M5./8-BQ[<VK9`*M7ZQNH)+M;4<O=GMSM.I&0VRME%L
MV6:E05Y@[`TN$?A1[J;53M?I-E.#R0D9$\#C%FEPR#3)RB=)N#G'L6$L!#CV
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M7YE=$XTCDT/+0YIU3>YMC@E,,3K4*U.>E5$#&4>4,`LARI58-NN_<)":1"*3
MO+9&<,-K[OW?TX(*\7VE0-%S5E'Y[1^O%Q1+8UYC;['H[)#GC71G@&PN41TP
MC*&=J$,^:U$_CXY`E-R3:33E8)())P,TP)18"PC.,,..$``<``(XTX0S33A!
M#C)II@A#,,R(8LY$+/.K8?0](U\F@R2#5!6,0(K)))D%<@C4#BS+F!HIJ:G4
M3-+#S&]J3FQPF7J$B51*@M`TF9&H3$'O65QQ0!X[8XI3CCCBE....*5$YN+7
M]BR#:2M9#%(-(7UI(B>N[(JD:&#$RQOCYF>HCK2\29T2*'1C>V9IDD3KM+*9
MPC?,IPND.;V-9-$*AOPRC<4\;6KX-[J$D6H%#,:.\V&$,R/7DU$B?8!.UK#*
M&>S+:L21[:NMT`C>KKY`125"F7.P2WN>WU0\G@@D,-ES;&9XOF!IT]G5V4W&
MK'5A5&<62P6:J97P!:UZE\3@RQ\AT$9#I5&H:2\3"0G+6Q&`:A_E384DC$9^
MNB>+6TAY?T<141]B=W-)TD^]4;6>+/%K()4W7)'&FJU-S,WUX.M12@,4L:94
M)/XW5]AP*IEJ/UUQG\Q3SF916-QIM;F@E--GAYRUQ%P>'-FDB)E4KK[>W91]
M<-=]7;'H"Q;@B,-NK:B@8A*I74U:.KQ<)M+2M?+`V$GCM=2*O)5,4[OEI9#Q
MN)+=7RR;,;>B<'1B;RG1"G,!@I$[FZB:]+!P/C]N&EE*$Y`1J>2;K6W%1O99
MB'N9;$04.V[9^:H;DE,/BS4QHIV1.:"6N%#B8F:3R2S&7*VR,GQ**R003<"F
MK(J78.[+KK)PJN`:7WVKC[4S61!UK9/8B\P>HJP?DCG]:&/A`M--,O%N.\0A
MP86K=FJ1-JUD/C+@O)?PFCQ^V`ZNF((T(7:G:`L&?&QJ%[A2*X(Z^MC<@?J\
ME6KU(L5HH*U=AL4M<F(AVEH+$K:8#E#4\2V-AK-Q5JF,;M*%8&]G4K"V*R[>
MRL[`A]55K*=DI#%F*^++11)]G,2M63XF4K>^HY>K-8S7;JIAU9F$7>H"U:ZD
M56\,9DSMG6B,,$,GSW94"FDG,1I10OFUQL&[2JGY4Z3>Y-Q5;-/&:R[,E:5I
MA[.T+:F,IKJ+T\EJQAK_`!"*A2R]G3N.LT@F"MV:W`Z2OED1:'%3$0#CVUS6
M*9!F#J/QF+`,C=NQ>72&R4;S*U$EBM#U38<V<*YKN!,%2'S6PK,8#3'!W8F:
M.2>TT#(I*CYTL6.BD"Y'#$4M-B<Q6-?-'3J8:^L3O9T?D4?NM@?:_3L2AA87
M.J'PN26_]=MQ`H&'IJFBZ56IE#PX3*VU35%HDVREGA;A(4;VT3-K3'P!9F5%
M*5&C,K3VRJBSZG8(G%=E89!(WL`XR=\;H!2S^55,JJN;=4&X4=H/"R'59J18
MY,H=4NL1:"4RE7.[6H;+<PRE@M:`$V1,90Z.Q?4ITAW"TWJ>/6Q6%>6`C?@-
MNFU%KJ_=XH4WES^0W?&]F:!K5*,$F9P*CSZ@V4LV@9Y+$32O0J"X2.3IG0A1
MEP:\$31,744H!X7YC[BW6K#IQ\,TO&05[.JR?8I.%,FNZZ9W03`RMS(YF`P\
M?6S8U:S)/-G]G5KXBQQIK+FR*1NT1<VIX6YAR>O8'.'"'/$PAL8E3G7TE!,X
M&X2%C;7I5#Y:4V.#,3*(R>X)U`V5_*:75R;R'ENR0X$HW!822H`!09@2E1>[
MFQK9F&Q&G@54OFD]MV!ZI[(14=XL55QJ53T%G&16C&1IEJ$\<0>T4?D,V>6]
M_D@(PWI4K!)EK;A(N8G5OCZ9(BP:V-?.H-K;66U-A1;8+;*5%0H&ZL+KA1.H
M35[\V,L4B]*PR=T!/FP::FF)/(I?^Z\M?(K"Y-(%;BT3,+A]8#J@?PH4&$=E
MCMC&.V/+&,=L8QY8QC]';_W?-\G..2^'Q:?1MVB$T8&J41=^3>I/+`^(B7%J
M<TF#2C\)UJ)0$1*@G!Q!)O@&'(?2%@%[0XSQ2H!HM*>H1)[#M5NJ.?[92:DJ
MM;]DI[KS(;MIEKKN=WY/XI0VMKS"J:MA-.ZAJ9\15PU;$R:SVF*+SVFN'ZPT
M*>7PY+*5T-@6'M1\#]VCJ$0JNW6UJ/4[@;$PJ'R.MHFWQG8#7Y'7MOS:?W]2
M\W@4R(50HVN(!*#:OUTV87:\6:]RTJ'M\>BT.?MB&!ME,LA4(:B8S8[P$.._
M;&,=\YSG].19[Y[_`#]\YS[>/#CYL?[>7_)Y=OF\O9Q2J^LMKG=Z,O6P$<@U
MH;"1/-:5?LC:2&=5E459MZ_9[86L=:.GNV52]S-6KI]Z23=1/;")O08(^PEH
MG.<A3/4)PN/8X(C9FC[-+W_LFOW^K.*SVX]@#`6-:^\D7G]$/M,1M@UEB4*I
M5J,'0PZ<MTF!(%LR?S(^>SR"<!06E.WA5+'N2-4\9*Z<(:W14$^.<8SWQGSQ
MG&<9Q\F<9\L^7^W_`+^=-Q77BC(/9LON:(5+7\;M6>@5`F$_9HNU()2__"!C
M:<[#7NR=.!0(U]/9F13(3R<DGR)4R,JI],<5#0W&I5*@0N:4;NO.RDED[&=L
MW(KKJ2Z-_'&GJ8(U_`NUCC%>1G2VYF+4>?1RQ54`0Q]ZEEBO,HBY)Q3S<CB3
M-+'G$K@+NTQQ+$D*.+_*M.[]T6&`'!JVTMWY/5A5IG9K27V5KQ,*QV'LQ23K
MPG?9;`U;LRZ;6LX1DB'6_@+U5R2S]8F*!7'*39K3[E9;?!(C'ECE9H\.//R]
MO?OCY,]_;WQ[//Y?+GCPA^;^/&<XSGY.V<XSWSC]&>^/+'EY8XI5?B4-N[!P
M;;?ZQ7;#T4WQ-@W:ON,06O:>K9O-LNWPWU7CU4C%8*?%92U/-'1XBQ\U*=6*
M)NOK-I#>7YX'(Y%AN:'HCEFME[;#O&^4%B-A7+L`[%V,OZAW[I%+2^GH]%]=
M8,CH:VZ^B5!%T):*.M&$Z=ITU>/P54H7,]I6L-]D#PY.,]S7,H:TL'!.YVQ[
M/D]G^W_R^;Y.=.PS7JC:ZL.;VQ!*FK^)658YJPZ;S>/Q9I:Y))#7-<G=7@;B
MYI4Q:@0GUX2IGN0Y)$3]<+XG(>WS#B[DEK0J5W'QQQQ2G(^.HS![DL6JJZBU
M25S(;)2J+@95MC-<7F+G'W-!#$,1F8D;B?%VW8353-DM&9J;%$CE%5M\1-O;
M/3IINL9YH7$_K872#\<4J`*HM2-N)$W4M9EKMU]M5MUW$.F57REO?MD'7"4E
M/6DD=H=O2]NL=B-QO,#ERR>01R>%<CD[\*2R.PHZ?'#6Q6KE#806AP\Q3D_U
M?IW7F(7VQW36^M3:ZQR$OM3M&X#%KQ*I-/JYK/9]Z)>&FRY!?L%0XA+%,@MU
MFN$:/MF+J)^4?#):WQN?Y@+C""[8';'S?[>W_E\^?,=F1G?D?P<]M3:[H,J$
MJO*%T0I7!'E4A5%+42C*582<1D]&L))5I3LE^D3JBBE!(@'%@&%2JU&LM-=0
M:5RK2*S7T=Q.$?S2.B[Z*P7B4$+2XQ#6?7%D^R%@=GJ9#LA"E[O*+%LD<L'-
MTKMJ19;]-W"80R4M]EPTV*IB:VD8T6U.LFD6HV)62*TE\9L/2W5=GMO-@WO-
M;5<W;:-$EMUFV)<$SR_S^4/3`^K6-T@2)V?H6K98X[$(63+`I/.CY8T,J.,8
MQ_R?I_E]O_Y^>>*55_I;6C=FM7_0A/%=<[KAD,U]CNH40EBE#;I2\XF*1=1+
M6'9)K=&5XV^CL9:&XY]DJIV<XV@HJY7*VH*DCTD0SYC4,L=@\6Z2V"KNQ]=(
ME3M:3^6;,OVP2_6O6&00ANC.\;BSRE@V@ENR0(GLG)95!W*XFN17\38$>55_
M7T08:YC=RLT?BL9?80VPVL"983,Y-;L[8]G;';YNV/G[_P#+Y_P\^:L96=P7
M-;FN:VY8XLABDYF7JD*50M:35B<216:V*SBAJ&\Q4E$),I,1F$C4)\Y(.R,K
M.0<4JLY:6FN[-H-^[K+9L%MR9L\NA6SRS*1NF:1K8;Y>A;(Q2>:O-,0&7M_*
MC%KA!:H8%3;$"4M(ZMML80F*X#*\S4Q[$<7DR\Z?[4R>>V#9SB9<9;]$9HR2
M77A(CV%D#$P(@N/4FO*TGU<YPUKLELC3JL#JF^5TQ*44^;UA.(.L55B21@_#
MVQ@G<[8SW[XQGOY9\O;CYL_/QVQ\V/Y.*573Z8TDD#QNNO2"D]QRUX3:U7^I
MV7E4BVB(O6JIQ?P=K(+&8_,HE7#9/)4"A2U#!%YXR0R%2J$T;)&V',RF%IZR
MQB!OCKFQ;SYB!E9VM0YJVUK;F]4]+,.+PI1(DJ0]U<,)R4F%SD<G*+,7K,)4
MY";"I6(Y1A.241@ST18`!^GQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4J(N\>M)
MJ7K5.U5:7O%MD*QFB8K*HIHD=$20)#LW8%@.'>-O:%>M8)2S9'_HA.T;='5O
M*4!&E/4%*BS"0]/?;$O3A_&"Z?<G)_UGDK6Q&L-$[65^MK*^ZXCUAQ53Z4U&
M6ZIQ%.\><3"_1A>XE(D0T[[%'TC&,>A=V%>A5^'N2<,Y.,P@=.K?[ZG^N^@/
MAJR=4CWS8.HDP5+@LA`TY!MX0M"`0QB`2UMQ"9%:;8D)\/\`NR,(T$OP'O@V
M).82CW076=C</[&6/&*QQN7%\#Q1LD5WQ*U^YETYR`$-Q)89VKL<\H;IBN9"
MI<RNV@\QVKONR'@F\O,)3"\8PU<W94L)_NA;IF"=[;I>97"*!D9K9<\M3/;Q
M(I8S=_;$O3A_&"Z?<G)_UGC[8EZ</XP73[DY/^L\H4'$G)SCTZ@DY.H3'G)5
M*=0480H2JDX\E*$JI.<$!R94G-"(I0F/++/(-"(LXL!@1!Q_/G9!V#MBR`1-
MCA!R((OK7(CAQ_R?X<O7UY\J[L.UHYXL(X<^=G<>#+/_`%WH/RFK[?VQ+TX?
MQ@NGW)R?]9X^V)>G#^,%T^Y.3_K/*$G''<-V+^&QSTZUZ/[OZ/7UY^=V':WX
M/!_!_J=QT?IO0?E-7V_MB7IP_C!=/N3D_P"L\?;$O3A_&"Z?<G)_UGE#1H:G
M)^=FIB9D9[B\/CHVLC.W)L!$I<7=X7)VQK;TP1C+`)0N<%:9(1@8P`R<<#`Q
M@#W%CL&5TG;,%C#E-)G`9!%HFTV1):@6O[Z6B;F_%FPLQ05,88A&<MP<\NL2
M/2'II,<R$N32Q*P@1.;DF6'IR#;+]A782)XXI+W%HY92!%')B=DDDI)``C1K
M$,Y)!`"@D\>?(YW4[+6V<B/)':X9)'$,Y)$P^[9(P-.9=EO"J#QEB!WWRWBO
MMB7IP_C!=/N3D_ZSQ]L2].'\8+I]R<G_`%GE"#!Q.0X'@\@0,A$/`PG%"!D`
M<^$0\"P/(<@`+[D8^_A`+[D6<9\N9`T?JSL1LKB2"H6HI9:88@:QIY,*,Y8P
M`9E$F$X!CR=6-[>6<`E#R)I<@MR=*)0>I$B/P`ON$.!>7'87V"LX7N+N^Q6U
MMX].\GN<4L8(4ULJ)KEEL4C76[*BZF&IV51F3D?8.RSMK=2K!;6F'7,[YZ(;
M?#KN:5]*ZFTQQW;.V2JS-DIR74QX`FKKWVQ+TX?Q@NGW)R?]9X^V)>G#^,%T
M^Y.3_K/*'$C8WB'R%\B4L;%T9E,9=')DD<;?DYC4^,+PS*C43LV.[6LP4K0+
M6U60<G6D*"@"3FEB"/MC&,Y^8EQA:>C3)#"#SW!:E;D0`*$_^ZEZU04E2I"1
MB-"4(\]0<42`'CQGQC#XLAQWSBZ.PAL2RAUN,:9"H<.+^T*E"`0P86!!4CB&
MS((.>9&>=L]E_:\,4,.$APVDH;*Y#!@0"I4WN8;,$$$9YDC+.K[7VQ+TX?Q@
MNGW)R?\`6>/MB7IP_C!=/N3D_P"L\HB2^*R*`RR302:-"N-3&&2%UB<JC;ID
M@MT89*QKCVUV9'`HD\\H"]`O3'I#BRCC@9-*'@HPT/86?6+Q>13=>XM</9G"
M3N31'I++75`QDX<%3=%X8S*Y%+9`M))'D2=IC3"@7/#TL,[%H6Y&I4F_<%#[
M4]Q/8;="?E>,;@H)!-]T;/=&,@,)!)R#04*]\'STD$',@G.KNN[8[S<\GPO>
MA]V8N076\U@A2A3EFK6&4@KEF"2",\ZO>_;$O3A_&"Z?<G)_UGC[8EZ</XP7
M3[DY/^L\H1XSC.,9QYXSC&<9^?&<=\9Q^C.//'//+G<-V+^&QSTZUZ/[OZ/7
MUYV^[#M;\'@_@_U.XZ/TWH/RFK[?VQ+TX?Q@NGW)R?\`6>/MB7IP_C!=/N3D
M_P"L\H2<<=PW8OX;'/3K7H_N_H]?7F[L.UOP>#^#_4[CH_3>@_*:OM_;$O3A
M_&"Z?<G)_P!9X^V)>G#^,%T^Y.3_`*SRA]'8Y(9>_,\5B;"]2F3R%>2UL$;C
MC4O?']\<U&?"2WL[,UD*G%R6&9S]RG1ICC,![F#P$L(AAL^:!?4[$KE@F:S-
M['!7"HX/"9P04!#WDG$S=BL]C@$V5-6L:A)%$A@?`%5&88J6R(8#!%+)3'U!
M9R',<VC['/8NV4M>58SB>,PEE)M[2.^M);V[*Y9K;6PL0[C,!6E<I!&6&^E0
M',[[`=O.R-M)<\FPK#\*F"E1-<O9W$=I;`E>^GN&O"B\`6$:ZYG&K=Q.014]
MFJ?54UPW1FPH3K]&+\EHT)@@225K*8D3#`(=C"8U24&5S9U4D,32K58*P6A:
M/65#XN&86)(UG$>D.+[7W2WMJO1"&M]D79"KP<*V4848>9]5U3/EG1F%FE')
MR"`SQ1&E)BV()7`:D`4#R\H$[`<:$24QV)6"*3&9)U94M9TC"&2MZD@T8KN"
MQTC"=GBT2:$C,T(\>$.#3\)DA8/6%RK(<&KG)6)0XN!^1*%RM0>,1F>=+4*-
MR2*D#@E3K4*U,>C6(U9!2E*K2*BA$J4JI.>`PE0F4$C&4>G.+,).*&(LT`P"
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M#D\]XLP&<EM)-$LR<V9`W.4B#W\9(&??:3WHW4<<$GX);/PJ2`?X<1TBK_\`
M]L^=+3\9;Z_L_P`P_6>/MGSI:?C+?7]G^8?K/-</QS;]IF$>_O?/1_4>V9Z,
MKG)HO[7R_P#2MCQ]L^=+3\9;Z_L_S#]9X^V?.EI^,M]?V?YA^L\UP_'':9A'
MO[WST?U'MF>C)R:+^U\O_2MCQ]L^=+3\9;Z_L_S#]9X^V?.EI^,M]?V?YA^L
M\U^]>ZU7];'[GG[FE1S2;AME]L*-5R./H4BDJ5/-2M#-(+1(2'G+DY#<BKUB
MD+(\S%]?S6>/,+6Y)ER]V*3X.&5T:<820>H2FJ4>#T@S2U)9:U(?Z+))F2C!
M9,3GFE#)P/&/`I*,&F.`(LXDXPDTHP="[(8*Q*K-=,R_A*MQ"2O?,G?`0YCO
MXY$XY=\KKSJ0')HO&W[0Z>CH/R&MCU]L^=+3\9;Z_L_S#]9X^V?.EI^,M]?V
M?YA^L\UU<*A\GL>8Q:O8(R+97-YM(V:(1.,,^"#75^D\B7)VQC8D!9YZ<C+@
MZ+U29(D+4'IRQ&GE^,TL`O'CN'8/4[935$Z,$[(4M-Z:#-4[NIB*R9)VH#3)
M"X^I(2/I;0^LCL\L:M8RJ%24MV;<.07-NPK2FJT9)*D@PSP[(X&LB1-<7*RN
M"4B:YA$C@<250PAF``.94$#CS9</.3Q9Y9G,\PU#,_JRJ_G]L^=+3\9;Z_L_
MS#]9X^V?.EI^,M]?V?YA^L\UP6%"<1F2@J4XCL!\>2<*"<G8!X<#\>2L#])@
M/@S@SQ>'P^CS@??PYQG/,%L'EK?!(I9RQA6$5[.9',8A#Y@(:,;)(I17Q,=4
M39A;#B51AYCE&2);&3G0DU.2$!;V@RG,4>,W!-1V.P=2H,EV"QTJ#/$"S9%M
M*^X\3I5FR''(,>8</>31?VOE_P"E;$W[9\Z6GXRWU_9_F'ZSQ]L^=+3\9;Z_
ML_S#]9YK@#%24K&!&JDI6!!&,.3%!(/&$OOZ3(/$/&1^#.,X%X/%G`L9#G'B
M\N<NF$*E]?/F8S.HR\Q&0X9XU(<LC^B&WN6&&9QQKF$1>,I3,Y'AODL4>V:1
MLJC/8*YF=$"XKN4H!G+M.P<$*9+O402%,\69"Z0Q`W.9`)`)'`:AGEF*<FB_
MM?+_`-*V*/VSYTM/QEOK^S_,/UGC[9\Z6GXRWU_9_F'ZSS7#\<J[3,(]_>^>
MC^H]LST9.31?VOE_Z5L>/MGSI:?C+?7]G^8?K/'VSYTM/QEOK^S_`##]9YKA
M^/9C.<YQC&,9%G.<XQC`0XSD0A9SVQ@(<8SD6<YQC&,9SG.,8X[3,(]_>^>C
M^H]LST9.31?VOE_Z5L>/MGSI:?C+?7]G^8?K//NQ?ZI4Z;4WDC'#H6/9B7R^
M3N)+1&XK%M9[!D,DD#JIS@)#:R,31ZXZ.BTW.>^$Z)*>8$&!&C"`H`QAIX].
M/HG;>]1!4T2]G9LTMKHH5`]?ONQ&E8%O>D0!]E(*HAHCFYYLY;VP,LIU3*6:
M"$'!&!3,!*B1-QE^?I_]*34/IT1LLFEH1\-V@XM9;=,;WG>$;[:LK"+L-6D+
M>`I4Z*(1LX_&!EQ"%HF1BQ@H@QP)=%X!N!T;Q:QV:PW5%')>7=V.&YCN(M$;
M<WNTH@*H1D<T4-)GP*H"&%B1($S`U,WB##@?[1RX?JS/5SUFDJM42*I4UL*:
MYM/!9K`WR)37B>(@76HWIEV"AF(%4);W56H&^MQ)OIG%B0+5SH1Z(Y,4F/7%
MB2\CH5=:W21"J5(5R^WD2U"I.1+D2RH9*D6HEB8>2U*-:C4C*4HUB<S&2U"1
M244H(,QDLXH`\9#B6[MCMV[8[?-V\L?-VQ\G;Y.1];@]-S7O;Q,K>WMJ%`+8
M]!X$%KPU&C3OB@PLO($Y$P;!!*;INV%_<!]$[9+>$Q(/1-+ZV=\YSIL+;!C,
M4Q>&\$+MWL]G,@,()'"2)XI#*G]I&#J,^\D)`$.VF3:P6^_V5N,+-S$I+V&)
MVTCK<Y'5[A=1W,(AE(&D)-&T3DC.6$!F:)3;;:+I9[CRAMF%A6/M1%'MN@"R
MM\&P.MXV84)@/EK=.D2QM!8U>V*;#9(V2II;W#ZYZ\.A[W(4*5/&IJLE$43I
MF(G^MB;0=)^SX:=#91+-GL%#>K[EB1^:8>L:Y"TSC82RV2Y))-FA6G8_5$4@
MB-H1MAF%>^%`-J9%K6G1.K8_M(CT!T6FV.A6PFGSF:98D<"^U^<IP0SVS$2E
M:^$+_2CR!,G=S3"L+(<\G>0<-$C`06<;W+:7-X!CTV<+LXSCRSCMGYL\Z5:[
M%;,WL*7%K<WEQ"XS62.ZA93S9@Y6V:L.(9&`92<F`(RKY\Q#LN]D+";N2QQ+
M#\+LKN$Y207&&W4;@<P89WV3QOD2DJ%HY%.I&9<B;&Y6Y/3*7TGL52$\M#:Z
MU&S:&:O]AVE-)Y!4)DV'+'J/P6.(5L:Q%H=%H5'T$21UM#38HP$0L^/HCV<!
M3DUN[>I6(5'"F;8CI0-D(>(2OGFT;^7(F?8IF?GQ36L:C*U>GV<@48K2P#$<
M<KFO(17,8^#(?#V!!$$$-@T<9&M4E4NSDU/3LYN:U97]XYD=H&!>_P`0](BZ
M/T;H/R]%87=NVS^"P3T&XZ/T[H/RU86E6TO3#?K'=K7CET;L51-Y0HFJ:;/=
M2-JN'.,QAT^<ZW>G^OU[SB,N$@CK"4\5@R.3!(X`\0VSXPH=Y87'K`;4LA5I
MP]*-4MZ1C$Y/#HR7)NLTJ5GJ2AA4((3"4SI#GR.WLP[(P&7MLF*J4$METWKV
MV6`IX9)A;;]93_(V9Q=8K92Z=QQ20VI85.??98K(Y&BE#DQ,RYU00F/9EDM5
MHP%C*C\;P[M+!EY</&:6/"+X;?6=KQD@!YPECDE+"2+`Q"!XVP6`(,VEOU&8
M&;7,*C,E5`S-N!FQ.0'A+`#CE52=FO;:1M*6^#.V3-I3#[EFTHNMVR6])R5%
M=F.62J"QR"YU.(DVPT0QMEJ]?K_:-]3]KU;K_8`#5*K-99]-+AL^V=@Y,WKE
M+E.$H6)BKYJ@-2,Q4I%5$=C8$[+$G"?JF:"0:NXY%4GP[)=\=OHUCV/%J^ZE
M_P#\_E1J=P685A(11*PX\OADI`@:W,^.O^4J-Z1I'M"2YM>7!N"I-4MBM4@4
MIE66MR`D=DA2@C"Y`E,-+`+B.!@%G`<#!D6<BQ@.!!SG.09[#QC&,]\Y!GR'
MC_@9\A=L\\38+9^15=)KZ1'`972Z@964Y$%66W(((SR()&1Y^%>R=FK;>&1X
MIK;"(I8F*21R8==QR(ZD!ED1KT,C`@@JP!!.1%7$_CM]&OPQ:ONI?_\`/X^.
MWT:_#%J^ZE__`,_E6-UUBV#9*P372Z5#,DM4JF5HDA4Z]6;E#(&//YI9#*_*
M0HG)2YH69R/-))3N:]O2HO2G$EFG%"-!@70F5";&,"RH3X#D0@8SD\K&,C#V
M\0<9R/MD0>^/$''F'OCOC'?'>F+8;9R8,8;B\F".8W,5Y;R!77261BEN0K@'
M,J<B-0S'-5RX[,>WMH8UN['#+9I8UFB6XPN]@:6%CDLL8EO%+Q.5;3(N:-QR
M)R-7%_CM]&OPQ:ONI?\`_/X^.WT:_#%J^ZE__P`_E0MDC+_)$LJ6L+4I=4L'
MCHI=+SD>2!XCL8"[-+")\<P#.+-*;PO+ZS-N3"BS3,*7))CT7HQB,!Q\1A8<
M9R(PL(0AP/(LF`P'`!9[!'D61=L`%GR"+OX19\L9SGE8V"P`E@);\E"`P%S"
M2I(5@&`M\U)!S`.7!@1PRJT>S7MLJHS08.JR`M&S6%T%D56T,R$WV3`.C*2I
M(#!E/$$5<4^.WT:_#%J^ZE__`,_CX[?1K\,6K[J7_P#S^5!C(\^E1MNF)C2O
M!%'=[=(VUR/)&?@9QD#&@;'1Y94:[`LEGN36VO30O7)0=QITCFA.']P>'GQ^
M!L#@#<1)?L`2IRN83DRD!@<K?@0001S@G(\11NS7MLFD/!@ZEE5U#6%TNI&"
MLK#.^&:NO?*PX$-F"0>-Q'X[?1K\,6K[J7__`#^/CM]&OPQ:ONI?_P#/Y3NX
MY[V@8%[_`!#TB+H_1N@_+T51W;ML_@L$\'^HW/1^G=!^4U<1^.WT:_#%J^ZE
M_P#\_CX[?1K\,6K[J7__`#^4[N=\:_ZSW9L]+PPRF(,Y2E:283A[>AXRWQ&)
MISN^0K99*%!>6UF*]'@1A2/(E#RO"'(6IJ7FYP7RW-L-LY;Q/-/<7L,48U/)
M+=P(BCAQ9FMP!F>`X\20!QRK(M>S'MY?7$5I9V6%75S.X2&WM\-NY9I7.7>I
M&EZS,>!)R'`$D\`35IC/6XT9"$0A/5IA"'&1#&*JWX(`!Q[1#$(_`0AQ\HA9
MQC'RYY(10U\QW86&XGT/BEDQZ+JC"<,BZQ80XP11)$IQ/I@NC"UO1H'16SYQ
MD("74Y&E0K1"P-O.5D8&<&.O3/I`4KKYEHG-P9;KOMU)Z%80:Z-_>MX>X`R$
MP`XM%5X!Y=W!(9WP3)94!4KP,(5+6TL)F?!B8,(<!QVQCMCV?R>6/Y,>6,>S
M&/+';'.;XQ]P(W,.#+>S:6[Z[N9EW;Y99B&`01N5/PDC*><",C)Z[[LH-MYX
MA=[6283:ZTSCPRPMI#<1E@,FN[MKN:%7!S.X@20<06N`=48B'MSK6Z?T+.WB
ML[D8=BJZG3&8/"V/2:AY4B4')L&C*)=6E5A28WOS"MR#QM[^QK'%F7%B")*N
M-[YQCK3[81Z=OX=N;W+2;]9Y)ELUJ/K[M]!3(!?=<LTU:R<*3&)V,"8W2V'N
M"DO!8G:&RQOR0^1MPQD)0C<H%84;@$H"9V1."+(TPZ>&^O0NV`UER]6%0>7C
M8FE$F%CBI3M;8`5P05K)[G"S(XJUEX*FC8A3Y%Z:2PI+A;@I.:J=(@U)PB5B
MYKC%SM-A^J:T6SO;09DZ;:3E,2\/ZR-9^_`X^Z1`\`6>.-1Q^P^QG@78&VRY
M/A>T=QM+LMM%)IC5;C';$8+B,IR`%E?RX0.2RR-GIL[]D(+)%!=WDK9"=W[8
M1Z=OX=N;W+2;]9X^V$>G;^';F]RTF_6>42_G[>?80P9_0,L60&`%CVA&6/&0
M&`%V&6,(@#"$0<XPY$NW;&?>V/F)/K^OV''Z-^]5[%_QC:O]\6/1_<_MGU97
MM/MA'IV_AVYO<M)OUGC[81Z=OX=N;W+2;]9Y1+XX[=L9][8^8D^OZ_8<??O5
M.Q?\/M9^]['^3^V9Z,KVGVPCT[?P[<WN6DWZSQ]L(].W\.W-[EI-^L\HQQV/
MO<MD##%(TV*GJ22E[:(W'65"$`USP_O[BF:65I1`,&46-8Y.:Q*B2A,-++$>
M>7@9@`YR+'+9-4EEPR(I9]+84^1J&+YK*ZZ;I(]EI&]M=)M!5&4<TC[1D]8%
M4[GQ1=CX.D#@V)E;*UNF0M*ET`YB"DS6NV6.LK.L-HR*"69;68JH&D$LPG(`
M!9023PU+GSC/&D_HP=B2&:*WEQ+:**XG94@@EQ_#(YIG<2,BQ1/A2R2,ZP3L
MJHK%A%*5!$;:;M_VPCT[?P[<WN6DWZSQ]L(].W\.W-[EI-^L\HCX.)SCQ8.)
MR'P8,\6#2\A]&+.0A'XO%V\`A8R$(^_AR+&0XSD7ES(>FM4-D=AVE]?:/IJ9
M6>T1IV2L+XMBX&4P"!\7-PW=$S>A<WEM5K'16VEC6)D+:G6J3RL=BRQ&B"6+
MV+;''IG$<,%K-(<R$BM9I'('$D*DS,0!F2<N`XG@#G3>_P!&3L089;O>8EBN
MT&'6D919+J_VAPJSMD:1E2-7GN,+BB5I'(1`7!9F"J"2!5S'[81Z=OX=N;W+
M2;]9X^V$>G;^';F]RTF_6>43UY)K4N6MCH6-L<FQ2K1N3<X!RB7MRM`H&D7)
M5Z-5Z)2C4(U99B942I**,3J`")."`P.0\_='F=REC_'HM&DHGJ0RU]:8Q&6A
M":F$K?9"_.25G9F=NP:<42<N<75:D0)B\F@#E2H*`8,O&<BQ0-M,:)"B.R+$
M@!1;RYDD@9`;_/,G@!SYD?KR&_HL=BM(S,]WM0L*H9&E;&L/6-8U74TC2'"`
MBH%!9G)"A<V)`XB]%]L(].W\.W-[EI-^L\?;"/3M_#MS>Y:3?K/*+#JVKF-V
M=6)W3&-SPR.S@Q.[:IR6%4WO+2M/;G)L4@`8,(5:-<E4)CBP#'CTA(_1B&#L
M+/[H_&G^5E24^,M"Z0$PV,.<UEIK05A<"-1!F4MZ-WDST(D><(&5M5NS8F6K
MCNQ1!R](6+S.#ST;9XV6T[NS+<<U%M+JX#,\-_GP`)/B'/S'.EOZ+78I2,3/
M>[3K"0A$K8WARQ$2,JQG>'"`F4C,JH<\F+@+F2M7F?MA'IV_AVYO<M)OUGC[
M81Z=OX=N;W+2;]9Y1,SC.,YQG';.,YQG&?;C./+.,_P<\<I[=L9][8^8D^OZ
M_8<;OWJG8O\`A]K/WO8_R?VS/1E>T^V$>G;^';F]RTF_6>/MA'IV_AVYO<M)
MOUGE$OCCMVQGWMCYB3Z_K]AQ?>J=B_X?:S][V/\`)_;,]&5[3[81Z=OX=N;W
M+2;]9X^V$>G;^';F]RTF_6>4;XA#9=8,G985`XO()I,9(L`@C\5BK.O?I"]+
M1YQC"=M:6TA0L5"#C/C.&`KT"4K`CU1I"<`S0V@]#?J>A:NRT65O6XB0I?\`
M<Z]OU[A;U_NHW[H)@2;0GK0=D)0,A#X5,5@2O(LX'@"V9Y#ZPV9V6&[0;3XK
M+N[2WLF4$"29H)5@BSRXO(9R,\N(10TA'%4.1J"[<=AOL!=CVQY9M)C6U$$L
MB,UGA=OB^'W&*X@5X96EDN$JQ34-+7,[06<;'3+<1DJ#.'JCU+J%W2D:QBH*
M*7K)&]H]9#(9LZU"^1FO8ZJ(2&*RFMVFCTK3LH'M9X`$I&%$<N>A"/*/.0$(
M?2K"G,W8%7L%JV)LL$KB(QR#0R.)`(6*+Q1G0,3$U)08_P!Z1-K<0G2DY&+.
M3#C<%Y.4&B&>H--.,&8)SH-LMPL2BZECFGYW>&(PQYG+O41GD;(<1J9\VSSR
M7@!\9XW/@MQB,\FS^'WN'84#IM;?$;],1O2JD^ZW-S#:V4)DD&1,<5NJ1#)`
M\I!E?F//&<8SCMG'?'^WG^C./DS[<?)SSQR_6HJ)K?GH]:N[S%.DO/;/W'KZ
M4%>)-<T$;$85CTI*+$`@FR8OD:1JL%#V\!8EBLYMER8DHDEME2-,7E*92EW7
MZ<6T.A\@&FN2'?"%?K5^447N>'85.U9R01F1Y2)CW,9):R(/YX`#SF,2],V.
M!@RS/@D][2@"N,V7_/@R>*QJ;1]WBDPC[+*8Q($)S8^QV1-:%Z8WEN4!\)Z!
MU:7(A2@<$9P?(Q,K(-*%Y9R#OC&<=-V-[*6/[*&*TF8XO@R9+R"ZE82VT8(_
MQ"Z(=[?2!WL+K+;99A8D=MX.=[5]C?!-I!)=0JN%XJV;<MMXQNIW_3+8%$F+
M<<YD,<^>1:1U4(=3;G&<9SC.,XSC/;.,^6<9Q[<9Q\F<<<N!;^?4ZC`_?#%F
M:'.2*(O`@G+E^O<Q=C\0]R.^[,,+K6:.`U*N'*#<X"!+&)28XQ@1H_1(GZ*H
M@`(Q4XLJK[%IN:O5<VO")/7<\CIN"GF)R]I4LSTBP/.<$J?5E`?`L;5>,9&@
M>&XY:SN178YN7JB<X,S]4;+[:8!M=;[[";L&X1`UQA]QIBO[;F!WD&IM<8)`
MW\#2P$D+O->:CYOVBV3QO9B?=8G:D0NQ$%[#G+97&7P<P4:7RS.YF6*8`%C'
MIR8^*M?VZ)VA64K>#%!3/%;*KV4.YJ,D2A64TQN:,3XZ&I$X.PU"HMO0*1IB
M`9P,\\)90/NAXY-Y*NH?J%;FT-&;1VI#W5,ZT-<]Y0I-6D>KA0LK*4Z]3E[L
MF3TM>,>AJUX):8C<E92R7MDCM*'FJ$"RTW5`DE:%Q)EC8G`5$MJ#3##L5M)0
M-$RB0*HM'+8M*-0I[?D`D@')"V.1IQRPMI&N*/1`>G(I)EG93%2=206[.*(P
M:57@.$QN9Z36^HMFY=$6BN]:+QTOC;5-KSCEA6.]/L@NRN%$7IV)K)@Y^NBM
M9UKM5$[9BR9.B26$>Z36-TTP-[L4[O;S'1D%DFZ_:B/`9\0C^ZC8C#+:X5>F
M:]LIH(H[3#\1@O;>=9$=S=7#W<5K=1)'8VMW-$T:3%;=]Q-6;L\^,0V3MAPL
M98[C$K41VEU%++)=7UA-9SPE"J<G@2UDN;65WN[BVBE5WBU3IOHJS]@&W-%6
M)-MM+R?FZ-2JKZ`KO7?82%S8V(I*P76+N;2J&7PJ`$.$"G\]F5C2Q=<"*6HF
M652`.#%CNFJ]N=I(@83#4ZEYB8USVE@5/4)L/%K"JJN[^G]G7)KG83!$KA8I
MJZU\J.KG%QK)A+W!7!9A!UR62('6;-`V-`J=C6UT3NKR`]M4@2@]#E>HZ2L'
M0V&YU^];5%)WEWN,BEZ4<6VD3)*@G;Y(-4(GM9&7.1N;59!J*!LRJ.2;$9?U
MS4OF:0"XA&YQ\Y_;%IIB']M(=/\`I-)7T:D%ARA=9=L25/TU)ZLKA9#)_#JV
MA4*W.V&B$>+;`6@PS!N#:)[S6;R8SR]&UH8JX1%V4GCB;P<Y-;DO:XW;3;$V
M-G=K%?8G?6U\^R[0PPV=_!.MM9R6D>'NL[PVT*Q37<3/?W,+642%A::(KI8A
M+OIX=K;NYM&DL["SFLUV@62:6YLIHVFN4G:\#Q)+/(SQ6\JI9P3"Z=]+7&N2
MW,FZ^#%.I$P.CEK.[7049*"<[-;*;`;:,#/5\16HGJ26#)4;O1\G8TTC2FE2
MQ+43LL73EFKLQ[2L1CBPH&Y]RY+52547W(T;^:[()TZ+S[KGYEI?N$TY!I#O
M0'4:"*)K;S]!;WDUD6!&W.B5#J`AD;)[5;O%J>Q.')Q*>EJ:#IOA\(&525Z;
MIMOZ?56((%>TID$N?7NS'&@-EKBH^H(M7DXS$HPTP/:@C7F`/BRUD\F6!D$J
M+=VUY(Q4BYA=U*UI=64:MY<Y'ZN4LYS(^EU1=.&RQQL>^9I/X\GUKW6EZ<F&
MUS'&F50JYM3FJ`+7QO>V1MNF0ICT#<5.25!$/DKQ'9>8ZI#XU/XS#%6/2%6K
MD;`2R/&),3@<R7D$4%M8#*YDM[B3%;D1*^'2QS0VO*&MMW<,</O+:UMX7CO_
M`+GVDL%=N=M(D1]W83(([6:2>XNR3!'/!%AT#2LM[&\4MSN5G+Q#EUK-<3RH
M]F+RYCF][:W*TVL9)=TW)D$\2SQYB'4WKR"00^F!F-4N3[>W"Y6A5$V>;"^'
MP#B0F%G5@BRUJ51Y>^,SH/"OUQO9TXE!W9+GU':$37(VR.#WW;$2KN1UQL7`
MXNR-.J\"BOV(,*M*BD<+K:KH^[Q1>5.KA9J_L]M:Y7DA"O21,0FE!)20XD:E
M>;SHF6](QH@\OIB"R;;>MV^32^2-4:N-NPQLJ@^JSGVEEMT-;W'TR:RCUS_$
MQI4`H2MDUJ):/;6Z2.#(^K!%0EQR]D83[7ZKLFL,SG$*-LMZD[PP.%5JXBD<
MJJ=(V7,H%9<%=9:HF?UU,\HFM=I0QQS1(8VB2,,OE;9/BW!1)8<_*6ED=2BL
MFPPS8;%98+*SQ7$KUY;.]DMH7M#(BVE[<BVEEB:YP8H@CNY=[',6$J1REI7?
M#I"C8][B&U^'1RW5WAUA:K%=6<=Q(EQNV-U:0"YC258,4U.9+>/=R1Z3&SQZ
M8T6^C#KAT//<0LY,R;G(A=S1!R$1N?%GN:(.<YR$1O\`O@@YSG(<CR'.<YQG
M//7CG=]`:W7EM)/DM94'6TCLF7GX)-5I65,`MJCR`\S!07F7R-<8F8(DR!&+
M&,N;^X(B3L_Z%$%8J$6F,ZK<7%O:027-U/#;6T"&2:>>1(88HUYWDD<JB*/"
MS$`5SJ"":YFCM[>&6>>9PD4,*/++(['@B(H9W8^``$FND/DSG/;&,8R+.<YQ
MC&`XQWR(6<^6`XQYYSG.,8QYYSC')4]"^D1M+O2H:94UL^:DH94>`2NZYXV*
MPH'="$P0%&*TBN34+M8:ON6:46XISVJ&DG`&%3*<J"LH3;%6@'U/Q3%%B9+,
MVV4L=_VPE&F<4,"*3'FT?#%I60FE8-:7,@A9:#HE-#C/PA+$:.+A'GNEA@CR
M"',=BQ*E3(DY"1&G)2I4I!29,F3E%D$)TY``E$)R"2@@*)()+"$LHDH`"R@!
M"`L(0AQC'S_MGV;88-[A^R"+<3<4?&;F(\GC.1!-C:R`&=@>:>Y5805.FWN$
M97';ME.Q#--NK[:AS!%P=,)@?W=QP(%Y<(2(%(YX8"TI##.:!U*5@+I'TT]7
M-#V`!=2P_P"%[&7MP$,JN:9X2/%DR0(NPU24MT`F(1Q9@..Q@0(O$D;0S>$L
MDQ<4Y+0#7&R`XQC'EC';'S8XXY\XW^(7V*74M]B-W/>W<[:I;BXD:61CX!J8
MG2BCO41<D10%154`#O5E8V>&VT=G86T-I:PC*.""-8XU\9R4#4['B[MF[MFS
MLS$FG''',.LNG,=MF=3]>MPZU<*FV-JR+VA"UOI3DJ1^1Y"ZQYR&7Z,#]#Y&
MB&F?X?(T^,8RF?8VXMKB7V]&,XT@1A(\B>.5([QNLD;M&Z$,CHQ5E8<058$$
M$>`@YUZ"0<P2".8C@1^NM?)U)_J:J_=<<O\`:NF"B0[*TNE].XK*W4$D*-@X
M,@P(0S`HF]O3(V^X&=$5D&<*8VC:YR63C.#8D_#+/=!5B%*=0C4JD:M.>D6(
M52A"M1JR#DJQ"N2&B(5H5R12`I2B7)#@B)5HE11*I*<$1*@DHT(@8W2.<8SC
MMG'?'^WG^C./DS[<?)R&CJ/]$+4/J%IW:9KF?]Q/8HY,/*&]JX:F\ET>U8`"
MPF(M.+9]4:+.;`9\)>5+D:W3%&0'!3/+VXK`B3)SA.V$D>B#%5,J<%%W&HWB
MCF&^C4`2`>%TRDR&921B365'<D<).(]\!Q'6!S]8X]!K5_\`')'-^NE=M]TZ
M)$(F\H.!XK)>X90Q6^8#A:]U/(QF#R%(D7.9B<IP@<C4X\@Q6<)6I:H-P8!A
M6R),5E<*./.,XSG&<9QG&>V<9\LXSCVXSCY,XY/X+B"ZB6:WE2:)QFKQL&4^
M,'+F8>%3DRG@0#68&##-2"#X1[>JIM-2]_-?J\TF9-%;D12%!`KNDFW,>V'M
M"#0YP5VW3L-M5#0SM3<KJY_1NC:*7QP4ZK!<?=E-8R:BG\70MC:Z@48*1MZ_
M*)HZD=`D4/HQ2FL<(8GJ[:=LK4%M8ZM>Z7/BK>KLJJILN;;>LB/71+;09*XC
MK5M;''=U:92F>8>&6KVZ>*6:SG9G^M1'(DT7.D=+4[*:HW4V1N&N7^]F_4JK
MJKD\>H%AFTCKM-.W:V[3)KE7,)Q+8.2HGK;754-05,CD`8B!,J5."YE+=G!*
MS`5A.S(J[I50?;:>6LYQXBX=#(NL%"6NGJ6V)BS/9"YSGTPH9ZO!5$P6-(IW
M5KR_0=8S-21RA*!GB5AWF*#25NE$UA"9E;E+XKCUW#A<<UR9VN(UBG,\SDJ]
MNUS*$D93"A-R^<5W"'*1K'NE";X.)=5IEC!.>8`)8\>!8Y9\/PCP*YY#+(`9
MCCG_``VHOC7"C.K)J^S50O--U&Z=]LT[%VQXCB9ODK@Z(XQ=2N]KSD3=];N1
MHI8Y$3*8/D2;#&P]00YI(,U)D)YI60&&</KCJF-\<F$O,8*BI;6Z`P>H=Y''
M7V-T96,C?T"C:38QIB39#[<G:.W9;:IJI_,+A$8+-5+A%0^+9:RSLQXS(L8!
M_*/])*/3ABJ=HK?9].YV]-5'3C/F-?R.E':,PVOHQU&HQ\,0)Q;+(2S=U!-G
M2OUB1Q*D#`WQ1F*<FD+4-`Z)WA:J:V[M"2]/G6L-$M[A2+FZVJ_RS4J])\QV
MU;L.LFCWH=D1#J1TKJO%G8FJ3K!>&N'"9F">ND77GO)DIC#PRA4R<R/DRK)9
MK0UX1HMX9))[EPB6A<Q2KW[I)(UQ*)E1-4XDD?4V\+J[&)6&MJ\]RR49DY`*
M#D<^/$DY@#,YYGG)\`K^R+J'ZIG:IP&#3XJ66:8@A.O+)+=/7+7VOFV%`V!K
M_9%BMR_-QB]EBU9;R]2>^X$BET47Q/X+(=CU5@.,>?0D1%K2&E=U7_U$]-;X
MCS_5$VV-MR:L%@UEU'($&Y%NFC-$'&E6S:)]UID]!19NJR*RIJQ.T%6,M.OM
M;'R9M=F5W*P-K,`6CBA*%4'JR3])6@R6J&P&+7K/USW#]D=YZ^V2OQYHEX@R
M&&Q_4>KZA6OC"VP"Q+@CL!(AJ"Q)0ZA9[VF-A5W%U[9*&Q/+%S>K;T+2?]4W
MHP5>L>$NO#%?STKO[.^,QH@=J*X&F35,IHR+Z8Q7;U6^"9`V::%-+DM?O1KL
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M,Y#($CQ@>,`GK\',,@,@XY_=*E5+E21"A2JERYP5IT#>A0ICUJYP7JS,$I$"
M!$E+.5KERLX024J)(2<J4FB"40288+`<V@>FU]31WUL+F/6MNLJ?M;J<5>@<
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MC6^/HQ9<7URP#P&OTMD*TQ5()A(U..V%3_)G-T=30X`5ZR`@LHDO(3G.,6VK
MO+[5#9ZK.U.8S4Y7,J_VY%/N8(YTB/A*M(ZG*L&2X9^"]ZO_`!'K/@ZA^LD5
M^9(C2H$R=&B3D)$B0@E*E3)BBR$Z9,G+"40F3D%!`40G(*`$LD@D`"BBPA`6
M`(,8QC]/''(G6/3CCCBE?,>65GD36X,;^U-SVRNR0Y`Z-#NA2N38Y(5`,EJ$
M3@WK2CTBU(>6(0#4ZDDTDP.<X$#.,\@(W*Z),6E.':?:CK44'D8_3+55.OZL
MPN!.QN>YAA4-?3?3JX.K,%@64[0X8<HJ,T84Z8<:2X$:&P5QS989BU_A$V^L
M;AHB<MY&>^AF`_%EB/>MPS`;(.N9*,I.=1_:'9?!-J+0VF,64=P`&W-PN4=W
M:L?Q[:X4;R,Y@%D):*3("6.1>]K77V-6E@5%+W2`V?#W^"S%F'D*^/R-"-"M
M"5XQ`+6I!]S$CHU*<AR)$\-*E<TK@=AHUIX<]^<'YL!MAM7:0VCB&8=<T';I
M.D3X/&QO0/$W2J*K#R_`)PBTE1^!T9E/?`!&DDG#;E^"P$NB!<F\1&:M^Y/2
M&O+7;+K-:F"YWG424)RT]2TMP?W2HBA+P(TS,EBC<$6)`@1DX[G2.(DF8]&`
MQ2XQUE3%B.%UK`]M+#$]$%YIL+TY`!VRMIFX#W&5CWC,>:*7(YD*CRFOF';'
ML2XWL[O;W"Q)C6$KJ<O#&3?VD8X_X5;(#O$1?PKBV#)DK/+%;KE41/,P=.MD
M6_6"06[/!LK+(Y.ZU(3'Z^8I/'S9%%W*9I+5K.8)2Y`G*.)P@2IVB+O"UO>!
MB%\&/R9I5E%FJ2R`"P]QG&<=\9QG&<YQC.,XSCN'.0BQWQWQW"+&0BQ[0BQD
M.>V<9QSO'6BK6B[M@Z:J&0/2B/,=CV"Q15V>$>4X5Z1`N,--4@;1*P&I0.BX
MM/EL:QJ"3R@.*U*,:=1@/H#)1?QV\MG<"ZU&V6,RSA<R6BA(F89`$D,$R(7B
MRD@$$@CG."37T&+6#X84&(/<);V;/EI6XN\[6)LV(52K3!E9N\1@&8%009+Z
MQVYT]K0[84UF)D3CBYYP"U#C;*J]_LIT?6&50M[0S37*9N!4UC"R0HV:;.BM
MV:Y<]/2J)R5`YIW%S,+D;$4K-Z;V3L>/@T\UY1#1-J&Z[TBE<"MC*1;''%49
M66M1<MB].O2K+(>K4M"ZQ4LI9W)V1NYJ1]6G0`LQS0)Q%B$HXNFHRMK[DD:;
M830UM:LL;=*[;8II.75W>;6@QS!6,=529?E7FQ'&$J([9$>((2IYJ:X2IBJY
MF1N13BZNC((D!1G-S.G#$FZ:.4)<=AP)')[M(FKZP5ME3&O2";/;SKE'=BX^
MY2-:U3@2**-QS&^X87A>D5RH@"XI(N9#GE$L&)+%T3!K>ZBFEN;R.X0QWDT$
MZFZD:*T5K>,-)9":((LBQ74J[R5\X(G81JC`=$DDVIOK"XM;>QPJXLI1-A=K
M>6;KAMO'<XI+#?3M'!BQM;DRR6[W&'PRF&VCT7MPB-<22HS=:S#<%@*BU?PN
MOZ\@"52?K91%%VO;R^,R?]UA<QPQ<T.L[@C2H5R@<3Q&!+&-O3H79#$0.S@A
M`:46Y>,P)I>2<3WKJE;<5YS.6S.30]H?+^899$71CH6$38VP]6(LNEXQ:L.<
M?<`-`8&VRO#Z0[JWE6%86L<EK@9*5AZQ(F-,X!4VF=4IX:QO$UD"R>6,^I]$
M9BI@RF*S.+P2*Q3::ZXVR%H06"T25"&P3G.!N9C9)DC<ECJZ-.*@T<=<S%Z!
M:L0?'1:85ZCA]NR%ZDKP[3Y;35\6?4]9QZ%2S,;8&V';#E4G#7=38I+\J"\R
M(#DA<R?W-U;.Y'JFUQ:\J'5>^>A*5>RG`)!)"1=<)5MM\(B[2R3FUGUH9XI,
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MT0<B1`EI1Q49?71DDIC@F.8IFQ1=1CT@.I+NT38:)20$4MV#C1SJZR&.QFSV
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M2"WX/`DJ,D"*O-L5Q6YQBZ%W=Z=Z(HX>]>=QHBS$8SN)IY,U4A?P^^TZWU2O
M)([G[VMJ='QS;V5D;7%Y>7=62WM+.T(5;H[.B]0+`2$+:VH"5"Y>L.%GL4E2
M)SCS,]_"7G&,YQG7I_TY=@]P%2)YCS3B`U,,[LNMN8HE1;(J)+,R6H*A;0`2
M9QG+@#P&@`)N,21X@\O)+C(D9WA)':QU*T`U[T_;"E$"CHG^Q%"+"1]M>6A3
M.4U<L&`QZVE;3@%`111D/,\6<,D<3HB3"\%?":AT4EY5CC^.;78=@^N%"+V^
M&8Y-"XTQ-^D2@,L>7AC4/+S9HH(:IQL?V,,>VJ,5U(APK!V*L;^ZC;>7"$\>
M0VQ*/<9CFF9HK;+/3*[KNS"?IKT39?,O@J?;;*UT#C(Q)UJ.H&!<4&;O2?(0
MG!*FDA2#/30U(=C(`GLS(:MDXBQ&%*'2-JRQDYLGUI5M>4[$&J`U?#F"#0]E
M+R!N8(Z@*0(2AB[>F5'8!XCUK@J$'!BUS7G*G%<=D1RM4<:(0\\^QC&/+&.V
M/FQQSD6+8[B.,RZ[R8[M3G%;1YI;Q?[,>9U-D<C)(7D(X:LL@/J39C8S`-DK
M?=85:#E#J%N,0N-,M]<\V8>?2NB,D`[B!8H`1JW>O-BXXXYIZE5.>,XQGRSC
MO\O\&?DSCYLX^3.//'R<\\<4J'C?3HRZU;DY>IY&$I-&7XN`<J%8T.:R!,4N
M<O#D17[ID)*,1-TCR<9W`HDC6<RS((3/&<\N11!:$5-';O1'9722588+R@IZ
M)A7K1HXM9L<RI>JQF6<9%DH#)*/54P4;L86'TAD8D29FDI&.X@MJA-@*PS9:
M\XC.H#";.BCW!;$B<>F\-D:,;>_1>4M"%\8G9&9V[D+VQQ)4)5`0BP$PH8B_
M2D&@`<G,*.``P,8QC9:PQ/7-$!9WAS.]B4;N5OS\0R#$\<Y$TR$G-BX`6N^=
MC3^D#M;L'R?#<0=]I=FH],8PZ^G;EMA",AEA6(.))(4C4#197"SV84%(4M6=
MIAJM?9[>.6L]]?J>DPK+S9FB;A@0,B.7+==YB\^$L`<^(PPFKIZ\J1"*[9^Y
M2Q2=JQ$9[Y+0S)$2!.V\JYS.$S&N92]P:P(K(83,XTK&@D$4E30M8I`S*P9S
MCT+@UN!)"HC!F,>-,?X!)5A.0J$1ZA,,LX7,<2PB_P`*DT7<)522(YTS>"7+
MWD@`&>7$HX60#B5`(K[ZV'[)&R79#L>6;-XDDTT:*]YA=R%M\6P\MD,KJS+L
MVC40@N;=Y[.1\UBN'8,!S"A9>R5[>M(V!)3%A,;@EQU9-9$<WIC%CB2P1*>Q
M^0O1K>D*S@U4O+;&Y4-&F+S@Q0H"62#.!#QR8I/U!-4)_L15>SMHQUTB\ZKU
MLOZCB(G%ZY=WJLHY!),MF[SKSL77,1+?TN(7,8,IDN&^SH&Q.;;(7QZ6CLF+
MK<2A`9ZQ`X,7@+,'X<CR6689@`?]8>0`$/``]N^>X^WAQVQGSS[,^SDKEL:]
M4O7,.;*BCVL5XVE8[CIU6FSHMH(3.9"<C0OE@,+=*5:M361K6;6A^O\`$U+L
MDKYZ=$RW]T$3R0I4(EZEY,2HA7\+GO(XIA!R?=1R13,L\<LFN=6$D"H(E=@^
M<#:6.B,`LLD@#J#J=O<(V;O;_#'Q=<:Y??V.)83#-A%[A]ER;")8FML7FN9,
M3F@MFMM&*P[Z%#=WLKBVDLK*5K:5ES%9-L*IDL6W:V*^`XFJ9Z<EL)L;623%
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MMI$LD\^)V^*XC?)$^&B8WUW>/#:X>DET>#U;U`XJWDZSMMCO+IDIJ<=OY]>;
M^V5#"Y2NC^PEU32PWRDKW:FA\1IPV(=3JR<GS%JA1;PC9FUP.7%)$)[T0A'C
MOZNNH-K/&+8=I0*S)Y')02?IBJG>RC?JW"G24[5IJ)<9:IO*/2.M0N96:F)M
M\U\ARP,F3*3GI>*NT:^0%_"YZ0@['V%:+U/.R:+GDNE9M45NMJ/20V5)(-`+
M!M>16#:&S5RVE`D!#RB#,RED-;7=JK9S'+IHQ*4[)'#3F9-%84:Z*1%+/HR?
MIK5^D8KDM51;#U"V&`7#/%2&HLPMM>'H_7V-;<)]<P/,:DCY:31,)>[%$KRS
MFZ1`@N("Y+D9C*JL/$G"N(3>Q/CJ*C(MM,(U696>8AA#%;+;-+D;B)D72A);
M2EP\K2F(M"TB&QB,'8BN;JZMKFXQO#);R9\-GBML,B:%L1O\??'(K$.F#WT-
MU*TMW&BVY>[PBVP]</%^D6(VUA<1_B=MH=27BJI6XK7:9J;./H3;>BF^M#JD
M[Q^2FW'M\OV"ATV76E\/Y^"O7((YF0LY"ICACVR.0#S%SFC;L$@4][3OJ&4D
MY2*XDL,V&MAHB5M43L;`(*6BU6@L%3ZZ,TZ45^ZTS1J-1#7,J:V-'89];4FC
M678U:&%QPMZ(?F<@Y4YO@R^J+@Z7U>,Z?9^>0R_VR$Q.`V]L[`*,@MEH&!"Z
MR\[67)1TTC4AD[E9!#X6M5K#CXS7CQ&X?.%,G]4;9+.$4"32$I&DB-F[$P1U
M]`W1F3JI>TC88FZX>5D2>X0HPXOL7:'I[9A,$@&-RP"-/*]='2GGQ9;Y,4V`
MD31V:G-&'&-<WN*V`TS0VT8=8HPT<C@RK"&0/E%=!V#I^$2BJ%,;JL;LCG?8
M#LSV.]L':3#,3QV^>WN+^_D@O;*W*8?/B4EI=2V^N_V?>WAEM+H*(EBN))I9
M8KRTN)K^TMKFWCX@#_4!CT>"NQ8,>A"+`\$]@8QZ+`\8Q@>"O][P+&,8%@/B
MQC&,]N>W',@M<=6+[VSG1=>4'7+U.WT`T^7I>G+]1BD01*!=@NLVEBL(6:,-
MWA[C+]>/$Y.&`Y*9VQT4Y"G%'8HI)I$BB1Y97(5$12SNQ\"JH))ZAZJ[9?W]
MEAEI<8AB5W;6%C:QM-=7EY/';6UO$.=YIYF2.-<R!F[#-B%&9(!Q\SG`0B$+
M(0A`'(AC%G`0`"''<0AB%G`0A#CS$(6<!QCSSG&.2W:'='?9K=,;/-'1$?2%
M"+<E*?W4IFSJ!NLJ0>D#@?[F4*/-0KY*$X&1^@DKJ<SP\/@&8F<GHTO*`=AG
M0KH041KIEBL?8PQIV$N9$(AQ2-:Y`9^XY!W,L032A,,5<2\'3-T1##_HY'-R
M#4P3L!5M,59%!99W)[RRBR0!+*`$L``A````X"$(`8P$`0A#C&`A`'&`A#C&
M`A#C`0XQC&,<G^#[%EM-QBY*C@RV43=\>8Y7$JGO?"#'"2>8[U2"M?'/9,_I
M2Q0\HPCL;Q+-(-<4NU%_`=RAX@MA&'3J#,1P*7>(QK$"&"V$JE)ZPJTYZ?NL
M^C\7RSTO!R0RIQ1%))9:<G$0]V9,?`()@P.\D$F(]0:\G!`:3&8XE98PE&`!
MI+3E3Z129FQ[/9QQSH,,$-O&L,$20Q(,DCC4(BCH"@#,\Y/.3F223G7Q?BF*
MXGC=_<8GB]_=XEB%VYDN+R]GDN+B5N8:I)&9M*C)40$)&@5$544*''''+M:^
MG'''%*<<<<4IS$C;71[6S=B%?69?E>-\B,1$G@C$T;<A9;#@ZD_`NZR'S%*4
M)S:NYF<&J6L[UV/N>0A+>&9P)[E\RWXYD6EW=6%S%>65Q-:74#AX;BWD>&:)
MQ^,DB%64Y9@Y'B"0<P2*L7-K;7L$MK=P0W-M,NB6">-98I%Y\F1P5.1`(S&8
M(!&1`-4$-[^B1M'I@M<+3IT]\O>E6!86^HYI"42I%;5<%MYX%Z-PF$08LY7B
MPS'$`4AG<!$J0I!I0NKBU1(!8<AC3>=SMMI--(O9;_LS=TAG4/9GE@B,P=['
M?G5V86*2)LHI&U-1ZI4<D`@D2;&$\B*$F.P_`*(P\"6C2IA$[1K.,9]N/_EG
M'\&<>>,_IQG&>0==0'H::X;<B?;&J@*#7B_7`:IQ526--`#:]GCH:`1F16'!
M40TA`5ZT_&,J9C$QM,BR:<-6\$2C!8$8N_;)]F&TN6@LMN;&VNF1'MX<>2RA
MF=(IE$<R7UJ(F.[F3-9Y;)0)%"K)9OWTE<2VF[%=U;K-=['7D\"LZ3RX,]U)
M$K/"VN)K2Y+@%XF[Z*.[8E&S9+I3I2J23IM5LL^2%KEKU?-J.TJ9).FFS3(W
M"7."I\03%'"4];)942YFYRK%(2:^2)86%W/-.6BC:8AL&<,@H&,&_:K9EJ@,
M5JMNOZW4=9P9=&7.&0`F<O7UHQ5PA<E23&'K6%C&>-&W*(K*D"-^CIA`,99G
M%,48WX(*QDD7+]K]*-D=*IH"&;`UTOBX7!2H(BTS;AB>ZYG):?&!B/A\S3$E
M-[B?@D0#U#$O+:I2W%F!RZ,*+`@Y%BGSZ"L[?`,1M+:YL;;";RR98Y+2:W@M
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MABQBS+3Q@),Q.<J#3(6'"K`Q+$0H48A>A5$:JHNYPH6%M<("B3(")^_B`&4;
M9LF1.=9%$[?;6IB:P3I]D[R((I7':HRB;,E18*Z#\#CCOABV`N&/4@8CIIT=
MP6=ZR`,>//8`APSGG(C..S&_;_MP+^QSNV+,L7%B2R+2*0L[\_NDC',)K&FD
M<8A;@<VBP><X/;(RJ#&&-(T!.,I$1PD+<B_TGA%DKI%TU=H]\GPK]R2)!9*U
M2K\(Y)=DU+5M=<,F2A!PL3-BHLOU^<R!.$7_`'.Q$I:82=D!;VXL!(_6PW7M
M">D3J[HJF;I0T-&;5O0"3);C=4\;T9SRA-/"'"I/7\?")2T5VV#QC)7=I$JD
MBM/D13Q)G,(L@#SS:[;G8W8UFC2RL+_'8P1%86-O:K+;MON4@WEVL3+9*;@\
MH*>Z7+3%9Q;DG>B=;+[&[5;5!7-U>66#N09+Z\EN#',HB%N1:VS2*UVVXS@#
M#1`(E,+3J`(S73T!^I][GO/X$LK;E2]T%52G!*]'720"<F[Y>DR(`@%N:9:0
MK056V*B_%G)CTE<IH(&,`#'&(1A3@&XA0&MU'ZNP!!65#UQ&ZXAZ+(334+$C
M\*UX7X!@!CS)GM4-0]2A]/#C&%#T_N#BY&!P$KU@)("R@=X8QC&.V/+''/F+
M:K;G:#:^<MB=T4LT?5;X9:ZHK&#+/2=WJ+3R@$^[W#2RC-@C(A"#Z'V:V-P3
M9>$"PMA)=LFF?$;@+)>2Y@:E$FE1#$2![C`L:'(%P[@N7'''(?4JIQQQQ2G'
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ME-8V,,EDJY>K6J'-W$Q#$P'JCAX];CX28^L`H9$R5O(VDNYV@.J^^]?_`+G^
MR58-<L"A*4?6G-FX6&&RJ_6J`BP)Q@LZ0E?#+&/)F0'*VH8UL:>1$E$O[$[)
M0^@S0YZDWU/=M5I/\/V93)3MM#KB@PM<E$CBC&+-M5TS$!$H&.R*\:L*#7AL
M;TV!^MSF`E+VK!*4]Q?XY#4N0AST/#-H<+Q0B.\A@MKR151A,D;13Y$%529U
MS_#`9(92"&R"-(W&LR.:.3@P56/#CED>;PGIY@?74+H]A[X'Z?O<=C@RI34X
MC.$GE+@C-$EUW_[PI!9R(:<]."F_+-;92F$#BF<!RVC*R`&0\ML;<7;"X#W9
M5:^R%SV.I?H8YUR\J)G.W=]/<H`]2QAGCK"U)RLP1GULKIK%HU*SF<H123#^
MPM;B264<E#G.-P1!&`)@!!,+'CN`PL01@'C&<XSD`PYR$6,9QG&<ASG&,XSC
M/GC..>>2CD]OFK;B'4OX+;I,UX*.].G->"(.&7!5',!61D/$.'-PYN;YA\@K
M+]SZ@N]3V^QJ3O>X&Q;U(H:@D#5%7IXM*1.K@P-<L9&R.2AN;SEZA1@*&1LC
M*T('Q*>$\ET^#$*U8`US3%KL<<4;K;@*G-X>U&S]YC>Y!/(5:3X]!L5^(=W:
MS*X9T,>@E@KW1.H)7J)G%F%K;69MD8E/PH8UH$:%Q4+B$Y8`XQ\[*J&F[6OZ
MPF"J*4KV66C9$H.]$R0V%M![P\JRPY['KSP%^!(TLR(/<QRD#VK;6!J)"(YS
M<TA6,CY0;:SC4NT%K&B*<V,42JB!M9S8J`JAN_.9`#=]S\:\TJ..2CAQX`<.
M?Y/#7,YWM5LU:8;**LF_;;GY=RF00=K$RV:.SZ786:N/5*:U*DQ*TPPM:F@*
MA:M/B"$D"9"PG+%9B!*4-2=D>4V@72HV^ZC$A+!24)"PU8C791RB_;`+7LM4
M,(B3`!6HFEQ*3&+[!DJ8(L8S%X20XJ$YHBPOSC'4P\K06;.FS]3`0Z(88K:Z
MB;BVV+)\!(<4&M4/=#QULQ'_`'!Q1-GS-`8E6V0M(SGPJXQ'1-4%"<`:9>X3
M9"+OFW7&(M&H3'V>*0^/LL5B\>;T[2PQR.-2!C861K2`P4E;6AG:TZ5N;$"8
ML(2R$:),0G*`'&`%X[<AV)[66UJ'M\(BCD?F:XT!;=2JJ@,:+I,S*JA58Z8U
M"(%WJ<!C27"KFL8!/OLN]'`#AXR!P\0R'.*B0Z<71*U!Z>"9LE[,R9N?8<M-
MX7"^[(:VY0^M1YQ0"U::L8V#"IFJ]I-P$9?C9C%TL6)SC4[W+G8D02BYC,8P
M'&,8QVQCY/\`;^7.?ESY\\\<@%S=7%W*T]S,\TK<[R-F<O`JCF51X%4!5Y@`
M*PV8L<V))/A-....6*\IQQQQ2G'''%*<<<<4ISQG&,^W_P#/C].,X\\9_3CG
MGCBE16[F]**B-H?A::1`I/35S*PFJ1S"--A0XU*E_;(\9GL/3C1I',]2/Q!.
MD;08UR7`C,'+%;N42!".K3L7J?L%I[,4K9:D6<8\'#F$</L:.*E2N&R)6@."
MJ1KHK+D@$HTKN0,HE<4U.`&>4MI@"U`FTK`"U(K]'.*36#0VR(R[0R?1ABF,
M4?4PDCQ'I(V)'=H<"!8\@J4*THTD0RA8":G/"$*A,<`L].:4<6`89?@>V&(8
M4$M[C._L1DNYE8F6).;*"5LR%`YHI-4>0TIN\RU<MVP[%>![2F6^L0N#8RQ,
MG*K9`+:YESU9WELND%V;,FY@,<^HZY-_I"509==HMDWR5L,Y>[YMIXF,6;'1
MECDD=)N]+W1E:7PCU5];4`U2@U.6D?$_A)>BAIS/A<!9/PEE4).0(KY3CL->
M[N]-\D=+@L-QD+2_D2MM?%LE6*'9'*$T4)@A$C*7F9RI$]E0M.GBH7,XPU7E
MA(*;AFC)+#C$Y6Y71$7-V'2?:>KS7%'CUA:MI*5NN!+R`8SZ3)5>3%S-QZZ$
M(<Y"1'9DJ"H\(,!22DX8BD/*]\EC,DAC^ZQ67L#U%9.Q*AH7N.R)L6,SVT+`
M9S@2=Q;%Y)"M*9GMD1>3"L`.!V-(&:4((\]3PF^P/%XA+8):EDC,;P-!%'<0
M1L26C>+3F(RS-Q35"[%M+,2U?-FTV#;8;+W1M\:EQ%5EF$T-XEY<SV5Y+&$"
MSQ7&O)YT1(\A*$NHE5`Z(`HKL='L/?3?#H]7B&Y;*2P.)*V)?%H:5+73ZVH\
MMBSZFD\95L[0,T:5"?'9$C2O+(82#&6Q<06-'@DO`BQ>$^PU\HX@ZP!)<MF)
MH.^KWMT>(BGF#N3'G)RDCJ%]?URIL`?A.)4[O@?AI::`)>1N^1N9?HEQAIX^
MG>.;;D=IQ_P6WXR;T^X1<9<\]X>]XR9DG7^%F>>HS]T\2&0&(7PTP\F7*[N!
ME;Y`;@92<(<E`W0]SR`&G(5WZX[5;+.[PU2!TOFU'%[8@20ME=5DM6GKVLJ8
MH$S9+B41XL>(DB4(420F0)\8R0[C3%*UQ9RX/K7/GE;*[#DEU^27>-J8)JC(
MLUD4*:O)I<$$)H/C_I(R`Y08!O-`PJ5#&0=X33DK.><V)3"$1@R,]*``,TPL
MHH`S33C2R"2B@#-.//.'@LD@@HL(C3CSC!!+)(*`,TXP02R@#&+`<S2Z:=&N
MW;K^"9UL&8[TI6*CT*Q/&LD%E6W*D>1A$'`&M>0<E@3>J+P/PKY$G52`0!%C
M3QD@!I:X&OQ";!<)M]_>I9P1A66--Q$9),PX:.&)4+N6$KA@HT@2N7(5V)WN
M!V>UNTM[R/")<5O)V9'FEY9<"&#28BD]U<O*(X@AMX2CR/K+01"(,\<:B*:I
M*:M.^IHC@%10E]GDM7B`:)`S)L#(;DQQN`"=9`[*!$M4=9BS!]SW9[6(D0?,
M)9IIV0DBLQZ:=%BN*SRTS[:!2U6W.R!)UZ*O46#QU5&E(.QI8'8M44G66(X)
MQX!X\NJ=#%0CP,O$?<_`4O%+E2&OM/ZY0Q/`Z<@S+"H^7DLU;AO)$:Z/JXL&
M09=9*^*A'.\B=C,"%XG!W5JC@!%Z%/DA.$LD'<O.7XYMM?8AKM\/UV%F<U+*
MV5W,O]N13E"I'.D1SRS#2NI(KZ,V.[$&#X'NK['#%C6*+I=8W0G#+5QQ]R@D
M`-VZG/*:Y4)P5DMHG76?S(T21N2ID*!*G1(D:<E(C2)"2DR5*E3EA*3IDR<D
M!9*=.04`)9)!(`%%`"$``!#C&.?IXXY!^?GKL(``````&0`X``<P`\`%....
M*]IQQQQ2G'''%*<<<<4I[?;S"_<#036?=Z,`9+N@I*F0MJ0]+%;+C9A3%94-
MR<+TG9BDY2<X9[=DW_2GQU^2O,96#^[5-!AN`&AS0XY:FAAN(WAGB2:)QD\<
MBAT8<_%6!'`\0><$`C(@&L_#,4Q+!;ZWQ/"+Z[PW$+1Q);7EE/);7$+\Q*2Q
M,K`,"5=<RKH61PRL0=?]OET<-F-+Q.\V84BB]*&1>G6"LJ%LZ@#]$&X`AB#F
MS80G&N7,!:<L/<^4LAKQ$,AQ@]>MCYAH&\$=HMC;^.JA-1N;OM0RE$XB#D=6
M@GD@S`"@D+_A=*6F8"UV$06\AU[.J1M+_P#T2G<\!<DZ,M8`!X=H@86`T(@&
M!",`PB`((L8S@018["#G&>^,A%C.<"QGR%C.<9QG&<XY`YOOT)Z%V4R]6+KV
M-HUYNI7Z=<J2MK:(-/SIS,R,TPR41)L*]+%71:9D.#Y1"22>X\C5N\9D"@8C
M,0'%=CY8MY/@LKJ'5EDLFE969#Q9(IBPUHV0SBG/'+^L;@H^QNQY_28P_$>0
M81V4\/M)9+:>&6RVHAL(IXH;J/O8KO$,.6)S:W,>IB,1PJ,%=0'(HEWDYIXR
MG;3:"<`)+F6P-M2D*=!+6I/\/3!>Y"(;9[&,PN<HBC%'B,`1,XH(3#*PA'@4
MA0#,^%A*E)@U(O:&[;[25V>N4P'8>Y(8>YLL(CCD9&9Z]L_K[!6K2!@KYG5E
MI%!91Z"&,)8&./$C!GU%FP)K\1B$PQ./SLGJG?NH\Z'7M^UT\0=Y-&?EC=#`
M_",0F*,C./$YPJ7(P999(B\&0C.*2G%NS=G.27EK;%(!D!QXY!99KZ&9EFEN
MXIXVR8223)*C:=.3:F#@Z#EQYU.7,:^N+##=D<4PR";#,.V<O\'O(5>W>SL<
M,N,/N(#*)U,9AB>WDC$ZB7(9A9UUD"1<QWG#-G=CJY<$CM7U[6Q!W1!"&FM$
M3A%)L\L2M+7S`ZKGUBAA!S>>2($>97IT<G9I0X[_``<X.*Y2C,)&K/\`'^A7
MM1LJOB#S7Z^^;66P:1&OQS[$5<P<5#`[&RB3"FC^-<WFB$4=\)S`PV5&`QX2
MTLA/4O#<!$N5*3C>A./]OY/;RV+JY"Z1<3A<BND32!=+9:ER#99-D-0YFR&8
M.59SX#@4DHGDP3"))Q)%*)GPRR>;>P:MS+O&@+[R'6^Z?5JCUMH(U'/(EWV[
MVI?VZQVA[V-NET:K@+)+M5N5V%(!([#`0QHXP#$L(`K`!TR9&VY!'U@Q8+,<
MV5&F;'4:Y(4$K'5\CE5C7!+D"^4/4LLF=.R:.1%J.6Y7264.J9C;DL?BD:;$
MR4D]Q<<MS6E2-+*U(4QZ@*4@E,G*'X,<S?T>Z7^SV]3BC=(''@0:G\*Q$.]X
M3I&M2PP`"#,@6)H>B*P2Z6(]%9`,K"./9+94JK`2'V2LF1!R*Y_H[TMM7]&&
M]*ZP>.CG%OFH/5'R[)T0D7S-3D\L(5R2,)RP?!<"85`\#QAIC))*I0GR64^/
M#X<7ZT*0X5@&*XR%DFEFALB0QGN7D?>#-FS@B=LY3F[,')6/-G.LN64\5[('
M9B['78O::SPZPPW%-J(D:%<(P2"SMN1MNX(=WBN(00M'8((K6VC:U59[W=V]
MJAM$@2*6.O?H;]3\V7:.&BR-S5SO3\%-PG7H*=85*8%KR1*8`)P`3!W!ZVAK
M5`<`0,'-:0#K-A@$82IS$%I6,YMLTQ1=1:\P1KK2E:^C-<0EHQD25BC+<6C)
M.4B"`)SDYJA9-<'MY58``2Y[>E:]W7&8\:I::+MV[8QC&,=L8QC'S8\L<<Z7
MAF"V&$QZ;6+W1AE)<29//)S9@OD`JD@'=QA$S`)4MQ/PCM[V4=L.R+=[[:#$
M2+&.0R6>"V6NWPFRYP#';:W,\X4E>5W<EQ=9,4$JQY1JXXXYM:YY3CCCBE..
M..*4XY0(^V$>I3^.%,>Y5M_:+C[81ZE/XX4Q[E6W]HN=C[AVV?PN"^FW'1^A
M=/JZ\N4]V+93X'%_1+?H_3.GU=>5_?CE`C[81ZE/XX4Q[E6W]HN/MA'J4_CA
M3'N5;?VBX[AVV?PN"^FW'1^A=/JZ\G=BV4^!Q?T2WZ/TSI]77E?WXY0(^V$>
MI3^.%,>Y5M_:+C[81ZE/XX4Q[E6W]HN.X=MG\+@OIMQT?H73ZNO)W8ME/@<7
M]$M^C],Z?5UY7]^.4"/MA'J4_CA3'N5;?VBX^V$>I3^.%,>Y5M_:+CN';9_"
MX+Z;<='Z%T^KKR=V+93X'%_1+?H_3.GU=>5[>SZJK>Z82^5Q;$(C%A062)A)
M7J+2UG1O3.N!D.<%FC2+"S,$K4HL^F0N*41#BW*0EJD"I,I*+-#4KW_^IV)-
M%?ANS]$7!7,(^`)[BOU[E[N`<O;"PY$:<364X=CR4\H3%`R+"6+354D?PE$^
MC12R0+#D[=C!S[81ZE/XX4Q[E6W]HN9;:&=;'?._]RM<*5LB454L@EEV6BB\
MJ2L]4(&9T4-![*^+C"T+J6^*#$"C*A`GSA0`@W.`8&#P9\??&_P78KLF[!QW
MF*X?B.$K9VMO->WV'O>7,]G=Q6L)FD#VS6J#?&-"J2Q/!./P%F12PK1XMM=V
M/=M'M<.OK#%#=W,T-I9WR6UM#=6TMS*D4>FX%RYW0DD!:*1)8CEJ,3,.%>V)
M4#=\ZMG]P>(U)8;Y=`')0TJJN315U3S=K6HQA`NP_,;B0B41Q&W^()CB[2'+
M6SMQ&0JEK@G2B"<*UUH#]3LQ.)?`MG;UN#?/9(7E*XM]!15Q.,KYF.Q@)P2+
M&DZ;"99/UI(\A`JCS&)LA@#"C4RY;,D)N!<L[)HO&DCZOEZ6/,::5/3>V-3O
M)$[0WDO[HUMQIIC<VN+R6G"YKF]O,5*3$")6J.2HQJ#AIRBQ&#R*C'9W7SZC
M$6LRR8NT2ZG@-,9L:?1MJ+44VW*%!;7'IB]LK86>HS(094'@0(4X3C\@!DXW
M`S<A#D?;&PBVRVX[)L-UAVRJ6.SL=G;VQQ*5KV;EEP]SO%*VUTEJ6MH-43\(
MT2<#2#<LK,@PI-E-C^Q[):W^TK7F.O=SS_<^%+2+DL*VYB;5<V[W(6>8+*G&
M1V@)SR@!57J]+'8W'XBR-4:BK&T1N.L:$AL96%@;43.RM#<E!@M,@:VIN)3(
M&]$0`(0$I4A!)!8<8P$&.?:Y0(^V$>I3^.%,>Y5M_:+C[81ZE/XX4Q[E6W]H
MN1$]@_;1B6:?!F9B2S&^N222022399DDDDD\2>?PY2A>S!LDJJJP8LJJ`JJ+
M2W`4````<LR``X`>`#P<<K^_'*!'VPCU*?QPICW*MO[1<?;"/4I_'"F/<JV_
MM%SSN';9_"X+Z;<='Z%T^KKR][L6RGP.+^B6_1^F=/JZ\K^_'*!'VPCU*?QP
MICW*MO[1<?;"/4I_'"F/<JV_M%QW#ML_A<%]-N.C]"Z?5UY.[%LI\#B_HEOT
M?IG3ZNO*_OQR@1]L(]2G\<*8]RK;^T7'VPCU*?QPICW*MO[1<=P[;/X7!?3;
MCH_0NGU=>3NQ;*?`XOZ);]'Z9T^KKRO[\<I1:7=<#?R[=N=:Z?GLIJA5";-N
M>#PJ5IFJI4#2YGL#ZY>K.)2!S+?CQMZL97D2K`2:(D7W6`"]F9+/J@WJ2;1]
M.Z)ZK.^LSU!F9;;$LM5HF(IM!$LW*4(HG'(BYLP6XI2Z-F&TPM4\+1*30".R
MI+$47D(,%8%F'X]L)C>SN*6&$7[V+7>(V[W-N;>>22(1HTJL)'>"-E;.)L@$
M8$99D$D":;+[3X=M;!/<86MRD=O.+>07<:1-O-TLW>B.68%=#CB2#GPRJQCQ
MS6S?;,G58_'>AO<$U_M7Q]LR=5C\=Z&]P37^U?+':;B_OK/STGU/3_'Q&I7R
M63QI\I^;VR/1GLF>.:V;[9DZK'X[T-[@FO\`:OC[9DZK'X[T-[@FO]J^.TW%
M_?6?GI/J>G^/B-.2R>-/E/S>V1Z,]DSQS6S?;,G58_'>AO<$U_M7Q]LR=5C\
M=Z&]P37^U?':;B_OK/STGU/3_'Q&G)9/&GRGYO;(]&>R9YXR'`O;CV>S/GC.
M/TXSCMG&?TXSCFMG^V9.JQ^.]#>X)K_:OC[9DZK'X[T-[@FO]J^.TW%_?6?G
MI/J>G^/B-.2R>-/E/S>V1Z,[1_4K^I[M6=VA2*T*=`W:R;)./IW!1+HDQE#K
M.PW80<F9%9]<MXD"03DX&X\*N=0\QEE63CS%[X5+_1`;QT.MT=!-I]`IYF#;
M+UHNB:=:J/(B5B-1IC[5%@D$_=X4PN>DIDS:M4Y)$6>IC;L6S3!K"8$+K'4>
M/",<FWVS)U6/QWH;W!-?[5\X[)OJC;J6S1O(:9@Y:S2IK2NK6^IFZ2:T1A]0
M)WMD5%KF9X(1NLA5IB71I6E%+&QP+*"L0*BBU"0XDX`1XDN%6NTN'!8I6M+R
MU`R6.6XE$D8```BF-NQ"C@-#AU`!"A.)J_&LZ<"59?$6.8YN`.7J/#AU9\TZ
M;'U/-M/N@)@LV\BGG5S71:)(X$N\G9,@N2Q6<X(5`15[7[P27];K6X)\APFF
M]A)TB+T9Y*YCB<M2"]*&^#IOH3JUH;7H:\UMJ]IAY"LM/F53!9V>[&GZY.''
M9SG<Z7EY?)"HP/QF)4!AR=A:,&#3,+,U(\`3!H69^J9>JQG.<YG%#9SG/?.<
MT&UYSG/;&.^<_77WSGMC&.^?DQCC[9DZK'X[T-[@FO\`:OF'BF%;38JQ$TUG
M';YYK;132K$,N8O[CJE<<.^<D`YE%09@421SR'BRA?>@G+P<_#B>D^(Y9<,]
MDSQS6S?;,G58_'>AO<$U_M7Q]LR=5C\=Z&]P37^U?--VFXO[ZS\])]3T_P`?
M$:M\ED\:?*?F]LCT9[)GCFMF^V9.JQ^.]#>X)K_:OC[9DZK'X[T-[@FO]J^.
MTW%_?6?GI/J>G^/B-.2R>-/E/S>V1Z,]DSQS6S?;,G58_'>AO<$U_M7Q]LR=
M5C\=Z&]P37^U?':;B_OK/STGU/3_`!\1IR63QI\I^;VR/1GLF>.:V;[9DZK'
MX[T-[@FO]J^/MF3JL?CO0WN":_VKX[3<7]]9^>D^IZ?X^(TY+)XT^4_-[9'H
MSV3/'*SNK_4^VRM/HSO>ZLO?8"?>Z"^7F`)W-NK](W17$<16BRQ4@D44"['$
M#689UR@L:W*[`AJ,@49*QD'@SAO\=+O?^-%6^ZM!]-\ILMC\6OUN&@:S`M;J
M6SEWDSJ=]"J,Y7*%LTRD7)CD3QX#*N<[4]D7`-D,23"L5CQ%[E[6.[!M+>&6
M+=2RRQ*"\ES"VL-"Y(T9`:3J.9RN5<<IJ_'2[W_C15ONK0?3?'QTN]_XT5;[
MJT'TWS-[0,=]_8>D2?9ZC?=OV.^!QKT.VZ/T[I]77E<JXY35^.EWO_&BK?=6
M@^F^/CI=[_QHJWW5H/IOCM`QWW]AZ1)]GIW;]CO@<:]#MNC].Z?5UY7*N.4U
M?CI=[_QHJWW5H/IOCXZ7>_\`&BK?=6@^F^.T#'??V'I$GV>G=OV.^!QKT.VZ
M/T[I]77E<J]OMYB-M/I%K_MXP9;[3B99<G1I!IH[9,<]7:9_&NXLC++0OGJY
MV'%LP9D0C8^_)W1B.](:/U$I0(*@%8[XZ7>_\:*M]U:#Z;X^.EWO_&BK?=6@
M^F^7K?8C:2UE2>VN+2":,YI)%=3(ZGH*P`Y$<&!S##,$$$BL2^[,&P.)VLME
MB&'XG>6DZZ9;>XP^TEB<<""5>](#*>^1ADR,`RE6&8X/N-TP-@M31NDI3H3+
M8II*88:79$2;3O7&%#DS(2<V!%"AJUT:&#&08/>D1KK%<B$$9KJW&&!1@Z1U
M6TCO_;]\`DJN+^@B"58!+(+0DF3VV`,'W0?3EX=`$FG2)V*`+`\,$:)<7#OD
M&%PFQ./UL&49G6AWK-`,LV2U4868`99@!U0WC`,LP.0&`&$3UD(@##G(1A%C
M(1!SG`L9QGMSYS-UBMUHXUHF2/N5-,;,W%B);VEGIMF:VQ"4,P1HRD:!"ZD)
M$I8S1C,$`@DL(C!B'G&1"SG,YC;:];(PO#A$EZ,E2\-Q*J:<N+/;+;!6E\15
MTBS.9BR!5N-SIV+I,72ZAN=I[?""2\N%+96KRZ\U*Q0W\F(&1+8@D,LD4MP`
M"%N`6U16&]-^F)0&I1;=*/4<6A<A!7B46=+4*?)C0H,QCTQ<$COC5-T/2XQC
M!85I1B^2GE^,"Q_-*'ZN"2+&,8\L?[?IS\^?GSGSSRFM\=+O?^-%6^ZM!]-\
M?'2[W_C15ONK0?3?(5>;&[3W\[7%Y=6EQ,_.\EU(<ASA446X5$&?>HBJB_BJ
M*Z]A798['F"6<=AA6&8G8VD?X,4%A;+J8A09)7-\9)I6`&N:9WE?+-W)SRN5
M<<IJ_'2[W_C15ONK0?3?'QTN]_XT5;[JT'TWS%[0,=]_8>D2?9ZV/=OV.^!Q
MKT.VZ/T[I]77E<JXY35^.EWO_&BK?=6@^F^/CI=[_P`:*M]U:#Z;X[0,=]_8
M>D2?9Z=V_8[X'&O0[;H_3NGU=>5RKCE-7XZ7>_\`&BK?=6@^F^/CI=[_`,:*
MM]U:#Z;X[0,=]_8>D2?9Z=V_8[X'&O0[;H_3NGU=>5RKCE-7XZ7>_P#&BK?=
M6@^F^30=*'<Z]-MXO?CI<[G%W%97SO"T<;%'(L1&BR27MCD:]PPM+)6K,+1#
M4MJ7)0A9*R4`(P8P+TF<XP,2V1Q7"K.6^NFM##"8PXBF=WSED6)<E,*`]\XS
MS89#,\>:MWL]V4-F]IL6ML&PZ+$UN[L3&(W-M!'"-Q!)</K=+J5AWD;A<D.;
M9`Y9DB8KCE#11U^.HZ4H4E!E].8"4I4E`QFF6W.<`*4&%@QG/UPX[YP$.,9S
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M[OUQTC4VP,%=:TN>`1FQX.\A[K8]*&XM>D"I"`8"'%`=W+7,[PDP8,2![9U2
M!W;S!9-1+2!_=<J6;Z?4_%B5N)YLG2Q8Z6M"`"/7+:5?EA([0CB;`!G&%PI_
M4C3(K%;T_A$$AG=!-LT"7DHE.IEJL7,5/C_.H]^-].>YAM_:'C/7[ZCN<=LR
M^F\X^;-,-N<?\X>:K$\=V8Q:/3=6][O`,H[B.")9X^A7WQU+F2=#ADS.>G/(
MCH6P78D[/G8ZO!/L_C6R_(9)`]Y@M[BN(7&$7OX(9I;7[FH89RH"B[M)+>Z"
MKHWQC)1HMZOH"[+HL\%+U?5TUE]IX7&MZ^$(6):D>H\<F483+CI>4Z%H"86@
M;3L^%T<I8<S(6_MG"H\`_"`5L;0GZGYKFM?@6S-SUC1;T[*]`X(:<9S#SJAC
M2C&,&E%RI6:4C<+-=$AGH\FI#BFR$`/+,),:9,G]&N'#,AZZ^_K8\/D@;G*@
MT#])O4/KC>D5"1Y*[/WP62),V?#3DG>2UKK\')Q"(0_"!ZCU0D0BD_HR\Y#S
M[?Q_G4>_&^G/<PV_M#S387-LQ8R;ZY%[?RJQ,8DM8D@0`]Z3#RAP\F7.79D!
M_!0$!CT_;_"^S[M;:+AF`OLKLA82P(E^]CM!B%QBMW(R+OT3$A@EL]G:%RP2
M.TBBN60$373QR-"+X+4TM;$VH&=E;D+0TM:0AO;&ML2)T#<W($I824J%`A2%
MDI4:-,2`!2=*F**((+`$LHL(0XQCZ'*%WQ_G4>_&^G/<PV_M#Q\?YU'OQOIS
MW,-O[0\EW;M@PYDO?,1_7U\W'^BKV3V)9KK98LQ)).+7I)).9))PHDDDDD\Y
M.?Z[Z/'*%WQ_G4>_&^G/<PV_M#Q\?YU'OQOISW,-O[0\=NV#^\O?,1_7T^]4
M[)OQG97]ZWO\J]LCT9WT>.4+OC_.H]^-].>YAM_:'CX_SJ/?C?3GN8;?VAX[
M=L']Y>^8C^OI]ZIV3?C.RO[UO?Y5[9'HSOH\<H7?'^=1[\;Z<]S#;^T/'Q_G
M4>_&^G/<PV_M#QV[8/[R]\Q']?3[U3LF_&=E?WK>_P`J]LCT9WT>.4WM&^M#
MO5>VU=25/8<FJY9#)@IFY3VF:*K0L[B:!BJ^<RIO]6<BWM0-+D#PPMQAV0DC
M],G`<FSX<'9&%S<8?C5GB<+3VPF")*T)WJ*K:U6-SD`[#+3(O'//,'AS9\RV
MS[%>TVPN*6^$8U)A;W5S818C&;&ZFGA%O-<75L@9Y+6!A()+28LH0@+I(8EL
MA5PY]R,1URE\DCT39LMV'B4/C1'&CX7=VU@:\NKXX)VMM`XOCRI1-#.C-7*B
M"CW-U6)&U"`>5"U4G3`,-!\/GWXHFB2R3QU)/E[^UP54^-:>9N45;$3S*$44
M-6D@D*B-M+DXL[<XOX&G*O#.D7NK<A,<<I_6UA*<)F<_IG*S+%(RYZEC=ERC
M:4Z@I(RB0J\AS'"-65G_``5()!K\P8@K21JV6EG56S=8AD6`.<C!EC&7.[*0
MH[X@@5W#:>K-^TFV(W2U*W=X8!QGMDUJVMSDI:SY`Y2>H5*-%8QC='&U<N>E
MT6C*Y>C0'3I,B,A;BM/PG9WUP&6=Z/H]0T.Z/)>%;0[I!'+3VTD*MJ<4@CG-
M*,!2IL)PI2E>E<TIII12IN+\2U,::46>06,TL(IM;3ZGE06):49O^/QVZ:SM
M>NM>=L=4H$6T//UQ(DM8RZM)1%M49_\`7.\30QZ8[9BCW(!#N58W$'(W08$L
MK8U+DZMA2)1^EYZGE2VI+(.;?X;VLN`02_M-KT;(R\HXX_B&KH#6"1P^W6I.
M2[2L"5`;<^QAT>EDB68-.Q)XT-WDDCQ\/E)V,^#VV/[6+#"]YLN7D%M/-=K!
M,T+QS)=O#':6T&5VEPQ@,-PLQO425=Z=,14()=<8-LV9I5M=H0B&>&&V,T2R
MH\36R2O=3S!K5X%$^]@:+DCM$=V,Y03)4:]@Z5;-U79LLIR?5:OCUCPBGG&^
MY)&CGN-+3D=4-+4%Y<9.E6MKNK;G8Q(CR,HQA:E:N0Y<R%3.%K$Z)3T@..UE
MJI?MP1*<3JOZ_P`N<2K=T&QS9Z>Y?7T$(8WP#`OE(V,2:PI;$W!R>P1YL7N@
MF=F1N+E@A,,'JOK&0$"E=*ZIM)3N606V)C#[LHBX6>F]SJ)>YE2<@#:DB:X_
ML<O1SF`3R(S6U)9&Y`9+8!9;]8Z\IC</@]IC3"\-R.'N:<LA*D:_*KJ<T$O>
M;H6/!>Q4HBLH$QE*:WF-?:VRN,;:F,NK3%K^?*-DWIZ1*)I6$WDTI8B+!E+O
M73_-D:U&!O2(6Y%*T1[ZKQ!CVW`@$;;-PK>);1-*[+.\`N8[XVT\<4<%Q-'*
M+NW`N+1EQ$I:F16O)#;K)<)DG!MD3*77'I6M6G=8E#1+-N)+);B&25YH(G0V
MUP6@N0;+7<:&%LBS-'"T:2'1/;5>TUD^@I9X1,]PC2EU^X/DHKJ-)W(URAR^
MPF8A\^N.9M)D"42.#MB^5Q5/8A<3/E3&F$LCA;G@9(3/:8Z'[>P$V6XD]#S!
M,C@=9_NPS1^:E<7E,1BU<"2JUR62/<VB4A?8<A^$T*%4O8V0Q]S)9`WEX<6)
ME<4!I2D>9UR;R:RWA0^O-*S6)VZY,L=FNH:NW&@^(ULFS&H/KW6BJK+.216P
MT$G^OK8)^MQC7*%$7-NS#7^Y(B\3!%%Z!$;Z/&-3+N`0JNG<&SY<1)4[)L11
MNR-6P^'1H10&*)F6+'440IEC.8A.B!H00^LH<TLL11>HDK5$?8FE*D8T*@K'
MH^9UKB6V4\<DLV'6-L8EN"UN]C=%Y62Y@6W2&;[J`,S6[W2S$V^[$ULD\$DU
MK=1,N'<V&RT+QQQ7UW.)6A`G2[M]$8:WE:9I8ON><E6<6[1>[AS%.\,R0W-M
M*IP/SCMG.,^W'EGD@W2B_P#&1:9?\=C;_P`V91R/H6>XLYQ\N<Y_ESR07I1?
M^,BTR_X[&W_FS*.;W:?_`#:VA_W'BW_(7%:C9_\`R_@7^^<+_P">MZV4F/\`
M>2__`,#_`.('-5+>'_?MNG_CDMK_`*1I/S:M8_WDO_\``_\`B!S52WA_W[;I
M_P".2VO^D:3\X'_1_P#\;VF_[OAG_J7E=L[-G^*;._\`U<1__2QK@#.UJ7QW
M:61$8A*6O+HW-",US<430VEK'1:0@2"<'9R.3-S4API4%>MN3@I3H$"?TBM:
MH(3$FF@[[MK4O8:BF]4Y6S6CI"BT]H3>GBDC@X,JMW=)Q7#6WO4W*C[*TN+@
MZ2*+QYM=FI0LG[*E6P4T3BC(1R%2>8(L'0[(G8E;RT))2N<VR,*G1O325R9&
MU*\O3?'E"LDE[6L[.N7-B)U=DS6-4<V-JUR0(UJX!"=6L3)C#3@3?S_J<T3-
M+7IBYF:+7;`Y3K96FQFLU2IT:Y/)#'&@Y30DO@.ODVD3V[3D:IFO2,S]\3N5
MEJFA.H:G5C4%.2%V='6,-:$_NF-XAC=E=V2X7APQ"U>WQ"2]&Z?4DT-N9,/A
M2=9@$Y;<`V\C"UN>3J1-(H0C/C.$V6$W=M='$+\V5PL]C':G6A5XI9PE]*\+
M1$OR2`[Y%-Q;[XYQ(S,#I@Z6M;JVE#.<&IV0%%J3T0AKFIQ1APO2D@4*6_&5
M24G&7%.084<<W8SE<44<28-.$!Q8A9-3G2?9^M;)_<AG-5KX[8F:8>=@P1Q8
M^1DPTVI(]&'J7O<H)7)7@]N./;&..O1BN.EJQ24MQ;SF3X)R[Y+1CD-=^I;6
M=P$P:+[)K[\LVOH]->G;/7ID=B&*3FKI!K+5,T9MEUR-.\2](3EWOFQ7*-J%
MKZH5`7S"/A<7&6FH%J!`UG<Z-ZKM*6//*SN2=5[;=*VU"$F[L(4R6FG_`/=.
M>2(1MA$'EV8Y+&I79TJCSD@E]>W3(WY^88F(A-#HK'7$1,76$E%$LJ?2W&/;
M7J8]SLP%"6]VURV]>Z3?O8I<X8(6!LYY!RI9K.^CCLYC&S12+*B@"7;0X-LP
M5?>[0EBT]JL`W2V\FY6\,&(&52+F!&Y,\=W9N]U$'5)(S&[$F.*ZD=,]EMC$
MCJKIJLA2_#(_#B[HA4S:M8:^IGXIK+>SFT,9G\TBDE5&)VDT*Y2>B:%*1*2`
M_"A048E5`)^8CU%V<7DU6H3T;8F";QD#Y&:@&K9<-N+&<(VTI']]71;X34(O
M7HHV,2TI[43X?H($)G+6.I$F.;V]P4I<M+JW-J:9S?8>S8F@M-_MB6ZPT;J[
M5%TV2V1)/9;P0S(6F*[&WC9B]A>E^6*TK7KMH/@;>8PKI$J%'I*^DO+Z6K4'
MGJ/A:X[GQ2HXAJW&90.PE8Z=V3OJ?SDUO8XG.&]?2UST/`:9/@C+'9^\89)`
MD4I6&1M\F@SD&-LJJ).8D3)(FMU7%K&S*;$MK6MY;J/#;0'0@AL9;:Z%PLK8
M-/>OJN%O`)X%Q!K.R$G([24NMU$ULC".08PL-FUGCMGO[E@'?>WD<]ON7C&*
M06BE8&M<X939"ZNRG*KF(*;9Q.R[R,]0MN@.WSK*)[#B*95HWVLDT+730+[/
M*GC#,W(+'0NCG`7%ME<EG[3$94W3)N9'A;&W"(/S^C=D[:M&F.$).8$.'HP"
M`(0!X["`(8!8[XSV$`60"QW#G(<]A!SCOC.<9[=\9SC.,\GR8^J%KFU3=:!#
M'K>A],0V(:]0J-U!`J1UH+K6_H-2D8LQMD%96C7TV6RU92,5FSE9KTV-BZN[
M#FQS'"5"XI^;9),3B7X,":LXE0J5'ITA+>G/5*CT[>G&88G;TYZ@TY.WIS#>
MQIB=`2,M&G,-Q@TPD@`S,8&(6,9FSN(;0WTEX,<PZ&PCC@PZ2T,44\;.\]N6
MO%FWTTJZTE"LL4)<6R2"WGGEN(W(QL<LL$M$MCA%_+>.\M\ER)7A=52*95M6
MBW42$*\98,\NDS.AEBB2%T!S5Z:?_C"=*_\`[R=8?_UK')KOJO'_`+@-#/\`
MV_OG_F97O(4>FG_XPG2O_P"\G6'_`/6L<FN^J\?^X#0S_P!O[Y_YF5[SCG97
M_P`^]E?]U7'_`*M[7=>P9_DK%O\`>W_^""J1G'''-57>J<Y!$HPZS:5QB%L.
M6L+[+Y$R19DR]O;5&V?+S(7),T-1;I(7Y6@9&)"<X+$Q*AW>%R)K;P&94KU:
M9*6:<#C_`#DD.2PM=+HNBLAQDC/7:R0LZ6>NL.:4#]+F^&'KR"Y.IBK*Z.C&
MV.<D`RB6X8T;B\M:`QS$ERL6D)@FBSXQ(5B.<*2.]+<0#EWH(+?[(()Y@033
MV\==X7#I_LC0#4@=KCJQZ@8':R+5J=I:W58SJ),[S"DE"1':(VF+-3@X/SE$
M8HM7I$)]AHT)T$<UAN2&.0N>2%(B<?U+&^(L@PM8GU%DQP&T%X6LCJBR:\%A
M)&8SE^MHR/&\%@4IC#&D/=Q*+4IQF)@@/*$.?RTNK70EF[%TAM4WPV]JTLRB
M*@VVU<BK4TO!<P0&4=**4LZ!Z?SXF32*>&.[1=\2DLZ(,O(](4)I>PDDS%B<
M7-Y9T[:M_4FZN]1V>XULW[4J=D;C@5?3/II6U];#VGC,L`ZVAJ#15CLVPKEZ
M.0S0A,2IV#O-U@3L^RA1E0ZS2(HGETEY"=S;VQB5Z5+[%!&C2X;J;=EY@CE"
MK[]H]U$F4HD(C"2ZC*`RLV04C2+>I\AFF?#,\<N.K+(#CGPX\2.%126-H3MI
M4EUONN]B5"OC-Q1NFG_8%WARF1Q%4834D7A3Q8+_`"I,[M[XJ8W$3;%X^]GG
M,3>XJ9")U:UD=*:QOY66[/&:7TYV3V#8K`DU3UF-\8:L<6IFL!SD,TK>LT\:
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M(4XYL7GO7JE?M-:YT[:+?L/;+!&[2U6>+`*L:LM9FMVU]I:F:]25S=-/:\3R
ML4,0DMP(+M:B&X)2RUD<+&S-<+B&'8YWEH%LAS]?5CJNUO4^S%]VY<NMY5@1
M:]K1?Y;ERBL[ET)F%>5A'JNLVMJ3H&/Q>,NK+%'NIH@S2R.,A<7=G-.UQ0IG
M;)4PH7&106&83W!=8QNI).21,Z1RD0K&ZEG$B"/1)+<IJ`0R&13&A9XANF9)
MD<5:I,B=(S`/#(\3PRR)(SX$Y\W$<.<5$'!*PG%ELMD2.%LN'=BJ.N3;9L-T
M,<6QK1QR!@D<8B!+N::ZJT?KRI?)IE&V5H8FW"M]>%[F`EM;E/JZO)&4\%Z;
M6Z5E.&L;9"Z9&\JMQH=-)]KL+,YKUO1SN)UZF(5R]U5N+G*$:"&Y:$ZM&9ZC
M-5+`X+O7$8&]*J&J("/@,8NV$PW5*\:=BT??&"?WW=M1.<APF.PX1".Z\TRA
METMCE<-\D<EXY._.ZZW9(P.+D8Z-J<"MDKF.NC@XK'=>I1I9E-9^L9K]2M2:
MO0V2U[;3M,M;XCJ5#8](VAFBQB=G9V"T4KMN<F93%4Q1*E!-A5A"JZ9:_*/3
MH\/+WF0$2+ZW4!12M==O;G$XT9K.U24[\QHKJQ;=FW73*VF51DMVW?@'(P1M
MI.I@P,SC\%<^)'-GPTC(\XYF/'CQ`.7'C434"Z=FY5G5RJM.$4LJ>8J`N?J&
M5(;-ZU9IU/4%5*UR"R7>J*M?IDV67;+'"5C6Z)G][KR)R)L(/:W0A(J6'MRP
MDG])G3GV[!32>^"*\BCE`E-,(-B2D#-==(O%H9I!Q;@O)%FBI!OL(ZX\18EE
M$)Z7K`P<9K>SDJG-406D2*#2\SZYWVU(;9AJKL_/8GL;C:'1J+R.%T]7\,(K
ML5%W"A99_:\\I:03^=N\C36!49K2LMIP26[&8;$YBDG25A*RTN2`^0.0B/R_
M&>0I9`2JC5P!A:HJ'I8(=/";-9Z&K%)L8U[!H:[!'!.[?>C8\-MHCH!R>0'M
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MZDRH3K&3;*E4AUP42!VEL;=":RD3J]M32`"FT;[&LE*V*-FI/&":,YB8J`5:
MX8J6C`[P:U4L)6E$8<+3KD]X.;Q$>'AF,^!RYP,P#QSRSRK<XS@00B#G`@B#
M@01!S@01!%C&0B"+'?`@BQG&0BQG.,XSC.,YQGGGG\B"Q%$)RACP8,H@@H9F
M`8+P8,HH!8S,%A[!+P,0<CP6'&`@QG`0X[8QS^O)%5ZG'''%*N6Z-_\`T;:4
M?_>MDG_3I&N1Q<D=T;_^C;2C_P"];)/^G2-<CBY9V8_J\9_W]??^E:U\<=G?
M_/2W_P!R6G_.8A3CCCDFKBU...,9[9QGYL]^*5D9%]3-@)FTTH^QJ`#<VG8>
M0R:+5$M#(HNF*E#W#RW$V1I%.%3R2.-EMQ+0Z*,K).%H1J4Z%2>D//+*$+G2
M<CBLAB3W((Z_M"Y"[Q=RD32^)@D#6%HUL3<E31(@A6(@J$2M,T.*-2E6+D:@
M]"487W$HP$8,BDSI?>VMJTHRNZX=(Q,W"5UG#@$11X1(FC+>R3M]MFUAS9Y1
MGFOJ=7E$OHRTEC.D-RE`H-EK>F1'IB6T`'</S9/MU0LEA]CGF-=OHY\ZPS?>
MN80VDLL-,A![#MM9CI8\7?Y.Z#DF)`VND<"O"PO+(U-C@C`/Q.B9S7%$A1J8
M\F(8PMS*DN&Z[=9Y88GB#*S())VAG)UR]XT/)HVS1,I3-+F$"H)O)@NRTEC:
MR6^/F*^>SMKJZBG,<D<<C06*75HH$5OE.ER<1N(_=9`;9+6WR:9GF;$9=JE?
M#2_?6^^0DJ/*/KFE\,RZ/\DC37&<2N"P1%9,D8<R8YT$S^OIXDY-ZQ`'"C)+
MVX*RV%G.7/A:I`FZDB$$ETZDT.A\98'%;()](6**Q%(J($T$/#_)5"1,R-Q3
MD[^I-A)BTQ>D&$Q0L*(*3G@5G&@2Y]-R5)UZ@57/$I,?U([K):6G8:WK28XD
M!(S*8^Z1&T-845/I4KJC'-`)VR0Q.=HETB;T*5$X-QJ&4OSJ2XI'<]2E7<O>
M=TZIK=JUVC2R76G:(8C'>G')W2((C86\U'5F:$88S*K`=:S/+?OAG-LR80%4
M&E+(YHH^2A.^%2'=W5E^H)4%I,4QE0B288K321(5"[U%634XE)!$FH1QM#(R
MF2,?AQB4R$*,I]GME':22#:!DM8+F17>0V\LDD&[A:`#286C::5+J!)!!,P)
MCG>W6W1I'A@6-3DWY4>N(51):5S7LIRK*<[*'X5;#C2%[>4X!!E"H5IC"#<F
MD$*##0E@R=D'HLX'G^0T*XI)A>:A7%(,X+SA>:A5EH,X-R=@K.%PR`H\^ERG
M48*['Y]*).H"7XA$'8!)?;6[=?V#J*ST&RQV2L;VC:(S'EC`IC#,K@_KT8L1
M\F8[0:Y**>B-9I=)43IZL\)6RL$[\:M6NZ5SG+LQ'$D8YP7M-5L"U<H^M7N6
MVC.C7G6MAB#]3D6<H8*J8Z[!VAD$Z<)R]+%KFL?(Y>,<C$>"3%$YT9-+"FD#
M"N/7IFLQ8F497W3OQ'&SX6ZS/?M:[D2DL8%37RD,(F0!@&`5F$7,3<#/AKON
M!@CW$Z1[20FVAP:/$3=-;*$%[)*L7W/*&Z65BFM69T0W'$@69(XQ/#:'@LT"
M<QG>`*#$Q:TM.-H<P*3$1P@EDK2TXDF#S$1Q@P%DK"RQ)C31@*+-$8,(<\JE
M58V'"'1O9)7"Y(S.SK'HS*VYO/:5:A2JCTQ:BWN-.("T):KP8=6PSU@M(;DM
M>F&6H2+DB5<D5)B97+BZC\+DJ]5)JW>+C;)VWT=L[5L2FS@TE,\C9'2X+`K6
M65\O(?%]J6(_%D11JB\@;7)V"]X6(WA4G<XJPLZ%62@:>$G]0I,BP5)8[-K]
M3S]YA>CT:DKFN7)1&-N==9(O/N1O8Y%F7KW1P:+7:5`G@XY2E:E3^_/+XWR0
MDM,H5.*ZW'B.,.D3G"1'J)1HY)I`X??I&K%A![G$(2\Q)1BQ7=@*=)>_+@6R
M\+SQ=L[3F,)(D\-K!NFBY)+-)&J->9S7!NA%:*JRQJFO?$R*7$,4X4:P:82T
M"-8-$%4!"):!(I&BPN-#@92'*P)64H5QH,X&4BR=A48#.!@*$'.,\_0-H=RP
M*C#&=X++0DX4+C#&ER++0IA&FIPJ5PQI0A1)A*"#TX5"K))(E!!Y&!Y-(.`"
M62;=0"J)!1,MJMABDQCQCO-;!6$QO$38%D2?6R6;#J[B99^X.&+#1)8M/V-@
M4)F,1:*O9&]$N;6D*9YXC8#STQ7+8WU+(4<\;7+[#<[ZD#7<%B3U_K]E0A9R
MCTD"=HY(([!H8?(T<^CRJ&%QQ([^B5L3JTVY7F4ZE6L;8JDD!KBZ.PXIBNAW
M&"N"LKH(S<G6Z"2W2-URMRI+K)(^6H(@CXN3KT>#9[9K?0Q':V+*6WAE:<6(
M$,4KP7<DT3EKT2`0R00PCW,R2M/FL8`C,L+W'/0H.0%%`SVSDLHL&?#WP'N`
M`0Y\.,^>`]\?<XSYXQV[XY[\D%0FG'''%*<LI]`C_N&VS_\`:&M/^:\RY6LY
M93Z!'_<-MG_[0UI_S7F7(IMM_FY??[=I_P`Y!73>P]_V@X)_L8E_[9>53%6_
M]N+?_75O_P"5G\Y96]=S"W+`A=6U\TX?IU84D;(C$63*]O:\.L@>#O0-R#+D
M[*D36@P>;]SE6X+$J,G'<9YY8,9%SB:W_MQ;_P"NK?\`\K/YWSJ=;$>HC9R@
MKIEJ%V<HQ5=JQ.<O[>PITBMZ6M3"L$H5I6M*N6MR)0M.!G`"B52]&09W$$Q2
M5C/BY\$1+&]Q$DK:(FGC65\\BD32`2-F00"J$D'(Y9<QYJ_IJQ.:]M\(Q&XP
MV!;K$8,,O)L/MG5G6YOHK262T@9$>-F6:X6.-E62-F#%5D0D,/6XM7;PH@42
M'8</1X03M&]+8@^P680JV8P_!C;BC:9$D12>JY#,6,+JP.+BV)7AG5+4[HWC
M=6O)Z4('%((WHLUN<""D9Y[>X$$.)AQ3<>>@6$D.)J<\*504W'&D`*<#4ZH8
M$IY2(9YA"H8$QP0'B"7F1J!]1BPX\&Q!$)8U3/J^MM^U?0C=J[6D6IYDKVU;
MMDM;/#G9BE&Q+4RDE_<$<#3E.TQ)6N+^B-;6+#,D3C($K)S)?NJ_2SYG516H
MKZP1H*BE]9R.30#ZTX@>WUFMA%-2.JW254E-'^QY"C7R%<^OJ:RVMJ#6%7-:
MM]9T>)FO>7E.E>\;1;/"9B[1XB]NON>E)XE=\F9$D)97CU:&UL`(U8QF-LCE
M*4Y_)M+V1<-6"&[V)M,:G/+=]=8-B4UI;EHHI[JRC6WNK6],#7$)MK9Y7O9;
M=;Z.\BUH&LA<1`UQKE;EIISUL6C[:E;D=A,M5N+E,9/'H&A:9[(H7,;!9&!X
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MHQ]T&#!IA)FJ$'0`8QWK$1A\G36K3@L5*YK5GMI[(6\O6&Q<<D)BPHV?N]U"
MT9NY&AOI"9K827KVIE@NVM9;?"72WBGBE=)^`B8>6!U853PE<4H@@8G]TB[B
MY)NZUB"^,ZM2C6H4S^F"-H6#](E./3>KJQY6(?1KTX1I#2S<\I8:KL&2M]@N
MC5&''U2K(&&SIU\)A`Q*66"F26.Q`N0!0O8F]:YICI#*V)`02UIUBH_"T2LD
MD:-(L/(E4%U`J26UI'8HM<MJF1N;9XYJ)31T"'43-2]A-;EM\Z[$FW/(GB1E
MR60(KJQ#7!'#B4[)'VQS2/K`Q#)LT$3*<FMQ^QM=U&:<O2/3A`SDVR]R"2ZJ
MVYK\ED$PC"=K4*'68;7UC>T-6N*IXN.V)&;'V6&Q1\CRP]QE3LY$R`2838T-
M[$YX1,M/(,-"22?=)6*PJZ0A%5GD=6]S#F1N"-IS)C#L`P*1YHQO+M=MO)=V
M5GVBSP)/B<UI<XB]S--!;65O/;@7LD`M+=<[J`W!C5+R2&)G@>.>\,5U`F`M
M>Z/;*6I7K!9L$AD:>X[+DLW60UL-MBI66?38FN5:]#,\0FKW^;-=B3`]F5M;
M@G$ECL;<E"TU*86WEJAY`$71,DK271<N)FK$2-T!-*Y8;79\Q1S1S'*>%2,Q
MP+;UTA#&QN(HPXD";%6'AD?,(W)CSE/AV)2C4E`S+7JMU!*%I6D]?8E-,V@J
MD-)DWV5(H-':!H*5-EFH[6E4E?&YG:MAII)4=QTFF4-3[ACD3A6B-&K)`-6X
M)<+EP2A#Y)J/U+Z2H@$$1R1#=K8ACNKVN%,/Y$"9&$PQ[?Z5F5NR-V2MDB06
MC6LUCK>J2V&W$QR1&2!\C*XPAR+GM1O^$S0I!=6QPB1;0?=!H'EA5KAG:*58
MI-S`[`(F@JIE>:+3)('7=EM+`*9-=<[6]DJRN-H)!L9%BUK88E+#@]M9PW]A
M<W]C]T<5MHGDNKEKJ.686%MAE\)K.T>TE-[NC+`^]CLX/C6]P(1EN)S>X$MI
MN"<E.1R!:2VFX4%F&I\E.)I`$)N%!))QR?):@6#RB3C2?&64:(']\LKUA>4U
M997K#J>2!00U99W/#J>G-(&J*4$-?JGP@>G-2EF*BCRDPR34Q9B@L8B`#,#.
M^][\TI5M*Z^QP;A9EV>DUZUG&HUK<W6O7K7B&ND)VI=[J>WZ4NH52I\2;!)H
MI&B("XH#8,D2"0R=,YK%13`<4Q$>MA=4>FIY=#M+")'LK"D3Q2TWKQ@OZ"0:
M#,NQ]1N,LO&*6^2U1$U^NJ:'2>.@9H\Z5VXN*JQ(L!$U2IW!$XFU1PY0Q#H.
M&8>H75BR!],!,>Y7/.4,64/O]`R`7(L0$+#?;H$&LB+;O;2>1MSV.[I[7E&*
M0K>?=*;28[%H$BG-N,)-RVMWFUQ11R&Y6%AA3XA*K1U$U6NJ=X6^EB:NMXRS
MRDJ8QFUYDBPDFL02&,<6I0P@JPGN<?";PB*@:-`)23ED#*3FY3+`CP*-)W+V
M9ZPGU;2RMI5(H?)$K>I=8HG9%;^LBKNWS.-H$TA9FQ^:E`Y5&C7!@R0H0NZ,
ML9_KP227+"IJ&9Z\C4%`DW<.HC&BHW-6Z+.5[,SO+*TZD<4.>#W"*M+TZR;;
M1^@[S3<CEBRN#(/&E3C&E,<=W>:N$?B3.ECCTZ9-AK4YB4*E8^QG+J0TRX-M
MV%-#GM!5JB7R4J2H$-3H*@2(;S:U&G]=:ZE5C?8YL.3(&R$PN7PUYED>$GCE
MAE*F*5.^6YFC,P-1/#=Z;/"&C`2_=90T>IV",C*;;7)HCS3(K,#GJF.0(C4.
M^DNCVG[)$5Z[W.QUO/A[QWPAMX9+J*Y@FCQM;>T-S>K'=[V*;"W4Q\GPQ<W4
MW]P]M:;Y+:.NC],=B-C(PHE]1Q".O[(5-OW-TF7JT:L@;F_3X3$DDA4/BC)/
MIC&7:6R%0SKT2E,V1U(XJ%`U1*8H.5`_1\ZBDM33R)HH<M=F3)HIPSNCVTMK
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MI/8LJ&=7'3'A8(SU&HV.%(K#[IB5BENR.D>@`O(RSKNG8LYC0`@,\1S.9&DJ
M:LQ[6]D*YGMV&P+6$"W.,PW5O<WQN9)$M;&"7"91?6\*0VT=[=22)(\-MB2:
M%5$<31SQB&K+6Z!$Y`$UN@1LH,F/0!-B\(V0&#?09&]@$FP)F!@__09&YX2!
MP?C).<^DQD//P^SV\G\8^K34B2/W4F71BRRY59!4!?723'PR+S$VZ'EOU%A-
M`3:(W"B76I#T`F0^=1V03)ID<C1VLC7M\K=')1!FJ7Y*5Y@`+#X"BB\Y[Y+*
M++SGOG/?(`!!Y9%]UG'EY9%]UG'GG&,YSS!O;:UMQ$;:\%WK,VL"/=[L1R:8
MR?='),BYMED`,LU+JP:I5LMCF/XPV(+CFS$NSG)4PQK8R7O+!>/=V>_O%0BT
MMU5;*;3#J#R.Y?3-';S1215G]TNO_#TU\_\`7;/_`.@RTN..EU_X>FOG_KMG
M_P#09:7')QLA_DV?_OTO_+VU?*/])/\`SZPG_P`)V/\`[QCM1G>`?WHOYN?[
MN/`/[T7\W/\`=S9>_%?=._/MTNUNS_\`\IC'ZGST%TP>G4`18!Z8ZUA$:+(2
MPBJN+!$8((!#$$&,I,9'G``B'G`<9S@(<BSCPXSG'W/W?<#\A8KYZT^G7Y-]
MQ3&?+&&>;NOH>V1Z,]:+X!_>B_FY_NX\`_O1?S<_W<V7GQ7_`$[,XSG&E^MG
M;'MS^Y5%^V/X<^I^7/P`Z:73;,78;`:?:P#<1)#5X4`:UAPEN4)*G"(Y9A($
MC*C*4I7G"4Q1@OT):G."!CP;GP<=WW!/(6*^>M/IT[BF,^6,,\W=?0]LCT9Z
MU+P#^]%_-S_=QX!_>B_FY_NYLO/BO^G9Y?\`87ZV_=?ZO_6JB_G_``?[C\_X
MN?C-Z9_3>(6(VX[3O6,E>X@5&($1M91`I6M+0@*&L&D3&)PGJ@)`'D#4C3EF
M!(`<4(W(`F`R)W?<$\A8KYZT^G3N*8SY8PSS=U]#VR/1GK3_``#^]%_-S_=Q
MX!_>B_FY_NYLN_BO^G9V[_87ZV=OG_<JBW;R[YSY^I]O+&,Y_BSSS\5_T[.^
M,?87ZV]\^S'[E47[Y_@_W'Y_Q<=WW!/(6*^>M/IT[BF,^6,,\W=?0]LCT9ZT
M/P#^]%_-S_=R0;I1!%CJ0Z99R$6,?NV-OGG&?Q9E'Z.7M_BO>G=^9;K=[J8O
M^I\Y9!>GOI!6,PCM@5[JG1$-FT2<@/$9E4<KF/-3ZQ.A9)Z<MP:W%*E`H1JP
M$*5!(3B1!'@LXP.,]A9YK\6[..#8CA6)X>F"XG&]]A][9I(\MJ41[JVE@5V`
M?,JK.&8#CD#EF:SL,[#V+V.)8=>OBV'.EG?V=VZ+'<AG2VN(IF524RU,J$+F
M0,^<Y5E_C_>2_P#\#_X@<U4]X`'^[;=/W(O^_);/_!S^4:3_`*.;5WMCMC';
M';';MCY,>'MG'\G;';^#F#CGTS^GZ\N3B\.NG.NSBZ.[@O=G1P65=&CU:]S=
M%A[@XKE9XTF1G*EJU2>J4G#SD9IYQA@LY$+.><X[&VW=EL1-BTMY8W5Z,0BM
M(XQ;/$AC-N\[,7WK*"&$HTZ<^8Y^"I]M_L;>;7PX7%:7=M:FP>Z:0W"RL'%P
MMN%T;M6RT[DEL\N<99UK-?`/[T7\W/\`=QX!_>B_FY_NYLNA=,'IU@R`(],-
M:P9-'Z,O`JKBP<F#\(A^`&,I,9&+P`&+PA[B\(1"[=@YSCS\5_T[,XSG&E^M
MF<8\\Y_<JB_;&,^>,YSZGY=\>?.K]WW!/(6*^>M/IUS/N*8SY8PSS=U]#VR/
M1GK1/`/[T7\W/]W'@']Z+^;G^[FRNQTT>FYE<4VXT]U@RXG)E2TE#BM(?E8:
MD0J"4BQ46E]7]8,3)%2@A,I/`7DI.><42<,!I@`"_;\5_P!.SR_["_6S[KR#
M_P!:J+^>?FQ_N/S_`(N.[[@GD+%?/6GTZ=Q3&?+&&>;NOH>V1Z,]:)X!_>B_
MFY_NX\`_O1?S<_W<V6!W3/Z;R=4B0J-.]8B%KD)2!N2'5G$"52\2,G*E4%$G
M,3A.5Y3)\9//PG`;Z$G&33/"7]US]?Q7_3L[=_L+];.W?MW_`'*HOV[_`#=_
M4_;^CCN^X)Y"Q7SUI].G<4QGRQAGF[KZ'MD>C/6B>`?WHOYN?[N/`/[T7\W/
M]W-EY\5_T[/+_L+];?NO,/\`UJHOYX^?'^X_/^+GGXKWIW?F6ZW>ZF+_`*GQ
MW?<$\A8KYZT^G3N*8SY8PSS=U]#VR/1G0?Z:818ZA.E><A%C'V2=8>><9_#6
M/T<FM^J\,9S`-#>V,Y_ZO[Y]F,Y__P`,KWYN66(;T[M&*\ED<G4'U-H2)S&(
M/**0QB3,-;1YM>F%\;3/2H'5J<$Z4!Z)>C-_TB=22()A0O,.<9\^=D7YJ?K5
MM*EBZ'8RC*NNQ'"E3HNB2:RX>T2TB.+'M.D2.REG+=2#@H3W%,A1D+#",!$>
M4F(`/.0EAQCF&V79!L=I=HL'QJWL+NVAPVSEMI(9GA:21G>X8,AC8J%`F7/4
M0>!X<U=7['FRMUL;97EM>7,%VUU>\J5K82*JKR:.'2PE53JS0GAF,O#GPK3V
M^`?WHOYN?[N/`/[T7\W/]W-L#\4;TQOS#=5O<S$/U'CXHWIC?F&ZK>YF(?J/
M,+MXL_B5S^W%\]='Y4GO6]7SUJ?O`/[T7\W/]W'@']Z+^;G^[FV!^*-Z8WYA
MNJWN9B'ZCQ\4;TQOS#=5O<S$/U'CMXL_B5S^W%\].5)[UO5\]:G[P#^]%_-S
M_=QX!_>B_FY_NYM@?BC>F-^8;JM[F8A^H\?%&],;\PW5;W,Q#]1X[>+/XE<_
MMQ?/3E2>];U?/6I^\`_O1?S<_P!W'@']Z+^;G^[FTQE_3UZ/$"G]5U=+M.M2
M62>78NF;=5T>4T@QF*):MKV(JYW,2$BM*QGMJ++%$T*IZ4C=UK<4<G)$4D,4
MJ\A3B[(#TF.E\,&1@T3U2&'!A9.1!IV'"Q@TT0`EEBR%%G`1C$87@(19P+/C
M!Y?=A[NWBS^)7/[<7STY4GO6]7SUJAO`/[T7\W/]W'@']Z+^;G^[FSDIS53H
M>W_(2HW4.I6L$S6'U^LLY.XI-8W%MBZB(-UJSFE'%21,GR$-<4-=VVRJWF4?
M<8L!WS*$)+44_JF<J-NK,[N&2HNDQTO0^@\6BFJ(?6<X"G\5.PT/IQ"[>'!.
M<HL>ESGOC.,%^+N'.!8[ASC.7;Q9_$KG]N+YZ<J3WK>KYZU0W@']Z+^;G^[C
MP#^]%_-S_=S9WQK4;HB32;1"OH=J;JG+)'.)'?T08LQC77+\P%RK6!_;8M=\
M<D$O;(BHB<1?(7(75,T8;)4],ZN2+2G`J(EOP6IS&DR(STFNEW@L)N=%M3\%
M#R/`#,T_#,%C]&$0C/`/U/P#\`0#$/(19P#`!Y'X<`%G#MXL_B5S^W%\].5)
M[UO5\]:HCP#^]%_-S_=QX!_>B_FY_NYM>OBE^E_Z0LK[!/5+TIP,F%%_N.0[
MTAA>//)A8,HO$,&.^/$,.,A#C.,BSC&<<_OCI'=,;/\`YANJW\=,Q''_`"H>
M.WBS^)7/[<7STY4GO6]7SUJ?O`/[T7\W/]W'@']Z+^;G^[FV!^*-Z8WYANJW
MN9B'ZCQ\4;TQOS#=5O<S$/U'CMXL_B5S^W%\].5)[UO5\]:G[P#^]%_-S_=Q
MX!_>B_FY_NYM@?BC>F-^8;JM[F8A^H\?%&],;\PW5;W,Q#]1X[>+/XE<_MQ?
M/3E2>];U?/6I^\`_O1?S<_W<>`?WHOYN?[N;8'XHWIC?F&ZK>YF(?J/'Q1O3
M&_,-U6]S,0_4>.WBS^)7/[<7STY4GO6]7SU6JT;QG'U-M*,9QG&?LK9)Y=L]
M_P#OZ1KY.1Q=L_-G^3/+^\:T^U<AU/'Z_16@JGCU)*7PZ3'U6SPMG004V0*'
M,EZ/>3(X00!O$XFNR<AQ,59*]*)646?G.1AQGG#OB_M)OS6:,]W;#^K<HPG;
M6SPY+Y9+.YD-WB-Q>KH:(:$F2%0C:F&;`QDDCAQ&5<,[(O8SQ+;/'HL6L\1L
MK.),/ALS%<I.TA>*>YE+@Q(RZ2LX`XYYJ<QD0:H<]L_-G^3/';/S9_DSR^-\
M7]I-^:S1GN[8?U;CXO[2;\UFC/=VP_JW-MW1</\`)]Y^W!]*H%W!L<\N83YJ
M\^JZ_8\*'/;/S9_DSQVS\V?Y,\OC?%_:3?FLT9[NV']6X^+^TF_-9HSW=L/Z
MMQW1</\`)]Y^W!]*G<&QSRYA/FKSZKK]CPH<]L_-G^3/';/S9_DSR^-\7]I-
M^:S1GN[8?U;G6UL:N=-^C8?B>VK0-`P^(BE4`A`7I;6*-81F4VE.XY64!9_0
MM+2X+/32.=2V.QY*=ZMZHF4N92AP4(T!2E62[HN'^3[S]N#Z5.X-CGES"?-7
MGU77['A2"[9^;/\`)GCPY^0.<?P8[?Q^SV_/GY>7O@:$:.F",`#5^AQB*P9D
MP(:^CXA`P48,HS(@A3YR'`#2QEBSG&,8,`,'^L$6,8Z%UOTIE%O`HE#2%+.E
MH8M)32Z^/L]$/SNC8;(344AV3^MZ3R=NB"F*1@"JF7-NES8]/SX@C[L<N31A
ML=5<N-^`<.Z+A_D^\_;@^E3N#8YY<PGS5Y]5U^QX4S.V?FS_`"9X\.?O<_R>
MW].?+SS^G/+WF="]&\$B49UAH8)`!9`,X4`CH2@#P+PY"(T1&"PBP+[D0<BQ
MD(_N,XP+RYCG)J\Z4$3G"VMG.F:+63IIMJHJ/?XQ&J3=9@ZQ>R+WCYDKJMHE
MQ,4BKP7$FN51PK+P"6R(UNB#2B,(,?7UL&I3EF.Z+A_D^\_;@^E3N#8YY<PG
MS5Y]5U^QX4S^V?FS_)GCMGYL_P`F>7OOL"='?"8+.K]#X"2((3<YKZ/A]$,>
M0X``SQ)\>C,%D8<!+'X1B\0>P<^+'?QG0K1S`"S,ZPT-@LTST)8\P".^`PWO
MD/HBQ>@\(S?$$0?1@R(>1!$'`?$$6,.Z+A_D^\_;@^E3N#8YY<PGS5Y]5U^Q
MX40NV?FS_)GCMGYL_P`F>7QOB_M)L_\`FL49[NV''_*FX^+^TF_-9HSW=L/Z
MMQW1</\`)]Y^W!]*G<&QSRYA/FKSZKK]CPH<]L_-G^3/';/S9_DSR^-\7]I-
M^:S1GN[8?U;CXO[2;\UFC/=VP_JW'=%P_P`GWG[<'TJ=P;'/+F$^:O/JNOV/
M"ASVS\V?Y,\=L_-G^3/+XWQ?VDWYK-&>[MA_5N/B_M)OS6:,]W;#^K<=T7#_
M`"?>?MP?2IW!L<\N83YJ\^JZ_8\*'/;/S9_DSRRGT"<9Q!MLN^,X_P"J&M/;
M_P"R\RY+G\7]I-^:S1GN[8?U;G<=64%2M()7U%4-70>MTDG.1GR%/#8\@8B7
MHYN(4)D)CD6B++"K&D3JU)*<1OBR46>:$/;`\\TV/[9V>+X7<6$5G<Q23-`5
MDD:(H-U/'*<PK%N(0@9#G(SX5+=A^Q/BNRNTN'XY=8IA]U!9K=AX8$N5E?E%
MI-;KI,D:IWK2AFS([T'+B<JU>"T`_7%OW(O^W5O_``<__O9_Z.?F\`_O1?S<
M_P!W-D@+IE]/L8A#'IQKL(8Q"&,6:OC><B&,61C%G.4GGD0LY%G/RYSG//7X
MLGI\_F;:Z^ZZ-?JG/FX["WQ)/+;7B?>S?1Z_8\/UL7^EULJ%`.R>T'``?XQA
MW@'_`-6M;CX!_>B_FY_NX\`_O1?S<_W<V1WQ9/3Y_,VUU]UT:_5./BR>GS^9
MMKK[KHU^J<\[1+[X[:?LS?1Z_8\/?ON]E?R3V@](P[ZZM;CX!_>B_FY_NX\`
M_O1?S<_W<V1WQ9/3Y_,VUU]UT:_5./BR>GS^9MKK[KHU^J<=HE]\=M/V9OH]
M?L>#[[O97\D]H/2,.^NK6X^`?WHOYN?[N/`/[T7\W/\`=S9'9Z973YQ[=-]=
M?;C'_>NC?MSGMC_]4^?/.JJ>TWZ4U^UO$;<J+6?62:UW/&\;I$I,AJ=K0)WI
M`!R<&@2A.A>FAL=2@_"+6X)0`5($YIAB4T198@8P++M$OOCMI^S-]'K]CP??
M=[*_DGM!Z1AWUU:\;P#^]%_-S_=QX!_>B_FY_NYL!KQUVZ0.N1J1+;NMNO,=
M<G*O[BM!I9&R@U\TD#S"J#C+3,;9=&5@A$3D3NZJ8E&WQI<S&-$D.?G@I<45
M'VUU4!-)+[U;.G#TZ7=$B7H-/==C4[@WI'1+@RJ&%*I$B7)RU*8XU$J0$K$V
M1E&@\12@@HTHS(B30`.`,L+M$OOCMI^S-]'K]CP??=[*_DGM!Z1AWUU:X3P"
M^\SC^`.<=_TY[8\\_ISY\>`?WHOYN?[N;"RPM2.DS5CU#(U.M<-8&21V(GL!
M3`X^&J6QU?)@&K88OL*>DQMI9&9R7/"R-PYL6OBQ`B),6G)R?0(DZI:82E,Y
M/6NB?3*MNOJ_M"#ZBT$OAUGPR-SZ&JW:D2(H[N$7EC,B?F18OBTK8F64Q]::
MV."4Y<R2%G;'QG.,&B>&]"M).3ENT2^^.VG[,WT>OV/!]]WLK^2FT'I&'?75
MKK/`/[T7\W/]W'@']Z+^;G^[FR%#TUNG>/!F0:?:WCP4#)AF0UG%Q8`7C(@Y
M&/(4V<!!C(!X\8LX#W`/'?[@?A_J5TS^GJ<`)A6G.N9A8\=P&%U?&AECQ\X1
MA29`(.?D$'.<9\^V<]N.T2^^.VG[,WT>OV/!]]WLK^2>T'I&'?75K=?`/[T7
M\W/]W'@%]YGO\F?#GOC^#/;OCO\`+V]OR\V1WQ9/3Y_,VUU]UT:_5./BR>GS
M^9MKK[KHU^J<=HE]\=M/V9OH]?L>#[[O97\E-H/2,.^NK6X^`?WHOYN?[N/`
M/[T7\W/]W-D=\63T^?S-M=?==&OU3CXLGI\_F;:Z^ZZ-?JG':)??';3]F;Z/
M7['@^^[V5_)/:#TC#OKJUN/@']Z+^;G^[CP#^]%_-S_=S9'?%D]/G\S;77W7
M1K]4X^+)Z?/YFVNONNC7ZIQVB7WQVT_9F^CU^QX/ON]E?R3V@](P[ZZJ-G2Z
M"+&^FOG<(O\`MVS_`),_D,M+]''+WL)T!THK>4M,V@6K='1"7,0EHV:1Q^O6
M%L>&P;DV+F5>)$N3)@'I\K&ER<&Y1DL6,FHUB@@7<!HL9<E."8%/A=I);RSQ
M2L]P\P:,.%`:.)-/?`',&,G/FR(K@/95[+F%=D#:&SQFQPK$+"&VP:WPQH;N
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MK0R?UB,/,C]0>([7S\E"@2'W/7"519K7'M3G(V%`YI&%;*E+:N>&Y(O3QEK/
M+3.,C.1J%):@EB;U)Q*=<\F%@;DAQI92E46,80YXE6-ST[=C.X2"F[6K6VH^
MU..&=S>ZSG<6GK,W.WJB9P^"ESE%'9V0HW+"%:C6X0J#BE6$BM*IP5Z`\H8U
M*J5W5L[U:&(.O9E$O74SD41BD@+EK?*;RTEBT/F-\5VHW.9H2K8;DK^I-?;+
M4H7.+:\IGM\.>+4>])Y"^5^L9K!2U6MG9ZMDY^Z&UEOA4$LFZ^DJZV'LJ\:A
MNKZH;=*ME=^TDB=TR.1V$*$S34D^O+*?JXC3*KKZ^B26:6)QLLH*A$^LX#U$
ME2EO:F(N*Q^X"O=&EK"D&Y."!O"X+TC6B&M6)D@5CFO,]$A0)A*#2L*5RP[N
M4D2$Y&I4F=RR"QB[XYUW9]ZTA21+,?<]Q574B>1F.!,?.LZPXC`2'TUJ)3J'
M4IG,E;PTEN@VU.K2GN!:+)XD9*D@U1@L!Y8AJ56UJ":=4"W4\#KR/7!U#XU1
M,UWJI""IMDKSU:JZG]N&RF7K2?8"9;.IW^#O]$I(A%:LB6Q[)54<K*U)G32<
MA)*)"IB[-(;`:6ID='3JB'[']9DRZ^EA]>*7<9>R26NM<VK9>$L>LJ"+1N22
M%?>=@Q:YYI;4R7Z^S.!,ZLZL&Z+.$\BTNLC4U[KYL3$S*J<SI;*B,<M`O&T&
MM,<70=K?]A:.8G2S6IC?JW;'BVZ_;'"P623+0-D;>(0C72(A1+6J0.!@$#&X
M,('!&[+!@2MYR@\02\]Z8P'/GV[_`,/?S[?/W^7&?DSYXS\V>*5C7J=,'^;U
M(<]29\N.1N@;0O!M`[7K3(*'G@F=LN&;)8RVEP$MBCH,PQ@C06B/5W,#&P"Z
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MR@;[=E]`N=LW77%#H0M4)G\P9`J6F#/J5K2HB/T[';/=6N.0.LS]97[JA2QG
MB3E:L[@\TO;1Z+1*?WE'8_?E:QR-U_;==5;KK8S\J&BK?Z_GII>;:;M%U<Q@
M"LV39C#S*VID:G2X=#YK#+"CJ"70*61F;1-T,<"6R31%^:I+'7`UI<EC.ZE(
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ML+(A7N%L/(@>S(@^?R9SCMGOCO[._P`N//M\OMXQX._;&0]\]O9G'?/EWQ[/
M;CMYXQ[.WL\L<4JGF=L/UIFR<=-PA>9NE(2%*=DBEZ1:/:PL["GL):V[LV97
M+Q-K5G:W7J9ULTJ776UBA3S+8Q/Y/J6V,C`K!;%9SR7N4HRWLEGK5^8/TSB=
MB+I`^7$_GMNP-_L#8KNJF@TD^HXRTVE(28HQ1-@"Q1X4KJV.QT;:QUC:"E&H
M<[+B"!NECTXKWI>X'YR2\(<^W'?OV[]_E[>>._S]OD[]^WR<]N*4XXXXI3CC
MCBE....*4XXYAG-MZZ3KZUWZJY.WVPDQ$9S6]:32RTM0SITIJ$SFVFN)NL"8
M9A9[8UJX['?ADF>0I.H>'(PF/,:R4LY$@=VO"@9A2E8M]3[2>ZMN7:EW&H%L
M,19KZJ=_(>[#EC\N93/AW9/3"Q*&K8UOPC97?!Z1-/)0U'R-09D@;4Q`4N*4
MAR4$@0&Q:N'0]N6$Q5]B=;UEKG-*A/M7IL73,M69I;%@1"J]CY)KKKY:]6;)
M-EE/K;!YD)L<9;9,LK*WFV3N\5FR>Q9%5C.IG;$<?@`3+&&SFU=&Z?5PCM>_
MYF"$0=?-X97B5VRUNKR8;)YT\@9F9-A`RI%JW"1/V6.[ZY9)P@CT<:7F1.YZ
M5I:EJDKL%FMF$/\`*K1AC8Y*#W^G%$?33U*)M7$E-9TGB2:;,X4RLTD*9TPH
MCRLA6,3>8>%.:/*0[(%(1%X4JK3".BINC%=9V>IEF*$<U#+J;5%22"J!V]8Q
M58V<?`NJ)9.XD^H-]F>(,=+4U36Y04G15(\SE<QN3VN&O<&B3QE>T'.)RGBE
M[]%C=>Q46K0H)4.HU0H:`0M\LK.%5;?UKKTVM\L*W;2[!/<1A,XO"LK-E3RP
MK*C;F:-,/[BBG5MH:IP.1,.2DM+)(O!,VV:[GD:M.OX-9T,6&N,/L:'1B=Q1
MP4(U3<>NC<O9$,A8EAS>M+)6H35+6XI3S$:LDI4F&,1"@L!H!AQTL_[?T#%]
M@))K`_3<+;=47U^%L\MAZAH=PC74X1(G^+.$B87/U/X*?ES.[QU6!ZCK6K4/
M[6D5M#BK;RT#LC4&*57OD'1>VF,:[F@E0!H+7=I?[/ZQS]")O7DOD+2=(X[O
M<;!7S7=5+H]$('%7.*JH.QLSA0DK1LCV_+X97K:D>8,[+`&(HVDY/4?16G$@
M55LR7;0^L-9ZPG;LRF^9/HM6EF3FRZ4JVK\Z`SW7##=$WI^@M?AE;[;%_O##
M;,]B:&*1&)MZ`@*Q4HD[\-ZPNGC;]PZ(=*TL.W$<G<C(/5R2"+IDY"C#^6H;
MT]D5Q7EK1,:=L&APO<,KH5:,-<3P(B3A(%#@>W+,%+F]:23W7`;`B]F,*N2Q
M!:<O:$4OL."J#ST2I`,$CJVP)/6,R28(6%$G#*;YA#WUO(6!!E,X$)2W!$8<
MB5)SC%*JKUOT9-X8OL[TO+G?@40^J]4*7TPK2W+`DEQ2B7KV]#KPU25!8C9`
MH@Y4V5-T+X^)9$L;HB_U]>M>0"9!$WG7C5<K*:E!3I9!T\KV059K[#X/**HA
M-)/34]60L4UO7=H2VY(DR%2*SYE*$BYOL.<,<<DKRIDR5Z*E+RC6M"5-'7MZ
M<8TT"4,S0WJ#?I7SL_6VO:F$LLJ1S^63:R#9'B"5M4M<3"U[&DR"&(43E-']
M#$(2UNCB1&(BD=&<,@DKEZ@RH7-_C,?"M.D<HCK0Z?OI;9JEMA2PJ*AF`)@B
M,KNNK1+7)VIX;TWUIVB[6`P1@9V'9"@4H7TE^JZ<L,GBKBF1R:&OL?6LDJ:F
MEU+&C`I7??'.OZLLZ'W+`(Q9L!<#W2(2]ORZ,3@I;UK6>J1A5J463#&]P)(6
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MYO\`*(QL"_-%BG,Y+9'VUI;0*UT;<LF-Z!,?:-SGM_+C'S^W.,?_`#\_FQY\
MQ=:]Q:*>6JKW1OD+P<9;U^3?6:&LOUIR+$D,N.M'&S6ZP8N\Q_*#X4CQ4.S3
M]@.#^]O"=(RHF=D`\97#;W-K/6*560>>B-MG(M2F+7]+K-H[6#&X6G6[U:E:
MP38JYYHAL=[KK5:6TN+8E2\W;4-ATA&9S,K5>TDUEK4TZQND\=(D(UY<['>+
ML;6*P&ONG77HZ[6U3+*]D+S&Z"2R`4_Z,MIVK:#/8#JHGLE==&ZRC5=;+Q9W
M/'7Q3G*B9A)HXKM>+OSG*3,31X=R"I,VM;UA8Z$V>4U@P58SYD".8Q=8R86J
M&WX622!H5-V7))G(%+=A:G6FILN"<S&2CD.#<JBS?]&,D(_N>?,AEHPZ<,<4
M>FQP.:S9C"FZP&N-2M&HB4W2Q=Q()-"N?(3(`H).P#1#/`C=DSNV)3FAQP8W
M.(4ZTHPD*E5.8ET+=QDE5WM73HWZ[Q1WFE%0VE+"L"'7G<KS(M]K&1;PU'L0
M[;:;"$OD+:!UO9;%4T,G<19$:=VLB5CD-G25F;YXS0ALC2-%_/;_`*#>R\VK
M9SJ_7J%:\IX+&MT-QKBHJ`R&V'",5U5=;[!1.CDD&"*NG>B+4C2Y(SRR%V"\
MO#3"E=86E7BIZ"ZTY;3.IELI3EVZW*715F0&NCO)&!K;2"FP\]P<7IL0H227
MHX29G-.5JE9*8HIU4!R0VF#-"!>?C)201QF,AQR+V\4K$K6VLYO`9KL"[S6M
M:]BBN>2FJW;]T&$6-.Y8MN9QBE#UU6SS,I+"9H0>55*AK50TJ+,,:9))*`O$
M;:FZ32-V4RQR>E:W+7CCBE....*4XXXXI3CCCBE....*4XXXXI3CCC.<8QG.
M?+&,=\Y^;&.*5X%COCR^<.?Y!8SG_P!V.5*D?0IO]=6-;XE;?2SO<U'ZI:/U
MM2<KS/I2#-<711?4/NW8ZW97%W-/&DPV4;S1U@L\58Y:F0">W!:LDD1,(:V)
M8X*G6?Z0]0+6^,V(ZP)Q=IZ8UQNQV>FYE;S;4UCNM`0>WG]R;61KK>97@@CA
M]=1^1YD#TR1AV-6/?P!%Y>]M$-ECXQ2IP3LPLM2YA%#C'XHJ2L!IL6)]9DQ1
M;TV#-CR?PJA^G?2P*A"9R?`B6#]*Y82E^!(I'XO"G.R6I54B=]%?;I^N7;"9
M,T-UI;GNU:NZR44;]ER+EL,^Y+Y==_8TK)UE;;:AKA6@&:OFG7E`H0UB);')
MA*P(8VSI5,79VYO+/1NW<,RZ4VX)^P^T=I1JN]1Y3,K+A-R_N3;663=FS+7;
M$>C-B::1"@8AJ,[U;5N8A'5-/0BRF)[D(9#(9O+XNG87P$TB]5L5MD!?";*P
M)A%#/K<P7)&$S,P+$;%,%O+:/,F)`E`N,.CV`*LY>R2T1@%IIK7ZV66C$%4,
M02,X,YPRM+LK2VHO"9="Y.B6-EB,RV00],X9RROCTT-JLQ$X+DL>=,IGD1"%
M05D"P>$>0I<#)&HR6$XO(E*JO:L=#S9"D9E2LP=:AUN.;ZMVLM"S([%U]C1=
MU65O6MX:.Q&B'=XAKE"]:JVAJ*8P.^H@&XB8?%J[A[:[.1S*Z)ILJEB!?-#^
MP85T:=P&*SM+I%($M!RA]IZKNE0P?9*.=R6FGN#4(&CD9B[;LW4-`0E+!E<=
ML6"[8GM$B3NCTME5=)'0FP)5^Z7%I,2W1G*2TJFET66*S4*61L*E:2YFLIR,
MAY;3E13P1Z;TS4:F*5"/+<B<)S\G(!EA5E8)-](2'T8_#]=&M1N!`52!4F6I
MA#/*"H2'E*21&)CS4J@O!I(S"\C(4DG)S@8%XBCRC"3,!,+&'"E5.DO0KO6/
M5//6:*,%--\_NO4+<^F[[4M5RSN##M&=6KOS7>P=#Y=)HV5]+!^I0RC6B<1!
M`ZO,&DL=CS@]"@+O")-7<AD!/,Z>F1H/L/J7#M5HG<=-Z].*JM9WNC(39C`K
M<EK2[4+#KK^L]9#8U'8!%:Y@U-6M(;`<&AS3V&JCD&I6!UTA1LJROX6>[N,D
M/6S+R.Z:GB)3&=([#B+45);(9J>8C%#ZWC"YVC(5V&UG@*;T!YV12M:MSA.!
MD'@"\HS_`+8))#]US\%;WQ4]KUJUVW#)JRK(*YQEFEPW=<L3LXF5D?6DA\;C
MY0C<S4RJ+'C:E)*TY&_EMZE,2/`CRP8QG.%*[>XY\,B3QQ4H;4B9^9E"IY1`
M<FA.0ZH#3W1O,3B5%KFXDM0(U<C&E#E2!4D`<0-/C)X3,E8R/GW.*4XXXXI3
MCCCBE....*4XXXXI4/G4*H6S;4L![>XU3#Q=$)1Z[0U++X$A6,C>5;<?ANZN
MO]O6;0Z4Z0NC0Q.#S:E-0B<1]#'9$X-T9E(5@HU('-$T/"TX&#MF3NZY%/[1
MLV$4[?>O^O\`:PM4:_DUAM=$HM.-M7&();\%%'76^K#7J<MT[FDH9V68%"CL
MA30V,3]R9)5,&'6:0OLI)0IP69,XQGVXQGOC.,]\=_+/MQ_!GY<<Q8,D39;E
MY;"ZT63"8%,*IC5-Z]2DQAD\;22%+)U%N26_6V1M$K:GX3E'GID3EU+&CFE`
M8S%B*4GNABLU;Z1$%"I4$E=UMO#L5$-1+D:4RN^*LHK>.3NE8H;\NJ5M=UL0
M89NG?\"?[-MX$0K.?P:<F177I-%JS@S\DE"CZR&0^?N:Q@D,PDN7%EDYM.DM
MQ+$V$UTD@9U6$&6PJ';@-RZQ(Q3:^P8>V1:8R'6<RM(J^1N?SM(J23EZ3Q9_
M<ECZU.@FPS,9<$:!M3)U(QX_4IZCE#UU`*$25[2=JO*:WH3K<MIJKZ\C58,)
MQ*+8F32:"UA$@)7>?12%Q7#&MA[@.29$[I8U&6(!2M*O6`).3%<PA74HI2:Q
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MB;@V.$=B$_E<YK23)'"(K',Z#7+%:YF_UN.S`^EL)A"]66W9F8"$.19"'&,C
M%XAYQC&,B%@(0^(7;VB\(0A[Y\_"$./9C'92O;CCCBE....*4YBONTNNM+JO
M=*#7%D=7J]9;$AUS59C0,))T5F5GN*"NVNR5QXSDP4[!5&9.99TE4`/"I*8(
MBXY1%J%V4R8W*CGJ/MX<]\8S[.V!=NV1=\>''G\N1=NV?DSV^7BE59PZS[D:
M9U1*=3*X8K<:JJB=VMUP5&\:G1JZ4%7OT2LN@9@SR.E'F1598"K9"LG9GV'@
M[G<.)DR-%A5L*P+5BQ-QPU76STO"F[]:=4+<LV_G-ZE,=VXK=7(;P*N2=NZ>
MY+&;U\=/F'2N@%;%M\2MV+N3)'BLME\(9;$Y4GI(R-L.))&(PV*V)J@0H['3
M_N0_K!R6>V?OK$8\EH]V8:@9'69ZJ?`3R;)I3(8335[8U9V!7WHT-4O-/8UH
MK?`EE%8)TR**"=*LF,5=%)+@?A2L/R)BO5EJYGDE=5G;;:638TREQ+&^*(L^
M5LRM,2;9_L[9^NM*JP0R<VDUVM/C)`M@1:J8#J6'V%B"H!G2J8$1N/K$8"U*
MQ\ANN>YUIJJODMS6?NC%WB0S>/1BTVN&WO-:P84]<)>F3!W%P5D1Z!O;.TQA
M>LW;;7%0OED73M4K%-S7B/D.Q4&=7)B6<8K*3;YQ_9C6*26?"MMPQV--U&L%
MYN"MVF\MKR3Q-RT@/2S:4+8I'Y%'J/C(`;5.@"9<0Z0BP+T:I;'W&8NDZ@-.
MJF./)\K'3J_5FW0Q5/TVKFW+U%F2'2>UYBN9H751YL&H^/31QK-!<LD1*;A1
MJ\Q>9SN.S1GAD=82'RRG2/P.6V*M@S77#>EDZ_*RG=U:JO"TSJ<B<>FI$Y9R
M]@L3MN=VMC+(K@S7Z\"J$6HYDK0/SB2E4V=(LKI)4Q#?ER^NF`M+I)%@F<!!
M20]2LG8#,&^PX+"Y\THGEM:YQ$XY+VUND38:RR!`@DS.B>D:)]9SQ#/:7A*F
M7%$.;8<,1J!<6>E,$(96<YY;SQC&`XP$.,8P'&,8QCV8QC';&,?HQCRYYXI3
MCCCBE....*4XXXXI3D*U^Z$WA9.PUW3:+,L42-MJ7?K=;4.MM1M=?L:Q6>*7
MA]*LBPV1:BQ^%JZ0N=V0O57.SJRH)R_":904\,2.3*FU.P)?5)J>.*5$[LQT
MYIKM9/(+%+3V(LQQUWBD4V==UYP5=2CM9PL78B+XI9)$D;:KH%7722J:]H*7
M7+'H\\JFM?:H'^P$ZKZZ\FM`G55\[5JA]YJ)4N;98,6HBTC+0@FN\5M&STM]
M3=E?4#]5-/M=)S"7-T-7Z_.1<K/D2..H)^F0J9?&1'NKTY1U0J1%-Y+VOESX
MXI4>NLY&W])4O0-*SR@ZC6IZSC5!THLE%?[#R.5&KX[&HX1#YO8Y[&_Z_P`$
M)9DS"VQ]'(6^/&R!Q4OACH-A+7HUJ5,H<>I=R^G]8&P\QNJX*WE\.@%YMU6T
MY]B;/G@IR7E0^V:^;-G8]/HY92%&V"/4TK=$$O1/65@MS.J='!;'EKF_IV@J
M30Z'*12R<<4J$8WI5/;K3]Z,;U)3RK0F[+K4UU^9'[[O^-UDDQ2&N^NE8N`)
MU`HT[L,&DX5,SJ>4+DQ[]`9,:^QI5'27\(2PB9&G*BLT>X%`Q>T8FCH2HK"C
MJ:V-D++K]Z8]AI(AEDS)N?9J;6K%6)WA3A0!;5$%B.,V2I)D#AFP'YM:W..F
M8+.7-SAEP0R(\<4K"&^:LOI!L!5VRNOL>JNP7R.5;9M*3NM;9GTAJU&XQ:;2
MB`SV/2R'6'&JQME4T/;!*J_*;9!&W&'*&V4QZ1!<"G=K>(<VHWSI^I*EW=IR
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M,U9'7=`6P/9DI6OERWN$Q.V%KFP]PF'XXI4"&K73#M6(2^(8OJ`Z[*ZUBVSE
M:;*)HFQ/47DS:2Z0/2RR-9F]`1"81JMK;6"=UC4X6P.>15:DA0/0M9(3W)U7
MR^&M;DZ?-K+I;WK%GRMVR2-^N:P^-"J&1K-F$3].55\Q9LKW4%/KC)-;8PS*
M(,C(=:>ELD*>GL;P=8;"RCA]@SE([5"OF2@A_6V`>.*573EW3LW&L.!QM-/H
M!KR>]1**Z<UO'(]&KJ+?RT:77:H-G*VDUC.1UVZAV;3\JQ(EU[ITH*SL"B9T
MT`A*N1.K0\,MEL43=!SM4=$Y+`J7J2#S+,0^NV'5I!8M)L5\T',$$`_1Z,-;
M0ZEPQD4B$H:HL4L1FEL#>=X#$C6!*2(HCP8(+[2XXI3CCCBE....*4XXXXI3
MCCCBE....*4XXXXI3GC.,YQGM[?D[^SOCSQW_1W]O//'%*B-DNJNV9]9W/J(
MP-VO!VO]QW5:4NQ>+K+I<GM")U)?URNUS6I%SJ/*JAQB\HM)D6RZ9Q6`3DRX
MFEA5E'Q>:R=E`ZL+A''S'B7=)28$1*/#@44UOS*1N=@RN[(ZZ_"3'']F3WSJ
M%57MXCK6W94@K9\=I#$);`(O.89(WB3QZ5`8WZ0D("8G(8@Z/Y)D_/'%*@,<
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MNJ4;>:FE73W2G1BK9`\KF:SW/56S92\6;M,^.,KJJ,X8KFF,2FZQ.QLBI'*)
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M2J!'$`,7M3RI;5HSDX2`E..*5&IL9T\M?JL.UD8HDY700&;;4ZTURD=EUXV8
MO?ZZ@%49OZTJRA]4NYTA]9@+/")@]K531\#Y`N4MN$[$]+79E(`AYEBEZ6VJ
M1*:(I4:>W4#?'<M*F0-J2[K+"CMI\9+W>-FV^4W3@Z0''V;)OW=)))[`7NTC
M//,>%TD>&EX`OCIY+.0XXI7=]):=5/15A2JTHZZ6;+IS*6`<-*D%IV3)[&<X
MQ7P9@\3I#7T=<9(K5.7UL-4@?5)C:-_6OT@(0)6QJ&^G-[<F3@RMXXXI3CCC
MBE....*4Y^5:E"N1JD8SE*<*M,>F$>B4&)%A`3RADY.2JB<A-3*2L#](G4%"
M"82<$!H,X&#&>..*5ABNZ>VK*R!4;6I<&<VR*Z\0)^K&MT[-+9*U+P0>4QQF
MC<F8Y4ZHW(IPFA<A+CD??7A5*%#FN7RYD;)8>I$^I0+>?R+Z?VO**=1B>M`+
M/CRZ-.D:>ES!&K@L6/0Z=N4*M69W7!3[)C#1($;;-P0RQK`E+RR)7HLY&<WK
MB(P]IWB+-S<RI7'%*A4ZH]45[7$QA&NT+9'B-PEZU&10)R<6.Q;38I$YP^0[
MGU#"\1V3"8YRV1V?-##BUY?)8XW6+')<B:Y`O5E>KGQE^EL<D4EO3IB\8=[_
M`.J7?)<?;F>P)YO0ZU')5#1ZV4V+8MKK45:P^"FE(%BI=E&ZN!3P]/\`+%"4
M\I(]2=W7NI:%"`PM*4XXI4K?'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G''
M'%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4I
MQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''
=%*<<<<4IQQQQ2G'''%*<<<<4IQQQQ2G'''%*_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g585699.jpg
<DESCRIPTION>G585699.JPG
<TEXT>
begin 644 g585699.jpg
M_]C_X``02D9)1@`!`0$`V`#8``#__@`M35),3%]'4D%02$E#4SI;6$5.0T]2
M7TE.0UU814Y#3U)?2U],3T=/+D504__;`$,``0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`?_```L(`$L!&`$!$0#_Q``?```"`@,!``,!````````````"@@)`08'!0,$
M"P+_Q`!'$``!!`(!`P,"`P,&!Q$````#`@0%!@$'"``)$1(3%"$Q%4%1%G&Q
M%R(D88&1"A@9,C,YH2,F*30V-T)(5V=RA9;1UN'P_]H`"`$!```_`'^.CHZ.
MCK5;S=ZKK:G6>_WB<85FGTZ#D[)99^4+[+"(A8AH5[(/G*L8RM2`-Q+RD0DK
M.<N1MP((<HT*1?Y8=TCE!R*W):+M1-P;+T_JYN^=1VLM?TFQNZDB+JK<F!,)
M.S*AEMW4Q;YY`DR\VXDG3M$6=TF$BDMF$>G)V/>RWS#VARNXZ6YGN26<6N^Z
M;O@Z.>^.V[-N^N%?E*]'V*O/)S#!NU:N+'&!<NXB5D!-@KE0MH^3=X7(NGI2
MW&]'1T='1T='1T='1T='1T='1T='1T='1T='1T=&<^/KGK'G&?U^OV\XSC^.
M,?7Z?;[]+\=RKNF[ZTYOA?%OB)28&<O-5@8:?V7<;%77UQ7'/+"Q1,157K=;
M92$<T21I!.(Z5GIR5,\2A4LUC&4<$K9T]57RCN;=X<F,916*;X_7&A,_E]?S
MG_T_7K@W)SE-W/N4FI)75&WXA(-=NY&,G[&SIFM#4\\R&`(MZRCIYZ"2D%OJ
M^"1PVEW$8H0PGD(V.,X6037V"5:T;4NSMC;&J&HZ+7'L]?;W8F-6K<*E*@J<
M2K\BD)6],O&$,HM@!#B2F9(V4@C8AF_?GS@3=?7Z#/"/B32^%O'RH:7J:@R4
MFT0J=V!;L"R)U>=@RP6^;%97"58PL319``BX!BKS^%UR-B8[U+6W*4DN.M8N
MEQKVOJG8KQ;7IHVL5.'?V"P20(V4EUQT-%@4ZD9!4?"LI&3<`9-1D<N?B,G!
M!-A%.I&!"(I,%L=V#MZ9QC*>3=/5C.,93E,%?585C./4G*<IJ6<*PI.<93E.
M<X5C.,XSG&<=3;UUL:C;;I5=V-K:S15QI%L8)DZ]8X4^3Q\DS4185*'E:!F"
M=NX$9J\9N@@>L7@3LWC<#D)1(W7K1ME;+HFGJ/8MD[,LT93J-4V.)&PV.765
M#&-:*.)J)2T@$=R<[AT<#1FS:`</'KLX6K1N8Y4#5"A7=A[>B,*4KDW3\81A
M2E9_`;[],)QG*LY\5'\L8SGZ?7Z?3J?T++L+!#Q4[%D*:,FHUC+1Y3M';`Y&
M,DU$]9D,QD`-7[(I&YQK(T?-6SQNI60N6X3(6-/I='1T='1T='1T='1T='1T
M='1T='56'<BY=S.J(".T5J"7(TW)LAG[TC-Q14*DM=T<IE-C2H58POXEDLY!
MN(JM$\)<,&HI6?`L+EE&K+3W1ME[ZX2;!HMJ9W.?EFUL=13^V:ZF;#*S3*W0
ML@_$V,"382;EY\6?=B.4L'.-<"E6S[(%D*Y9E<M',W>XIVJ=R[TWPCE#Q6V%
M6ZG>K3!0D'LNHW.5EZTUE7%=9AB(>RP5BA(F;RW>F@@LHJP0DE'I`X5$M9%E
M(X.9TT7#!':Y[K"!I'C8>GL8QC&/IMZUX_AKWS^7U_7&?W^.7[7X?]S?B=1Y
MK?EODJE=JA0LMY2VQM(ODU;Y1C7,D]J3FWM=D:Q"X?5V+$I)+"1J5TYCXTA9
M(C)4>T?N6L5;NV'LJ"@.3_'*3>4R^4N6C;!)-JVX^-.46WQYD/6<Q&$%GU$C
MC.48,T65!6AA+-'/AF;%*$K4?;:YZU_F[IW#J8^!`;VUX-C";BI`,^PD,B1"
MQ1]VKS8BLE73[C\9PZ8)]15P<J&3K;PI#1X'#RQSK^"B&89`E0D@RH4,B%I2
MM"T+3E*T+0O"DK0I.<I4A2<I4G.4JQE.<XRF7W9>`I>*NS\;5UI$'%H#:LNX
M7'-6@EY9:UO3G!GTA1R+1C(VL!,)0ZEZ.HGH2%L.4K2<>(9@MY]/M8]P]YQ)
MV`/66SI@Y..FPIA*YDCE9#CU=:G^1-T7Z/$E)"IK[W*`-[Y'`QC'QDBL[01'
M\:];RKG+-ZTD&;:08.F[YB\;A=LWC,XG+5VU<B0=NY;.0J6$[=P$B#`.):A%
M"M!1K4-2593J[NG/HG)?9A-)ZQFE%T3JB;,-P_8.<K8[+V)&K,R?67W`Y]IY
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MF(^+!(2ID?'8ESA>G7(G\O(WWEOO]VF5E9>3<3A!&QE`)B>,+"(FNQ`2Y4IO
M!PS,36/9M49]#.(9@%G_`'8JU*[UP&X]3G*;<;[EWN%DIU0*C8BXUK"/AY^%
M:;C$F\#F$-U>$DK5$<(&ADG"?C2%H`@/A88)X([!W1U]=VT:OVKAD];@=LW8
M"MG35R(9VSEN<:A';N`%2H1P&$M8C!*E0C"6L9$J0M2<IP<^N*UI[97(5MN7
M44.9YQ5W%,.V8H!22NH:DSLC@KV9U1,YSE?M0;\"7<IKEXY_GCCV[NOX,MY`
MMR/N10]MM'&C85#YU<5'>7E>69;>U5,QR#C9J#?*"NUZUN(F^"82T?#&DD?(
M*"0D7*MHJQ1Z?EQ^$+<.XV<B-;\I]-T[=>K93Y]:M;+.3L7.1HF:Q/LE8;SU
M2LC-"UY86"O2&",9`&<J"?"02+`KF,?,79^[=<NW3IVA[]UA<=1;+ATS=-NT
M26*E6J5X"[;J]:'$?+13OTK4PFH21"UEH9^A.5LY)FV/C"DI4A2&7+3C%>^(
MN[;-IZ\H(\Q'*3+4ZU(:Y;,+Q29`QTPEG8(\J$(IL`*PG(\:R9B)YG(1^5*"
MEJ8T@*7W+M_4CAS:.(<<]41C*$%!U?8WXBY%::5J]^!TBT:[C,)3E10/U+"Q
MKDSAT!U58![-Q#01\9@G$-P3B'Q=NW+K>%6T[2T&8,W:DRUWM`VOOLJ+0XX[
M<<W8SHSZ`J<C08,978]:Q_BD\\CVF/#=+PH'U]4:NI6E-<T[56NH<,#2Z-"-
M(&`C!>E2AM6V,J*Z>&PE*GDI).B.)*7D"XR>1E';M\X4HSA:LZSR!W]K/C-J
MRR;>VQ.8A:I71#0D8!I=S,],N_4.)K5;C/<$26L$RX3D#!B-8QI2D[UZX9QK
M-Z];JI;\[W_+'8\W(@TWBNZ(I:E&#%MF$/$W2^%9^O.1N9FSV-F^AFKXH_2I
M;:`KK9NRSE012,CA*79.)TKN_<_:A*HDC[I:7II@@<N8.]46E2<0X2)?J]KW
M("'K,PSR3&<I(1E+MBYQZ<X\J1CIC'M\]T+7?-!"Z#9(IMK/?,9&GDW-,^>1
M]7[E%L4#S(SM`EG:1.G6&'KP:7K$DC$Y#-E?+$69BAFE!=)[EO*[87#CCNPV
MUK2&J$[8G6S*C32,KLREW\/B,GV<^X=G0"%F(-YA\-<6WPW)E[D"4K-@@"Y4
MC**>]`=][:<QM"*;<AJMJ2MZB;PEPE+-)4.LW1=R,ZB*K*R%;AZV&2NTHP<2
ML_9014,`#MI[&</5K<.F`!F?-XI;R[U',K9M@D3ZTGHC1-+4XSB'@*O`P-CL
MB&8B+4!<]<K5$ROSI$H\IR\3"Q<)&(5_1P!,-/R3]/XR=\CD+0[-&1O)$$9N
M?7;@K9K+3,1`1%8V9`M?/MDE8Q4(*-KEKRW0OWCPDA%1KV0]O*6<X!RI`3-@
M4B[5;8]/K5]I$VQL=0N$)&V.N3L<3W&<I#RS4;QB\#E6$K1@@2I]P)D#.W,D
MC=P,9Q$&FK/N&]U>E\/'ZM6Z^@X[9N]S,@/I"&>R!FE1UVR>@2XC7=V=1^<R
M+V7DVY!O8RH1A&;T\:I$E*RL(S=1BY%>VW]WKN`6J1_$![Q!3VR3$6WB*50J
M)$Q(L+5A6`YS,0=AE78QXQA"?FRSHN$^?4K.5*RJ2N@.^ER9HT^R;;[B*SNN
MEE*`4JYBX2,H>PX]OC/H(\B'L,EK4Y9P-&<EQ%2T)&H>K2D7X[&X7[N&GM+;
MHUUR"UK5]LZKL`;)2[8RRZCGJ!$:NVQP%6VD(F6CW&$NHJ:B'PC1\M&.T(<,
MW@2#5A8\B*3E/+GF%J'AIK;^4#:4@Z.\E3N(RDTF$2!Q:[S.@;_(7'0K0Y0@
M`S9#6(\W/2!01$&T*(KPZG#EBS>+`;D[WO,J_P`J_7KAW3-'5=?N#91E?KT9
M<;&!IG*O222MUS9/&QGN$Y\*/&5J%`)6/`A9SC!,\IHO>(Y\U-XAR3=$3L%B
MAP@SB*O%$I,NP<>GTXRW4\K<96)EL)>$_7#65`M*O4I&<*SGRP9V_P#NO:]Y
M?R3;5M]@VNJ][*:'<Q\$*0(_I]_"R!EP_-2)1XD3YM+,VZ"O'E0F,%D1L!%>
MQ,G/-6D@1C)KN#\D+MQ1XO7+=6O(JL3-HKTY18UDPM[63>P106>WQ,`_6Y;Q
M$I#/EE"S?%*UR)^-*'"1K*@P\*$JE'0G?BV4_N<N7D/3M71>NXBAV^<"#74#
M;6UQL5QCPL$U&IPAYJWS<4$L\_<F"X<OV:&;)H$S]R\:MVI5+AS>.\ISEO>Q
MV5@K%[AM75?%B:YBJ!5ZC6)F&!&N7S<"8^>F+3#2DU9CY:JPAT]R>'`8ZB'8
M1T8G(QCFCSUY,1^[.51:%-RV874FC)UW5F(UH,H<G:1^R*Z6YVU3ZE&,,R%U
MN"1G"L@C&+ER'*%3;K&?-I<'(\\=T5/16O'1ZWI>E1_XS;)4!!`>,*:Q=MVL
M@_$+*O)[/:7Q@1,5Z1'1'E=X?.4_$CEH(S33JA6Z!5J_2J?#LH"KU>)90<%#
M1X_::1\9'@2W:MQ8SY6O*4(]13E4L[DZRN7!"'*1:MEZ.CKB?(W7&G]L:0V9
M1M]M8H^HY:IRI[PZF'0XYK!PL2W7+&M`Y<GC\#?59;)$_&SB%(+$/H\#X:O4
M'TJ_/2QNF9U^'9>L-36^1LFHIB=FHV$F;)!"C92T59I*N$5R??0"BN00,O(1
M8VSQP()5%;K.0?ANE2FPKS?\',F=HKVMR1@VV)%QIO-&JLU8%JR;$-';3)/9
M8UKX:,H4U1,3-/%8T2N`Y$<D7!PBG62"`PQALSHZJ![T>J]&6[B1,[`V?+-J
MI>]<O1$TW8PM?ER\O;YM8Q+UN-D-8CR41=6K1>9,6"8'`YB@W%?@4`X29,OS
M]?S^^,??]/XY_//GT^<?EX\]-\=BV!T,VXP3<]KT^'^XI*U'9[W/)"`.=BY%
MH1V2EP;(:"$6FCCKQ<R-;=(SA$K*/+&Z=I%*A>LV-W6<^,9SG[8^N>D^^^+R
M)F-C\H&VBV,@;%(T/"Q:31P5J2U?;&N42VG9R7<IQE*7!HFMOX&!8*(E2F.2
MSR`*3B1<97(3M`=M_4.W]9N^2W(&I-=@,IJPR\#K"CSR')*F*-K+Q<7-6Z<B
MD+&WLCM_.A>Q<(RD<GB(YG%N7JV;M\_`2/MPY`=K_A[O&AR]98Z;HFK+2N-<
M"JM_UE58JG3E;F,")F/>N!0+>/8V*+0Y4C\3@YP#MI(,\E&A;1WAL];I:MW>
MR^,V[UN(UT2M;9T9LA\V0Y;+5Z&-OHLXZCG0<XS_`,9B9$S-RS<@+A0Y"#D#
MMCI6%R3"F8.[;M.+W=VP=,;=AD#!'[(ONC[D%J,BB)8$GJK:7SN,R1:4J6N,
M>D<QQ,Y3C.2-E?GTN+Q:T-+<G.0.KM%Q$DB$+?K`MI(S:AH,N$KD3'O;!9Y9
MNV*K`G;YE`14@N-:%5[3J34S"?.&ZS*PX1'=HO@*PHB:2O1,=)D_#,LBW:4G
M[(78SATH:<*F<VYM*M7+.445*3I1&MV<0W5E39M%BCUK:*40YA<>77%?DAM'
M1I9(TPQI\LS<5J:<8!AY*U"QQC2PUAZ_0VQ@")3$6_$QE4A&,2Y)BZ*$0@D$
M-+%_;$Y#.-2=J/8NU+*M4G'Z$FMX9KL>X*M27#>-PQM$)`XSZAY`!Y9[.N/$
MA"_`@N_*/'T0E7HAMA;WVK@CT[JW[3W!?A(,X<+6IQ/WB]SP6R<D)C"EC;FE
M9$8D)&G*&,<-`A(2W:H1ATSC/VMN*&B-;1%9LVJ*#N"]'8-57:_[&JL7;GLW
M.>TG+[,&TL#9ZUK%>`Y44,1$1(&RD,T!/)'?R9'+PM3G<S[21X":J6QN%.IK
M%+,[1)R$5>]3TW`GD76'8V.7\9;*TWEI`&8>$D%A=Q<M!">+CV<@2+/#-&@'
M+X*._P#96U?RVX_SVXM7;KT[?Z!K"SQ47?:Q)6L#$42QOL<\:U^9CF&&<N^]
MIU9H!W&NW"<MT),JK8+DF"J5[M)?<KY&3')'EYM.=)(E=TZ@V&5U9K=@@Q5Q
M[&L4R3<1+U^T"7/@3BU61K*6"0/Z<$/APP`I60Q[08KBNT5VV-43>I*_RAWW
M3HC8<_?E.I#6=.MT<&5JE8J#1XX8,;,]KSX9(Z:L5H*V<2+`\NV>LH>"S%DC
M&PW[QX\5:3R6[=G%SDG1I>N3&KZ=2K:2/**K[,HM8A:W;ZM*##D<:[P[B&K!
M$[$MEI&-]7)M+R*?L/=`D39SAL\;)`V&&OV@-O3=?_$'-7V;IK8<A&"EXLA0
M.(:XT2P&`UF(PN<X,D27[`,BQ]><^^Q,,9\+&<B5M!\[MX#Y(]FV.W;@"&KN
M^@TG(3;06,>RRM+'9\'"VQD'"?/I`ULD;*";ISXREO@/G&,]++\>-+3_`"*W
M?K+259<I82FQ;2S@LRRVJW@H**0)Q)6"P':(()3H,'`,)*4RW]T6'16PVZC"
MP;"\.7ZN[3_!76D!$QB]&5R_3#`3=3NW[*6^MUBEGXDC]4B?#UTF(C5D*C!T
M,(.*C8UH3/\`16H_3ZLU_P#=#X:II%O=\H:!$K)3K=(`1M^,;"]P59M;U8FC
M.\#&G&?8@[0?(&5@SZ<"C[(MM(J5[<\Z6VK!I=IN.D[O6=PZKDU0]MJKS#UL
MI&%J823,B?:DH67:(4G#V&F6>2L91DK./=`3W!+$]`U<!;5XP<CJ5RAU-![,
MIY,-3GQ^&6RLG.@TE4+8T$)4K`/\IPG)4BR4;N+?X0@<K#NF4B)*,'6(4A^C
MHSGQC.<_;'USTJ?WS.X-FTRTAP=T_,XS!PSIJ?D78HUUA8Y27;$;R$3J)L<"
MO3EK$%2VFM@(2M63228BKE\)9V%H5=VF46U;'N52UGKV"<62]7NP1M6JD$T\
M>_)34L?`&HE%5CTMFHL9(\D7QLX!'QS9[(N5)`U*K'Z!O!3B'4N%/'BI:<KY
M&LK8$X78]E7``,A+==AS`@9GYK.%I05,6UP!M!UEH5.%L*U%1;8F5N<.2EF+
MU].0D&,2P>RDH]:1T;&M'+^0D'[D+-BQ8LPK<NWCUVX6,#5HU;B(X<N#+0(`
M!D*124(5G"/G<SYR/^9>[#(K+]T/1FM7#^&U;%JR0(YXR\X;S6QW[9:1K^?:
M5!2*$$X1DL350L0(2%W*3&#<EHO!/?NP^+-^Y:URO*<:]HLM["(Q0CYL-HKD
M4ERB\76N-48_IM>HKE#=M*J2A1'V!6`T=DB:R[&Z\[A-RUMW#?>E?VG7OERM
M8=>S`[+IS<WI%<J*Y<H,\:`3E208G88F<S=3?$SC#:5#EHM6(^6D4&?"UYL2
MG[9H-7V3K^<:62FW6!9V"NS3%?J`^CGX/<$I2/\`2-G0%X(U?L3I&[CWX'+%
MV(3EN4:48>Y,(XN>?*A)QE&3.U7!4)*A:59`:M5HK8F,$^N1%`L9`J3_`#%B
M4A8\^C.,]:YK'B5S6V=1X.[:DU%N2TZ_FD/<P$Y4IA(H%VEC(NX^02R`BTL/
M9RVE&KUJZ&IFW7AT$V5)5E7K7OO^(9W'/^P'D/G_`,\5_P#-?U_M^GC[=>*;
MMS\]W+@CEUQ<W"Z<G)DIW+IO".G!BKSY48[AQ92&.57_`$BE(M:L_P"<K/5H
M7*^A;$UAV1^.]`VI5I6EWBK[JA8V4K,X)L"4BVF;;MQW"C=C9NG;?U&AW3%R
M):#JR0)Q*7A*\J0F"/9[SY[AVAO'VPUVEC[_`/=3</R_+^S'CS^>>G@4_;'[
ML?PZ29[S?^L)VSX\>?V1U)^__D!&_7_]X_?]^I.Z62[5V%N3^&>#95C=;Q;K
M`,J\XCT7[3"GZC83G&<M$ML+4ZPKRCV/5DF,I\]5P]O'+''.CBG^)^U\;^6B
MN81D_G"<OLM93$3C&,9\^[^,988!Y^F7'M>?.//E^9'GT(\_?TI\_O\`&//0
MK"<X_G)PK']:?5_L\9Z_GTH3]<)2GZIQYPGT_=2?&//C'Y^/[>OS=;L%PWN=
MU;N$%$\#<KB!P(OE)PN1666$41?5GU),,R%(7E7E6"85A6<Y\YR_+P;<1KKA
MMQ9-$J;+8YT!J<:%-!X$'W@4R)`\2E"4HQA:7HW"2Y].,J-@BLYSG.<YE.O_
M`#%?^%7\,](:=S`L6?GORD5#X\-<;*0$_P!59\R@*E5@3GC*EKS]9<;WSC&<
M(3GRA*1IQA&+&$"=C_P?LN7/CVB[AP5AX&0><,L\CQ)QZE+_`)IO+I+G*2AQ
M@7HRA&/*QKSF%':%SG_*'\?OK],JV;Y\9^F<?R2W?QC/_M_5Y^OWZ>+3]L?N
MQ_#KQ[%7H2V0,Q6+)&-)JOV",?0TU$/Q).RDXN2;$:/F+L2OH1NZ;%($B?IG
MTJ\IRE>$JPJ'RTXZ2_$K:KNEODOI#6-KR]E]4V=YG)LO(09$_*J\J[QC"%V2
MIJ<`9/E+PA<E'$C9M`\?-<B;Z+Q0Y53?$+=`;3%Y>2VM[9EI&;-I[525_B4.
M,ZOCS46!:L!19:TMP9[$$SD?SFQ7\&<R`2."MF10=P?AD<(CHY"4!*#"&5*3
M.91N9"2(2O"3-S1:#-S)PK&"@,E)0$PH14I(A6,?)_E`^&7E*<\B-<IRI24X
MRN2>C3Y5G"<94M<<E*4^<_52LX2G'G*LXQC.<:+S[Y0RNG.!^WN1.B96(M,F
M*KPS:BVZ&.UL$!'&NUHAZ6&Z"<M"F8O`5?,T:6"DBC-,RC%LVD!9!AR/")UI
MU_:ZS`1-\L[GYR;QE[-XEGDF.0DY)V[=N#R$C*N%E(X7(/7RG3IZ=[G#APX*
M9T;S[N%Y9_[&7`(M`K".:&VX0K>^;#A3,M)0DFV2AQ4=:2J,8>78@3)49M/;
M(;X0B+7Z0'8T7`OKYM+X0F,NC[??I<'O9<]/PA@ZX:ZGF\?BDPT;.M]S<:7/
MNQL&[&-Y$ZN"Y'_.$^L`%@F;DD*AE;U[,7"$(I%ADP`I3X,<0K5S0WK":TBE
MO(JEQ:0V/:EQ;CSA-6I0'*1G0S,H:Q9LMD.E4%5FRD+SAZ1S+&"2.A9#*7NZ
M90JAKZDUW7-/@(Z"I=5@&-8@:\S;HQ',(..9H8MF*0KPK!D?'1X<K/[A'A"&
M,Z44IRJ6G3W7.`1N)VT,[,US$$1Q^VI,NB08&HLJ:ZXN;I)G\A0'"D)]#>$?
MH2ZE*(4OI\1XWU<SE9H1L1[UCLX\^L:,O8>-.TYA(M1;1GQYI$W).?;9Z[V1
M+$2##8IRK]MI5;\ZRW:O,K4AK#VO+.45@09R:<(^?OG\;)>A\A(?D7$QIET;
M=D-%0T[)`%_1XO9].C/PPK)]E&5(;%LE/81$A%J)[>7KF"L&$IR5LO)-U[0W
M<BU;H*GS''/D'."IU178Y*UZXV!(-GCF!B7-AR,UBJ5F,S$[)"M'$L+,W"31
M6OX8EQ(RS&5=,?0P(:Y;;W=1X/:KIDI9V6[:3LV9;-7"X6CZPE6UOLMAD1I3
M[$<+$8DT?#!.1:,&F)YY'QC,/N'48JQI`1>O/>=Y_7"W9C:4YUV-S:K+\"H4
MN,U;'3KU#B=E?C5VJL7KE[A_,.TD=,XD3UP)+A\;'RRB#DBQCM+[Q;2_,>VU
MJQKM63CIG90=F:73?I*'8-8V)<W!5:M1+$J*8,UK;-XT<JMR!B@:UX4U$,F5
M*4O*LTQ=GS_6'Z&^GC^B;1_N_DIN/_WC^SIX!/VQ^['\.DF>\WC_`(0C;.?/
MC_>CJ/ZX^_TH,;G]V<>/RSY_JQ]^K7^U%J..WUVMMVZ;E3H:--D7W=M10_6E
M2DQKR5K52%%RN4)PI2_PN42RD/1A/E>&WIQ]_JLW(QNQ]`;9)'2S5Y3=KZ>O
M;8CANX%G#F"N=-F&T@T<)3A6$.6?SFC5^S,,GQY.(<-W#8RVCP15.+<:.[MQ
M+W-KZ'E-D;)J6CME`8C1<*1?9(D$Q;R@1C2\>56Q2(TQ-@K[TZEGB\B?XFFH
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MAL`L8Y)2M<4*U1-HE+!,92L<>F6=5YQ)MJS7D.\)7+3<N5N@+,9T1X7\BILS
M,E'Z=B;\VT?+%B[N6UMQ[`>NA,&(E+=6&[7B;<R!1`'G*LA;FD'QBK(56`QL
M6`KET1#9D4J6D^?^DFO''L\,M(M72'RM>`T?#2;\6%>Q)6`NRX&3L\F!*TH4
M@$E8G\H\!A2<+2$PDJ\YQGJDWM#?ZP[C[_4K9GW^_P#S2WC[?KC^O^/WZ>*3
M]L?NQ_#K/4&NXI6M/V+BQL#.WU$;-HL`7]%DHX;<EC9;)\$;U$=<0XSA)WDD
M]*J-DVBE);.:ZXF/G$`S$5R!??1/'*O2=?D+YM&1)`TB%`E3^32-!73]\L?D
M,?&(<J'@Y"+\Y3C*L8&'&2$]/TQG?,..%XU9`.7N1E#SE/\`H(P>/IGQC.,Y
M<YQXSX\?[?MG&>O"L[[B".,<_#5>3N?9)@*1KB$847T9PCU>HB\8QZO'GQC/
MG'TQC/5B/::H^=A:#Y#U"]UY5FT!=[@J#KM;M#<;^O3;=]!.66QFK=F;'M&C
MW1%PC>2*TPELJ<`_6%:)(#LB/$C^P?QE:[>A[=(;&VI8=.0<J.:9Z"GW<9(0
M1C!.ET&!D;KD0[1(4Q)4I"YACIQ-2+%'X?(6=RV*Y]^])LV;LVX&C0`6S5L(
M8&[=N-`0``%"1!"$(TI&((AI2,0AI2,8TI0A*4IQC'S=<]VNG9B]<7$6FOV4
M3M(\&[;48]Y=/V=28V!RE+=G)SQ(N+F7Y6,5[BY)3%M'&5)%:BCB+:A=$=@5
MDL'8MYMVF=FK19-MZ'L%DL4I(SL]-RMOV&XDIJ:E717TE)R#E>MU9(Z?O#E.
M=>$^A"E^D0TB&,:6`N!7#.L<*='1VOV3AC.WZP&%9-J71HUR#%DMA6^`X:QZ
MCH2\16*TUS^#UEHY]!$M4.9-P`,C+/TYFWUR[=&G:%OW6-PU)LN'1-TZZQ!X
MF4;84D3MJI7@K&7B7>4$5'S<*^&WE(61&G)6,BU;G1A6$J0M7"<[!'*8,S,`
MKVTM%R=>')/PPDA-3%XB9A_"I<E3&NI>,84:19QLHX9>R209L9%XU;/%&0T=
ME"D:^KZM1<:-AWSB0GC5SP'K_;;QHQQ5E66JR\[(FL-<BQ`54K(_DIB`KLI#
M;&KJDI;IGXQ)3N',8RG_`)N'[^1:XHGW_P!AW?E3FG\AQWN=3VM42GRN-@[E
M)BHNP8\12J]+-T[6S-39[#061X5+#D*X5YA"UYA0%\))&*![-G<&FI(<>]U+
M7JPV69`S3-BVE1,13="B91DZTUZ7L4L82,)]Q26L28^4*QZ!J4K*,7K=OOM'
M4SBA/Q^WMKV&/VENUBV*BOYC63AK1-=&=@(V>.JT"0PF1G[$5J4K1%JEVT?E
MDU,<<-"1ASG>FD;W+N*.PN8W'9AJ364Q3X.Q-=F5"Y+>79[+L(;,7`,Y]N\`
M@\+#3CO+XBY1OEN-3+`%)0;)#CRE&%UI\#.T9R/XO\J=9[POUTTU+U2FAN8I
M-A5)VX/)X^;%29^MLLL6TK2HA@3`GTHW*YR>0!E+5!EC]TN$"6QGCZ8QC],8
MZ7=[@7:7Y%<JN4UXW=KVY:=AZK9(*BQC%A;IRWLIX1ZS6&D*_4Z;Q-+F6*!&
M=`61JH3\JE@RE14")G(\6-]M'BCL+AQQV?ZEV9,5"<L;K9ENN0WE)?2[^'3&
M3S.`;LP+/-0T&\P^&N*<*<#PRR%*5AR,Y%*7A&I<\NV-J3FH@5Q#(DUCNV,C
M41T?L2)C`R+.P1[7&<L(6_P.#L<V%BQQE88J4:OF%@A!&4!L^=1J/PI:\UZ[
M*W/6I2CAE7Z51]EQR"80";INQJ]'@<I5A><$)&7I=1E&BDX3CW1J"X0A11I&
M8^,K6CKVANQ3R:O$TS<;WGJEI6H".A4FVBYACL'8#UMZ4D6")91&2U&-*;&5
M-\R$K/O\,BXR;\$D4(2(K1>@]!ZPXTZQ@=2:CKR*]48'!S^DAR/I6:EWRDDE
M;%8I4^/DR\_+G2DS]^?TXPE`6;,#2.:,V;?6N3W%S4O+;6+_`%=MN%(^C2'Q
M)0$]&D$SL].L(@D`TL58E%A/\&1`(I`'"8+F.E&)3QLLR>,3D#E87=78MY84
MB7>9T_+47=M564WX<14VTUY<?B80I242T#9%_LYEQX3@&215J.%PM2"):,QK
M4,/,J#V4N=]JE`Q\[1Z%JV+(3PXFK=L&N/6P$X]OU%%$T)=KDGI,H6KVD9&U
M010EC(Y!CT+4PWP3[8.G.%V57(KXFT=V/6"V+G8TW%@CFM=9NDYP^B]?UY)W
MR*VV>(S\>1EG#Z0L<LW2IL>2:QI5Q6.N]PCCA=^5W%ZY:5UY*5B'M-AG*+)L
MG]O=R;*"$"LV^*GWZ'+B(BYE\@IF;$PFF!,"I6Y4-)5A%E1$U/<$NT/R0XQ\
MJM6[POEUTS+52DJN&96/JL[<7L^X_:"C6.LL_@MY6E1+`GM/I=L5S[\@W]#0
M9UC]TN$!6QSCZ8QC],8ZSU01W![C-[#Y;5C2]KDD5W6M$K<!9([Y"\A8R#^S
MM7CB:M#G&29P\.U;LU5N*3E&,M,-I484^J2<*7&Z3C)KE]M^D<7M,K<0NO8=
M67MGFVPLD%!U*.*%%AMTGE&<"-)._<$RAVYU)2\F7L<Q0K#?!R#O/A^!W$"'
MB8R)1QYU7()C(]I'ID)FHQ4I,/DLVXV^'DM)N0J<R,DZP/WGSYPI1G;HA3DS
ME2\]>C_B/\0L_P#5NTS_`.@H3S_?\?J2,!7X*JPT=7:S#Q=?@8AJ-E%0L*P;
M1D5&LPXS@35C'LQ!:M&Z/.<I$`2$8SE2O&5*5G/K]'1T='1T='1T='6/&,?;
M&,?V=9Z.CHZ.CHZ/&,_?'GHZ.CHZ/&,?;'CHZ.CHZ.JO.Z%JC7]EU-';&F*Z
M(]XJSX<)"61L_E8R1;0\E[SQW%N%Q;YF.289=A2Z`TE!O`,W*S'9H`5PX678
M>V1JG7U*T*.Z5JMMV%LOLFZ7;;`5W)24K,(AC+#%-2.Y5Z^*UCV*7#@C>-8Y
M:QZ'+AP[^-ET<IEV1='1T='1T='1T='1T='1T='1T='1T='1T='1T='1T='7
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
